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PHARMACOKINETIC SYMBOLS 
t time (min or h) 
τ time constant (min or h) 
Τ zero-order infusion time (min or h) 
г rate constant (1/min or 1/h) 
С concentration (mg/1 or /fg/ml) 
Q amount (mg) 
A coefficient (mg/1 or /<g/ml) 
к clearance constant (ml/min or 1/h) 
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PREFACE 
In most industrialized countries hypnotic drugs are very widely prescribed for 
the treatment of insomnia. Several years ago it was estimated that in the United 
Kingdom alone 22 million prescriptions for hypnotic drugs were prescribed per 
annum. A rough estimate indicates that about one night's sleep in every ten 
was hypnotically induced in this country. There is no reason to believe that 
these figures are very different for those of other western countries or that these 
figures have decreased subsequently. Although insomnia is usually not regarded 
as an illness in itself, but as a symptom of an underlying physical or emotional 
disorder, the relief of this symptom may require adequate hypnotic drug 
treatment. 
After administration of a drug product to man, three main phases can be 
distinguished, as depicted in the following scheme: 
I Pharmaceutical phase II Pharmacokinetic phase III Pharmacodynamic phase 
dose 
disintegration of 
dosage form 
dissolution of 
active substance 
absorption 
distribution 
metabolism 
excretion 
drug-receptor 
interaction 
in target tissue 
During the pharmaceutical phase the disintegration of the dosage form and the 
dissolution of the active ingredient in the surrounding fluids are the pertinent 
factors. Biopharmaceutics is the study of the influence of formulation factors 
on the therapeutic activity of a drug product. This is generally assessed by 
measuring the extent (bioavailability) and the rate (absorption rate) at which 
the dosage form delivers the active substance to the general circulation. Also, 
physiological factors such as the metabolism of a drug during first passage 
through the liver are important in this respect. The pharmacokinetic phase 
comprises the kinetics of absorption, distribution, metabolism and excretion of 
a drug. The time-course of drug concentrations in plasma and other body-fluids 
is studied, so that certain important parameters can be calculated. In the phar-
macodynamic phase the actual interaction between the drug in the target tissue 
and the receptor occurs, which results in the pharmacological effect. The various 
processes which take place during the pharmaceutical and pharmacokinetic 
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phase mainly determine the onset and duration of drug action. Only for a few 
hypnotic drugs have the pharmacokinetics been well defined, whereas data for 
the influence of formulation factors on bioavailability and absorption rate 
(biopharmaceutics) are almost completely lacking. 
The investigations described in this thesis have been initiated since infor-
mation concerning these aspects is pertinent to rational hypnotic drug therapy. 
Several barbiturates and chloral hydrate, incorporated in different pharma-
ceutical formulations and administered by various routes, have been investigated. 
The results have been discussed in relation to the utility of the various com-
pounds and dosage forms for their use in general practice. In addition, the 
pharmacokinetics of hexobarbital, in patients with liver disease, were studied 
in order to obtain information concerning possible changes in the kinetic 
behaviour of a drug under pathological conditions. 
14 
SECTION I 
S C O P E A N D I N T E N T 
15 

CHAPTER 1 
KINETICS OF DRUG DISTRIBUTION AND DRUG ELIMINATION 
INTRODUCTION 
It is a common belief that drugs produce their pharmacological effect in 
biological systems by reacting with receptor sites, which are located in the 
target tissues. The intensity of effect of reversibly acting drugs depends on the 
degree of receptor occupation, which, in turn, is determined by the concen-
tration of the drug in the direct environment of the receptors (biophase) and 
the affinity of the drug for the receptors (Ariëns, 1964). Usually, it is not 
possible to determine drug concentrations at the receptor sites in man, since 
these are not accessible for sampling. However, all tissues are supplied with 
plasma and it is obvious that a certain relationship exists between drug con-
centration in plasma and the concentration in the biophase, although such a 
relationship may be complex. The plasma is easily accessible for sampling. 
Following the administration of a drug to man or animal, several processes take 
place: 1. absorption from the site of application to the plasma; 2. distribution 
from the plasma into organs and tissues, and 3. elimination by biotransformation 
(e.g. in the liver) or by excretion (e.g. through the kidney). As a consequence 
of these events, which partly occur simultaneously, the drug concentration in 
plasma changes with time. Likewise, the concentration in the biophase also 
changes and so does the pharmacological effect. In other words, changes in 
the time course of drug concentrations in plasma will affect the time course of 
drug action. It is for this reason that information on the kinetics of a drug in 
the body is of great interest in pharmacology. Pharmacokinetic data will help 
to optimize drug therapy, with respect to the choice of the proper drug and 
drug preparation, as well as with respect to a proper dosage regimen (van 
Rossum, 1971). 
Pharmacokinetics deals with the kinetics of absorption, distribution, meta-
bolism and excretion of drugs and other substances in man or animals. Its 
purpose is to study the time course of drug concentrations in plasma and other 
fluids, tissues and excreta and to construct models suitable to interpret such 
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data (Wagner, 1971). The relationship between pharmacological response and 
concentrations of drugs or their metabolites in body fluids is also pertinent to 
pharmacokinetics (Levy and Gibaldi, 1972; Levy, 1973). Several reviews on 
this topic have appeared in the literature (Dost, 1968; Gibaldi, 1968; Wagner, 
1968; Portmann, 1970; van Rossum, 1971; Wagner, 1971; Notari, 1971). 
PHARMACOKINETIC MODELS 
One of the basic tools of science is the use of models to simulate and sim­
plify real systems. In physiology and pharmacokinetics compartment models 
are most often used to describe the behaviour of endogenous substances or 
exogenous substances, including drugs (Riggs, 1963; Rescigno and Segre, 1966). 
These models assume that the biological system can be described as one or 
more connected pools, in which an amount of drug may be homogeneously 
distributed throughout an apparent volume of distribution. The transfer of drug 
between compartments is usually assumed to proceed by an apparent first-order 
process. In Scheme 1 a representation is given of the processes taking place after 
administration of a drug to the body. These involve consecutive and simul­
a i 
но 
central 
3 
brain receptor compartment 
ЧГ 
-* drug-
response 
peripheral 
SCHEME 1 
taneous competing rate processes or clearance processes, where clearance may 
be thought of as that volume of the total volume of a certain compartment 
which is totally cleared of drug per unit of time. The clearance constants 
(symbol k), which have the dimensions of flow constants (ml/min), govern the 
drug transport between the compartments and the environment. The rate con­
stants (symbol r), or time constants (symbol τ), which are a function of the 
clearance constants and the volumes of the compartments, determine how long 
and in what concentration the drug remains in the various compartments, in­
cluding the receptor compartment. It is evident that the model as depicted in 
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Scheme 1, is a rather complicated one, although it may approximate a real 
situation. In practice, sampling will generally be restricted to the central or 
plasma compartment, thus it may be impossible to obtain sufficient data for such 
a complex model to have any utility. For this reason, the simplest model by 
which the experimental data can be explained is the one of choice. Such a 
model is, of necessity, based upon specific assumptions, which must be re­
cognized and tested, whenever possible, by experimental data (Mayersohn and 
Gibaldi, 1971; Nooney, 1966; Westlake, 1971). The relatively simple models 
which are commonly used in pharmacokinetics and which are relevant to the 
investigations described in this thesis, will be discussed briefly. If necessary, 
further extensions will be made in this or the following Sections. For instance, 
the kinetics of drug absorption will be discussed separately in Chapter 2, 
Section I. 
1. The single-compartment open model 
When the rate of drug transfer over the various fluids and tissues of the body 
greatly exceeds the rate of elimination, the body may be considered as a single 
open compartment (Scheme 2). Generally the elimination of drugs from the 
1 
1 
SCHEME 2 
body occurs according to a first-order process and the elimination rate can be 
described by the following equation: 
d Q
_ _ k с or
 d C
- _ ^ c m 
dt" k d C p r л " v f
C p ( 1 ) 
where dQ/dt is the elimination rate (mg/min), k
el the elimination clearance 
constant (ml/min) and Cp the plasma concentration (mg/1). Elimination is con­
sidered as a clearance from a single compartment with a volume Vt (1). The 
concentration of the drug in the various parts of the body may be quite dif­
ferent, so that the volume of the compartment does not necessarily reflect a 
physical reality. It is called therefore an apparent volume of distribution, which 
is derived from the concentration of drag in plasma. Usually the total plasma 
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concentration is determined, including the protein bound fraction; association 
and dissociation of the drug-protein complex are assumed to occur very rapidly 
as compared to distribution and elimination and are also assumed to be descri-
bable by linear differential equations (Schoenemann et al., 1973). Integration 
of eq. (1) leads to the following equation for the plasma concentration: 
In C p = In A - t/Tcl or C,, = A e -
1/теі = A 2 ΛΙιι· (2) 
where A is the plasma concentration at t = 0, τ
ρ1 the elimination time constant 
and ti/, the biological half-life. Furthermore it can be derived that: 
е^і = ν,/k,, and t,„ = In 2 . т
с
, = 0.69 т
еІ
 (3) 
From eq. (2) it follows that the logarithm of the plasma concentration decreases 
linearly with time. Theoretical examples are shown in Fig. 1 and it is evident 
that semi-logarithmic plots give straight lines for single-compartment first-order 
kinetics. The biological half-life can easily be deduced from this type of curves, 
since it is the time required to reduce any given plasma concentration to 50%. 
plaema concentrahon (m^/ l , lo£ scale ) -i - - — --
t ime (h) 
FIG. 1. Theoretical plasma concentration curves based upon single-compartment 
kinetics after rapid i.v. injection. Straight lines are obtained on semi-logarithmic 
scale. Left: A variation in the administered dose leads to a proportional change in the 
zero-time concentration and a parallel shift of the curves. Middle: From the slope 
of the curves the biological half-life can be determined. A decrease of the elimination 
clearance (in parentheses) causes a proportional increase in the half-life. Right: A 
decrease in the volume of distribution (in parentheses) leads to a proportional decrease 
of the zero-time concentration and to a proportional increase of the half-life. 
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This parameter is generally used in practice to characterize the rate of elimina­
tion of a certain drug from the body. Many of these have been summarized 
recently by Ritschel (1972). A long half-life does not necessarily imply a low 
clearance. A drug with a high clearance value may still exhibit a large half-life 
when the volume of distribution is large, e.g. amphetamines (Rowland, 1969; 
Vree, 1973). Vf can be obtained from the intercept of a semi-logarithmic plasma 
concentration curve at zero-time (V, = A/Dose). It should be emphasized that 
it is not the biological half-life that characterizes the actual elimination process 
of a drug from the body, but the clearance constant (van Rossum, 1971). The 
total body clearance (kC|) is the sum of the clearance constants representing the 
various metabolic pathways, renal excretion and possibly other elimination 
mechanisms (saliva, sweat, bile, lungs). In formula: 
Κι = К + K+ (4) 
where k
m
 is the metabolic and k
r
 is the renal clearance constant. Since elimina­
tion of most hypnotic drugs occurs by biodégradation, the total body clearance 
of the compounds used in the present investigations generally equals the meta-
bolic clearance. 
2. The two-compartment open model 
Distribution of a drug throughout the various tissues in the body is, in many 
instances, not extremely rapid compared to the elimination process. In the two-
compartment open model it is assumed that there is a central compartment, 
consisting of plasma and other fluids and tissues, which is instantaneously ac-
cessible to the drug. The second or peripheral compartment consists of fluids 
and tissues which are more slowly accessible to the drug. On the basis of 
similarities in blood flow and tissue-plasma partition coefficients for a certain 
drug, various tissues may be grouped together, such that the two compartments 
may have some physiological meaning (Riegelman et al., 1968). This may vary 
substantially from drug to drug, since the physico-chemical properties of a drug 
mainly govern the extent and the rate of distribution in the body. For instance 
in the case of the anaesthetic barbiturates (thiopental, hexobarbital, metho-
hexital) the brain is likely to be classified with the central compartment, whereas 
for less lipophilic barbiturates the brain may belong to the second compartment. 
The two-compartment model is depicted in Fig. 2 and it is assumed that elimi-
nation takes place from the central compartment. The different rate processes 
can be described by the following differential equations: 
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-—- - = — kcI Cj k12 Cj + k21 C2 (5) 
dt 
-
d
,7 î ! - = - k 2 1 C î + k1 2C1 (6) 
dt 
- ^
1
- = kel С, (7) 
dt 
where Qj and Q 2 is the amount (mg) and С^ and C 2 is the concentration 
(mg/1) in compartment 1 and 2 respectively, Q
c l is the amount eliminated (mg), 
k12 and k21 are the clearance constants (ml/min) for distribution and kel is 
the elimination clearance constant (ml/min). Usually sampling can only be 
performed in the central compartment, to which the plasma belongs. Integration 
of eq. (5) gives the concentration in this compartment (plasma concentration 
Cp): 
C p = A1 e -
ι/ τι + A2 e ^А« (8) 
where A, and A2 are the coefficients (mg/1) and τ
ί
 and τ2 are the time constants 
(min), which now depend on the volume of the first (VJ and the second (V2) 
compartment (1), as well as on all clearance constants (Riegelman et al., 1968; 
Gibaldi, 1969). In general the biological half-life is calculated from the largest 
time constant (t,/, = 0.69 т,). The plasma concentration - time curve, which can 
be described mathematically by eq. (8), is characterized by a biphasic semi-
logarithmic plot. Such a time course is found frequently after i.v. administration 
of a drug, which indicates that two-compartment kinetics may be valid. In 
Fig. 2 a typical example is given for hexobarbital after i.v. infusion to a healthy 
volunteer. From the linear part of the post-infusion curve r2 and A2 can be 
deduced, whereas τ1 and Aj can be estimated by the feathering or subtraction 
method. In this particular instance the experimental values for Aj and A2 are 
not the true coefficients for i.v. bolus injection and have to be corrected for the 
duration of infusion (Chapter 1, Section III). Once the four experimental para­
meters have been determined, the important pharmacokinetic parameters for a 
drug in the body may be calculated from the following equations (van Rossum, 
1971): 
V, = ОДА, + A2) (9) 
k,, = ОД , + A2r2) (10) 
r
 _ •42_ _ _ _ fi\\\T2'jAl QJ\ 
Vj (Ai + A2) (AjTi + Α2τ2) TjT. 2 
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0 5 
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Γ
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·-.-
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FIG. 2. Plasma concentration curve on semi-logarithmic scale following a zero-order 
infusion of 6Ό0 mg hexobarbital sodium (equivalent to 548 mg of the free acid) to a 
human volunteer. After termination of the infusion the shape of the curve is typical 
for the two-compartment open model (see scheme). The dotted line, obtained by the 
subtraction method, represents the first term of the two-term exponential equation. 
This rapid decline is mainly due to the rapid distribution of the drug over the various 
tissues. The terminal straight line represents the second term, which is due to the 
elimination of the drug. The biological half-life may be deduced from the slope of 
this line. Furthermore, the apparent volume of distribution (Vf) and the total body 
elimination clearance constant (k
e
|) can be calculated. 
r
 _ _^2i_ AjT, + Α 2 τ 2 _ 
' 2 ( A i "I" Ag) T1T2 
γ _ γ /j , _гі2_ч _ D ( τ ι 2 ν η + τ 2 2Α 2) 
r2i (τΑ + Ά) 2 
(12) 
(13) 
where r1 2 and r2 1 are the distribution rate constants (l/min). Also, k1 2 may be 
calculated, although this is not possible for k21 since the volume of the second 
compartment cannot be estimated. 
3. The three-compartment open model 
For a drug which acts on the central nervous system, the body may be con­
sidered as a three-compartment open system. In Fig. ЗА the model is depicted, 
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FIG. 3. Example of a three-compartment open model (see scheme in A), with 
theoretical curves representing drug concentration in plasma (compartment 1), in 
peripheral tissues (compartment 2) and in the brain (compartment 3). The pharma-
cokinetic parameters underlying these curves are given in B. The clearance constants 
governing drug entry into the brain and from the brain (k;13 and k31) are varied and 
the influence on the brain concentration and on the concentrations in the other two 
compartments is shown. It may be observed that the brain concentration may vary 
considerably despite comparable plasma concentrations. 
where a central compartment (plasma) is equilibrating with the brain compart-
ment and with a peripheral tissue compartment. In Fig. 3 a set of theoretical 
concentration curves are given in order to show the influence of the clearance 
constants governing the entry of drug into the brain and from the brain upon 
the brain concentration time-course. It is evident that the brain concentration 
may differ considerably, despite a constant elimination clearance. The rela-
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tionship between plasma concentration and concentration in the brain may 
therefore be very complicated, although an unambiguous relationship exists. 
If a drug, however, is slowly eliminated compared to the distribution process, 
a steady state condition will result after some time and the brain concentration 
parallels the plasma concentration (Fig. 3). 
For a three-compartment model the different rate processes can be described 
by the following differential equations: 
dQ t 
dt 
dQ2 
dt 
d Q 3 
"dt 
= — (k
el + k i 2 + k i a) C, + k 2 1 C 2 + кз.С, (14) 
= kjgCj - k 2 1C 2 (15) 
= k^q - k31c3 (16) 
• ^ = ke.q (17) 
dt 
where 0 3 is the amount (mg) and C3 is the concentration (mg/1) in the third 
compartment, Q
e l is the amount eliminated (mg) and k13 and кз1 are the 
distribution clearance constants (ml/min) between the central and the third 
compartment. For the concentration in the central compartment (plasma con­
centration) the following equation is obtained after integration: 
С, = A1 e -V*! + A2 e -
ι/τ2 + A 3 e -*/*» (18) 
where τ
ν
 z2 and τ3 are the time constants (min) and A1, A2 and A3 are the 
coefficients (mg/1). These parameters may be deduced from the experimental 
curve and then the elimination clearance constant and the apparent volume of 
distribution can be calculated: 
k
e l = - p . (19) 
AJTJ + А 2 т 2 + Α 3 τ 3 
=
 D (A^! 2 + Α2τ2 2 + АзТз2) ( 2 0 ) 
(Α
ι
τ1 + А2т2 + A 3tj) 2 
Obviously, in practice it is only necessary to consider the body as a three-
compartment open system, when the experimental data require such an as-
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sumption, e.g. when the plasma concentration - time curve exhibits three distinct 
phases after i.v. injection. It is often very difficult to distinguish between a 
two- and a three-compartment model (refer to methohexital, Chapter 3, Section 
III). Even in the theoretical plasma concentration curves of Fig. 3, which are 
based upon the three-compartment model, the three phases are difficult to 
unravel. The model may be valid, for instance, in the case of thiopental kinetics, 
where the equilibrium between plasma concentration and adipose tissue is 
reached very slowly (Price et al., 1960; Bischoff and Dedrick, 1968). Many 
experimental data are required to permit a reliable fit to a three-exponential 
equation. Details of the mathematics underlying the three-compartment model 
have been given by Skinner et al. (1959). 
4. Multi-compartment kinetics 
As indicated earlier, the body should in principle be regarded as a multi­
compartment system, although in many cases it is not possible to distinguish 
between the separate compartments. This is mostly due to the limitations of the 
experimental procedure, which is especially true for human investigations. 
Nevertheless it is of interest to give a general equation for the plasma con­
centration, which is valid if all the processes involved are first-order, including 
absorption, distribution and elimination: 
η 
C p = Σ А,е- 1 / т . (21) 
i = 1 
where η is the number of compartments involved, A, the i\h coefficient (mg/1) 
and r¡ the t'th time constant (min). In the case of oral or rectal administration 
η is the sum of compartments including the gastro-intestinal tract. The cal­
culation of the pharmacokinetic parameters may be generalized: 
η 
\X = T>I Σ A; (22) 
i = 1 
η 
k
cl = D/ Σ Α,τ; (23) 
i = 1 
η η 
Vf = D Σ А,г^/( Σ Α,τ,)* (24) 
i = 1 i = 1 
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If elimination occurs from the central compartment by a concentration in­
dependent clearance process, then the following is also generally valid (Dost, 
1968): 
^ " = k
e l C p = kel Σ A, e"'/*. (25) 
dt
 1 = ι 
where Q,,, is the amount eliminated (mg). Obviously, the amount of drug elimi­
nated after sufficiently long periods of time (t > t/s) equals the amount that 
was introduced into the body. Therefore integration of eq. (25) gives: 
O
cl = keITcndt ^k^.AUC (26) 
о 
where AUC is the area under the plasma concentration curve from t = 0 to 
t = oo (mg min/1). Eq. (26) is important in bioavailability studies, since often 
the area under the curve can be determined, whereas the exact time constants 
and coefficients cannot If a drug is not given by i ν injection, but orally or 
rectally, it is possible that only a fraction F of the administered dose reaches 
the general circulation. This fraction (bioavailability) can be estimated from 
the area under the plasma concentration curve after oral or rectal admini­
stration, provided that the total body clearance has been determined via other 
independent measurements (i.v. injection). In formula-
F . D = k
eI AUC or F = k c l. AUC/D (27) 
The bioavailability of a drug depends to a large extent on the pharmaceutical 
formulation in which it is incorporated. This aspect, together with the kinetics 
of drug absorption, will be discussed in detail in Chapter 2, Section I. 
PLASMA CONCENTRATION DURING CHRONIC MEDICATION 
Often, drugs may be prescribed for longer periods of time, e g. antiepileptic 
agents and antibiotics are given on a multiple dosage regimen in order to main­
tain the plasma concentration above a minimal effective concentration. Hypnotic 
drugs are frequently taken each night, but in this case the plasma concentration 
should be above the effective concentration only during the night. Obviously, 
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certain limitations on the kinetics of a drug are exacted in order to be suitable 
in hypnotic therapy, as will be outlined in Chapter 3, Section I. 
If a drug is administered repetitively with constant dosage intervals (At), then 
the plasma concentration at any time after the commencement of the therapy 
may be described, irrespective of the complexity of the kinetic models involved, 
(provided linear differential equations are valid) by the following equation (van 
Rossum and Tomey, 1970): 
n
 τ _ -jAt/τ, . 
i = 1 ι _ e -A tA, 
where η is the number of compartments involved, A, is th ith coefficient, т, the 
/th time constant and j denotes the /'th dose that has been administered, while t 
is the time after administration of the /th dose. In the case of single-compartment 
kinetics after oral administration, eq. (28) is reduced to the following (van 
Rossum, 1968; van Rossum and Tomey, 1968): 
ς, = Α 
1 - e ^ . e . t / r e I _ 1 -• e j ^ a e . t / r a 
1 -^hci ι ρ -At/ra 
(29) 
where A is the extrapolated zero-time concentration (mg/1) after the first oral 
dose, τ(,| is the elimination time constant and та is the absorption time constant. 
Once Α, τ,,] and т
а
 have been determined for a certain drug, usually after a 
single oral dose, the theoretical plasma profile during repetitive medication can 
be calculated. This was accomplished for vinylbital (Chapter 4, Section III, 
Fig. 7) and butobarbital (Chapter 6, Section HI, Fig. 5). For most drugs ab­
sorption occurs more rapidly than elimination and if τ0[ is greater than At, 
substantial accumulation may occur until a certain plateau concentration is 
reached (see butobarbital). If т,,! is smaller than At, no real accumulation will 
become apparent and the plasma concentration fluctuates considerably during 
chronic medication. This was shown for instance in the case of heptabarbital 
(Chapter 5, Section III, Fig. 6) with a half-life of about 7 h and a dosage in­
terval of 24 h. It is evident that the accumulation of a hypnotic drug in the 
body is undesirable. 
CAPACITY-LIMITED ELIMINATION 
Generally all processes in pharmacokinetics are assumed to be first-order, 
so that the rate of elimination of a drug may be directly proportional to the 
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drug concentration in the plasma. The differential equations describing drag 
transfer are linear under such conditions. The proportionality factor for the 
elimination process is the clearance constant (k
cl), which is the parameter that 
characterizes the elimination of a drug from the body. Many drugs are elimi­
nated in the liver by metabolism where certain enzymes are involved. Under­
standably, the rate of metabolism may be limited by the capacity of these 
enzymes. If these are saturated, then elimination becomes a zero-order process 
as has been shown for ethanol (Lundquist and Wolthers, 1958) and for part 
of salicylic acid metabolism (Levy et al., 1972). If biotransformation proceeds 
via a single pathway, then the rate of elimination may be described by use of a 
Michaelis-Menten equation (Levy et al., 1972; Wagner, 1973; van Ginneken 
et al., 1974): 
_
dQ.
 =
 _ . _ Q . n _ . c (30) 
dt (K
m + C) 
where Q
m
 is the metabolic capacity of the enzymes (mg/h) and is related to 
,
Пі
„ when only one enzyme is involved. K
m
 is the apparent Michaelis-Menten 
constant (mg/1). It is assumed that the substrate concentration (C) in the clearan­
ce tissue is in equilibrium with the plasma concentration. If С equals the plasma 
concentration (Cp), it follows from eq. (30) and eq. (1) that: 
k
e l = - -
Q m
- — (31) 
For low plasma concentrations (Cp <^  Km) the metabolic clearance is a simple 
function of the enzymatic constants which govern biotransformation: 
Κι = Qm/K
m
 (32) 
Since the plasma concentration is directly related to the administered dose, 
increasing doses will ultimately lead to a concentration dependent metabolic 
clearance. If Cp > Knl it will be clear that dQ/dt equals Qm, which implies that 
elimination proceeds as a zero-order process. In practice a capacity-limited 
elimination may often occur simultaneous with a non-saturated pathway (e.g. 
excretion into the urine). The kinetics are more complicated in such a case, 
which has recently been discussed by van Ginneken et al. (1974). In patho­
logical conditions, e.g. liver disease (Section IV), the capacity of the liver 
enzymes may be far lower than for normal circumstances. In such a case k
el 
will decrease and elimination will be retarded. Also, if K
m
 decreases saturation 
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will occur at lower plasma concentrations and capacity-limited elimination may 
be encountered already at lower plasma levels. 
THE CURVE-FITTING PROGRAM "FARMFIT" 
The pharmacokinetic parameters according to the various models, may be 
fitted to the experimental plasma concentrations. For this purpose use is made 
of the non-linear least squares curve fitting program FARMFIT, which was 
developed by Drs. G. Fast of the Computer Centre, University of Nijmegen. 
The program finds a least squares fit to a set of concentrations C(t1) at times t, 
to a model function F(t), i.e. the program finds such values for the parameters 
that the sum of squares: 
к= Х;с(0-р(0(-' (33) 
(0' , 
is minimized, assuming the same accuracy for the concentration data Qt,). If 
the concentration data C(tl) have different (absolute) errors of measurement e,, 
then weights g, inversely proportional to e, are assigned to the data and the 
sum of squares: 
K = Σ
Ε ι
2 | С ( 0 - Р ( 0 { « (33a) 
(ι) ' ' 
is minimized. It is supposed that 1. no systematic errors exist in the measure­
ments, 2. the model function fits. 
Because the calculation of the least squares fit is straightforward for linear 
parameters, the function F is split up: 
F(t;A,r) = f 0 (t ;r)+ ΣΑ,ί,(ΐ;τ) (34) 
(]) 
where A is the vector of the unknown linear parameters A, with j = 1,2,... 
and τ is the vector of the unknown non-linear parameters rk with к = 1,2,... 
The function f0 may be identically zero. The separate f-functions are generally 
not dependent on all non-linear parameters т
к
. If F only depends on linear 
parameters А
я
 then it can be written as: 
F(t;A) = f 0 ( t ) + Σ A, f ДО (35) 
0) 
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where each fj is independent of А
г
 Then the least squares estimates of the Aj 
are the solutions of the linear system of equations: 
- - = 0 (normal equations), (36) 
öAj 
where К is the sum of squares (33) or (33a) after substitution of (35). 
If F is also dependent on non-linear parameters, a modification of the iterative 
method of Gauss-Newton is applied. Assuming that a set of parameters τ° is not 
far removed from the real solution τ, so that the difference Δ = τ - τ° is small, 
then Р(і;А,т) can be approximated by a truncated Taylor series: 
F (t;A,r) = F (t;A,T0) + Σ bF<-VéO
 Л к ( 3 7 ) 
(к) от
к
 v
 ' 
After substituting into (33) or (33a) the sum of squares К can be minimized 
with respect to Ak in the same way as with respect to Ад if F(t) has the form 
(35) because of the linearity in Δ. 
For given data points with given weights and for given τ the linear parameters 
Aj can be solved directly via the normal equations δΚ/bAj = 0, where К is 
the sum of squares (33) or (33a) after substitution of (34). So these solutions 
for A can be considered as functions А(т) of т. This is done by the program 
FARMFIT for the A¡ in (37). Hence for the partial differentiation the function 
F is only considered as a function with non-linear parameters. The derivatives 
òF/ÒTk are calculated numerically. After determining the improved values 
τ,
0
 + Aj for the non-linear parameters the linear parameters are adapted to 
these improved values via the normal equations. 
After a maximum number of repetitions of this process or after an increase 
of K, use is made of an interpolation method. If τ1 and τ2 are the last values 
obtained for the т-vector of non-linear parameters, then the line connecting 
the points r 1 and τ2 in the τ-space is considered. The interpolation process 
searches for the optimum τ on this line, where the linear parameters Aj are 
always adapted via the normal equations. After such an iteration - interpola­
tion cycle the resulting TJ-values are compared with the tj-values from the 
previous cycle. If the variations of the tj-values are sufficiently small the 
program either finishes or continues with a larger accuracy. 
The program also calculates estimates for the asymptotical covariance matrix 
and standard errors of the parameters Aj and т
к
. It may be expected that these 
estimates are incorrect if few concentration data are available and large errors 
of measurement are involved. 
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CHAPTER 2 
BIOPHARMACEUTICS AND KINETICS OF DRUG ABSORPTION 
INTRODUCTION 
Drugs are generally administered as drug products, which are referred to as 
dosage forms or drug delivery systems. During the last decade it has become 
apparent that drug products which contain the same amount of active drug, but 
which have been prepared in different ways, or contain different excipients, 
may exert different pharmacological or therapeutic effects (Wagner, 1971a). 
In other words, the therapeutic efficacy of a drug is not only a function of its 
intrinsic pharmacological and pharmacokinetic properties, but also of the 
physical form in which it is administered and of the various additives used as 
pharmaceutical formulation aids. Biopharmaceutics may be defined as the study 
of the influence of formulation on the therapeutic activity of a drug product. 
Recently, Wagner (1971b) gave a detailed definition of biopharmaceutics: "the 
study of the relationships among (1) the physical and chemical properties of 
the drug, (2) the physico-chemical and pharmaceutical properties of the dosage 
form, (3) physiological factors, (4) pharmacokinetic parameters, and (5) biologi-
cal, pharmacological and clinical effects". 
Several recent surveys of the field of biopharmaceutics have appeared (Levy, 
1970; Gibaldi, 1971; Notan, 1971; Garrett, 1971; Wagner, 1971a), some of 
which have emphasized the principles underlying dosage form design (Wagner, 
1971b; Benet, 1973). Often, evaluation of pharmacological and therapeutic 
responses in man in a quantitative manner is very complex. Because of the 
relationship between pharmacological effect and drug concentrations in the 
plasma, it is commonly accepted that concentration-time patterns of a drug 
in biological fluids can be used to compare the biological performance of drug 
products (Levy, 1968a; Ritschel, 1972; Guidelines, 1972). The determination of 
drug concentrations in the blood or plasma or drug amounts in the urine serves 
as a measure of the efficiency of a dosage form in delivering the drug to the 
general circulation. The relative amount to which an administered drug reaches 
the general circulation intact is defined as the bioavailability (Wagner, 1971a). 
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In the context of this definition, general circulation refers primarily to the 
venous blood (except the hepatic portal blood during the absorptive phase) and 
arterial blood, which carry the drug to the tissues. Often, the rate at which the 
drug reaches the general circulation also is included in the definition of bio­
availability (Guidelines, 1972). However, this may sometimes be ambiguous 
(Wagner, 1973; Moss and Rhodes, 1974) and in this thesis the rate is referred 
to by the term "absorption rate". Both, the bioavailability and the absorption 
rate determine the biological performance or therapeutic efficacy of a drug 
product (Levy and Barr, 1972; Breimer, 1973). Biopharmaceutics mainly deals 
with the study of the factors influencing these two aspects of drug products. 
Also the route of administration should be considered relevant in this respect 
(Riegelman and Rowland, 1973). In this Chapter the kinetics of drug absorption 
and the estimation of bioavailability will be outlined. In addition, some im­
portant physiological and dosage form dependent factors influencing bioavaila­
bility and absorption rate will be discussed, mainly in relation to oral ad­
ministration. 
KINETICS OF DRUG ADSORPTION 
When a drug is administered by any route of administration other than i.v. 
injection or infusion, many processes may be involved before it reaches the 
general circulation. Among these processes are the disintegration of the dosage 
form, dissolution of the active ingredient, transport to the absorption site and 
the actual drug absorption. These are time-dependent, simultaneously occurring 
processes, one of which determines the overall rate at which the drug reaches 
the general circulation (absorption rate). The kinetics of drug absorption may be 
assessed by measuring plasma concentrations at frequent intervals after drug 
administration. In spite of the complexity of the processes involved, the plasma 
concentration data, obtained from orally administered drugs, often appear to 
require only two exponential terms to describe the curve. If it is assumed that 
drug absorption and drug disposition can each be represented by a single first-
order process, the following differential equations are valid: 
dQi 
dt 
dt 
= k l C ( , - k ( , 1 C p (1) 
= k
cl C p (2) 
where Q1 is the amount of drug in the body, viz. the amount (mg) of drug 
absorbed minus the amount of drug eliminated (QC |); С0 is the concentration 
(mg/1) in the compartment from which absorption takes place (gastrointestinal 
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tract) and Cp is the plasma concentration; ka is the absorption clearance con­
stant (ml/min) and kC] the elimination clearance constant (ml/min). After in­
tegration of eq. (1), the following is obtained for the plasma concentration 
(van Rossum, 1971): 
Cp = A . (e - тоі_ e "Vb) (3) 
where т
е
і and τ
Λ
 are the time constants (min) of elimination and absorption 
respectively, and A is the coefficient (mg/1). In Fig. 1 an example is given of a 
curve that can be described by eq. (3). If absorption proceeds much more rapid 
than elimination (т
а
 <^  т
е1), then the elimination half-life of the drug can be 
deduced from the descending part of the curve (tV ! e I = 0.69 t o l ) . The half-life 
of absorption (t,/!a = 0.69 та) can be obtained by the subtraction method or 
method of residuals. This method involves extrapolating the linear elimination 
phase of the semi-logarithmic plasma concentration-time plot to t = 0 and 
subtracting the plasma concentration data during the absorption phase from 
the corresponding concentration values on the extrapolated line. The absorption 
time constant can be determined from the straight line representing the ab­
sorption phase (Fig. 1). The coefficient A, also called the "zero-time concen-
h?xob¿rbttal (rn^/l рідэгла, Іо^ ecale ) 
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FIG. 1. Plasma concentration curve, on semi-logarithmic scale, following oral ad-
ministration of 600 mg hexobarbital to a healthy volunteer. The dotted line, corres-
ponding to a half-life of 36 min, represents the absorption phase. The latter was 
obtained by the subtraction method. The experimental plasma concentration curve 
can be described by the bi-exponential eq. (3). 
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tration", is the concentration of the intersection of the elimination line and the 
absorption line. It may be derived that: 
A
 =
 -
F
-
D
- . _*«i-_ (4) 
where F is the bioavailability (0 < F < 1), D is the administered dose (mg) and 
Vf is the apparent volume of distribution (1). In practice crossing of the ex­
perimental lines often occurs some time after zero, which means that if first-
order absorption is valid, then it lasts some time before absorption commences. 
This could be due, for example, to a slow disintegration of the dosage form or 
to a delay in the transit of the drug from the stomach to the small intestine. This 
"lag time" (t0) has to be taken into account in eq. (3), where t = tnp -10. 
A computer fit of the concentration data may give the best estimation of the 
model parameters, including the lag time (refer to vinylbital after oral and 
rectal administration, Chapter 4, Section III). 
Other techniques, for the determination of the absorption time or rate con­
stants, have been described by Wagner and Nelson (1963; 1964), who make 
use of percent absorbed-time plots. Loo and Riegclman (1968) have developed 
a procedure for the calculation of absorption rate constants for drugs which 
distribute according to a two-compartment open model. However, even if a two 
compartment model is apparent after analysis of i.v. data, the plasma curves 
after oral administration are frequently better fitted by a single-compartment 
model. If distribution of the drug into tissues occurs at a much faster rate than 
absorption, then drug disposition may be described by a single exponential 
process (compare Fig. 1 to Fig. 3 for hexobarbital). Special consideration has 
been given recently to the determination of absorption parameters for drugs 
with incomplete bioavailability (Notari et al., 1972; Perrier and Gibaldi, 1973; 
Leeson and Weintraub, 1973) and to the absorption kinetics of drugs released 
from prolonged action dosage forms (Ritschel, 1973). 
In practice, it is often difficult to find the appropriate model that fits the 
concentration data during the absorption phase. Absorption may appear to be 
irregular, or too few data may be available to allow the estimation of the ab­
sorption parameters. An alternative method is the determination of the time 
after which the plasma concentration reaches its peak value (t, l i a x). This peak 
time may be regarded as a rough measure of the absorption rate (Dittert and 
DiSanto, 1973). In Fig. 2 the influence of r
a
 on the plasma concentration curve 
has been simulated. With increasing т
а
 the maximum plasma concentration is 
reached at a later time and its height is lower. Furthermore, it is evident that, 
with slow absorption, samples should be collected for a long period of time in 
order to obtain the appropriate terminal elimination half-life. 
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FIG. 2. Theoretical plasma concentration curves, on semi-logarithmic scale, based 
upon single-compartment kinetics and first-order absorption, following oral ad-
ministration of the same drug with constant elimination pattern. The elimination 
phases are represented by a set of parallel straight lines. Upper: The decrease of the 
absorption rate (increase of the absorption half-life) results in a reduction of the 
maximum concentration and a lengthening of the peak level time. Bioavailability is 
assumed to be complete, which means that the AUG is the same in every case. 
Lower: The decrease of the bioavailability results in a proportional decrease of the 
maximum concentration as well as of the AUG. 
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BIOAVAILABILITY ESTIMATION 
According to the definition of bioavailability, a drug administered i.v. is com­
pletely available (F = 1 or 100%). Any other route of administration may 
result in incomplete bioavailability, due to dosage form factors or physiological 
factors. Bioavailability of a drug from a certain dosage form may be assessed 
by measuring the area under the plasma concentration curve, multiplied by 
the clearance constant (eq. (25) - (27), Chapter 1, Section I). In formula: 
F = к,,. AUC/Dose (5) 
where k
cl is the clearance constant (ml/min) and AUC the area under the curve 
from t = 0 to t = oo (mg.min/1). The clearance constant can only be estimated 
after i.v. administration; it is assumed that this parameter is dependent neither 
on dose nor time for a certain individual. For any route of administration other 
than i.v. only the quotient Ιί,,,/Ρ can be obtained; the same holds for the apparent 
volume of distribution (Vf/F). A low bioavailability leads to an overestimation 
of these parameters. Measurements of the AUC can be made by using an ap­
propriate numerical procedure, such as the trapezoidal rule or by determining 
the weight of the AUC relative to a standard area. An estimate of the AUC 
beyond the last concentration determined must be included. According to Dost's 
law of corresponding areas (Dost, 1968) the following applies: 
oo t' oo t' 
AUC = Í Cp dt = Í Cp dt + \ С, dt = AUC / + C/ . τ„ (6) 
о о t' о 
where С
р
*' is the last plasma concentration determined and т
еІ
 is the terminal 
elimination time constant. 
Absolute bioavailability of a drug from a dosage form can be determined by 
comparison with i.v. administration, preferably in the same individual. An 
example is shown in Fig. 3 for hexobarbital. If no i.v. data are available, bio­
availability may be estimated relative to a standard dosage form: 
F«, = - ^ ^ 4 X 1 0 0 % ) (7) 
AUC^t. D
x 
where the AUCX and AUCRt are the infinite areas under the plasma concen­
tration curves of the test dosage form (x) and the standard dosage form respec­
tively. This method assumes that the plasma clearance is constant and that the 
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10 »ubjece M К. 
· — · ЬекоЬмЫШ sodium, linear ι ν infu&ion 
. 600mg, 20mg/min 
/\ • • hexobarbital, бООту.оглІ, tablet 
Λ . 
tJ.I.Ni 
FIG. 3. Plasma concentration curves, on semi-logarithmic scale, following zero-order 
i.v. infusion of hexobarbital sodium and oral administration of hexobarbital to the 
same healthy volunteer. The elimination clearance constant was estimated from the 
i.v. data (two-compartment kinetics) and subsequently the bioavailability of the oral 
preparation was estimated (approximately 100%). Note the identical elimination 
half-lives after i.v. and oral administration, which suggests that the assumption of 
equal clearance at the two occasions may be correct. 
AUC is proportional to the dose, viz. to F (Fig. 2). The best guarantee for the 
validity of these assumptions is the situation where the two preparations are 
administered in a cross-over manner to a panel of subjects (Wagner, 1971a). 
If two different panels of subjects are used a correction should be made for the 
difference in average body-weight if these are not practically the same (Rilschel, 
1972). In the case of intra-individual variation of the half-life of a drug, which 
could be due to either a varying clearance constant or to a varying apparent 
volume of distribution, then bioavailability is difficult to assess exactly (refer 
to vinylbital, Chapter 4, Section III). Wagner (1967) has proposed that a 
"modified AUC" should be utilized in such situations, which corrects for the 
different half-lives. Other methods of bioavailability estimation include cumu­
lative urinary excretion measurements or area measurements after multiple 
dosing (Guidelines, 1972). Van Rossum (1971) has proposed an elegant method 
for the assessment of bioavailability during chronic medication. For a given 
subject the plateau level is proportional to the bioavailability, provided that the 
elimination clearance constant remains constant. 
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PHARMACEUTICAL FACTORS AFFECTING BIOAVAILABILITY AND 
ABSORPTION RATE 
The absorption of an orally or rectally administered drug from the gastroin-
testinal tract involves disintegration of the dosage form, dissolution of the drug 
into gastrointestinal fluids, passage to the site of absorption and transfer across 
the mucosal barrier into the portal circulation. In this sequence, the dissolution 
process is frequently the slowest process (Levy, 1968b). The dissolution rate is 
proportional to the surface area of the dissolving solid (Nemst and Brunner, 
1904), and is therefore favoured by a rapid disintegration of the dosage form 
into fine particles. Absorption of slightly soluble drugs has been shown to be 
inversely proportional to particle size, e.g. griseofulvin (Atkinson et al., 1962; 
Fincher, 1968). Another variable is the crystal form of the drug particle since 
polymorphic forms may have different solubilities (Haleblian and McCrone, 
1969). Many drugs, including barbiturates, have several polymorphic modifi-
cations (Brandstätter-Kuhnert, 1969), which generally differ in their dissolution 
rates. Since ionized molecules are more soluble in aqueous media than non-
ionized molecules, the dissolution rate may be very dependent on the pKv-value 
of a drug and the pH of the gastrointestinal fluid. Basic drugs are more soluble 
in the stomach than in the intestine and acidic drugs are less soluble in the 
stomach when compared to the higher pH of the intestinal fluids. Administration 
of barbiturates in the free acid form generally results in slow absorption, due to 
poor dissolution in the acid medium of the stomach (Section III). The most 
effective means of attaining higher dissolution rates is to use a highly water-
soluble salt of the weak acid. The salt acts as its own buffer and raises the pH 
of an acidic dissolution medium in the immediate environment, surrounding the 
dissolving drug solids. The dissolution rate of the sodium salt of a weak acid 
may be many-fold higher than the dissolution rate of the free acid itself, even 
though the final equilibrium solubility of the drug and its salt are the same 
(Higuchi et al., 1958; Nelson, 1958). If the sodium salt is subsequently precipi-
tated as the free acid in the bulk phase of an acidic medium, it will usually do 
so in the form of very fine particles, which have the proper characteristics for 
rapid redissolution. In this connection refer to the rapid absorption of hexobar-
bital and heptabarbital, when administered as their sodium salts (Chapter 1 
and 5, Section III). 
Many excipients used in the preparation of solid dosage forms (disintegrants, 
lubricants, fillers, wetting agents, etc.) can influence bioavailability and absorp-
tion rate (Levy, 1970). Complex formation and micelle formation are important 
processes that may interfere with drug dissolution, either by increasing or by 
decreasing the dissolution rate (Levy, 1970; Gibaldi and Feldman, 1970). Also 
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changes in drag manufacturing processes sometimes lead to variations in the 
biological performance of a drug product, e.g. digoxin (Lindenbaum et al., 1971). 
The critical factors for the different dosage forms have recently been reviewed 
by Polderman and Weekers-Andersen (1973). Special attention has been attri-
buted to dosage forms that are intended for rectal application (Bevcrnage and 
Polderman, 1973). 
It should be emphasized that bioavailability studies in vivo should be preceded 
by careful pharmaceutical analysis of the drug products to be investigated 
(quality control). This includes tests for identity, assay for active constituents, 
stability control and sometimes in vitro disintegration or dissolution tests 
(Pernarowski, 1971; Blake, 1971; Breimer, 1973). If, for instance, a dosage 
form does not contain the stated amount of active ingredient, the in vivo study 
will be useless beforehand. An in vitro dissolution test is only meaningful if the 
differences in dissolution rate can be correlated with measured differences in 
bioavailability following administration of the dosage form to human subjects 
(Benet, 1973). In future much effort has to be directed into this area of biophar-
maceutics in order to find such correlations. Satisfactory results have been 
obtained already for digoxin (Dunning et al., 1973). In practice most bioavaila-
bility problems arise with drugs which exhibit a poor aqueous solubility (Riegel-
man, 1969). In this respect very limited information is available at present on 
hypnotic drugs. 
PHYSIOLOGICAL FACTORS AFFECTING BIOAVAILABILITY AND 
ABSORPTION RATE 
The transport of drugs across the gastrointestinal membranes is often a simple 
diffusion process and depends on concentration gradients, diffusion properties, 
membrane area and partition between membrane and solvent (Turner et al., 
1970). For weak acids and bases partition is determined by their pKa-values, 
the pH of the medium surrounding the membrane and the lipophility of unioni-
zed drug (Schanker, 1971). For barbiturates an excellent correlation has been 
found between the chloroform-water partition coefficient of the unionized form 
and the degree of in vitro absorption by the rat colon (Schanker, 1959). There 
is good evidence that the unionized form of a drug will be absorbed faster than 
the ionized form at any particular site in the gastrointestinal tract. However, it 
has recently been emphasized, that the rate of absorption of a drug from the 
intestine will be greater than the gastric absorption rate, even if the drug is 
ionized in the intestine and unionized in the stomach (Benet, 1973). The mem-
brane surface area in the intestine is several fold greater than that found in the 
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stomach (Gordon and Bruckner-Kardoss, 1966), which favours rapid absorption. 
For example, Doluisio et al. (1969) showed that the absorption rate for the 
weakly acidic drugs salicylic acid and barbital from the intestine of rats (pH 6.0) 
was 5 to 12 times higher than the gastric absorption rates at pH 3.0. In humans 
the absorption of warfarin and acetylsalicylic acid from the intestine was found 
to be two or three times faster than from the stomach (Siurala et al., 1969; 
Kekki et al., 1971). If the intestine is the major site of absorption of most drugs, 
then it may be expected that stomach emptying is a rate determining step for 
drug absorption. Recent studies in man have shown correlations between 
stomach emptying and absorption rate of, e.g. digitoxin (Beermann et al., 1971), 
L-Dopa (Bianchine et al., 1971) and paracetamol (Heading et al., 1973). There 
are many factors which could affect the stomach emptying rate and thereby 
retard absorption, including food, volume and viscosity of stomach contents, 
pH, osmotic pressure, age, health and position of the subject (Davenport, 1971). 
Food was shown to decrease the absorption rate of pentobarbital sodium in 
healthy subjects, but not to affect the bioavailability (Smith et al., 1973). Al-
ternatively, large volumes of liquids with low viscosity (water) may enhance the 
rate of absorption by increasing the initial rate of drug transfer to the small 
intestine (Levy, 1970). Bed rest may be another contributing factor, since Barr 
et al. (1972) showed that tetracycline absorption diminished in bedridden 
patients when compared with ambulatory subjects. Therefore, Riegelman and 
Rowland (1973) have emphasized to examine the bioavailability of drugs in 
conditions simulating clinically relevant circumstances. In the present in-
vestigations with hypnotic drugs, the volunteers were requested to remain in an 
upright position for about 15 min after drug administration and then to lie 
down for a few hours. This procedure was chosen in order to simulate as 
closely as possible the taking of a hypnotic drug in practice. 
One of the most important factors affecting bioavailability after oral admini-
stration is drug metabolism. When a drug is absorbed from the gastrointestinal 
tract it must first pass through the liver before reaching the general circulation. 
If metabolism occurs in the liver, part of the drug will be inactivated during 
first passage through the liver. If the metabolizing capacity of the liver is great 
for a certain drug, then this "first-pass" effect on the bioavailability may be 
substantial. The area under the plasma concentration curve after oral ad-
ministration may be considerably less than the corresponding area following 
i.v. administration. (Harris and Riegelman, 1969; Gibaldi et al., 1971; Gibaldi 
and Feldman, 1972). Rowland (1972) has shown that the unmetabolized 
fraction ( ) of an oral dose appearing in the general blood circulation may be 
given by: 
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= ι — 
hepatic clearance 
liver blood flow 
(8) 
Thus, if the hepatic clearance for a drug is large compared to liver blood flow 
(about 1500 ml/min), a substantial "first-pass" effect may be expected. For 
example, the bioavailability of lidocaine (Boyes et al., 1971) and propranolol 
(Shand and Rangno, 1972) after oral administration is significantly reduced 
compared to i.v. administration. A similar phenomenon was observed for 
methohexital (Chapter 3, Section III). For every drug with a high metabolic 
clearance a "first-pass" effect should be considered when given by a route 
which initially leads to the liver after drag absorption. It has been stated 
frequently that rectal administration would result in the bypass of the liver. 
There is, however, no convincing evidence for this supposition and Schwarz 
(1966) has criticized this assumption on physiological grounds. 
In addition to liver metabolism, enzymes within the gastrointestinal fluids, 
microflora and mucosa are capable of drug metabolism to a greater or lesser 
extent (Sheline, 1968; Aito, 1973). For instance salicylamide (Barr and Riegel-
man, 1970) and isoprcnaline (Dollery et al., 1971) are glucuronidated and 
sulfated respectively in the gut wall, which results in poor bioavailability. 
Riegelman and Rowland (1973) have discussed recently the influence of 
saturation phenomena on the bioavailability of drugs which are subject to 
substantial metabolism in the gastrointestinal tract or the liver. The extent of 
the dose and the rate at which the drug is presented to the metabolizing en­
zymes appear to be critical factors. 
When a drug product is found to exhibit poor bioavailability, it is important 
to distinguish between dosage form and physiologically modified bioavailability. 
If pharmaceutical factors are involved, then suitable changes in the formulation 
or manufacturing processes may often lead to improvement. Unfortunately, 
physiological factors are more difficult to control, except by parenteral ad­
ministration. The choice of another drug substance with comparable phar­
macological activity, but with more appropriate absorption and metabolism 
characteristics may be the best solution for such a case (Ariens, 1971 ; Riegelman 
and Rowland, 1973). 
EFFECT OF BIOAVAILABILITY AND ABSORPTION RATE ON DRUG ACTION 
As stated earlier, the bioavailability and the absorption rate of a drug from 
a drug product will determine the therapeutic efficacy of the product. Incom­
plete bioavailability of a drug from a certain dosage form is basically equivalent 
to a reduction in the administered dose. This results in decreased drug levels in 
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plasma concentreition (m^/l ) 
FIG. 4. Theoretical plasma level profiles illustrating how changes in absorption rate 
may influence the onset, intensity and duration of drug action. The size of the dose 
and the bioavailability of the dosage forms А, В and С are the same. A: Due to the 
very rapid absorption the concentration exceeds the maximum safe concentration. 
However, by decreasing the dose this could be a suitable preparation if a very rapid 
onset of action is required. B: This profile may be regarded as normal after oral 
administration. C: Due to the slow absorption there will be no effect. However, by 
increasing the dose this could be a suitable preparation with prolonged action. 
the body (Fig. 2) and in decreased pharmacological effects. Wagner (1971a) 
and Prescott and Nimmo (1971) have reviewed a number of examples concer­
ning incomplete bioavailability of drug products. The great variation of the 
bioavailability of digoxin from various tablets is another example, which is of 
great clinical importance (Lindenbaum et al., 1971; Dunning et al., 1973; van 
Zwieten, 1973). Often, only the absorption rate of a drug varies from one 
dosage form to the other. In Fig. 4 the hypothetical plasma concentration profile 
of three oral preparations is presented, each containing the same amount of 
active drug and exhibiting complete bioavailability. Absorption, however, occurs 
at different rates. The onset of therapeutic activity is assumed to occur at the 
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time the drug concentration reaches the minimum effective concentration, 
whereas toxic effects may become apparent above the maximum safe concen­
tration. It is evident that dosage form A would be the suitable choice when 
rapid onset of action is desired. However, the dose of this formulation should 
be diminished in order to avoid adverse reactions. Absorption from dosage 
form В is slightly slower than from A, however, there is less risk of toxic 
effects with this preparation. Dosage form С is formulated in such a way, that 
no therapeutic action can be expected. However, by increasing the dose, this 
formulation could be beneficially used as a prolonged action product. The ab­
sorption profile of a drug product should be known in order to allow the jud­
gement of its usefulness for a certain therapy. Firstly, the desired onset and 
mg hexobarbitul 11 pUama 
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FIG. 5. Plasma concentration curves following oral and rectal administration of 
hexobarbital or hexobarbital sodium to a healthy volunteer. Note the ressemblance of 
these plasma level profiles with the theoretical ones in Fig. 4. Hexobarbital sodium, 
when administered orally, may be used for the rapid induction of sleep. Possibly a 
lower dose would be sufficient to achieve this purpose. If the maintenance of sleep 
is the primary prerequisite of hypnotic drug treatment, then hexobarbital free acid 
could be used. Administration of the suppository results in a rather constant plasma 
level for several hours. This may be beneficial in instances where a constant degree 
of sedation is required. 
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duration of therapeutic action should be defined and secondly a proper choice 
of drug and dosage form can be made. Fig. 5 may be regarded as a practical 
illustration of the various possibilities indicated in Fig. 4. Hexobarbital, when 
administered as the sodium salt, is very rapidly absorbed which is favourable 
for rapid sleep induction. Absorption of hexobarbital after administration of the 
free acid is much slower. However, if sleep maintenance is a prerequisite of 
hypnotic drug treatment, then the acid form could be used. Finally, the sup-
pository yields a relatively low plasma level, which remains constant for several 
hours. This preparation may be considered a judicious choice for sedative pur-
poses, since the intensity of effect should be constant for longer time periods in 
sedative drug treatment. It is evident that the same active drug, incorporated 
in different pharmaceutical formulations or applied in a different chemical form, 
may positively be used for different therapeutic objectives. A prerequisite is 
knowledge pertaining to the plasma level profile of the various preparations. 
Often, plateau or steady state drug levels are achieved during chronic drug 
administration. These are usually independent of absorption rate, but the height 
of the plateau level is directly proportional to the bioavailability of a drug 
product (van Rossum, 1971). Only if the dosing interval is greater than the 
apparent biological half-life will there be significant fluctuations in drug levels 
that could be modified by changing the absorption rate of a drug. It should be 
emphasized here that the importance of differences between drug products, 
with respect to bioavailability or absorption rate, depends primarily upon its 
intended therapeutic use. For a short-acting hypnotic drug, for example, a rela-
tively small difference in the rate of absorption may have significant influence 
on the onset of action, which in turn may affect its therapeutic usage; whereas 
a similar difference in bioavailability may be of no importance. However, for a 
chronically administered drug a relatively large difference in rate of absorption 
may have a minimal effect on its therapeutic usage, whereas a small difference 
in bioavailability may become highly significant, either by reducing the average 
steady state concentration below the effective level, or by increasing the con-
centration into the range where adverse reactions become apparent. 
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CHAPTER 3 
HYPNOTIC DRUG THERAPY 
PHARMACOKINETIC AND BIOPHARMACEUTICAL ASPECTS 
INTRODUCTION 
Hypnotic drugs may induce sleep when given at night or cause sedation when 
given during day-time. They are widely used for the treatment of insomnia, 
which of all sleep disturbances is the one most frequently encountered in 
general practice (Kales and Kales, 1974). However, insomnia cannot be 
regarded as an illness in itself, but as a symptom of an underlying disorder 
(physical or emotional), which remains to be diagnosed and treated (Polliti, 
1973). Nevertheless, it may be necessary to prescribe a hypnotic drug for the 
temporary relief of these symptoms, until the underlying cause will be ade-
quately dealt with. 
The effectiveness of hypnotic drugs in inducing and maintaining sleep is 
generally determined by clinical evaluation. This is assessed with regard to 
the subjective impressions expressed by patients, nursing staff and physicians 
(for review: Zelvelder, 1971). More objective measures have been developed 
recently in the so-called sleep laboratories (Kales and Kales, 1970; Kales et al., 
1970) which are mainly concerned with assessment of drug effects on the 
whole night's sleep, during several consecutive nights. Sleep is divided into 
rapid eye movement (REM) and non-rapid eye movement (NREM) stages. 
During REM sleep there are intermittent bursts of eye movement, a marked 
decrease of muscle tone and a low amplitude, fast frequency electroencephalo-
gram. In NREM sleep there is a progressive slowing of the frequency and 
increase in amplitude of electroencephalogram waves (Jouvet, 1967; Kales, 1969). 
These various stages occur intermittently during normal sleep and sleep distur-
bances may be characterized by deviations from the normal pattern (Kales and 
Kales, 1974). Psychoactive agents, including hypnotic drugs, have been shown 
to affect the relative proportion and duration of REM sleep or other stages, 
but the significance of these findings in relation to insomnia and the choice 
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and use of hypnotic drugs is not yet clear (Hartmann, 1968; Oswald, 1968; 
Kales et al., 1970). 
Important requirements which a hypnotic drug should fulfil, in addition to 
satisfactory pharmacodynamic properties in terms of facilitating sleep induction 
and maintaining sleep, concern its onset and duration of action. Since most 
hypnotic drugs are taken by ambulatory people, the central depressant effect 
of the drug should have declined sufficiently to be unimportant, both subjectively 
and objectively, the morning following the night of drug intake. The ability to carry 
out various skilled tasks, including the driving of a motor-vehicle, should be un­
impaired. Inactivation of most hypnotic drugs occurs by metabolism in the 
liver, which results in a decrease of the plasma concentration and a concomitant 
withdrawal of the drug from its site of action in the central nervous system. 
The kinetics of drug distribution and drug elimination are pertinent to the 
duration of action, where the plasma half-life is regarded as a measure for 
the rate of drug inactivation (Chapter 1, Section I). With respect to the onset 
of action the rate of drug absorption, which mainly depends on biopharma-
ceutical factors, is of great importance. 
PHARMACOKINETIC ASPECTS OF HYPNOTIC DRUG THERAPY 
It is generally appreciated that a distinct limitation to the duration of drug 
plasma concentration (mg/{ ; І о ^ э с э і г ) 
40-
FIG. 1. Average plasma level profile of the compounds which were investigated 
(semi-logarithmic scale). For half-lives see Table I. 
50 
action is an important aspect of the treatment of insomnia. Therefore, it is 
remarkable that the pharmacokinetics of relatively few hypnotic drugs have 
been well defined. The historical classification of the barbiturates, for example, 
into long-, intermediate-, short- and ultrashort-acting categories is based upon 
the duration of action when injected i.v. into rabbits (Tatum, 1939). Mark 
(1969) has seriously questioned this classification by arguing that every barbi-
turate, in principle, may be described as long-acting or short-acting, dependent 
on the administered dose. The duration of drug action is determined by the 
dose applied and the rate of inactivation, assuming a constant minimal effective 
concentration. A special situation is encountered with the barbiturates used 
for i.v. anaesthesia, where the redistribution of drug from the central nervous 
system to other parts of the body is primarily responsible for the termination 
of the anaesthetic effect (Price et al., 1960). However, in this case the rate of 
elimination will also determine the duration of the residual depressant action. 
For many barbiturates the half-life of elimination is not known after adminis-
tration of therapeutic doses to man. Martindalc's Extra Pharmacopoeia (1972) 
erroneously suggests that the half-lives are similar for those compounds classi-
fied as having the same duration of action. 
In Fig. 1 and 2 the average plasma levels of the drugs described in this 
thesis are shown. These compounds are all used for the same purpose (with a 
possible exception of methohexital), viz. for the treatment of insomnia. Hexo-
plaema concentration (mg/I ; linear ecale) 
Irme ( h ; 
FIG. 2. Average plasma level profile of the same compounds as in Fig. 1 on linear 
scale. 
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barbital, heptabarbital, cyclobarbital, vinylbital and butobarbital have been 
classified as intermediate-acting barbiturates (Martindale, 1972). Their average 
half-life varies from 4.4 h for hexobarbital to 37.5 h for butobarbital. Ob-
viously, considerable differences in duration of action between these compounds 
may be expected, which may only partly be corrected for by adjusting the 
administered dose. In Table I the half-lives of some of the drugs used for the 
treatment of insomnia are listed. For many drugs in common use the dis-
appearance rate from the body is fairly slow with respect to their intended 
duration of action (8 - 10 h). Also, the formation of active metabolites should 
be considered. For instance, flurazepam can only be detected for a short 
period of time in the plasma, but its N-desalkyl metabolite, which has com-
parable pharmacological properties (Randall and Kappell, 1973), possesses a 
half-life of 47 - 100 h (Kaplan et al., 1973). After oral administration of 
chloral hydrate, its metabolite trichloroethanol causes the central depressant 
activity (Marshall and Owens, 1954). Metabolites of barbiturates are usually 
not pharmacologically active. 
Due to the long half-life of many hypnotic drugs, central nervous system 
depressant effects are likely to persist into the following day. This may give 
rise to feelings of „hang-over" and drowsiness and furthermore to an impaired 
ability to perform daily tasks. For many hypnotic drugs these effects have 
been described, although in few clinical trials on the effectiveness of hypnotic 
drugs, this aspect has been evaluated in an objective manner. Only recently 
has evaluation thereof become part of sleep laboratory studies (Bixler et al., 
1973). Malpas et al. (1970) have studied the residual effects of nitrazepam 
(5 and 10 mg), amobarbital (100 and 200 mg) and placebo. Although all vo-
lunteers who participated in this study reported a good night's sleep and con-
sidered themselves to be alert on awakening, they were unaware of significant 
impairment of performance 13 h after all drug treatments. Similarly, perform-
ance of simple tasks was impaired at least up to 8 h after a single oral dose 
of 100 mg pentobarbital (Goodnow et al., 1951; Von Feisinger et al., 1953) and 
100 mg secobarbital (Kornetsky et al., 1959; Bixler et al., 1973), whereas 200 
mg secobarbital caused impairment at least up to 22 h (McKenzie and Elliott, 
1965). Residual effects on both psychological and physiological functions have 
been found up to 18 h after butobarbital and nitrazepam administration (Bond 
and Lader, 1972). These authors also found, that the subjects who slept in-
adequately after intake of a placebo, did not exhibit impairment of perform-
ance the following day. This suggests that incidental lack of sleep does not 
necessarily lead to comparable after-effects as encountered with hypnotic 
drugs. The cited literature data on the residual effects of hypnotic drugs are 
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in agreement with the long half-lives of the drugs investigated (Table I). Also, 
residual effects were shown to exist the following day for flurazepam (Bond 
and Lader, 1973; Bixler et al., 1973), which is consistent with the long half-life 
of the active N-desalkyl metabolite. 
Another consequence of the persistence of hypnotic drugs in the body may 
be the exaggerated central depressant effect, when alcoholic beverages are 
taken even a long time after intake of the drug. This may give rise to dangerous 
situations. Doenicke (1962) studied the influence of a single dose of 200 mg 
butabarbital combined with alcohol in relation to traffic safety. He concluded 
that abstention from alcohol is essential for up to 24 h after barbiturate ad-
ministration, since even small quantities of alcohol, administered at various 
times after butabarbital, caused severe impairment of mental and physical 
performance. 
Frequently, hypnotic drugs are taken every night. Substantial accumulation 
of a drug will occur if its half-life is longer than a dosage interval of 24 h. For 
phénobarbital, when used in anti-epileptic therapy, this is of advantage since 
a constant steady state level is required for such therapy. For the treatment of 
insomnia the accumulation of a certain compound is definitely undesirable. 
Substantial accumulation was shown to occur in the case of butobarbital (Chap-
ter 6, Section III), with a half-life of 34 - 42 h, when administered for several 
consecutive nights. The accumulation is counteracted to a certain degree by 
the development of microsomal enzyme induction, which results in a shortening 
of the half-life. Often, this also causes an enhanced rate of metabolism of 
other, concomitantly administered drugs, which should be reckoned with. 
Accumulation of a hypnotic drug in the body does not necessarily imply that 
there is a concomitant intensification of central depressant effects, since phar-
macodynamic tolerance is likely to develop (Sharpless, 1970). It should further 
be considered that prolonged use of hypnotic drugs often leads to drug 
dependence (Jaffe, 1970). The marked sleep and dream alterations associated 
with drug withdrawal are primary factors in the development of hypnotic drug 
dependency (Oswald and Priest, 1965; Kales and Kales, 1970). To what extent 
pharmacokinetic factors are involved in this phenomenon is uncertain, although 
it may be speculated that the continuous exposure of the central nervous system 
to relatively high drug concentrations may be a factor for consideration. 
It will be clear that many of the undesired effects of hypnotic drugs may be 
attributed to the persistence of the drug in the body. Therefore, it seems more 
suitable to use drugs with a relatively short half-life. Arbitrarily, one could 
require that the half-life of a hypnotic drug should not exceed the duration of 
a night's sleep (8-10 h). During such a time period at least 50% of the drug 
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TABLE I. Plasma or blood half-lives of drugs used for the treatment of insomnia 
(mean values in parentheses). 
Drug Half-life (h) Reference 
Barbiturates and 
related compounds i) 
allobarbital 
amobarbital 
(Amytal®) 
barbital 
butobarbital 
(Soneryl®) 
cyclobarbital 
(Phanodorm®) 
glutethimide 
(Doriden®) 
heptabarbital 
(Medomin®) 
hexobarbital 
(Evipan®) 
methohexital 
(Brietal®) 
pentobarbital 
(Nembutal®) 
phénobarbital 
secobarbital 
(Seconal®) 
vinylbital 
(Bykonox®) 
30 
20 
14 
4 
34 
8 
5 
6 
3 
0.7 
1.2 
23 
2 
28 
18 
-50 
-25 (22.7) 
-42 (24.8) 
- 5 days 
-42 (37.5) 
-17 (11.6) 
-22 (11.6) 
- 11 (7.6) 
- 7 (4.4) 
- 1.0 (oral) 
- 2.1 (i.v.) 
-30 (26.3) 
- 6 days 
- 34 (23.7) 
Lous, 1954 
Balasubramaniam et al., 1970 
Kadar et al., 1973 
Wilbrandt, 1964 
This thesis; 
chapter 6, Section HI 
This thesis; 
chapter 7, Section III 
Curry et al., 1971 
This thesis; 
chapter 5, Section III 
This thesis; 
chapter 1, Section III 
This thesis; 
chapter 3, Section HI 
Smith et al., 1973 
Maynert, 1972 
Fazekas et al., 1956 
This thesis; 
chapter 4, Section III 
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thiopental > 8 Brodie, 1952 
(Pentothal®) 
Benzodiazepines 
nitrazepam 
(Mogadon®) 
21 -28 (25.1) Rieder, 1973 
not measurable flurazepam 
(Dalmadorm®) 
l-desalkyl-flurazepam 47-100 (65.5) Kaplan et al., 1973 
diazepam 20 -42 (28) 
(Valium®; Levium®) 
desmethyl-diazepam 42 - 96 (57) van der Kleijn et al., 1971 
Miscellaneous 
bromide 
chloral hydrate 
trichloroethanol 
meprobamate 
methaqualone2) 
7.5 days Wilbrandt, 1964 
very short; not 
measurable after 
oral administration 
7 -10 (8.0) This thesis; 
chapter 8, Section III 
6 -17 Hollister and Levy, 1964 
11 -15 (12.5) Held and von Oldershausen, 1969 
20 -42 (32.6) Alvàn et al., 1973 
!) For reviews of the metabolism of barbiturates see Mark (1963) and Parke (1971). 
2) Morris et al. (1972) reported a half-life of 2.6 h for methaqualone. However, 
these authors measured plasma levels up to 8 h after drug administration 
and determined in fact only the half-life of the distribution phase. Alvàn et al. 
(1973) measured plasma concentrations up to 130 h after a single dose by using 
mass fragmentography. 
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will have been inactivated, which may be sufficient to decrease its concentration 
in the brain below the apparent minimal effective central depressant concen-
tration. It should be realized, however, that this is very dependent on the dose 
administered and it may vary substantially from one person to the other. 
BIOPHARMACEUTICAL ASPECTS OF HYPNOTIC DRUG THERAPY 
Patients who suffer from insomnia have been divided into at least three 
categories (Karacan and Williams, 1971): 1. those who experience difficulty 
in getting to sleep; 2. those who experience intermittent or lacunary sleep, with 
one or more periods of wakefulness in the middle of the night; 3. those who 
experience early morning awakening. It is commonly recommended that the 
first category of patients are treated with a „short-acting" hypnotic drug and 
the other two categories with an „intermediate-" or „long-acting" drug. In-
adequate attention has been paid to the biopharmaceutical aspects of hypnotic 
drug therapy, in spite of the fact that these may offer a more rational approach 
to the treatment of the various categories of insomniacs. A prerequisite for 
adequate treatment of the patients who have difficulty in getting to sleep is 
that the drug should be rapidly absorbed, in order to be effective within 30 min 
after retiring. When early sleep is not obtained, the patient may be tempted 
to take a second dose, which may lead to overdosage and prolonged effects. 
Thus, such a dosage form should be used from which the drug is known to 
be rapidly absorbed. This is the more important, since most patients who take a 
hypnotic drug at night, have not been fasting for a few hours prior to retiring. 
Food may delay the absorption of a hypnotic drug as has been shown for 
pentobarbital (Smith et al., 1973) and for capuride (Johnson et al., 1973). The 
half-life of a drug which is used for the treatment of difficulties getting to 
sleep should be short, since the required duration of effect is relatively short 
and natural sleep should predominate again as soon as possible once sleep has 
been induced. 
For the second and third category of insomniacs, rapid absorption is not 
primarily required. Even delayed absorption may be desirable if a drug with a 
short half-life is used, such that at a later time an effective concentration is 
reached. This is more preferable than a drug with a longer half-life, since the 
latter brings along a higher risk of residual effects during the following day. 
Firstly, the desired onset and duration of hypnotic or sedative action should 
be defined and then a proper choice of drug and dosage form can be made. 
By applying the principles of biopharmaceutics underlying dosage form design, 
the same drug incorporated in different pharmaceutical formulations may serve 
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different therapeutic aims (refer to Chapter 2, Section I). This seems to be a 
rational approach with regard to hypnotic drug therapy. 
THE INVESTIGATIONS DESCRIBED IN THIS THESIS 
The primary aim of the investigations described in this thesis was to study 
the pharmacokinetics of hypnotic drugs in man, in order to obtain important 
information concerning their utility in general practice. Barbiturates were 
studied, since they are still an important class of hypnotic drugs. Their clinical 
effectiveness has been well defined, whereas pharmacokinetic information of 
many barbiturates after administration of therapeutic doses to man is lacking. 
Further, it was considered of interest from a more fundamental point of view, 
to study the kinetic behaviour of structurally closely related compounds. Al-
varez (1971) and Yih (1974) found considerable differences in elimination half-
lives for the various barbiturates in animals. Based upon their findings a 
number of compounds with varying half-lives was chosen for the study in man, 
where the major attention was paid to the compounds with relatively short 
half-lives, since these seemed most rational for hypnotic drug therapy. Chloral 
hydrate is still a widely used hypnotic drug and was therefore included in these 
studies. 
For a study on human pharmacokinetics the primary prerequisite is the 
availability of a method for the quantitative determination of drug in plasma. 
The method should be specific and sensitive, in order to allow concentration 
measurements for relatively long time periods after administration of a single the-
rapeutic dose to man. For barbiturates such a method has been developed by 
using gas chromatography with nitrogen selective detection (Chapter 1 to 8, 
Section II). For chloral hydrate and metabolites head-space analysis with 
electron capture gas chromatography was employed (Chapter 9, Section II). 
Usually single dose experiments were performed in healthy male volunteers 
in order to assess the main pharmacokinetic characteristics of a drug. Additional 
information was obtained by administering the drug repetitively to a certain 
individual. Accumulation and the development of enzyme induction, parti-
cularly with barbiturates may become apparent after repetitive drug administra-
tion. Although the central depressant effects were not objectively assessed in 
these investigations, it was tried to obtain some information on this matter by 
interrogation of the volunteers at regular times about feelings of drowsiness 
and sleepiness. The conclusions drawn at the end of each Chapter of Section III 
as to whether a certain drug should be used in general practice are solely 
57 
based upon its pharmacokinetic behaviour, though. Obviously, the ultimate 
choice of a drug to be used in actual therapy depends upon many other factors 
as well, including the pharmacodynamic and toxicological properties of the 
drug and the particular complaints and condition of the patient. 
In addition to the pharmacokinetic aspects of the various hypnotic drugs 
were the biopharmaceutical aspects studied. Several dosage forms were in-
vestigated in order to assess their ability to deliver the active ingredient with 
the appropriate rate and in sufficient amount to the general circulation. Already 
existing drug products were included in the studies and new dosage forms were 
developed, according to the absorption rate required. 
With hexobarbital also more fundamental aspects have been evaluated. This 
barbiturate possesses an asymmetric centre and it was considered of interest 
to investigate the kinetics of elimination of the separate enantiomers, both in 
man and in rats (Chapter 2, Section III). Furthermore, in cooperation with the 
Medizinische Universitätsklinik at Würzburg, GFR, the kinetics of hexobarbital 
were studied in patients with liver disease in order to obtain information 
concerning possibly impaired drug metabolism and other kinetic changes 
associated with pathological conditions (Chapter 1, Section IV). 
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SECTION II 
A N A L Y T I C A L P R O C E D U R E 
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CHAPTER 1 
THE GAS CHROMATOGRAPHIC DETERMINATION 
OF BARBITURATES IN PLASMA 
INTRODUCTION 
Two important methods for the analysis of barbiturates in plasma are 
available; ultraviolet spectrophotometry and gas chromatography. The U.V. -
method implies the extraction of the compounds from plasma, usually with 
chloroform, and then re-extraction takes place from the organic phase with 
strong alkali. Quantitation is based on the absorbance difference between buffer 
pH 10 and the barbiturate solution. However, this procedure does not dis-
tinguish between different barbiturates or barbiturate metabolites with intact 
pyrimidine ring and is therefore unspecific. Gas chromatography on the other 
hand is primarily a separation technique, which offers the advantage of far 
greater specificity. In addition a greater accuracy and sensitivity can be achieved, 
which makes gas chromatography the method of choice for the determination of 
barbiturates in biological fluids (Hathway, 1971). 
Since the first attempt to employ gas chromatography in the identification of 
barbiturates was made by Janak (1960), several reports on the qualitative 
and quantitative analysis of barbiturates in biological fluids have appeared. 
McMartin and Street (1966) have reviewed the literature up to 1965, which 
mainly dealt with column technology in relation to a good separation and 
resolution of mixtures of barbiturates. Since then several methods for the 
quantitative determination in plasma or blood and urine have been described. 
However, these lack sensitivity for measuring therapeutic levels in man (Anders, 
1966; Martin and Driscoll, 1966; Leach and Toseland, 1968; Bloomer et al., 
1970; Sine et al., 1970; MacGee, 1971; Street, 1971; Fiereck and Tietz, 1971; 
Cooper et al., 1972; Berry, 1973). All of these procedures are suitable for the 
determination of overdose levels, which are in general higher than 10 mg/1 
plasma (Winek, 1970; Hathway, 1971). Therapeutic levels, on the other hand 
are lower and particularly if it is intended to study the kinetics of a drug, it is 
necessary to follow the plasma concentration for longer periods of time until 
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very low concentrations have been reached (van Rossum et al., 1971). An 
exception is phénobarbital, which is used as an antiepileptic agent, the steady 
state levels of which are much higher than those encountered in sedative and 
hypnotic drug therapy (Kupferberg, 1970; Baylis et al., 1970; Meijer, 1971; 
Berlin et al., 1972; Gardner-Thorpe et al., 1972). Sensitive methods are 
available for amobarbital and pentobarbital (Inaba and Kalow, 1972), but these 
are sometimes laborious (Balasubramanian et al., 1969; Smith et al., 1973) or 
they require the formation of derivatives (Ehrnebo et al., 1972). Williams et al., 
(1973) obtained a higher sensitivity by adding formic acid to the carrier gas. 
The application of combined gas chromatography - mass spectrometry for the 
determination of barbiturates in plasma was described by Draffan et al., (1973). 
This technique is particularly suitable when only small plasma samples can be 
obtained (e.g. in infants and children). The same holds for the radioimmunoas-
say technique that has been developed for barbiturates (Spector and Flynn, 
1971; Flynn and Spector, 1972). 
In all gas chromatographic procedures described hitherto, use has been made 
of the normal flame ionization detector. As already mentioned, sensitivity and 
probably also selectivity is unsatisfactory for a rapid determination of thera-
peutic levels of barbiturates in man. Therefore the nitrogen selective flame 
ionization detector was selected, which seems to offer new possibilities for the 
sensitive determination of nitrogen containing drugs in biological fluids (Donike 
et al., 1970). Goudie and Burnett (1973) have described the simultaneous 
determination of phénobarbital, primidone and phenytoin in serum using a 
nitrogen detector. Other nitrogen containing drugs such as amphetamines and 
narcotic analgesics have been analyzed in this way (Riedmann, 1972a; James 
and Waring, 1973). 
THE NITROGEN DETECTOR 
The nitrogen flame ionization detector - also called alkali flame ionization 
detector - is a nitrogen selective version of the thermionic detector, first 
described by Karmen and Giuffrida (1964). It consists of a rubidium bromide 
crystal in a normal flame, which leads to an enhanced response when nitrogen 
containing molecules and also phosphorous containing molecules enter the zone 
between the flame jet and the salt. The rubidium bromide evaporates and 
rubidium atoms react with the nitrogen containing molecules (Aue et al., 1967). 
The operating principle of the detector is probably based on the Lassaigne 
reaction, as all thermionic detectors give selectivity for those hetero-elements 
which can be identified by the Lassaigne test (Hewlett-Packard, 1970; 
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Riedmann, 1972b). The detector responds proportionally to the percent nitrogen 
content of the organic compound, and is claimed to be independent of the 
chemical structure (Hewlett-Packard, 1970). An important factor for proper 
detector operation is a high concentration of hydrogen in the flame (hydrogen 
flow rate 25 - 30 ml/min, air flow rate 180 - 220 ml/min). Optimization of the 
sensitivity and selectivity towards nitrogen containing compounds can be 
achieved further by selecting the proper collector salt position, which is variable 
in the Hewlett-Packard 15161A nitrogen detector. The combined characteris-
tics of sensitivity, selectivity and wide linear dynamic range have been proved 
to be very useful in the analysis of some nitrogen containing compounds in 
biological fluids (Donike et al., 1970). Less time consuming sample clean-up 
procedures have been accomplished by using this detector (Riedmann, 1972a). 
A further advantage is that a minimum of solvent peak tailing, due to the 
detector selectivity, allows fast elution of the compounds on relatively short 
columns. Liquid phase bleeding even at elevated column temperatures is sup-
pressed by the detector selectivity. High resolution columns are not generally 
required, because of the high signal suppression of sample endogenous material 
and strong enhancement of the nitrogen compound signal, resulting in a "sepa-
ration by the detector" rather than by the column (Riedmann, 1973). According 
to the same author a 1 p.p.m. signal of a nitrogen containing compound is only 
interfered with by 2% or less in signal by 1000 p.p.m. of a non-nitrogen con-
taining compound of the same retention time. 
The experience gained with the use of the nitrogen detector in the present 
investigations on the determination of barbiturates in plasma, definitely endor-
ses the above mentioned advantages. On all occasions a single partition step 
between the plasma sample and the extraction solvent allowed the quantitative 
measurement of less than 0.1 /ig barbiturate per ml plasma. No purification of 
the plasma samples or derivative formation was necessary, except in the case of 
cyclobarbital where an endogenous plasma constituent produced interference. 
With hexobarbital a comparison has been made between normal flame ionization 
detection and the nitrogen detector, which illustrates the high increase in sen-
sitivity and selectivity using the nitrogen detector (Breimer and van Rossum, 
1974; chapter 2, Section II). The linear calibration curves which were obtained, 
were highly reproducible and the calculation factor always remained the same 
in the case of hexobarbital, methohexital, butobarbital and cyclobarbital. With 
vinylbital and heptabarbital there was some variation with time, so that it was 
necessary to construct a calibration curve for each sample series. The reason for 
this variation is not clear, but it is probably due to a changing sensitivity of the 
detector, which is slightly different for the barbiturate in question and the in-
ternal standard. 
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It should be mentioned here that the nitrogen detector is more complicated 
to handle than the normal flame ionization detector, as gas flow rates, the con-
dition and the position of the rubidium salt are quite critical with respect to 
optimal performance. Gough and Sugden (1973) have studied the stability of 
this detector and they have concluded that variations in response of the nitrogen 
detector are higher than those of a normal flame detector. However, when 
working with internal standards and careful manipulation of this detector, it 
must be concluded that highly satisfactory results can be achieved. 
EXTRACTION PROCEDURE 
Barbiturates are weakly acidic drugs with pK^-values ranging from 7.4 to 8.3 
(Table I). The unionized form is lipophilic and it is in this form that they pass 
through lipoid membranes, such as the blood-brain and other blood-tissue 
barriers. It has been shown that the rate of transfer depends upon the lipid 
solubility of the undissociated molecule (Brodie et al., 1960; Mark, 1963). The 
true partition coefficient (TPC) is a measure for the lipophility of unionized 
drug, whereas the apparent partition coefficient (APC) is generally used to in-
dicate the situation at physiological pH of 7.4 (Table I). The proportion of 
barbiturates in the aqueous phase at this pH is dependent upon the pK, 
values. Nevertheless it can be seen that with all compounds there is still a high 
affinity for the organic phase under these circumstances. There is also a 
variation in lipophility between the barbiturates used in the present study. 
Organic solvents with different polarity can be applied therefore for the ex-
traction of these compounds from plasma and urine, depending on their relative 
lipophility. Hexobarbital and methohexital for example, which are the com-
pounds with the highest partition coefficients, could be extracted satisfactorily 
by the strongly apolar solvent light petroleum. A small amount of amylalcohol 
had to be added to increase polarity, so that reasonable recoveries were obtained 
(Brodie et al., 1953; Cooper and Brodie, 1955). For the less lipophilic bar-
biturates the more polar solvent diethylether or a mixture of diethylether, light 
petroleum and propanol have been used. Chloroform is often chosen for the 
extraction of drugs from biological fluids, but it gives rise to the formation of 
emulsions. Light petroleum offers the advantage that the extraction time on the 
whirlmixer is not very critical, while extractions with other solvents which last 
longer than 5 sec occasionally give interfering peaks with a concomitant in-
crease of extracted endogenous substances. With cyclobarbital an interfering 
peak always appeared and therefore this compound had to be derivatized 
(methylated) prior to gas chromatography. 
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TABLE I. Physico-chemical properties of the barbiturates and the extraction solvents 
used in this study. 
Extraction solvent 
Light petroleum 100/ 
amylalcohol 2 
Light petroleum 100/ 
amylalcohol 2 
Light petroleum 49/ 
diethylether 49/ 
n-propanol 2 
Diethylether 
Diethylether 
Diethylether 
') According to Doornbos and de Zeeuw (1969). 
2) APC = apparent partition coefficient; TPC = true partition coefficient. The par­
tition of the barbiturates between phosphate buffers of various pH-values 
(6.5 - 10.5) and chloroform was determined. The volume of both phases was 5.0 
ml and the total amount barbiturate added was 50 ^g. The concentration in 
both phases after shaking the mixture until equilibrium, was measured by gas 
chromatography. The percentage barbiturate in the organic phase was plotted 
against the pH and from the pH 5 0 (50% in chloroform and 50% in the water 
phase) the TPC was calculated, while: pHS 0 = pKa + log (TPC-1); the APC 
a t p H 7 . 4 = - - T P -
1 + i07-4-PKa 
s) According to Bush et al. (1966); the partition coefficients in this study were 
determined by using 1-chlorobutane as organic phase. The TPC of hexobarbital 
between this solvent and the aqueous phase was found to be 15. It must be 
concluded therefore that methohexital is the most lipophilic barbiturate found in 
the present investigation. 
4) According to Yih (1970). 
In the present study no systematic approach was made for the extraction of 
the barbiturates from plasma or urine. In each case several solvent systems 
were tried and the one with the best result, with respect to reproducibility, was 
chosen. The same applies to the choice of the internal standard, of which hexo-
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/- ^ ы ., APC at pH 7.42) „ _ „ , Compound pKJ) , .,
 t ч TPC
2) r a
 (chloroform) 
Hexobarbital 8.3 1114) 129 
Methohexital 8.33) 95э) 110 
Heptabarbital 7.45 18.2 36.6 
Vinylbital 
Butobarbital 
Cyclobarbital 
7.89 
7.86 
7.51 
12.0 
11.94) 
5.8 
15.5 
15.5 
10.5 
barbital often proved to be very suitable. For each compound the assay proce­
dure will be described in detail in the following chapters. 
GAS CHROMATOGRAPHIC CONDITIONS 
Since the gas chromatographic conditions have been almost the same for all 
compounds studied, details will be given here and they will not be mentioned 
separately in each of the following chapters of this Section. Some information 
has been summarized in Table II. 
TABLE II. Gas chromatographic conditions of the barbiturates investigated. 
Compound 
Hexobarbital 
3-Keto-hexobarbital 
Methohexital 
Heptabarbital 
Vinylbital 
Butobarbital 
Cyclobarbital 
Stationary 
phase 
OV-17 3% 
OV-17 3% 
OV-17 3% 
OV-17 3% 
OV-17 3% 
OV-17 3% 
OV-17 3% 
Column 
temperature 
230° (240°) 
240° 
230° 
240° 
240° 
240° 
220° 
Retention 
time (min) 
3.6 (2.3) 
6.4 
2.3 
4.2 
1.5 
1.3 
2.6') 
Internal 
standard 
Methohexital 
Codeine (E.S.)2) 
Hexobarbital 
Hexobarbital 
Hexobarbital 
Hexobarbital 
Cyclopal 
') After flash-heater methylation by trimethylaniliniumhydroxide. 
2) E.S. = external standard. 
Apparatus. A Hewlett - Packard, Model 5750 gas Chromatograph, equipped 
with a nitrogen detector (rubidium bromide; Hewlett - Packard, Model 15161A), 
was used. 
Column. A glass column (1.8 m χ 3 mm I.D.), packed with 3% OV-17 on 
Gas-Chrom Q, 60 - 80 mesh (Applied Science Lab., State College, Pa., U.S.A.) 
was used. The retention times of the compounds are given in Table II. 
Temperatures. The temperatures of the column for each barbiturate are given 
in Table II. The temperature of the injection port was maintained at 280° and 
the detector at 380°. 
Gas flow-rates. The carrier gas was helium at a flow-rate of 25 - 30 ml/min. 
In order to obtain optimal performance of the nitrogen detector, an auxiliary 
stream of carrier gas at a flow-rate of 20 - 30 ml/min was led directly into the 
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detection system. The hydrogen flow-rate was 30 ± 0.5 ml/min and the air 
flow-rate 200 ± 10 ml/min. A very constant hydrogen flow-rate was required 
for the nitrogen detector and this was achieved by using a differential flow con­
troller before the normal flow control of the gas Chromatograph. 
Operation of the nitrogen detector. The distance between the collector, con­
taining the rubidium bromide crystal, and the flame is very important with 
respect to the achievement of high sensitivity and selectivity with nitrogen-
containing compounds. At the beginning of each day, the collector was moved 
step by step in the direction which gave the maximum ionization current 
(maximum recorder deflection, range 103, attenuation 32). The crystal was 
cleaned twice a week by carefully wiping it with a soft brush. 
CONCLUDING REMARKS 
Finally it must be emphasized that the methods described here have been 
developed as a research tool to measure low levels of barbiturates, without 
interference from endogenous materials. No guarantee is offered that other 
drugs will not interfere, or that mixtures of several barbiturates will well separate 
under these gas chromatographic conditions. For information concerning the 
separation and quantitative determination of several barbiturates in toxicological 
cases, the reader is referred to the extensive study by Berry (1973). 
It should further be mentioned that the identity of the compounds eluting 
from the gas Chromatograph was checked with the combined gas Chromato­
graph - mass spectrometer (LKB 9000). 
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CHAPTER 2 
HEXOBARBITAL IN PLASMA AND URINE 
INTRODUCTION 
The structure of hexobarbital, an N-methylated barbiturate (l,5-dimethyl-5-
(l-cyclohexenyl)-barbituric acid), is shown below. Due to the presence of the 
N-methylgroup at position 1, hexobarbital has a relatively high pK^-value (8.19) 
and also it is highly lipophilic (Chapter 1, Section II). A further consequence of 
this N-methylation is that the compound contains an asymmetric centre at the 
5-position (indicated with an asterisk in the structure). Knabe and Kräuter 
(1965) have separated the optical antipodes, but in practice the racemic mixture 
is used. 
a 
ι 
N 
N 
H
 О 
hexobarbital 
In a recent article Bush and Weiler (1972) have reviewed the physicochemical 
properties of hexobarbital and also the methodologies for its quantitative deter­
mination in biological fluids and tissues. Prior to 1965 U.V.-spectrophoto-
metry was used, when the fate of the drug in animals or man was studied. 
More recently the compound has been discussed in studies concerning the gas 
chromatographic determination of barbiturates in general. None of these techni­
ques, however, are very suitable for the determination of low hexobarbital levels, 
as has been outlined in Chapter 1 of this Section. Therefore a specific and 
sensitive gas chromatographic assay for hexobarbital was developed, using the 
nitrogen detector (Breimer and van Rossum, 1974). This detector allows the 
determination of very low levels, sufficient to study the pharmacokinetics of 
the drug after administration of therapeutic doses to man. Furthermore, a 
column chromatographic purification procedure has been developed, which 
can be applied when plasma samples from hepatitis patients contain high 
amounts of interfering endogenous materials. 
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MATERIALS AND METHODS 
Reagents 
Hexobarbital was obtained from Onderlinge Pharmaceutische Groothandel, 
Utrecht, The Netherlands. Mcthohexital was obtained from Eli Lilly, U.S.A. 
(a gift of methohexital for reference purposes is greatfully acknowledged). Light 
petroleum, boiling range 40 - 60°, and amyl alcohol, were of analytical-reagent 
grade (E. Merck, Darmstadt, G.F.R.). A standard hexobarbital solution was 
prepared at a concentration of 1 mg per 100 ml of absolute ethanol (analytical-
reagent grade, E. Merck). A standard methohexital solution was prepared at a 
concentration of 3 mg per 100 ml of absolute ethanol. Silica gel (Kieselgel 60 
für Säulenchromatographie, 70 - 230 mesh) was obtained from E. Merck. 
detector reeponee (% Î 
100 
2 3 4 
time (mm) 
FIG. 1. Difference in response of a normal flame ionization detector (FID) and 
nitrogen detector (AFID) to methohexital (a) and hexobarbital (b) after injection of 
20 ng of each. 
72 
Extraction procedure 
Normal plasma. To 2.0 ml plasma in a conical tube was added 2 ml of 
distilled water and 0.1 ml of internal standard solution, containing 3 /tg of 
methohexital. The mixture was extracted twice with 10 ml of light petroleum-
amyl alcohol (100 :2) on a Cenco whirlmixer. Mixing was carried out 
vigorously for 5-10 sec (twice). The upper organic layer was removed each 
time with a Pasteur pipette and transferred into a conical evaporation tube. 
The solvent was evaporated to dryness at 40° in a stream of dry air. The residue 
was dissolved in 0.1 ml of absolute ethanol and 2 - 5 /Л of this solution were 
injected into the gas Chromatograph using a Hamilton syringe. 
Hepatitis plasma. Plasma or serum samples from hepatitis patients sometimes 
showed strong interference with the hexobarbital and methohexital peaks in the 
gas chromatogram (Fig. 3). Simple purification was obtained by transferring 
the light petroleum-amyl alcohol extract in 0.2 - 0.4 ml of absolute ethanol into 
a silica gel column (I.D. 8 mm, height 4 cm) and eluting with absolute ethanol. 
detector response ( % ) 
100 
5 0 
0-1 
Ц time (mm) 
FIG. 2. Gas chromatograms of a 2-ml plasma extract (FID and AFID) obtained 
from a subject 4 h after receiving 600 mg of hexobarbital orally. Injection volume 
2 iti. a, hexobarbital (concentration in plasma 2.1 Mg/ml); b, methohexital (internal 
standard; concentration in plasma 1.5 μg|m\). 
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1 
Gaschromatography of hexobarbihal 
in serum of hepabtis pa hen ta 
a Gaschromafogram of the crude 
petr ether extract 
b Gaschromato^ram oFthe same 
extract after purification over a 
a\Ucagel column 
H . heAobarbital 
M = methohexita/ ( IS ) 
V 
FIG. 3. Gas chromatography of hexobarbital in serum of hepatitis patients with a 
high bilirubin content: a, gas chromatogram of the crude light petroleum extract; 
b, gas chromatogram of the same extract after purification through a silica gel 
column. H = hexobarbital; M = methohexital (internal standard, 1.5 .«g/ml plasma). 
The first 3 ml of eluate were collected and then concentrated to a volume of 
0.1 ml; this solution was analyzed by gas chromatography. With the aid of 
calibration graphs, it was verified that the peak area ratio of hexobarbital to 
internal standard was not changed by the purification procedure. 
Urine. Although very little hexobarbital is excreted into the urine unchanged, 
its renal excretion rate and cumulative renal excretion were quantified in the 
following way. In a conical tube 10.0 ml urine were extracted twice on the 
whirlmixcr with 20 ml light petroleum-amyl alcohol (100 : 2). The combined 
organic layers were evaporated to dryness and the residue was dissolved in 
0.1 ml of absolute ethanol, containing 8 «g cyclobarbital (external standard). 
This solution was used for injection into the gas Chromatograph. 
74 
Gas chromatography 
As described in Chapter 1, Section II. 
Preparation of calibration graphs 
The concentration of hexobarbital in plasma and urine samples was calculated 
with the aid of calibration graphs, which were prepared by adding known 
amounts of hexobarbital to 2.0 ml of blank plasma or 10.0 ml of blank urine. 
The samples were analyzed by the same procedure described above and the 
ratio of the peak areas of hexobarbital to internal or external standard was 
plotted against known concentrations of hexobarbital. 
Recovery studies 
Recoveries of hexobarbital at different concentrations were determined by 
adding known amounts of hexobarbital to 2.0 ml of blank plasma. After extrac­
tion, 3.0 μ§ of methohexital were added and the relative peak area ratio (Rj) 
was calculated. This value was compared with the ratio (Rn) obtained by GC 
of the same standard amount of hexobarbital with 3.0 ¿(g of methohexital: 
Recovery (%) = χ 100. 
R I I 
RESULTS AND DISCUSSION 
Gas chromatographic sensitivity and selectivity 
In Fig. 1, typical gas chromatograms are shown of hexobarbital and metho­
hexital standards, obtained both by normal flame ionization detection (FID) 
and by nitrogen-selective detection (AFID). A large increase in sensitivity is 
evident when using the nitrogen detector. Barbiturates contain two nitrogen 
atoms, and as the detector signal is proportional to the nitrogen equivalent in 
the molecule, the presence of two nitrogen atoms favours high sensitivity. The 
position of the rubidium bromide crystal with respect to the flame and the gas 
flow rates are important factors in obtaining a high N-C ratio and the influence 
of these factors has been extensively studied (Donike et al., 1970; Karmcn, 
1969). The negative detector response shortly after injection has been observed 
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peak area hexoloarbital 
peak area methohexita! (I 5) 
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FIG. 4. Calibration graph for the determination of hexobarbital in plasma, using 
methohexital as internal standard (1.5 .wg/ml). Mean values and standard deviations 
of at least six determinations. 
by several investigators using a nitrogen detector (Gerhardt and Aue, 1970). 
The detection limit is about 0.5 ng per single injection for the two barbiturates 
under investigation. 
In Fig. 2, typical gas chromatograms are shown of a plasma extract con­
taining hexobarbital and methohexital. With the normal FID, there is inter­
ference of a plasma peak with the hexobarbital. However, when using the 
nitrogen detector there is a large increase in selectivity towards the nitrogen-
containing compounds. There is hardly any solvent peak and the base line has 
become horizontal. Time-consuming purification would have been necessary if 
normal FID had been used, whereas the extract can be analyzed directly by 
using the nitrogen detector. Purification is required only in some cases of 
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hepatitis patients with very high plasma bilirubin contents. This can be achieved 
satisfactorily by running the extracts through a silica gel column (Fig. 3). Con-
centrations in plasma down to 50 ng/ml can be determined. 
Extraction procedure and precision 
The extraction by light petroleum-amyl alcohol (100 : 2) was chosen as it is 
suitable for the highly lipophilic barbiturates hexobarbital and methohexital 
(both N-methylated). Cooper and Brodie (1955) already have used this sol-
vent system for the extraction of hexobarbital from biological material. A small 
amount of amyl alcohol had to be added in order to get a reasonable recovery. 
peak area hexobarbital recovery 
peak area methohexital • 
cone hexobarbital (utí,/ml) 
FIG. 5. Peak area ratio of hexobarbital to methohexital as a function of known 
hexobarbital concentrations for the determination of recovery. Mean values and 
standard deviations (и = 4). 
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The only disadvantage of amyl alcohol was an impurity that eluted from the 
gas Chromatograph a few minutes after hexobarbital. Two samples in succession 
could be analyzed and then it was necessary to wait for the two "amyl alcohol" 
peaks. Later on this peak was no longer present, when using a different lot of 
amyl alcohol. No interfering plasma constituents are extracted, except in some 
cases with hepatitis plasma, and the formation of an emulsion never occurred. 
Vigorous extraction for 5-10 sec (twice) gives highly reproducible results. From 
the calibration curve in Fig. 4 which is composed of at least six individual 
calibration curves prepared on different occasions over a period of 1 year, it 
can be deduced that the procedure is highly reproducible and has a good 
precision over a large concentration range. Standard deviations did not exceed 
± 5 % , except at the 2.0 /(g level ( ± 7 % ) . 
The extraction yields (recoveries) were determined in the same concentration 
range as those encountered in practice and they appeared to be constant, with 
a mean value of 65% (Fig. 5). Standard deviations were in the range 3 - 5 % 
(n = 4). Although in general an extraction should give a high yield, in this 
particular instance the low detection limit and the good reproducibility permit 
the use of light petroleum-amyl alcohol as the extraction solvent. 
The size of the plasma samples was 2.0 ml throughout the investigation, but 
it is reasonable to assume that smaller samples can also be analyzed satisfactorily 
by this method. This could be of advantage in clinical situations where the 
sample size is a limiting factor. 
CONCLUSION 
This method for the assay of hexobarbital in plasma is rapid, sensitive and of 
good precision. It is therefore suitable for pharmacokinetic studies in man and 
also in patients with liver disease. 
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CHAPTER 3 
3-KETO-HEXOBARBITAL IN URINE 
INTRODUCTION 
3-Keto-hcxobarbital is an important metabolite of hexobarbital, which has 
been identified in the urine of several species. The structure of this compound 
is shown in Fig. 1. Bush et al. (1953) were the first to identify this compound 
in the urine of dogs after hexobarbital administration. Tsukamoto et al. (1956a; 
1957) have reported the isolation of 3-kcto-hexobarbital from rabbit urine and 
human urine. This compound is formed also during hexobarbital metabolism in 
mice (Noordhoek and Gerritsen, 1969; Gerber et al., 1971) and in rats 
(Holcomb et al., 1969; Yih, 1974). Other important metabolites of hexobarbital, 
are 3-hydroxy-hexobarbital, 3-keto-norhexobarbital and barbiturate-ring clea-
vage products (Bush and Weiler, 1972). None of the oxidized metabolites has 
hypnotic properties (Bush et al., 1953; Yoshimura, 1958). There appear to be 
no quantitative studies available on the excretion of metabolites after hexo-
barbital administration in man. 
When studying the pharmacokinetics of hexobarbital in man, it was con-
sidered of interest to measure the renal excretion of one or more metabolites 
simultaneously. With respect to the comparison of the fate of hexobarbital 
antipodes in the same subject, this would yield additional information about 
possible different metabolic pathways. Also in patients with impaired liver 
function it is interesting to determine whether the metabolite pattern is changed 
in comparison with healthy controls. It was attempted to develop a gas chroma-
tographic method for the quantitative determination of 3-keto-hexobarbital and 
of 3-hydroxy-hexobarbital in human urine. Unfortunately the hydroxy-com-
pound could not be determined successfully. Norhexobarbital was omitted 
because it is only excreted in trace amounts. A simple and sensitive assay for 
the determination of 3-keto-hexobarbital in urine is described below, which 
involves a single partition step between urine and ethyl acetate, followed by 
gas chromatography with nitrogen selective detection. Gas chromatographic 
procedures for the quantitative determination of hexobarbital metabolites in 
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biological fluids have not been reported previously. Tsukamoto et al. (1958) 
have measured hexobarbital metabolites in urine by the use of buffered paper 
chromatography in conjunction with UV-spectrophotometry. Anders and Latorre 
(1970) have included hexobarbital and 3-keto-hexobarbital in a study on the 
applicability of high-pressure liquid chromatography to the resolution of mix­
tures of barbiturates and hydantoins. The employment of this procedure to 
biological fluids has not been published yet. 
MATERIALS AND METHODS 
Preparation of 3-keto-hexobarbital 
The compound was prepared according to the method of Tsukamoto et al. 
(1956). To a stirred suspension of 5 g hexobarbital in 40 ml acetic anhydride 
was added dropwise a solution of 5.6 g chromium trioxide in 40 ml acetic 
anhydride, during 1 h. The reaction mixture was stirred at 35° for 1 h and then 
allowed to stand overnight. The solvent was evaporated completely under 
reduced pressure and 100 ml water was added to the residue. This was extracted 
three times with 100 ml ethyl acetate and the combined extracts were dried over 
anhydrous sodium sulphate. The solvent was evaporated under reduced pres­
sure and the residue was repeatedly recrystallized from methanol, until gas 
chromatographically pure 3-keto-hexobarbital was obtained. Calculated for 
C l a H 1 4 0 4 N 2 : С, 57.59; H, 5.64; Ν, 11.20; Found: С, 57.61; Η, 5.77; Ν, 10.93. 
Extraction procedure 
In a conical tube 2.0 ml urine was extracted twice with 10 ml of distilled 
ethyl acetate (analytical-reagent grade, E. Merck) on a Cenco whirlmixer 
during 10 sec. The combined organic layers were evaporated to dryness and 
60 μ% codeine, dissolved in 0.1 ml absolute ethanol, was added to the residue 
as an external standard. After evaporation of the alcohol the residue was dissol­
ved in about 0.5 ml acetone (analytical-reagent grade, E. Merck) and 5 /Л of 
this solution were injected into the gas Chromatograph. 
Gas chromatography 
As described in Chapter 1, Section II. 
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Preparation of calibration graphs 
The concentration of 3-keto-hexobarbital in urine samples was calculated 
with the aid of calibration graphs, which were prepared by adding known 
amounts of 3-keto-hexobarbital to a 2.0-ml blank urine sample. The samples 
were analyzed by the same procedure described above and the ratio of peak 
areas of 3-keto-hexobarbital to external standard was plotted against known 
concentrations of 3-keto-hexobarbital. 
RESULTS AND DISCUSSION 
Since 3-keto-hexobarbital is not commercially available, the compound had 
to be synthesized for reference purposes. During the oxidation of hexobarbital 
with chromium trioxide not only the 3-keto-compound is formed, but also some 
6-keto-hexobarbital. Due to possible sterical hindrance of the 6-position, the 
yield of this compound is only about 10% of the amount of 3-keto-hexobarbital 
that is formed (Tsukamoto et al., 1956b). The two compounds are well sepa-
rated on the OV-17 column, the retention time of 6-keto-hexobarbital is a 
little less than the 3-keto-isomer. The pure 3-keto-hexobarbital was obtained 
after recrystallization. In Fig. 1 the mass spectra of the two isomers (LKB 9000 
GC-MS combination, ionization potential of 20 eV), are given. Distinct dif-
ferences in mass spectrometric fragmentation behaviour can be observed. With 
6-keto-hexobarbital the molecular ion (m/e 250) is also the base peak, whereas 
with the 3-keto-compound the cyclohexenone fragment (m/e 95) and the M-15 
fragment (loss of the methyl group at C5) are the major peaks, which have 
about the same intensity. The metastable ion at about m/e 221 is also charac-
teristic of the 3-keto-compound. Further fragmentation behaviour can be ex-
plained in accordance with previously published data on the mass spectrometric 
behaviour of barbiturates (Gilbert et al., 1970; Skinner et al., 1973). 
Analysis of a urine sample, by means of GC - MS, from a human subject 
who had taken hexobarbital, showed that one of the compounds eluting from 
the gas Chromatograph was identical to synthetic 3-keto-hexobarbital (Fig. 1). 
No 6-keto-hexobarbital could be identified in human urine, whereas norhexo-
barbital was found to be excreted only in trace amounts. Also small amounts 
of unchanged drug were detected. In Fig. 2 the gas chromatogram of a urine 
extract, containing 3-keto-hexobarbital, is shown. Most peaks which appear 
before this hexobarbital metabolite, also show up after extraction of blank urine. 
The peak eluting with a retention time of 5.4 min probably represents another 
hexobarbital metabolite, but its structure has not been elucidated yet. Ethyl 
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FIG. 1. Mass spectra of synthetic 6-keto-hexobarbital, synthetic 3-keto-hexobarbital 
and biological 3-keto-hexobarbital (LKB 9000 gas Chromatograph - mass spectro-
meter combination). The biological material was extracted from urine of a subject 
who had received 600 mg of hcxobarbital orally. 
acetate has often been used for the extraction of the rather polar barbiturate 
metabolites from urine (Bush and Weiler, 1972). The recovery of 3-keto-
hexobarbital from urine by the double extraction with ethyl acetate was ap-
proximately 86% (determined at the same concentrations as in the calibration 
graph of Fig. 3). 
The choice of an internal or external standard has proved difficult in the 
assay of this metabolite. Several compounds, e.g. barbiturates and related 
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substances, have been tried. However, most of these had shorter retention times 
than 3-keto-hexobarbital. This was undesirable since interference with en­
dogenous materials was liable to occur (Fig. 2). Other compounds showed 
extensive peak tailing on a 3% OV-17 column and were therefore excluded. 
Finally it was decided to use codeine (free base), because this compound ap­
peared to have an appropriate retention time and linear calibration graphs 
were obtained over a great concentration range. Naturally this substance, with 
basic properties, cannot be used as an internal standard for the determination 
of weakly acidic drugs such as barbiturates. Therefore it is added after extrac­
tion and must be considered as an external standard. Although the choice of 
codeine cannot be considered as ideal, satisfactory results have been obtained. 
In Fig. 3 calibration curves for the determination of 3-keto-hexobarbital in 
urine are illustrated, using codeine as standard. The results revealed that the 
ratio between 3-keto-hexobarbital and the external standard at a certain con­
centration, varied slightly in the time. This might be due to selective changes 
3% OV 17 
240 °C 
AFID-d.tecbr 
Зкеіо 
hexobarbita! 
26>ij/ml urine 
cod«ine(ES.) 
FIG. 2. Gas chromatogram of a 2-ml urine extract obtained from a subject 6 h after 
receiving 600 mg of hexobarbital orally. Codeine base was used as external standard 
(concentration 30 /tg/ml urine). 
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FIG. 3. Calibration graphs for the determination of 3-keto-hexobarbital in urine, 
prepared on different occasions, using codeine base as external standard (30 i"g/ml 
urine). 
in the sensitivity of the nitrogen detector towards one of the two compounds. 
The same phenomenon has been observed in the assay of vinylbital and hepta-
barbital in plasma. The variation was in the order of 1 0 - 1 5 % , so that the 
preparation of a calibration graph was necessary for each day when a series of 
urine samples had to be analyzed for 3-keto-hexobarbital. This disadvantage is 
only of minor importance, as it must be realized that the preparation of a 
calibration graph does not take much extra time. Concentrations down to 
5 //g/ml urine can be determined by this method. 
It should be mentioned that strongly varying results were obtained initially, 
when the extraction residue was "dissolved" in absolute ethanol. It appeared 
that 3-keto-hexobarbital was poorly soluble in ethanol and therefore acetone 
was used. A relatively large amount of acetone is required, otherwise dissolution 
problems arise. 
CONCLUSION 
This method for the quantitative determination of 3-keto-hexobarbital in 
urine is reliable, rapid and sensitive. It is specific and less time consuming than 
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the methods described previously for the quantitative determination of hexo-
barbital metabolites. A calibration curve should be prepared with each sample 
series. 
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CHAPTER 4 
METHOHEXITAL IN PLASMA 
INTRODUCTION 
Methohexital (a-dl-l-mcthyl-5-allyl-5-(l-methyl-2-pentynyl)-barbituric acid) 
is a N-methylated compound, the structure of which is shown below. The 
allyl-group and pentynyl-group also considerably contribute to its great lipid 
solubility. Bush et al. (1966) have compared the partition coefficients of several 
barbiturates, including hexobarbital, thiopental and methohexital between buf­
fers of different pH and 1-chlorobutane. They have reported the highest lipo-
phility for methohexital. The compound contains two asymmetric centres (in­
dicated by asterisks in the structure) and four stereoisomers are possible. In 
practice the a-dl-racemic mixture is used, because the β-ά and β-\ optical 
isomers produce excessive motor activity (Gibson et al., 1959). 
сн3 о 
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Previous studies on the physiologic disposition of methohexital in man after 
administration of high doses have been performed with the aid of UV-spec-
trophotometry (Brand et al., 1963) or gas chromatography with flame ionization 
detection (Sunshine et al., 1966). Both methods, however, lack the sensitivity to 
measure plasma levels for a certain period following administration of thera­
peutic doses of the compound. Therefore these cannot be used in pharma­
cokinetic studies and a more sensitive assay had to be developed. A suitable 
method is described in this chapter, employing gas chromatography with 
nitrogen selective detection. 
:
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MATERIALS AND METHODS 
Reagents 
Methohexital was obtained from Eli Lilly, U.S.A. (a gift of this compound 
for reference purposes is greatfully acknowledged). Hexobarbital was obtained 
from OPG, Utrecht, The Netherlands. Light petroleum, boiling range 40 - 60°, 
and amyl alcohol, were of analytical-reagent grade (E. Merck). A standard 
methohexital solution was prepared at a concentration of 1 mg per 100 ml of 
absolute ethanol (analytical-reagent grade, E. Merck). A standard hexobarbital 
solution was prepared at a concentration of 3 mg per 100 ml of absolute ethanol. 
Extraction procedure 
To 2.0 ml plasma in a conical tube was added 2 ml of distilled water and 
0.1 ml of internal standard solution, containing 3 /ig of hexobarbital. The 
mixture was extracted twice with 10 ml of light petroleum - amyl alcohol 
(100 : 2) on a Cenco whirlmixer. Mixing was carried out vigorously for 5-10 
sec (twice). The upper organic layer was removed each time with a Pasteur 
pipette and transferred into a conical evaporation tube. The solvent was evapo­
rated to dryness at 40° in a stream of dry air. The residue was dissolved in 
0.1 ml of absolute ethanol and 2 - 5 /Л of this solution were injected into the 
gas Chromatograph. 
Gas chromatography 
As described in Chapter 1, Section II. 
Preparation of calibration graphs 
The concentrations of methohexital in plasma were calculated with the aid of 
calibration graphs, which were prepared by adding known amounts of metho­
hexital to 2.0 ml of blank plasma. The samples were analyzed by the same 
procedure described above and the ratio of the peak areas of methohexital to 
internal standard was plotted against known concentrations of methohexital. 
RESULTS AND DISCUSSION 
The assay for methohexital in plasma is in fact the same as for hexobarbital 
(Chapter 2 of this Section). When studying the determination of hexobarbital 
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FIG. 1. Left. Calibration graph for the determination of methohexital in plasma, 
using hexobarbital as internal standard (1.5 μg|m\ plasma). Right. Gas chromatogram 
of a 2-ml plasma extract obtained from a patient 10 min after receiving 200 mg of 
methohexital sodium intravenously, m = methohexital (concentration 3.8 /<g/ml 
plasma), h = hexobarbital (internal standard, concentration 1.5 /^ g/ml plasma). 
in plasma, methohexital proved to be a very reliable internal standard. In the 
present assay hexobarbital is used as internal standard. The entire procedure 
appears to give equally good results for the two compounds. In Fig. 1 a gas 
chromatogram is shown of a plasma extract containing methohexital. There is 
no interference with other peaks and the nitrogen detector permits the deter­
mination of very low levels (detection limit approximately 50 ng/ml plasma). 
Sensitivity is at least 50-fold greater as compared with normal flame ionization 
detection (Sunshine et al., 1966). The short retention times of the compounds 
on the 3% OV-17 column and the rather simple extraction procedure make it 
possible to analyze many samples in a relatively short period of time. The 
slope of the calibration graphs (example given in Fig. 1) was always the same 
and equal to the slope of the hexobarbital calibration graphs. An extraction 
recovery of about 65% was found for methohexital. 
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CONCLUSION 
This method for the assay of methohexital in plasma is rapid, sensitive and 
reproducible. It is therefore suitable for pharmacokinetic studies in man, when 
therapeutic doses are administered. 
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CHAP'IER 5 
VINYLBITAL IN PLASMA AND URINE 
INTRODUCTION 
Vinylbital (5-vinyl-5-(l-rnethylbutyl)-barbituric acid) is a barbiturate con-
taining an asymmetric centre in the side chain, the structure being illustrated 
below. Knabe and Kräuter (1965) have described a procedure for the separation 
of the optical isomers, but in practice the racemic mixture is used. The com-
pound has moderate lipophilic properties in comparison to hexobarbital and 
melhohexital. 
H
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No specific and sensitive method for the quantitative determination of vinyl­
bital in biological fluids has been reported previously in the literature. Therefore 
such a method was developed, using gas chromatography with nitrogen selective 
detection, for the study of the pharmacokinetics of vinylbital in man. 
MATERIALS AND METHODS 
Reagents 
Vinylbital was obtained from BYK-Nederland, Zwanenburg, The Netherlands 
(a gift of vinylbital for reference purposes is greatfully acknowledged). Hexobar­
bital was obtained from OPG, Utrecht, The Netherlands. Diethyl ether, light 
petroleum boiling range 40-60° and propanol-2 were of analytical-reagent 
grade (E. Merck). Diethyl ether was freshly distilled before use. Phosphate 
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buffer pH 6.0 was prepared by adding 61.5 ml of a solution containing 6.745 g 
Na 2 HP0 4 . 12 H2O/250 ml distilled water to 438.5 ml of a solution containing 
4.54 KH2PO4/500 ml distilled water. A standard vinylbital solution was 
prepared at a concentration of 1 mg/100 ml absolute ethanol (analytical-reagent 
grade, E. Merck). A standard hexobarbital solution was prepared at a concen-
tration of 2 mg/100 ml absolute ethanol. 
Extraction procedure 
Plasma. To 2.0 ml plasma in a conical tube was added 1.0 ml of phosphate 
buffer pH 6.0 and 0.1 ml of internal standard solution containing 2 /«g hexo-
barbital. The mixture was extracted twice with 5 ml of diethyl ether on a 
Cenco whirlmixcr. Mixing was carried out at half the maximum speed of the 
whirlmixer (about 20 r.p.s.), twice, during 3 - 4 sec (this period was quite 
critical, since longer extraction resulted in the concomitant extraction of in-
terfering endogenous plasma substances). The combined organic layers were 
evaporated to dryness in a stream of dry air. The residue was dissolved in 0.1 ml 
of absolute ethanol and 2 - 5
 («1 of this solution were injected into the gas 
Chromatograph. 
Urine. To 10.0 ml urine in a conical tube was added 0.1 ml of internal 
standard solution containing 2 fig hexobarbital. The mixture was extracted twice 
with 10 ml diethyl ether - light petroleum - propanol-2 (49 : 49 : 2) on a Cenco 
whirlmixer. Mixing was carried out at half the maximum speed of the whirl-
mixer, twice, during 10 sec. Further procedures were the same as described for 
plasma. 
Gas chromatography 
As described in Chapter 1, Section II. 
Preparation of calibration graphs 
The concentration of vinylbital in plasma and in urine samples was cal-
culated with the aid of calibration graphs, which were prepared by adding 
known amounts of vinylbital to 2.0 ml of blank plasma or 10.0 ml of blank 
urine. The samples were analyzed by the same procedure described above and 
the ratio of the peak areas of vinylbital to internal standard was plotted against 
known concentrations of vinylbital. 
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RESULTS AND DISCUSSION 
Several organic solvents were studied for the extraction of vinylbital from 
plasma. Many of these, however, gave interfering peaks of endogenous plasma 
materials in the gas chromatogram. Only light petroleum, alone or in com-
bination with 2% amy! alcohol, gave completely clean gas chromatograms, but 
the extraction yield for the drug was too low when using these solvents. Initially 
extraction was carried out vigorously (maximum speed) on the whirlmixer for 
about 10 sec but unsatisfactory results were obtained. It was determined that 
the extraction time was critical with respect to the interference of endogenous 
substances. Mixing times greater than 5 sec at half the maximum speed gave 
interference, whereas the compounds to be analyzed had already been extracted 
detector response (%) 
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FIG. 1. Gas chromatograms of a 2-ml plasma extract obtained from a subject prior 
to (left) and 8 h after (middle) receiving 150 mg vinylbital orally. The right gas 
chromatogram was obtained after extraction of a 2-ml blank plasma sample to which 
0.25 ,ug vinylbital (VB) had been added. Hexobarbital (H) was used as internal 
standard (concentration 1.0 /'g/ml plasma). 
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sufficiently in this time. Another improvement was afforded by using 5 ml sol­
vent instead of 10 ml and adding 1 ml of phosphate buffer to the sample before 
extraction. Finally, 3 - 4 sec were chosen as the optimal extraction time and gas 
chromatograms obtained in this manner are shown in Fig. 1. There still appears 
to be a plasma peak, but this does not interfere with vinylbital and hexobarbital 
and consequently the latter compound was chosen as internal standard. Vinyl­
bital concentrations down to 50 ng/ml plasma can be measured. 
A recovery of about 86% was found for vinylbital at each concentration, 
when the extraction lasted for 3 - 4 sec (Fig. 2). For hexobarbital this value was 
ptale area vinylbital 
peak area hexobarbital 
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FIG. 2. Peak area ratio of vinylbital to hexobarbital as a function of known vinylbital 
concentrations for the determination of recovery. The plasma curve was obtained in 
the same way as described for the preparation of a calibration graph, except that 
2.0 ,iig hexobarbital was always added after extraction. The standard curve was 
obtained by comparing known standard amounts of vinylbital to 2.0 μ% hexobarbital. 
9 1 % . In Fig. 3 calibration curves for the determination of vinylbital in plasma 
are given and it appears that there is a little variation with time. This might 
be due to selective changes in sensitivity of the nitrogen detector towards one 
of the two compounds. Another possible explanation is that the extraction 
yield of vinylbital might vary slightly, as this is somewhat dependent on extrac­
tion time. It was necessary to prepare a calibration graph for each day when 
a series of samples had to be analyzed for vinylbital. This disadvantage is only 
of minor importance since it is not time consuming. 
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FIG. 3. Calibration graphs for the determination of vinylbital in plasma, prepared on 
different occasions, using hexobarbital as internal standard (1.0 ^g/ml plasma). 
With respect to the determination of unchanged vinylbital in urine, the best 
results were obtained with a mixture of diethyl ether and light petroleum, to 
which a small amount of propanol-2 had been added. Extraction time was not 
very critical with this solvent system and quite clean gas chromatograms were 
obtained. Possibly one or two metabolites are co-extracted, but these have not 
been identified. The procedure is suitable for measuring vinylbital concentrations 
down to 1 /(g/10 ml urine. 
CONCLUSION 
This procedure for the determination of vinylbital in plasma and urine gives 
satisfactory results. The method is rapid, specific and sensitive; the extraction 
time is a critical factor. A calibration curve has to be prepared with each 
sample series. 
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CHAPTER 6 
HEPTABARBITAL IN PLASMA AND URINE 
INTRODUCTION 
Heptabarbital (5-ethyl-5-(l-heptenyl)-barbituric acid), whose structure is 
shown below, has a relatively low pKa-value (7.45), and the highest lipophility 
of the non-N-methylated barbiturates used in the present investigations (Chapter 
1 of this Section). It is the only barbiturate with a seven membered ring, that 
is used in therapy. 
hrptabarbitcil 
No specific method for the quantitative determination of heptabarbital in 
biological fluids has been reported previously in the literature. Therefore such 
a method was developed, using gas chromatography with nitrogen selective 
detection, for the study of the pharmacokinetics of heptabarbital in man. 
MATERIALS AND METHODS 
Reagents 
Heptabarbital was obtained from CIBA-GEIGY, Arnhem, The Netherlands 
(a gift of heptabarbital for reference purposes is greatfully acknowledged). 
Hexobarbital was obtained from OPG, Utrecht, The Netherlands. Diethyl ether, 
light petroleum, boiling range 40 - 60° and propanol-2 were of analytical-
reagent grade (E. Merck). Diethyl ether was freshly distilled before use. 
Phosphate buffer pH 6.0 was prepared by adding 61.5 ml of a solution con-
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taining 6.745 g N a 2 H P 0 4 . 12 H2O/250 ml of distilled water to 438.5 ml of 
a solution containing 4.54 g KH2PO4/500 ml of distilled water. A standard 
heptabarbital solution was prepared at a concentration of 1 mg/100 ml ab­
solute ethanol (analytical-reagent grade, E. Merck). A standard hexobarbital 
solution was prepared at a concentration of 2 mg/100 ml absolute ethanol. 
Extraction procedure 
Plasma. To 2.0 ml plasma in a conical tube was added 1.0 ml of phosphate 
buffer pH 6.0 and 0.1 ml of internal standard solution containing 2 fig hexo­
barbital. The mixture was extracted twice with 5 ml of diethyl ether - light 
petroleum - propanol-2 (49 : 49 : 2) on a Cenco whirlmixer, for 10 sec twice. 
The combined organic layers were evaporated to dryness in a stream of dry 
air. The residue was dissolved in 0.1 ml of absolute ethanol and 2 - 5 μΐ of this 
solution were injected into the gas Chromatograph. 
Urine. The same procedure as for plasma was followed, except that 10.0 ml 
urine were extracted twice with 10 ml solvent. 
Gas chromatography 
As described in Chapter 1, Section II. 
Preparation of calibration graphs 
The concentration of heptabarbital in plasma and urine samples was cal­
culated with the aid of calibration graphs, which were prepared by adding 
known amounts of heptabarbital to 2.0 ml of blank plasma or 10.0 ml blank 
urine. The samples were analyzed by the same procedure described above and 
the ratio of the peak areas of heptabarbital to internal standard was plotted 
against known concentrations of heptabarbital. 
RESULTS AND DISCUSSION 
By utilizing the experience gathered with the analysis of vinylbital (Chapter 5 
of this Section) the extraction was tried initially with diethyl ether alone, for 
3 - 4 sec. A clean gas chromatogram was obtained during the first few minutes, 
as was shown in the case of vinylbital. Heptabarbital, however, has a realitively 
long retention time (4.2 min) and it was apparent that there was still slight 
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FIG. 1. Gas chromatograms of a 2-ml plasma extract obtained from a subject 6 h 
after (left) and 24 h after (right) receiving 200 mg heptabarbital orally. Hexobarbital 
was used as internal standard (1.0 ("g/ml plasma). 
interference with concomitantly extracted endogenous plasma material. A 
mixture of diethyl ether and light petroleum was tried therefore, and this gave 
satisfactory results, although a small amount of propanol-2 had to be added in 
order to increase the extraction yield. In Fig. 1 gas chromatograms are shown 
of plasma extracts containing heptabarbital, with hexobarbital as the internal 
standard. Once again there is the same plasma peak as noted with the diethyl 
ether extraction, but there is no interference at 4.2 min. The extraction time is 
not very critical and 10 sec was chosen subsequently. It is evident that the 
recovery of heptabarbital from plasma is high (about 92%) (Fig. 2) and constant 
over a great concentration range. The extraction yield of hexobarbital by this 
procedure was about 92%. 
Calibration graphs (Fig. 3) are linear over a great concentration range. There 
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FIG. 2. Peak area ratio of heptabarbital to hexobarbital as a function of known 
hcptabarbital concentrations for the determination of recovery. The plasma curve 
was obtained in the same way as described for the preparation of a calibration graph, 
except that 2.0 «g hexobarbital was always added after extraction. The standard 
curve was obtained by comparing known standard amounts of vinylbital to 2.0 ,ug 
hexobarbital. 
is some variation with time, but this does not exceed ± 5%. The data are, 
however, non-randomly distributed around the same mean curve and it is 
recommendable therefore to construct a calibration graph at regular times. 
Equally good results were obtained for the heptabarbital determination in 
urine. Two extra peaks were present in the gas chromatogram, probably repre­
senting hcptabarbital metabolites. No attempt has been made yet to identify 
these compounds. 
CONCLUSION 
The procedure for the determination of heptabarbital in plasma and urine 
gives satisfactory results. The method is rapid, specific and sensitive. It is recom­
mended that a calibration curve is prepared with each sample series. 
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FIG. 3. Calibration graphs for the determination of heptabarbital in plasma, prepared 
on different occasions, using hexobarbital as internal standard (1.0 ^g/ml plasma). 
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CHAPTER 7 
BUTOBARBITAL IN PLASMA 
INTRODUCTION 
Butobarbital (5-ethyl-5-n-butyl-barbituric acid), whose structure is shown 
below, is one of the oldest barbiturates used in hypnotic drug therapy, but no 
pharmacokinetic data are available when therapeutic doses are given to man. 
Most likely this is due to the lack of a sensitive method for the quantitative 
determination of the drug in blood or plasma. Therefore such a method was 
developed, using gas chromatography with nitrogen selective detection. 
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MATERIALS AND METHODS 
Reagents 
Butobarbital and hexobarbital were obtained from OPG, Utrecht, The Nether­
lands. Diethyl ether was of analytical-reagent grade (E. Merck) and was freshly 
distilled before use. A standard butobarbital solution was prepared at a con­
centration of 1 mg/100 ml absolute ethanol (analytical-reagent grade, E. Merck). 
A standard hexobarbital solution was prepared at a concentration of 3 mg/100 
ml absolute ethanol. 
Extraction procedure 
Plasma. To 2.0 ml plasma in a conical tube was added 2.0 ml of distilled 
water and 0.1 ml of internal standard solution containing 3 μ% hexobarbital. 
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The mixture was extracted twice with 10 ml diethyl ether. Mixing was carried 
out at half the maximum speed on the whirlmixer (about 20 r.p.s.), twice, 
during 4 - 5 sec. The combined organic layers were evaporated to dryness in a 
stream of dry air. The residue was dissolved in 0.1 ml of absolute ethanol and 
2-5 μΐ of this solution were injected into the gas Chromatograph. 
Gai chromatography 
As described in Chapter 1, Section II. 
Preparation of calibration graphs 
The concentration of butobarbital in plasma was calculated with the aid of 
calibration graphs, which were prepared by adding known amounts of butobar­
bital to 2.0 ml of blank plasma. The samples were analyzed by the same 
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FIG. 1. Gas chromatograms of a 2-ml plasma extract obtained from a subject 1 h 
after {left) and 72 h after (right) receiving 200 mg butobarbital orally. Hexobarbital 
was used as internal standard (1.5 /¿g/ml plasma). 
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FIG. 2. Peak area ratio of butobarbital to hexobarbital as a function of known 
butobarbital concentrations for the determination of recovery. The plasma curve 
was obtained in the same way as described for the preparation of a calibration graph, 
except that 3.0 //g hexobarbital was always added after extraction. The standard 
curve was obtained by comparing known standard amounts of butobarbital to 3.0 μg 
hexobarbital. 
procedure described above and the ratio of peak areas of butobarbital to in­
ternal standard was plotted against known concentrations of butobarbital. 
RESULTS AND DISCUSSION 
Special attention was paid to the purity of the butobarbital sample used in 
the present investigation. De Zeeuw and Wijsbeek (1973) found that in a variety 
of commercially available batches of butobarbital tablets a second compound 
was present. They identified this component as 5,5-di-n-butyl-barbituric acid 
(dibutylbarbituric acid), which is a by-product of the synthesis of butobarbital. 
In the bulk sample of butobarbital used for the assay and also for the in vivo 
studies, this compound could not be detected by gas chromatography. Injection 
of 100 ng of butobarbital sample resulted only in one major peak and it was 
therefore concluded that the sample did not contain dibutylbarbituric acid in 
levels higher than 1%. 
The extraction procedure of butobarbital from plasma gave no special 
problems and it is similar to that for vinylbital. Also, the extraction time is 
again critical and should be restricted to 5 sec. The best results were obtained 
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FIG. 3. Calibration graph for the determination of butobarbital in plasma using 
hexobarbital as internal standard (1.5 «g/ml plasma). Mean values and standard 
deviations of at least three determinations. 
by adding 2.0 ml water to the samples and extracting twice with 10 ml diethyl 
ether. In Fig. 1 gas chromatograms are shown of a plasma extract containing 
butobarbital and hexobarbital as the internal standard. Butobarbital has the 
shortest retention time of all of the barbiturates which were studied. A plasma 
sample extract is always injected twice into the gas Chromatograph, so that a 
single analysis lasts approximately 6 min. A 78% recovery was found for buto-
barbital by this procedure (Fig. 2). Concentrations down to 50 ng/ml plasma 
can be determined. From the calibration curve in Fig. 3, which is composed 
of at least three individual calibration curves prepared on different occasions, 
it can be deduced that the procedure is highly reproducible over a large con-
centration range. Standard deviations did not exceed ± 4 % . 
CONCLUSION 
This method for the assay of butobarbital in plasma is rapid, sensitive and of 
good precision. It is therefore suitable for the study of butobarbital kinetics in 
man. 
REFERENCE 
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CHAPTER 8 
CYCLOBARBITAL IN PLASMA 
INTRODUCTION 
Cyclobarbital (5-ethyl-5-(l-cyclohexenyl)-barbituric acid), whose structure 
is shown below, is structurally related to hexobarbital, since it also contains a 
cyclohexenyl group. Its lipophility is however much lower, since it is not 
N-methylated. 
cyclobarbital 
No specific assay is available for the determination of therapeutic plasma 
levels in man. Such a method was developed, which requires the preparation of 
derivatives, using gas chromatography with nitrogen selective detection. 
MATERIALS AND METHODS 
Reagents 
Cyclobarbital was obtained from E. Merck, Darmstadt, G.F.R. and cyclopal 
(5-ethyl-5-(l-cyclopentenyl)-barbituric acid) was obtained from Siegfried, Swit-
zerland (a gift of this compound for reference purposes is greatfully acknowled-
ged). Diethyl ether, light petroleum, boiling range 40 - 60° and propanol-2 were 
of analytical-reagent grade (E. Merck). Diethyl ether was freshly distilled before 
use. Phosphate buffer pH 6.0 was prepared by adding 61.5 ml of a solution 
containing 6.745 g Na2HP04. 12 H2O/250 ml of distilled water to 438.5 ml of 
a solution containing 4.54 g KH2PO4/500 ml of distilled water. A standard 
cyclobarbital solution was prepared at a concentration of 2 mg/100 ml absolute 
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ethanol (analytical-reagent grade, E. Merck). A standard cyclopal solution was 
prepared at a concentration of 4 mg/100 ml absolute ethanol. Trimethylanili-
nium hydroxide (TMAH), about 0.1 M in methanol, was prepared according to 
the method of Brochmann-Hanssen and Оке (1969). 
Extraction and formation of derivatives 
Plasma. To 2.0 ml plasma in a conical tube was added 1.0 ml of phosphate 
buffer pH 6.0 and 0.1 ml of internal standard solution containing 4 fig cyclopal. 
The mixture was extracted twice with 5 ml of diethyl ether-light petroleum-
propanol-2 (49 : 4 9 : 2 ) on a Cenco whirlmixer. Mixing was carried out 
vigorously for about 5 sec (twice). The combined organic layers were evaporated 
to dryness in a stream of dry air. The residue was dissolved in 50 /Л methanol 
and 25 μΐ of TMAH solution were added; after homogenization 2 - 5 /Л of the 
mixture were injected into the gas Chromatograph. 
Gas chromatography 
As described in Chapter 1, Section II. 
Preparation of calibration graphs 
The concentration of cyclobarbital in plasma was calculated with the aid of 
calibration graphs, which were prepared by adding known amounts of cyclo­
barbital to 2.0 ml of blank plasma. The samples were analyzed by the extraction 
and derivatization procedure described above and the ratio of peak areas of 
cyclobarbital to internal standard was plotted against known concentrations of 
cyclobarbital. 
RESULTS AND DISCUSSION 
With the assays of vinylbital, heptabarbital and butobarbital in plasma 
(Chapter 5, 6 and 7 of this Section), it was observed that a plasma peak with 
a retention time of 2.5 - 3 min always appeared in the gas chromatogram (see 
Fig. 1, Chapter 5). This represents endogenous plasma material that was ex­
tracted with the common organic solvents. Unfortunately, cyclobarbital coin­
cides with this peak on a 3% OV-17 column. Therefore derivatization of this 
compound was necessary, in order to change its gas chromatographic behaviour. 
Barbiturates may be methylated readily to dimethylbarbiturates, which are 
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FIG. 1. Gas chromatograms of a 2-ml plasma extract obtained from a subject 7 h 
after (left) and 33 h after (right) receiving 300 mg cyclobarbital calcium orally. The 
peaks in the gas chromatograms represent the dimethylated derivatives of the parent 
drugs. Cyclopal was used as internal standard (2.0 i«g/ml plasma). 
more volatile than the unmethylated compounds. Cook et al. (1961) have used 
diazomethane as a methylating agent, while Martin and Driscoll (1966) prefer­
red to use dimethyl sulfate. Also, Stevenson (1966) reported quantitative on-
column methylation with tetramethylammonium hydroxide. The best results 
were obtained by the procedure of Brochmann-Hanssen and Оке (1969), who 
improved the procedure by using trimethylanilinium hydroxide, which affords 
efficient flash-heater methylation. Their method was applied by Ehmebo et al. 
(1972) for the plasma assay of amobarbital and pentobarbital and these authors 
reported highly reproducible results. In the present study also trimethylanilinium 
hydroxide was used for the determination of cyclobarbital in plasma and the 
gas chromatograms obtained are shown in Fig. 1. In contrast to non-methylating 
procedures, a large peak immediately after injection appeared. This is probably 
due to the elution of the methylating reagent or decomposition products, which 
contain a nitrogen atom and give rise to a high signal on the nitrogen selective 
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FIG. 2. Peak area ratio of cyclobarbital to cyclopal as a function of known cyclo-
barbital concentrations for the determination of recovery. The plasma curve was 
obtained in the same way as described for the preparation of a calibration graph, 
except that 4.0 μg cyclopal was always added after extraction. The standard curve 
was obtained by comparing known standard amounts of cyclobarbital to 4.0 μg 
cyclopal. 
pea к area eye l о barbital 
peakarea cyclopal ( I S ) 
3 0 -
25 
20 
15 
10 
05 
05 1 
/xg cyclobarbital /ml plasma 
FIG. 3. Calibration graph for the determination of cyclobarbital in plasma using 
cyclopal as internal standard (2.0 ,«g/ml plasma). Mean values and standard deviations 
of at least four determinations. 
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detector. The compounds to be analyzed, however, are well separated from this 
injection peak. There was no interference with concomitantly extracted plasma 
material and concentrations down to 100 ng/ml plasma can be determined in 
this way. Recovery of cyclobarbital was about 90% when extracting with the 
mixture of solvents (Fig. 2). From the calibration curve in Fig. 3 for the deter­
mination of cyclobarbital in plasma, which is composed of at least four in­
dividual curves prepared on different occasions, it can be concluded that the 
procedure is highly reproducible over a large concentration range. Standard 
deviations did not exceed zb 5%. 
CONCLUSION 
This procedure with derivative formation for the quantitative determination 
of cyclobarbital in plasma yields highly satisfactory results. The method is rapid, 
specific and sensitive and therefore suitable for the study of cyclobarbital 
kinetics in man. 
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CHAPTER 9 
CHLORAL HYDRATE, TRICHLOROETHANOL, 
TRICHLOROETHANOL-GLUCURONIDE AND TRICHLOROACETIC 
ACID IN BLOOD AND URINE, EMPLOYING 
GAS CHROMATOGRAPHY WITH HEAD-SPACE ANALYSIS 
INTRODUCTION 
The principle metabolites of chloral hydrate (CH) in man are trichloroethanol 
(TCE), TCE-glucuronide (TCE-Glu) and trichloroacetic acid (TCA), while the 
CNS depression that follows the ingestion of chloral hydrate is probably due 
entirely to TCE (Butler, 1948; Marshall and Owens, 1954). Recently, Garrett 
and Lambert (1973) reported extensively on the pharmacokinetics of TCE and 
its metabolites in dogs. No detailed studies on the pharmacokinetics of CH and 
metabolites in humans have been reported so far. 
A prerequisite for such studies is a sensitive assay for the simultaneous deter-
mination of unchanged drug and metabolites in the same blood or plasma 
sample. The spectrophotometric methods based on the Fujiwara reaction 
(Fujiwara, 1916) are in general not specific enough for pharmacokinetic studies 
after the intake of therapeutic doses in man (Seto and Schultze, 1956; Friedman 
and Cooper, 1958; Leibman and Hindman, 1964). A specific gas chromato-
graphic method with electron capture detection was described by Garrett and 
Lambert in 1966 and a modification on this method was reported by the same 
authors in 1973. However, time-consuming extractions of the rather polar sub-
stances into water-immiscible solvents are necessary in this procedure. Direct 
GC injection of the biological sample has been described for the determination 
of CH and TCE (Jain et al., 1967), but the risk of contamination of the column 
and electron capture detector in this technique is substantial. 
It was the purpose of the present study to develop a simple, sensitive and 
specific method for the assay of CH, TCE, TCE-Glu and TCA in blood and 
in urine. Trichloroacetaldehyde (dehydrated form of CH), TCE and TCA 
methyl ester are relatively volatile and this property offers the possibility of 
head-space analysis. When a dissolved substance is sufficiently volatile, the 
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determination of its concentration in the vapour phase can be used as a measure 
of the concentration in the liquid phase, provided that an equilibrium between 
the vapour and liquid phase has been reached. The head-space is the vapour in 
equilibrium with its liquid phase. With a gas-tight injection syringe, part of the 
head-space vapour is injected directly into the gas Chromatograph. In the litera­
ture, several volatile substances have been analyzed in biological samples by 
applying this principle e.g. inhalation anaesthetics (Yamamura et al., 1966) 
and ethanol (Bassette and Glendenning, 1968). 
In this Chapter the head-space analysis of CH, TCE and TCA is described. 
MATERIALS AND METHODS 
Materials 
Chloral hydrate (OPG, Utrecht, The Netherlands); trichloroethanol (Koch-
Light, Colnbrook, Great Britain) was redistilled before use; trichloroacetic acid, 
p.a. (E. Merck, Darmstadt, G.F.R.); sulphuric acid, 9 5 - 9 7 % , p.a. (Merck); 
dimethyl sulphate (BDH, Poole, Great Britain); lead acetate, p.a. (Merck) was 
used as a 20% solution in water. Sampling bottles were volumetric flasks 
(25.0 ml), cut at the calibration mark, with self-sealing silicone rubber caps 
(Beekman, Amsterdam, The Netherlands). Gas-tight Hamilton syringes varying 
in volume from 100 to 1000 /Л were used for taking head-space gas and in­
jection into the gas Chromatograph. 
Procedure 
For the quantitative determination of CH and its metabolites in whole blood, 
a sample was divided in two portions immediately after it had been taken by 
vein puncture and a small drop of heparin solution had been added as anti­
coagulant: 
(1) 1.0 ml for the analysis of unconjugated TCE (free TCE); and (2) 2.0 ml 
for the analysis of free TCE plus conjugated TCE (total TCE), of CH and 
TCA. These two portions are analyzed as follows. 
(1) A 1.0-ml volume of freshly taken whole blood was added to a vial con­
taining 1.0 ml of lead acetate solution. The presence of lead acetate prevents 
the in vitro conversion of CH into TCE. The contents of the vial were gently 
homogenized and the vial was then placed in a 60° water-bath, such that the 
water level was just below the rubber cap, until equilibrium was reached between 
the liquid and vapour phase (3 h). With a gas-tight syringe, which was main­
tained at 60° so as to prevent condensation, a known amount of the head-space 
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vapour was taken and analyzed directly for free TCE by gas chromatography. 
(2) A 2.0-ml volume of the same blood sample was added to another vial 
containing 1.0 ml of concentrated sulphuric acid. The function of this substance 
is outlined under Results and Discussion. After homogenizing the sample, the 
vial was equilibrated at 60° for 3 h. A known amount of the head-space vapour 
was taken and analyzed for CH and total TCE. The TCE-Glu concentration was 
calculated from the difference between the total TCE and free TCE. Then 
0.10 ml of dimethyl sulphate was added by means of a syringe in order to 
convert the TCA into its methyl ester. After re-equilibration for 4 h, the head-
space vapour was analyzed for this compound. 
The procedure for the analysis of urine samples is exactly the same as that 
for whole blood, except that the lead acetate solution is omitted. When relatively 
high concentrations were encountered, the urine samples were diluted with 
distilled water until proper measurement was possible. 
The concentration of CH and metabolites in the samples was calculated with 
the aid of calibration graphs, prepared by adding known amounts dissolved in a 
maximum of 0.1 ml of distilled water to blank samples of blood or urine. These 
samples were run through the procedure as described. The peak height per 
1000 /Л of head-space vapour was plotted against known concentrations of the 
compounds. The detector response was calibrated daily by injection of a known 
amount of standard solution of TCE in ethanol (0.10 mg per 100 ml). 
Gas chromatography 
A Hewlett-Packard gas Chromatograph, Model 402, with a Hewlett-Packard 
nickel-63 electron capture detector, Model 2-6195, and equipped with a 
Hewlett-Packard strip-chart recorder, Model 7127A, was used. Glass columns 
(1.8 m χ 3 mm I.D.) were packed with 10% OV-17 on Gas-Chrom Q, 80 - 100 
mesh (Applied Science Labs., State College, Pa., U.S.A.). The injector block 
was maintained at 150°, the column at 125° and the electron capture detector 
at 200°. Flow-rates were 20 ml/min for the carrier gas (nitrogen) and 60 ml/min 
for the purge gas (argon-methane, 95 : 5). The electron capture detector was 
operated at pulse 5 and the electrometer setting was kept continuously at range 
10, attenuation 8. 
RESULTS AND DISCUSSION 
A major advantage of head-space analysis is that no time-consuming extrac­
tion procedure is required before analysis can be carried out. This advantage 
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is particularly important for the relatively polar substances studied in this 
work, because they are difficult to extract into water-immiscible solvents. 
Garrett and Lambert (1966; 1973) used diethyl ether, for which the following 
partition coefficients were determined: CH 0.191 and TCE 22. No partition 
coefficient is available for TCA, but it seems likely that it is very unfavourable 
with respect to the organic phase. Therefore, only TCE appears to have suffi-
cient lipophility for a substantial extraction yield. Nevertheless, Garrett and 
Lambert seemed to obtain satisfactory results for all compounds with extraction 
by diethyl ether. The other gas chromatographic method that has been described 
for the analysis of CH and its metabolites is the technique of direct injection of 
the biological sample (Jain et al., 1967). However, it has been our experience 
that direct injection of aqueous solutions results in poor peak reproducibility 
with electron capture detection. 
It is the relative volatility of trichloroacetaldehyde, TCE and TCA methyl 
ester that offers the possibility of head-space analysis, although a relatively 
¿» timcffmn; 
FIG. 1. Left: Gas chromatogram of trichloroethanol after direct injection of head-
space gas, in equilibrium with a 1.0-ml blood sample + 1.0 ml of lead acetate 
solution. The TCE blood concentration was 8.0 ^g/ml. Right: Equilibration flask 
with rubber cap. 
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FIG. 2. Gas chromatograms of chloral hydrate (CH), trichloroethanol (ТСЕ) and 
trichloroacetic acid methyl ester (TCA) after direct injection of head-space gas, in 
equilibrium with a 2.0-ml blood sample + 1.0 ml of concentrated sulphuric acid. 
Blood concentrations of the compounds were: CH, 10.2 ¿ig/mljTCE, 12.6 /ig/ml (in-
jection volume 1000 μΐ) and TCA, 10.5 ^g/ml (injection volume 500 μΐ). 
high equilibration temperature and a long equilibration time are required. In 
Fig. 1 and 2 typical gas chromatograms are shown after direct injection of the 
head-space gas in equilibrium with a blood sample containing CH, TCE and 
TCA. The times after which equilibrium was reached between the concentration 
in the liquid phase and in the head-space were verified by analyzing five stan­
dard solutions of CH, TCE and TCA at several time intervals. In Fig. 3, the 
curves obtained for TCE and TCA are shown and it can be concluded that 
TCE reaches equilibrium after about 3 h and TCA after about 4 h. Also, a 
time of 3 h was found for CH. The relatively high temperature of 60° has 
been chosen arbitrarily; it results in an enrichment of the head-space vapour 
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FIG. 3. Change of concentration (peak height per 1000 «1 of head-space gas injected) 
of TCE and ТСЛ methyl ester in the gas phase during equilibration at 60° (2.0 ml of 
blood + 1.0 ml of concentrated sulphuric acid). Concentration of TCE, 5.0 ,«g/ml 
blood (injection volume 1000 «1) and concentration of TCA, 18.0 ^g/ml blood 
(injection volume 250 «1). Mean values ± standard deviation for five determinations. 
and it was observed that shorter equilibrium times were required than at lower 
temperatures. 
When using the column packings described in the literature, CH and TCE 
exhibit relatively broad peaks. Therefore, several stationary phases were in­
vestigated, including OV-17, OV-17 plus orthophosphoric acid, Carbowax 20M 
and Carbowax 20M-terephthalic acid. A loading of 10% OV-17 on Gas-
Chrom Q (80 - 100 mesh) proved to be the most satisfactory packing. A good 
separation was obtained and for all compounds symmetrical and well defined 
narrow peaks with short retention times were obtained (Fig. 2). The repeated 
injection of the same sample demonstrates the good reproducibility (standard 
deviation ± 3 % ) . The gas chromatogram of a blank blood or urine sample 
treated in the above manner is completely clean and there are no interfering 
peaks due to normal blood or urine constituents (Fig. 1). 
It seems obvious that for the quantitative determination of this type of com­
pounds, an electron capture detector should be used. The response of a normal 
flame ionization detector is determined by the number of C-Η bonds per 
molecule and these are few in CH and its derivatives. However, the response 
of an electron capture detector depends on the electron affinity of the compound 
to be analyzed, and this is high for halogen-containing substances. Garrett and 
Lambert (1966; 1973) found that the sensitivity of the flame ionization detector 
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is only slightly greater than the Fujiwara UV method according to Friedman 
and Cooper (1958), while their own method with electron capture detection 
was much more sensitive. In the present study, use was made of a nickel-63 
electron capture detector with 0.75-^sec voltage pulses and intervals of 5, 15, 
50 and 150 /<sec. Although the sensitivity increases with increasing pulse inter­
val, the sensitivity obtained with the lowest pulse interval is satisfactory for 
physiologically encountered drug concentrations. A practical disadvantage of 
the electron capture detector is its small linear dynamic range. However, this 
gave no problems when using a pulse interval of 5 and electrometer settings of 
range 10 and attenuation 8. Every response smaller than full-scale deflection 
(25 cm) proved to be out of the linear dynamic range (Fig. 4). If this was not 
the case, the injection volume was reduced. The quantitative parameter used 
in this study was the peak height per 1000 μΐ of head-space vapour. That there 
is no essential difference in choosing the peak height or peak area as a measure 
for the detector response can also be concluded from the results shown in Fig. 4. 
cm resp. cm 2 . 
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FIG. 4. Calibration curves for CH in blood. For each concentration, the injection 
volume was 1000 μΐ of head-space gas. Note the linearity over the first 25 cm, which 
corresponds to full scale deflection of the recorder at range 10, attenuation 8 (electron 
capture pulse 5). Also, there is no essential difference between choosing peak height 
or peak area as a measure of the detector response. Mean values ± standard deviation 
for five determinations. 
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FIG. 5. Calibration curves for TCE, ТСБ in the presence of sulphuric acid and TCA 
in blood and in urine. The detector response was measured as the peak height per 
1000 /Λ of head-space gas. The volumes injected were such that the detector response 
was in the linear dynamic range. 
Calibration curves for the different compounds obtained by the procedure 
described are shown in Fig. 5. There is a linear relationship between detector 
response and concentration, provided that the injection volume has been adap­
ted to the linear dynamic range of the detector. The sensitivity, however, is 
dependent on the composition of the liquid phase, blood or urine and the com­
pound in question. Also, sulphuric acid has a great influence on the concen­
tration of the three substances in the head-space gas. It enhances the formation 
of trichloroacetaldehyde, which is the more volatile form of CH. The increase 
in response of TCA methyl ester is about a factor 10 in the presence of sulphuric 
acid. The primary reason, however, for adding this strong acid to the samples 
is to achieve hydrolysis of TCE-Glu into TCE, so that total TCE can be deter­
mined and then conjugated TCE can be calculated by difference. Sulphuric acid 
also prevents the in vitro conversion of CH into TCE, as does lead acetate. This 
is necessary, for Butler (1949) reported on the very rapid in vitro reduction of 
CH by erythrocytes. Therefore, it is important that immediately after they have 
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been taken, the blood samples should be mixed with sulphuric acid or lead 
acetate. Analysis may then follow within 48 h. 
There is also the possibility of determining plasma concentrations instead of 
blood concentrations, in which case the blood has to be centrifuged immediately 
after the sample has been taken. 
For the esterification of TCA, dimethyl sulphate is used, and as this is an 
equilibrium reaction it could be expected that the amount of dimethyl sulphate 
added influences the amount of ester that is formed. It was observed that the 
addition of 0.30 ml instead of 0.10 ml of dimethyl sulphate results in an increase 
in the response by a factor of about 2.2. This effect means that the amount 
of dimethyl sulphate must be carefully added by means of a calibrated syringe. 
At first, it was tried to determine CH, TCE-total and TCA simultaneously, as 
there is a good gas chromatographic separation of the three compounds. 
However, dimethyl sulphate appeared to influence the response of TCE in an 
irreproduciblc manner and therefore TCE has to be determined in the absence 
of dimethyl sulphate. This requires a separate equilibration period for the 
analysis of TCA. 
The detection limits, under the conditions applied, are ca. 0.5 /<g/ml for 
CH and TCE and 0.1 /<g/ml for TCA in blood or urine. Lower detection limits 
can easily be obtained by increasing the pulse interval. The precision was deter­
mined by measuring the peak height after adding known concentrations of the 
compounds to a blank sample of blood or urine. Standard deviations did not 
exceed ± 6 % (five determinations), except for free TCE, for which the standard 
deviation was 6-8% (five determinations). 
CONCLUSION 
The method described for the determination of chloral hydrate and meta­
bolites in blood and urine is simple and sensitive, and the precision is satis­
factory. It is therefore suitable for the study of pharmacokinetics and metabolism 
of chloral hydrate in man. 
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SECTION III 
P H A R M A C O K I N E T I C S A N D Β ΙΟ Ρ Η AR M A C E U T I C S 
OF B A R B I T U R A T E S AND C H L O R A L H Y D R A T E 
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CHAPTER 1 
HEXOBARBITAL AND HEXOBARBITAL SODIUM 
A. GENERAL INTRODUCTION 
B. INTRAVENOUS ADMINISTRATION 
С ORAL AND RECTAL ADMINISTRATION 
A. GENERAL INTRODUCTION 
Hexobarbital was introduced into drug therapy in 1931. Its sodium salt has 
been used widely as an anaesthetic agent which is administered intravenously 
for the production of complete anaesthesia of short duration or for the 
induction of general anaesthesia. This application is similar to that of thiopental 
sodium, but hexobarbital has been largely superseded by thiopental, metho-
hexital and non-barbiturate intravenous anaesthetics (Price and Dripps, 1970). 
The description „very short-acting" or „ultrashort-acting", which is often 
associated with the anaesthetic barbiturates (Sharpless, 1970; Martindale, 
1972), is misleading and this has been referred to by Mark (1969). These 
compounds are not rapidly inactivated in the body, but the prompt recovery 
from anaesthesia following small doses, is due primarily to redistribution of the 
active substances from the brain to other less well-perfused tissues (Mark et 
al., 1949; Richards and Taylor, 1956; Price et al., 1960). Higher doses may 
result in CNS depression of a very long duration (Tatum, 1939; Brodie et al., 
1951; Brodie, 1952). The pharmacokinetic behaviour of many of these drugs, 
including hexobarbital, is not elucidated yet. The reason that hexobarbital can 
be used as an anaesthetic agent may be explained on the basis of its moderately 
high lipid solubility, as evidenced by its partition coefficient compared to non-
N-methylated barbiturates (Chapter 1, Section II). It has been shown previously 
for barbiturates, that a high lipid solubility favours rapid brain penetration (Bro­
die et al., 1960; Mark, 1963). Although the lipophility of hexobarbital is suffi­
ciently high to permit an instantaneous passage through the blood-brain barrier, 
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it is lower than some other barbiturates used for i.v. anaesthesia, including 
thiopential and methohexital (Bush et al., 1966). This may explain the prevailing 
opinion that the duration of hexobarbital CNS depressant action is a reflection 
primarily of metabolism rather than of redistribution from adipose tissue, as 
has been shown for thiopental (Richards and Taylor, 1956; Price et al., 1960; 
Bush and Weller, 1972). This explains why hexobarbital has been used as a 
model substrate in hundreds of studies concerning the activity of the mixed -
function oxygenase system in the liver, where the compound is metabolized 
(Cooper and Brodie, 1955; Toki et al., 1963). Its hypnotic (anaesthetic) action 
is such that suitable and convenient doses, injected i.p. to rats or mice, produce 
a profound sleep of moderate duration. Thus, either shortening or lengthening 
of the sleeping time can be measured with acceptable accuracy (Stitzel et al., 
1966; Bush and Weller, 1972). The change in sleeping time is then considered 
as a measure for the change of oxidative enzyme activity. 
Bush and Weiler (1972) have reported an extensive review of the fate of 
hexobarbital in different species. In man information is apparently very scarce. 
Brodie (1952) has measured blood levels after i.v. administration of 3 g hexo-
barbital sodium to one human subject and it has been deduced, from the blood 
concentration curve, that the half-life of this drug was about 5 h. However, 
it should be realized that the administered dose was exceptionally high. Blood 
levels after oral administration of hexobarbital sodium to human volunteers 
were reported by Bush et al. (1966) and by Sjögren et al. (1965). Concen-
trations, however, could only be followed for a few hours, so that the estimation 
of half-lives was impracticable. It is evident therefore, that even though hexo-
barbital is a drug that has been in use for many years, its pharmacokinetics 
have not been well defined. Improvement in the sensitivity of the assay for 
hexobarbital (Breimer and van Rossum, 1974; Chapter 2, Section II) makes 
it feasible to determine the pharmacokinetics after therapeutic doses to man. 
The primary reason that hexobarbital and hexobarbital sodium were in-
cluded in the present investigation on the pharmacokinetics of hypnotic drugs 
in man, was based upon the impression that hexobarbital was rapidly meta-
bolized in man (Brodie, 1952). Alvarez (1971) showed that this compound was 
the barbiturate that was most rapidly metabolized in rats, when compared with 
several other barbiturates. A further advantage may be the fact that its duration 
of action is not complicated by a strong accumulation into fat tissue (Richards 
and Taylor, 1957). In a clinical trial on the effectiveness of several barbiturates 
in insomnia, hexobarbital (as free acid in a 500 mg dose) was shown to be 
moderately effective. Bush et al. (1966) showed that the sodium salt of some 
anaesthetic barbiturates, including hexobarbital, did produce rapid and intense 
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sedation with relative short duration. These and other authors (Way and Tre-
vor, 1971) concluded that the sodium salt of thiopental or hexobarbital may 
be desirable for patients who have difficulties in getting to sleep. If the half-
life of the drug is relatively short, natural sleep may predominate again shortly 
after falling asleep. On the other hand, hexobarbital as free acid may be used 
for maintaining sleep, since the absorption rate of this form is probably slower 
(Sjögren, 1965). 
Firstly, the pharmacokinetics of hexobarbital were studied following intra-
venous administration of the drug to healthy human volunteers. The advantage 
of i.v. administration is that bioavailability uncertainty does not exist by de-
finition, so that reliable estimation of parameters is possible. Moreover, these 
healthy volunteers serve as controls in the study on the pharmacokinetics of 
hexobarbital in patients with liver disease (see Section IV). 
Secondly, several pharmaceutical formulations of hexobarbital and hexo-
barbital sodium were studied, mainly with respect to their absorption rate. 
This will be discussed for a comparison of the usefulness of a certain prepara-
tion in hypnotic drug therapy with hexobarbital. The administered dose was 
usually 600 mg, because it appeared in preliminary studies that following this 
dose the plasma concentration could be measured for sufficiently long periods 
of time. Furthermore the results of Hinton (1963) have indicated that a 500 mg 
dose of free acid is only moderately effective. 
Finally, plasma levels during repetitive hexobarbital administration were 
measured in order to determine if accumulation of the drug in the body would 
occur and also to ascertain whether the half-life of the drug would remain 
unchanged. 
B. INTRAVENOUS ADMINISTRATION 
METHODS 
Hexobarbital sodium (EVIPAN) for i.v. injection was obtained from 
BAYER AG, Leverkusen, GFR. Solutions were prepared by dissolving, im-
mediately before use, the sterile contents of an ampoule in sterile water (100 
mg/ml). 
Fourteen healthy male volunteers, ranging in age from 20 - 25 years and in 
body-weight from 50 - 83 kg, participated in the study. They had received no 
regular medication during the 4 weeks preceding initiation of the experiments. 
After an overnight fast, at 9 a.m., the subjects received hexobarbital sodium 
intravenously by 30 min or 60 min zero-order infusion. The doses applied 
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(calculated as hexobarbital free acid), were in the range of 7.23 - 8.82 mg/kg 
(see Table I). A relatively slow infusion procedure for i.v. drug administration 
was preferred in order not to discomfort the volunteers and to avoid systemic 
reactions which often follow rapid i.v. administration anaesthetic barbitu­
rates (Price and Dripps, 1970). The volunteers were kept lying for about 3 h 
after drug infusion. Blood samples (5 ml) were taken from a forearm vein at 
the following times during a 30 min infusion: 5, 10, 15, 20, 25 and 30 min 
and at 10, 20, 30, 40, 50 and 60 min in the case of a 60 min infusion. Further­
more blood samples were obtained usually at 10, 20, 30 min and 1, 2, 4, 6, 
8, 10, 12, 18 and 24 h post infusion. The blood was heparinized, centrifuged 
and the plasma was separated and frozen until assayed. The hexobarbital 
plasma concentrations were determined by gas chromatography with nitrogen 
selective detection, as described in Chapter 2, Section II. Five subjects collected 
their 24 hours' urine after hexobarbital administration and the amount of 
unchanged drug and 3-keto-hcxobarbital was determined as described in Chap­
ter 2 and 3 respectively, Section II. 
RESULTS 
During i.v. infusion of hexobarbital sodium a rapid rise in the hexobarbital 
plasma concentration occurred until the zero-order infusion was terminated. 
After this event the plasma concentration-time curve exhibited two distinct 
phases; an early phase with a relatively steep slope and a latter phase with a 
more gradual slope (Fig. 1). This suggests that the early rapid drop in hexo­
barbital plasma concentration is dictated by rapid tissue localization, whereas 
the subsequent more gradual slope is a reflection of the elimination of the 
drug. This kinetic behaviour is consistent with the conception that for hexo­
barbital the body consists of two kinetically distinct compartments: a central 
compartment and a peripheral compartment (Riegelman et al., 1968). The post-
infusion plasma concentration curve can be represented mathematically as a 
sum of two exponentials according to Loo and Riegelman (1970): 
C p = A,* . e-t'/ti + A2* . e"
1
*/^ (Eq. 1) 
where Cp is the post-infusion plasma concentration Aj* and A2* are the coef­
ficients (concentration intercepts of the exponential terms at t* = 0), τ1 and τ2 
are the time constants and t* is the time after the end of the infusion i.e. t* = 
t - T, where Τ is the infusion time. 
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FIG. 1. Hexobarbital plasma concentration curve on semi-Ioganthmic scale during 
and after a 30 mm zero-order i.v. infusion of hexobarbital sodium into a healthy 
volunteer. The post-infusion concentrations were fitted according to Eq. 5. The 
curve during infusion was calculated on basis of the parameters of the post-infusion 
curve; the concentrations during this phase (triangles) have not been used in the 
fitting procedure. The picture has been taken from a direct computer plot. 
During infusion the plasma concentration, based on two compartment kine­
tics, can be described by the following equation: 
Cp = A, . ^ (1 - е-*/*,) + A 2 . ^ - ( 1 - e"1/**) (Eq. 2) 
where Aj and A2 are the hypothetical intercepts with the ordinate for an 
intravenous bolus injection of the same amount of drug (i.e. Τ — 0). It is 
evident that Aj and A2 are equal to A / and A2* if Τ = 0, but the differences 
increase as the infusion time increases. The relationship between Aj*, Aj, and 
A2*, and A2 is shown by the following equations (Loo and Riegelman, 1968): 
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FIG. 2. The same experiment as in Fig. 1, but now concentrations during infusion 
were included in the fitting procedure, according to Eq. 6. It can be noted that 
there is now less agreement between the experimental data and the computed 
curve than in the case of Fig. 1 The picture has been taken from a direct computer 
plot. 
A,* = A , . - ( l - e " T ^ (Eq. 3) 
A n — **-2 ( 1 - е -T/r2) (Eq. 4) 
Once the hypothetical intercepts A1 and A2 together with the time constants 
have been determined, the pharmacokinetic parameters intrinsic to a two-
compartment open model can be calculated. 
In the present investigation with hexobarbital, use was made of the FARM-
FIT computer program and the post-infusion plasma concentrations were fitted 
according to the following general equation: 
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η 
Cp- Σ Α,. гі(1-с-Щ.^Т-^ (Eq. 5) 
i = 1 Τ 
A two-term exponential is assumed to describe the curve adequately (two-
compartment model, η = 2). The initial graphical estimates of x1 and τ2 were 
used as a start guess. A relative error of 5% in the plasma concentration was 
taken into account, since this is the standard deviation in the assay procedure 
(Chapter 2, Section II). An example of a fitted and directly plotted curve is 
given in Fig. 1 and it illustrates the agreement between the plasma levels and 
the two-compartment open model. The curve that was obtained during the 
infusion period, was simulated on the basis of the post-infusion parameters. It 
may be noticed that the experimental data, obtained for this subject during this 
period, are somewhat lower than theoretically expected. Initially these data 
were included for the computation of the best fitted total curve, which occurred 
according to the following general equation, and is valid during infusion: 
Cp= Σ Ai.-^l-e-tAi) (Eq. 6) 
i = 1 Τ 
A two-term exponential was supposed to underly the curve during infusion. 
The results of the combined fitting according to Eq. 5 and Eq. 6 are given in 
Fig. 2, for the same experiment as in Fig. 1. It can be observed now that there 
is less agreement between the experimental data and the computed curve, 
which also became apparent in the higher estimated standard errors of the 
fitted parameters. Although it is unlikely that the kinetic behaviour of hexo-
barbital during infusion is fundamentally different from the behaviour after 
infusion, it may be expected that the plasma concentration during the relatively 
rapid infusion period does not always follow two-compartment kinetics exactly. 
If these data are nevertheless included in the fitting procedure for the two-
compartment model, relatively large errors may be induced. It was therefore 
decided to use concentrations after infusion only, to obtain the more accurate 
model parameters. 
In Table I the pharmacokinetic parameters of hexobarbital in each of the 
fourteen volunteers as well as the mean values, are given. All the values for 
each individual are reported since it is considered important to present the 
degree of variability of the kinetics of a drug in man and also to examine the 
validity of the model for each individual. For the fitted parameters (τ,, τ2, Aj 
and A2) the estimated standard errors are given and it is evident that these 
are usually substantial with respect to τ1 and Aj. These parameters describe the 
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 TABLE I. Pharmacokinetic parameters of hexobarbital after intravenous administration to fourteen healthy male volun-
teers, according to the two-compartment open model (estimated standard errors of fitted parameters in j 
Name 
Age (yr) 
Body-weight (kg) 
Dose (free acid; mg) 
Dose/kg (mg) 
Inf.timc (min) 
τ 1 (min) 
r 2 (min) 
ti/£ (min) 
A 1 (mg/l) 
A 2 (mg/l) 
V, (1) 
V/kg (1) 
V, (1) 
Vt/kg (1) 
к,,] (ml/min) 
kd/kg (ml/min) 
r 1 2 (l/min) 
r.,, (l/min) 
K.H. 
22 
73 
548 
7.51 
60 
15.1 
366 
254 
13.7 
4.94 
29.5 
0.40 
89.8 
1.23 
272.2 
3.73 
0.040 
0.020 
(43.1%) 
( 7.4%) 
(51.3%) 
( 8.0%) 
1 
1 
H.R. 
23 
80 
548 
6.85 
30 
11.7 ( 8.4%) 
369 ( 2.1%) 
256 
17.1 (10.1%) 
5.41 ( 2.0%) 
24.3 
0.30 
83.9 
1.05 
249.5 
3.12 
0.055 
0.022 
B.W. 
23 
80 
548 
6.85 
60 
8.6 
290 
201 
30.2 
4.94 
15.6 
0.20 
80.0 
1.00 
323.9 
4.05 
0.080 
0.019 
(39.0%) 
( 6.2%) 
(54.1%) 
( 7.1%) 
1 
1 
E R . 
24 
74 
548 
7.41 
30 
5.95 (19.2%) 
365 ( 5.5%) 
253 
54.4 (30.3%) 
5.63 ( 4.5%) 
9.13 
0.12 
72.9 
0.99 
230.5 
3.11 
0.127 
0.018 
parentheses). 
K.B. 
25 
63 
461 
7.32 
60 
22.8 
230 
160 
8.70 
5.30 
32.9 
0.52 
65.3 
1.03 
326 
5.17 
0.019 
0.019 
( 8.4%) 
( 3.3%) 
( 9.4%) 
( 3.0%) 
» 
1 
к,., (ml/min) 1180 1340 1247 1162 627 
TABLE I continued. 
Name B.E. F.B. M.K. B.B. D.A. 
Age 
B-W 
Dose 
D/kg 
Τ 
и
'/
г 
Α . 
V/kg 
V, 
V/kg 
Κι 
k
e
i/kg 
* i . 
23 
69 
505.1 
7.32 
60 
31.0 
441 
306 
9.05 
6.20 
33.1 
0.48 
67.5 
0.98 
167.5 
2.43 
(37.2%) 
( 6.1%) 
(16.8%) 
(10.2%) 
0.015 
0.014 
497 
25 
77 
563.5 
7.32 
60 
19.6 
343 
238 
18.1 
3.90 
25.6 
0.33 
91.6 
1.19 
332.6 
4.32 
0.03C 
0.011 
755 
(31.9%) 
( 6.6%) 
(40.8%) 
(11.3%) 
1 
24 
70 
512.5 
7.32 
60 
28.4 
389 
270 
9.95 
5.56 
33.0 
0.47 
72.7 
1.03 
209.2 
2.99 
0.017 
0.014 
566 
(32.6%) 
( 4.6%) 
(31.1%) 
( 8.0%) 
22 
73 
534.4 
7.32 
60 
33.5 
368 
256 
9.96 
4.20 
37.7 
0.52 
87.8 
1.20 
284.5 
3.90 
0.014 
0.011 
539 
(49.2%) 
( 6.4%) 
(49.3%) 
(13.6%) 
24 
69 
505.1 
7.32 
60 
28.2 
299 
208 
17.0 
3.86 
24.2 
0.35 
67.9 
0.98 
308.8 
4.48 
0.017 
O.OOS 
405 
(25.9%) 
( 9.3%) 
(28.6%) 
(16.3%) 
Γ 
> 
TABLE I continued. 
Name 
Age 
B-W 
Dose 
D/kg 
Τ 
4 
τ2 
A, 
ν,/kg 
V, 
V tAg 
k
e l 
k^/kg 
ж12 
:.G. 
22 
50 
366.0 
7.32 
60 
81.6 
505 
351 
6.79 
4.79 
31.6 
0.63 
52.5 
1.05 
123.1 
2.46 
(21.4%) 
( 4.0%) 
(11.4%) 
( 7.9%) 
0.004 
0.006 
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W.G. 
23 
80 
585.6 
7.32 
60 
42.6 
635 
441 
13.2 
3.33 
35.5 
0.44 
111.9 
1.40 
219.3 
2.74 
-
(19.5%) 
( 6.6%) 
(18.8%) 
( 8.6%) 
0.013 
0.006 
458 
P.F. 
20 
83 
600 
7.23 
60 
39.6 
304 
211 
6.52 
4.64 
53.8 
0.65 
94.5 
1.18 
359.3 
4.33 
(35.0%) 
( 8.7%) 
(23.9%) 
(12.9%) 
0.009 
0.012 
506 
• 
S.M. 
21 
68 
600 
8.82 
60 
48.7 
366 
254 
6.70 
6.82 
44.4 
0.65 
70.0 
1.03 
212.6 
3.13 
(35.1%) 
( 8,2%) 
(19.5%) 
(10 8%) 
0.007 
0.012 
300 
t 
Mean ± 
22.9 
71.6 
530.4 
7.37 
29.8 
376 
261 
30.7 
0.43 
79.2 
1.10 
259 
3.57 
0.032 
0.014 
694 
S.D. 
± 1.4 
± 8.2 
± 61.1 
± 0.46 
-
± 19.7 
±99 
±69 
-
-
± 11.1 
± 0.16 
± 15.2 
± 0.12 
±69 
± 0.83 
± 0.034 
± 0.005 
±384 
rapid initial drop in plasma concentration after termination of the infusion, 
due to the distribution of the drug into the peripheral compartment. Only a 
limited number of plasma samples can be obtained during this short period of 
time. Consequently this is the main explanation for the relatively large errors 
in the parameters describing this phase. Usually, the errors in A2 and τ2 were 
much smaller and this substantiated the evidence for the single first-order 
kinetics of the elimination phase. The plasma half-life of hexobarbital in man 
is seen to vary from 160 to 441 min, with a mean value of 261 min. The main 
factors governing the rate of elimination of the drug in the body are the meta­
bolic clearance (k
e
i) and the apparent volume of distribution (Vf). This volume 
(per kg body-weight) is relatively constant in the subjects, whereas there is a 
substantial variability in the metabolic clearance constant (Table I). It can be 
concluded therefore that the observed differences in half-life are mainly due to 
individual differences in the hexobarbital metabolizing ability of the liver. Sie-
gert et al. (1964) found also a substantial individual variability of Ult in dogs 
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FIG. 3. Hexobarbital plasma concentration curve on semi-logarithmic scale during 
and after a 60 min zero-order i.v. infusion of hexobarbital sodium into a healthy 
volunteer. Fitting and plotting occurred in the same way as described for Fig. 1. 
It can be noted that with a 60 min infusion the plasma concentrations during 
infusion remain much lower than in the case of a 30 min infusion. 
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for hexobarbital, which they attributed to fluctuations in the amount of drug 
metabolizing microsomal protein. 
The calculated parameters Vj (the volume of the central compartment) and 
r1 2 (the distribution rate constant from the central to the peripheral compart­
ment) vary considerably due to the fact that their calculation is strongly 
dependent upon A1 and τν It is clear, however, that the volume of the central 
compartment is a factor two to three fold smaller than the overall apparent 
volume of distribution Vf. This indicates extensive tissue distribution of the 
drug, which may be explained by its relatively high lipophility. The smaller 
distribution rate contstant from the tissues to the plasma compartment (r2 1), 
when compared with r12, is a consequence of the apparent large volume of the 
tissue compartment. 
All of the volunteers displayed typical signs of central nervous system de­
pression during infusion (drowsiness, incoherent speech and sometimes sleep). 
These effects, which varied considerably in intensity from one person to the 
other, became more pronounced as the infusion proceeded. This was evident 
especially in the case of a 30 min infusion. Obviously, when infusion proceeds 
more rapidly the plasma concentration and also the brain concentration for 
this lipophilic drug rise more rapidly. The peak plasma concentrations were 
approximately 1.5 fold higher with a 30 min infusion than in the case of a 
60 min infusion (compare Fig. 1 to Fig. 3). After infusion recovery occurred 
relatively rapid and all the subjects were able to go out for lunch within 4 hours 
after drug administration. The plasma levels attained at this time were usually 
in the range of 2 - 4 mg/1. 
TABLE II. Cumulative renal excretion (24 h) of hexobarbital and 3-keto-hexo-
barbital after i.v. administration of hexobarbital sodium 
Subject 
W.G. 
B.B. 
D A . 
S.G. 
B.E. 
Dose administered 
(mg free acid) 
Mean percentages 
585.6 
534.4 
505.1 
366.0 
505.1 
Hexobarbital 
mg % of dose 
1.84 
1.37 
2.43 
1.51 
1.31 
0.31 
0.26 
0.48 
0.41 
0.26 
0.34 
3-keto-hexobarbital 
mg % of dose 
270.8 
221.3 
335.1 
148.4 
156.2 
43.7 
39.1 
62.6 
38.3 
29.2 
42.6 
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The results of the 24 hours' urinary excretion of unchanged drug and 3-keto-
hexobarbital for five of the participants are summarized in Table II. Hexobar-
bital is excreted unchanged only to a very small extent; it accounts for less 
than 0.5% of the administered dose. This is explained by its lipophilic proper­
ties and the relatively high ρΚ,-value, which make reabsorption from the ultra-
filtrate in the kidney self-evident. A metabolite which has been detected in the 
urine of several species, after hexobarbital administration, is 3-keto-hexo-
barbital (Bush and Weiler, 1972). Tsukamoto et al. (1957) and Frey et al. 
(1959) identified this compound in the urine of man, but no quantitative data 
on the renal excretion are available. The present findings suggest that 3-kcto-
hexobarbital is an important metabolite in quantitative terms, since its excretion 
accounts for 29-63% of the dose administered in 24 h. Information on the 
renal excretion rate of this metabolite will be given in Chapter 2 of this Section. 
DISCUSSION 
The first-order elimination of racemic hexobarbital is surprising, since in a 
previous investigation (Breimer and van Rossum, 1973; Chapter 2, Section III), 
it was found that the optical isomers of hexobarbital are eliminated with dif­
ferent rates in man. The (-|-)-isomer showed an average half-life of 4.6 h 
and the (—)-isomer of 1.4 h. As a consequence of this 3-fold difference in 
elimination rate, the elimination phase of the racemic mixture should not give a 
straight line from theory. Two different time constants are underlying this phase 
for the racemate. However, it can be argued that if a drug with a half-life of 
1.4 h is infused in a time period of 30 min or 1 h, then a great deal has already 
been eliminated during infusion and during the distribution phase. When the 
pure elimination phase is reached, the contribution of the (—)-isomer may be 
almost negligible. This is in agreement with the fact that the estimated half-life 
of the racemate is almost equal to the half-life of the (-t-)-isomer (4.4 h versus 
4.6 h). In fact, the half-life of the ( + )-isomer is being determined by the pre­
sent experimental procedure. Only when the racemic mixture of hexobarbital 
is administered by rapid i.v. infusion it may be possible to distinguish between 
the half-lives of the two enantiomers (Chapter 2, Section III). It should be 
realized that in the present experiments the infusion phase and distribution 
phase are in fact complex functions of the rapid elimination of (—^hexo­
barbital, the slower elimination of ( + )-hexobarbital and the distribution of 
the two compounds into peripheral tissues. 
The present pharmacokinetic data may provide information on the role of 
adipose tissue in hexobarbital elimination. Brodie et al. (1950, 1952) showed 
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that thiopental is taken up by adipose tissue to a considerable extent. Price et 
al. (1960) found that the uptake was a slow process, the equilibrium between 
plasma and adipose tissue was reached after 4 -5 h. The previously reported 
data were reconsidered by Bischoff and Dedrick (1968) and it follows from 
their calculations, that thiopental kinetics should be consistent with the three-
compartment open model. After 4 - 5 h a distinct slower phase may predo­
minate the elimination process, which is due primarily to redistribution of the 
drug from adipose tissue. The affinity of hexobarbital to fat is less than 
thiopental (Brodie, 1952), whereas it has a relatively high susceptibility for 
metabolic degradation (see clearance values). It is the combination of these 
two properties which is responsible for the fact that adipose tissue plays a 
minor role in the elimination of hexobarbital. At later times following drug 
administration there were no indications for a slower elimination phase than 
that corresponding to an average half-life of about 4 h. It seems likely that 
lean tissues (e.g. muscle, connective tissue, bone, lung, skin), are primarily 
responsible for the rapid depletion of hexobarbital from the central nervous 
system after i.v. administration, similar to thiopental (Price et al., 1960). This 
is an explanation for the rapid regain of consciousness after rapid i.v. appli­
cation for anaesthesia. Furthermore, it can be concluded from the present 
experiments that metabolism is also a main factor in the termination of CNS 
depressant action. The half-life of hexobarbital is such that it may be suited 
for hypnotic drug therapy. After a 9 hours' night's rest approximately 75% of 
the administered dose has been inactivated. Thus, the risk of residual effects 
is small, provided that a normal dose has been administered. 
С ORAL AND RECTAL ADMINISTRATION 
METHODS 
Composition and preparation of the dosage forms 
Seven dosage forms, containing hexobarbital and hexobarbital sodium were 
used in the present investigations. The compositions are outlined in Table III. 
The EVIPAN-tablets were obtained commercially and the other dosage forms 
were prepared at the Dutch Pharmacist's Laboratory, The Hague. The hexo­
barbital or hexobarbital sodium content was determined by the bromometric 
method of the National Formulary XII. The tablet content was determined 
acidimetrically. 
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TABLE III. Composition of the dosage forms containing hexobarbital or hexobarbital sodium. 
Hexobarbital1) 
Hexobarbital sodium2) 
Colloidal silica3) 
Methylcellulose 400cp*) 
Microcrystalline cellulose5) 
Dried potato starch«) 
Heavy magnesium oxide 
Adeps solidus7) 
Content (%)8) 
I 
300 mg 
-
1.7 mg 
-
60 mg 
-
-
-
98 
Capsule 
III 
300 mg 
-
1.7 mg 
1.4 mg 
60 mg 
-
-
-
100 
ν 
_ 
300 mg 
3 mg 
-
-
60 mg 
-
-
96 
VI 
_ 
300 mg 
3 mg 
-
-
-
60 mg 
-
97 
Tablet 
VIH») 
250 mg 
-
-
-
-
-
-
-
99 
Suppository 
IV 
600 mg 
600 mg 
-
-
-
-
-
1.4 g 
109 
VII 
_ 
-
6 mg 
-
-
-
-
1.4 g 
96 
i) Onderlinge Pharmaceutische Groothandel, Utrecht; 2) Siegfried S.A., Switzerland; s) AEROSIL 200; *) METHOCEL 400 
MC Dow Chemical; 5) AVICEL pH 101; «) water contents per cent; 7) WITEPSOL H15, Chemische Werke Witte; 
e) actual hexobarbital content in percent of stated content; β) EVIPAN, Bayer A.G. 
Hexobarbital acid was passed through a 150 /<m mesh sieve before mixing 
with the additives in preparation I, III and IV. Hexobarbital acid is only 
slightly soluble in water (1 g in 3000 ml according to Martindale, 1972). It 
was tried in capsule III to increase hydrophility of this compound by moisten­
ing with a 3% solution of methylcellulose in water. The mixture was passed 
through a 300 μτη mesh sieve, dried at 40° С and mixed with the other consti­
tuents (Cox and Smulders, 1969). 
Hexobarbital sodium is very hygroscopic and readily soluble in water. There­
fore additives were used which are effective water absorbents (magnesium 
oxide in capsule VI and dried potato starch in capsule V). Mixing was 
accomplished with a ball mill in order to prevent absorption of air moisture. 
The capsules (no. 0) were filled with a Feton fill-and-close hand apparatus. 
Suppositories IV were prepared by mixing the drug substance with the 
melted fatty base (Witepsol Η 15). The mixture was poured into 2 ml moulds. 
Suppositories VII were made in the same way using a mixture of hexobarbital 
sodium and colloidal silica prepared in a ball mill. Witepsol Η 15 is a mixture 
of mono-, di- and triglycerides with a melting range of 33.5 - 35.5° C, congeal­
ing range of 32.5-34.5° C, a specific gravity at 20° С of 0.950-0.980, an 
iodine number less than 7, a saponification value of 230 - 240 and a hydroxyl 
value less than 15. 
All preparations were stored in well-closed containers and protected from 
light. Hexobarbital sodium capsules were stored in well closed bottles containing 
anhydrous silicagel in the snap cap. 
In vivo experiments 
Twenty-eight healthy male volunteers, ranging in age from 18 - 26 years and 
in body-weight from 58 - 86 kg, participated in the study. They had received no 
regular medication during the 4 weeks preceding the initiation of the experi­
ments. After an overnight fast, at 9 a.m., the subjects were given 600 mg hexo­
barbital or 600 mg hexobarbital sodium, together with 150 ml water. Two of 
the capsules, 22/5 of the tablets and one suppository were required to achieve 
a dose of 600 mg (Table III). Initially, the volunteers were asked to remain 
in an upright position for about 15 min and then to lie down for at least 3 or 
4 h. This procedure was undertaken in order to simulate as closely as possible 
the situation of taking a hypnotic drug and going to bed. No food, fluid or 
tobacco was allowed for at least 3 h after drug administration. Blood samples 
were taken from a forearm vein at frequent times during the first 4 h. These 
differed somewhat for the various dosage forms but they can be deduced from 
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the plasma concentration curves given in Fig. 4 to 7. For several volunteers 
blood samples were taken also at later times, in order to determine the plasma 
half-life for hexobarbital. Hexobarbital plasma concentrations were measured 
by gas chromatography, as described in Chapter 2, Section II. 
Some volunteers participated several times during the present study; they 
received either the same dosage form or an alternative one. Intervals between 
any two trials were at least one week. Three of the volunteers who had re­
ceived a suppository containing 600 mg hexobarbital sodium, also received a 
suppository containing 100 mg hexobarbital sodium in order to study the 
influence of the dose on the absorption rate and the relative bioavailability after 
rectal administration. 
Participation in a study of repetitive hexobarbital administration is recorded 
for two volunteers. On the first day of the experiment the half-life of the drug 
was determined by administering 300 mg hexobarbital orally and taking blood 
samples at regular times. From the first night the volunteers took 300 mg 
hexobarbital sodium (capsule VI) with 150 ml water, each night. The next 
morning, nine hours after drug intake, a blood sample was taken usually and 
the hexobarbital plasma concentration was determined. After 9 days hexo­
barbital was given once again in the morning in order to determine the half-
life of the drug after repetitive administration. In Fig. 10 the time schedule of 
drug administration and blood sampling is indicated. 
RESULTS 
The plasma concentrations in the present experiments were in many cases 
only followed up to 3.5 or 4 h after drug administration, since the primary 
aim of this investigation was to ascertain the differences in hexobarbital ab­
sorption rate from the various dosage forms. In Fig. 4 to 7 all the individual 
plasma concentration curves are given for the seven preparations. Three im­
portant observations can be made: a. there exists a substantial intersubject 
variation in absorption profile for each dosage form; b. hexobarbital reaches 
the general circulation more rapidly when it is administered as the sodium 
salt; с plasma concentrations during the first 4 h remain much lower after 
rectal administration when compared with oral administration. Also, for each 
preparation the average absorption profile was estimated (Fig. 8). It appears that 
the mean curves of capsules V and VI (containing hexobarbital sodium) and 
also of capsule III (containing hexobarbital free acid) show two maxima, 
whereas almost none of the individual curves shows such a profile. This is 
explained by the fact that in some volunteers relatively rapid absorption occurs, 
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FIG. 4. Hexobarbital plasma concentration curves after oral administration of 
capsule I (/e/f) and capsule III (right). 
while in others, receiving the same dosage form, this was substantially slower. 
In this way the „unnatural" average curves are obtained. It may be concluded 
that average values alone do not yield appropriate information in a study such 
as this. 
As already mentioned, in most experiments the plasma concentrations were 
not followed long enough in order to permit the individual half-life to be deter­
mined. In consequence it was impossible to estimate the half-life of absorption 
and the lag time for each curve. Therefore two other parameters, characterizing 
the absorption process are given in Table IV, which are the peak concentration 
(Cma.x) and the peak concentration time (t i n a x ). The suppositories have not been 
included in this Table, since absorption had not been completed after 4 h 
(Fig. 7). With respect to W and C
m n I , the oral preparations with hexo­
barbital free acid were significantly different from capsule VI, but not from 
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FIG. 5. Hexobarbital plasma concentration curves after oraJ administration of 
tablet VIII (left) and capsule V (right). 
capsule V. Differences among the free acid containing dosage forms were not 
statistically significant (P > 0.05) except for Cmax between capsule I and III. 
Also, for preparations V and VI no significant difference became apparent. 
In many cases where the hexobarbital sodium capsules (V or VI) were 
administered, the subjects felt a strong tendency to sleep, within 15-30 min 
after drug intake. Feelings of euphoria were reported often. All evidence for 
CNS depression was registered and afterwards it could be deduced from the 
individual plasma concentration curves that they occurred around the time 
of the peak concentration. Subjective recovery was apparently complete within 
4 - 5 h after drug administration. With the free acid containing dosage forms 
the CNS depressant effects were less pronounced and feelings of sleepiness 
became apparent mostly after 1 - 2 h. None of the volunteers receiving a 
suppository experienced CNS depressant feelings. In a separate study, at the 
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FIG. 6. Hexobarbital plasma concentration curves after oral administration of 
capsule VI. 
Institute for Perception TNO at Soesterberg (Trumbo and Gaillard, 1974), it 
was found that volunteers receiving hexobarbital sodium in a suppository 
(dosage form VII) showed reduced effects of immediate arousal to auditory 
signals, compared to a placebo session. This objective assessment of an impaired 
performance with this suppository may indicate that an average plasma 
concentration of 2 mg/l is minimally effective for hexobarbital, with respect 
lo CNS depression. It seems likely that somewhat higher concentrations are 
required for the virtual experience of sedation or sleepiness. 
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FIG. 7. Hexobarbital plasma concentration curves after rectal administration of 
suppository VII {left) and suppository IV (right). 
With respect to the bioavailability of hexobarbital from the various dosage 
forms the following equation applies, assuming linear kinetics: 
F x D = k c l . j Cpdt = k e l . AUC 
where F = bioavailability (0 < F < 1), D = dose administered, Cp = plasma 
concentration, kei = total body clearance constant, and AUC = area under the 
plasma concentration curve from t = 0 to t = oc. The clearance constant can 
only be estimated accurately after i.v. administration (F = 1). However, it 
may be assumed that the average clearance value was about the same for each 
group of volunteers receiving one of the dosage forms. An indication that this 
assumption is valid was found in the fact that the hexobarbital elimination half-
lives, determined in some of these subjects, showed in general no significant 
differences between the various groups. The average relative bioavailability of 
hexobarbital from each dosage form can be calculated, taking capsule VI as 
the reference: 
Frei = 
AUCZ 
AUC VI 
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FIG. 8. Mean hcxobarbital plasma concentration curves following administration 
of the seven hcxobarbital or hexobarbital sodium containing dosage forms. 
The plasma concentrations were measured up to 4 h after administration and 
consequently the AUC could be determined only up to this time. Therefore 
a correction had to be made for the remaining area. If at the time of the last 
plasma concentration, measured at time t = t', absorption has been completed, 
the infinite area is given by the following equation (Dost, 1968): 
] Cpdt = | Cpdt + JCpdt = AUC/ + С/ · т., 
where Tei is the elimination time constant and Cp1' is the last measured plasma 
concentration. The AUC's from t = 0 to t = t' of the mean curves in the 
present study were determined by weighing the corresponding areas under the 
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TABLE IV. Absorption characteristics of hexobarbital and hexobarbital sodium 
after oral administration1) 
Dosage form 
Capsule I 
Capsule III 
Tablet VIII 
Capsule V 
Capsule VI 
Number of 
experiments 
8 
8 
6 
8 
10 
Dose 
(mg free acid) 
600 
600 
600 
549 
549 
Mean і
тяк
 Mean C
m a x 
± S.D.2) H- S.D.2) 
(min) (mg/1) 
147 ± 24 5.48 ± 0.93 
129 ± 63 4.34 ± 0.98 
169 ± 15 5.36 ± 1.07 
83 ± 58 6.86 ± 2.20 
50 ± 36 8.39 ± 1.87 
·) t
m a x
 refers to the time after which the maximum plasma concentration (C
m : i x ) is 
reached. 
s) For t
m a x
 and C
m a x
 statistically significant differences at Ρ <C 0.01 (Student's t -
test) were found between dosage forms I and VI, III and VI, VIII and VI. Also 
a significant difference at P < 0.01 was found for t
m a
^ between dosage form VIII 
and V; at Ρ < 0.05 for t
m
,„ between I and V; at Ρ < 0.05 for C
m a x
 between 
I and III. 
TABLE V. Relative bioavailability of hexobarbital from the different dosage forms 
after oral administration 
Dosage form 
Capsule I 
Capsule III 
Tablet VIII 
Capsule V 
Capsule VI 
Dose 
(mg free 
acid) 
600 
600 
600 
549 
549 
t'O 
(min) 
220 
220 
240 
210 
210 
AUC 0-t' 
(mg.min/1) 
719 
613 
884 
931 
1069 
cone, at t ' 
(mgA) 
4.2 
3.0 
4.0 
3.5 
3.9 
AUC 0-oo2) 
(mg.min/I) 
2298 
1741 
2388 
2247 
2535 
Frei3) 
(%) 
89 
63 
86 
89 
100 
!) Time at which the last hexobarbital plasma concentration was measured. 
2) These values were obtained by multiplying the concentration at t' by the average 
elimination time constant (376 min) and adding the result to AUC 0-t'. 
3) The bioavailability was calculated relative to capsule VI and corrected for the 
differences in dose, assuming a linear relationship between dose and AUC; the 
dose was not corrected for the assayed content of the dosage forms. 
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FIG. 9. Hexobarbital plasma concentration curves after rectal administration of 
suppository IV and VII to the same volunteer. Note that in both cases a relatively 
constant plasma level results during a few hours. 
plasma concentration curves, whereas the remaining areas from t = t' to t = =o 
were calculated by multiplying the concentrations at t = t' by TC1. For the latter 
value the mean id after i.v. hexobarbital administration was taken (376 min). 
In Table V the results are given for the oral preparations. The suppositories 
were omitted because absorption was not complete when the plasma concen­
tration measurement was stopped. It follows that only the dosage form III 
as a hexobarbital delivery system is inferior when compared to the other 
dosage forms. 
As mentioned before, absorption from the suppositories was not complete 
within 4 h after administration (Fig. 7). Therefore some experiments were 
undertaken to follow hexobarbital plasma concentrations for a longer time 
period after the administration of these formulations. In Fig. 9 an example is 
given of the curves obtained. An interesting fact is that in both cases the plasma 
level remained relatively constant for a few hours. A bioavailability relative 
to capsule VI of 4 0 - 6 0 % was estimated for both types of suppositories (de­
termined in three volunteers), which is substantially lower than after oral hexo­
barbital administration. Since the possibility existed of the amount of drug 
influencing bioavailability, further experiments were carried out with three 
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TABLE VI. Relative bioavailability of hexobarbital from suppositories, containing 
600 or 100 mg of hexobarbital sodium, after administration to the same volunteers. 
cone, at t' 
(mg/l) 
0.58 
0.18 
0.69 
0.22 
0.82 
0.31 
Tel2) 
(min) 
270 
270 
342 
342 
354 
354 
A U C O-oo 
(mg.min/1) 
1128 
288 
1134 
228 
1446 
312 
Frri») 
(%) 
72 
100 
91 
100 
83 
100 
1) Time at which the last hexobarbital plasma concentration was measured. 
2) The elimination time constant was obtained from the descending part of the 
plasma concentration curve after administration of the suppository with the 
higher dose. It was assumed that the time constant was the same at the second 
occasion. 
3) The bioavailability was calculated relative to the suppository containing 109 mg 
hexobarbital sodium and corrected for the difference in dose, assuming a linear 
relationship between dose and AUC. 
4) The assayed content appeared to be 109 mg hexobarbital sodium. 
volunteers who had received a suppository containing 600 mg hexobarbital 
sodium previously and who also received a suppository with 100 mg of the same 
substance. Plasma concentrations were measured up to 12 h and the bioavaila-
bility relative to the suppository with 100 mg, was calculated for each indivi-
dual, as indicated in Table VI. It follows that for the higher dose, absorption 
efficiency (bioavailability) diminishes which indicates that the amount of hexo-
barbital in a suppository influences bioavailability. 
During repetitive hexobarbital administration (300 mg each night) accumulation 
of the drug in the body did not occur (Fig. 10), which is in agreement with its 
short elimination half-life. Plasma concentrations 9 h after drug intake were 
always in the same range and had decreased below 0.5 mg/l. The half-life after 
10 days had not changed, which indicated that no induction of drug meta-
bolizing enzymes had occurred. Barbiturates are considered to be potent in-
ducers of the microsomal enzymes (Remmer, 1972), also with respect to the 
acceleration of their own metabolism. Hexobarbital probably does not remain, 
however, in sufficiently high concentrations in the body to cause such an 
induction. Further investigations are required to see whether higher doses 
Subject 
S.H. 
E.G. 
W.E. 
Dose 
(mg) 
600 
1094) 
600 
109 
600 
109 
fi) 
(h) 
11 
9 
12 
9 
12 
9 
A U C 0-t' 
(mg.min/1) 
972 
240 
900 
160 
1158 
300 
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FIG. 10. Plasma concentrations of hexobarbital during and after repetitive hexo-
barbital administration to two volunteers. During the first and the last day of the 
experiment the half-life of the drug was determined. From the first night a 
capsule (preparation VI), containing 300 mg hexobarbital sodium, was taken each 
night and usually the next morning (9 h later) the plasma concentration was 
measured. Note that these concentrations were always in the same range. Also 
note that the plasma half-life after repetitive hexobarbital administration was the 
same as prior to the experiments. 
and more frequent administration of hexobarbital will accelerate drug meta-
bolism. 
DISCUSSION 
Hexobarbital versus hexobarbital sodium 
One of the most evident results of the present investigation is the difference 
in absorption rate between hexobarbital and hexobarbital sodium. The rate of 
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absorption for many drugs is limited by the rate of dissolution in the 
gastrointestinal fluid, because a drug has to be dissolved before it can pass 
through a biological membrane (Garrett, 1971; Benet, 1973). Hexobarbital 
free acid is very slightly soluble in aqueous fluids, whereas its sodium salt is 
readily soluble. This explains the more rapid absorption when the salt form is 
administered. In vitro dissolution experiments (Levy beaker method; 500 ml 
0.08 N hydrochloric acid; 80 r.p.m.; 37° C) revealed a relatively rapid dissolu-
tion for the hexobarbital sodium containing dosage forms and slower dissolution 
for the free acid (Cox et al., 1974). Higuchi et al. (1958) discussed that salts 
generally will show higher dissolution rates than the corresponding non-ionic 
drug at any pH, even though the final equilibrium solubility of the drug and its 
salt would be the same. This is explained by the fact that if precipitation occurs, 
generally a suspension of fine particles results, which has the proper character-
istics for rapid redissolution. This phenomenon apparently applies in the case 
of barbiturates, since their sodium salts will be precipitated in the acid medium 
of the stomach, but nevertheless a higher absorption rate is observed than with 
the corresponding free acids. Sjögren et al. (1965) demonstrated this for 
several barbiturates including hexobarbital. In Chapter 5 of this Section similar 
findings are reported for heptabarbital and heptabarbital sodium. Also, the 
very rapid absorption of hexobarbital sodium in aqueous solution is in agree-
ment with the above hypothesis (Bush et al., 1966). The present experiments 
indicate that the absorption of hexobarbital is dissolution rate limited, when 
the drug is administered orally as the free acid. 
Careful analysis of the individual plasma concentration curves revealed that 
in cases where very rapid absorption had occurred (capsule VI or V), the post 
absorption phase consisted of a rapid drop in plasma concentration followed 
by a slower decline. This behaviour suggests that now absorption had occurred 
more rapidly than the distribution of the drug into tissues. The shape of the 
curve is consistent with two-compartment kinetics, similar to hexobarbital 
kinetics after i.v. infusion. After oral administration of pentobarbital sodium, 
Smith et al. (1973) also found a bi-exponential plasma concentration decay 
after absorption. However, in this case the „distribution phase" lasted longer 
than with hexobarbital, possibly due to the less lipophilic character of pento-
barbital. 
Influence of dosage form composition 
Part of the present investigation was devoted to the influence of some addi-
tives on the absorption rate and bioavailability of hexobarbital. As was pointed 
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out in Chapter 2 of Section I, formulation factors may greatly influence the 
amount and the rate by which a drug substance reaches the general circulation. 
The results with hexobarbital suggest that the main differences between the 
dosage forms used, are due to differences in aqueous solubility between hexo-
barbital sodium and the free acid. The differences between capsule V and VI, 
both containing the sodium salt, were not statistically significant. Yet, capsule 
VI is preferred since the differences for tmax between the free acid containing 
dosage forms and capsule VI were statistically significant, whereas they were 
not for capsule V. Besides, dissolution data (Cox et al., 1974) predicted a 
more rapid absorption for preparation VI. It appears likely that magnesium 
oxide (capsule VI), which has basic properties, partly neutralizes gastric juice 
when entering the stomach, thereby creating an environment which favours the 
dissolution of hexobarbital sodium or redissolution of precipitated free acid. The 
potato starch (capsule V) on the other hand has not such an influence and 
certainly does not enhance redissolution consistently. In conclusion, capsule VI 
is the hexobarbital sodium containing dosage form of choice. 
With respect to hexobarbital free acid, an attempt to increase the dissolution 
rate of this hydrophobic compound was made by granulation with a 3% 
methylcellulose solution (capsule III). The initial in vitro results showed that 
the dissolution rate of capsule HI was substantially higher than that of capsule 
1, indicating effective hydrophilization by methylcellulose granulation. This 
resulted in the prediction that hexobarbital capsule III should give better in 
vivo results than capsule I, yet the opposite became apparent. The plasma 
concentration curves obtained after administration of capsule III varied widely, 
some of which indicated relatively rapid absorption and others quite slow (Fig. 4). 
Besides, the average relative bioavailability of this preparation was substantially 
lower when compared with the other dosage forms. The present findings 
illustrate the problem of predicting even the rank order relationship of plasma 
levels from the in vitro dissolution data. It is possible that some of these 
discrepancies were due to the fact that the dissolution study was run too close 
to saturation concentration (Riegelman, personal communication). However, 
the reason for the unexpected in vivo results is difficult to understand. Previously 
granulation with gelatine was shown to increase the absorption of secobarbital 
(Sjogren, 1971), and in fact the same principle was applied in the present study. 
It is possible that the granulation procedure and the amount of methylcellulose 
are critical factors. 
The composition of the tablets is unknown, but it can be observed that its 
absorption behaviour is quite regular (Fig. 5). There are no essential differences 
between capsule I and the tablets, so there is no question of any preference 
between them. 
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Rectal absorption 
A variety of factors, physiological and pharmaceutical, may influence the 
rectal absorption of drugs (Wagner, 1971; Bevernage and Polderman, 1973). 
The physico-chemical properties of the drug substance and of the vehicle in 
which the drug is incorporated are very important. Significant variations in 
absorption rate and bioavailability have been encountered by changing for 
example the suppository base containing the same amount of drug (Kerckhoffs 
and Huizinga, 1967). There are two main types of bases; those which are lipo-
philic in nature (cacao butter, synthetic mixtures of triglycerides, etc.) and 
those which are hydrophilic (e.g. polyethylene glycols). For the present experi-
ments a lipophilic base was chosen, since Higuchi and Lach (1954) have 
reported that barbiturates may complex with polyethylene glycols, which results 
in reduced dissolution and absorption rates (Singh et al., 1966). However, it 
should be mentioned that the investigations with vinylbital, after rectal ad-
ministration (Chapter 4, Section III), revealed that absorption from a poly-
ethylene glycol base will not necessarily result in a greatly reduced absorption 
rate or bioavailability. 
It was previously shown in rabbits that the sodium salts of barbiturates are 
more rapidly absorbed from lipophilic bases than the corresponding free acids 
(Samelius and Aström, 1958; Neuwald et al., 1962; Fincher et al., 1966). The 
present results, for hexobarbital in man, are consistent with these earlier find-
ings and indicate that aqueous solubility plays an important role also in rectal 
absorption. Hexobarbital free acid absorption is very slow, since its partitioning 
from the lipophilic Witepsol base into the aqueous fluid of the rectum is very 
unfavourable. The interesting behaviour of both preparations, which exhibit a 
constant plasma level for a few hours (Fig. 9), indicates that the amount of 
drug absorbed per unit of time during this period, is equivalent to the amount 
being eliminated per unit of time. This is only possible if absorption during 
this period is an apparent zero-order process. For the free acid it is assumed 
that dissolution is in principle a first-order process. However, a severely 
limiting factor may be the amount of fluid in the rectum, which is only 1 - 3 ml 
(Bevernage and Polderman, 1973). The saturation concentration is readily 
reached and the amount dissolved becomes equivalent to the amount absorbed 
per unit of time. For the sodium salt there are probably no dissolution 
problems, as the pH in the rectum is about 7 and will be substantially raised 
by the presence of the salt. Since only the unionized form of a drug can pass 
through biological membranes, a high pH is unfavourable for the absorption 
of barbiturates. This factor, together with the limited absorption surface, may 
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be the underlying cause for the apparent zero-order absorption of the sodium 
salt. The dose may also be important in this respect since the plasma con-
centration curves obtained after 100 mg hexobarbital sodium revealed a normal 
behaviour, with a distinct absorption and elimination phase. On only one 
occasion was a constant plasma level evident for some time. A high dose is 
also unfavourable with respect to bioavailability (Table VI). 
In conclusion, the present findings emphasize that the rectal route of ad-
ministration cannot be looked upon as a routine alternate route of administra-
tion of drugs in general. The situation is more complicated than after oral 
administration and therefore appropriate in vivo data have to be provided when 
the rectal route is recommended (Wagner, 1971). Once the absorption profile 
of a certain dosage form has been established, it can be judged for which 
therapeutic purposes, the formulation may be used. In the case of hexobarbital, 
for instance, the suppositories could be applied in sedative drug therapy, since 
the plasma levels remain constant for quite a long time. They are on the other 
hand not suitable in the treatment of insomnia. 
concentration hexobarbital (m^/l plasma ,\ogscale) 
100 hexobarbital sodium 600mg~ 
capsule VI 
FIG. 11. Hexobarbital plasma concentration curves following oral administration 
of capsule VI at three different occasions to the same volunteer. Note the variation 
in absorption profile and the constancy of the hexobarbital half-life. 
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Intersubject and intrasubject variation 
It may be observed from the individual plasma concentration curves that there 
was a substantial intersubject variation with respect to hexobarbital absorption 
from each dosage form. These differences could not be related to differences in 
body-weight and may be explained only in part by differences in elimination half-
lives. It cannot be excluded that on some occasions fasting regulations were not 
obeyd strictly. Food will undoubtedly retard the rate of absorption, as was 
found in preliminary experiments with hexobarbital sodium. The question 
arose of how constant the absorption profile of the same dosage form would 
be, when administered twice to the same volunteer under identical circumstan­
ces. Some additional experiments were undertaken and the dosage forms were 
administered with an interim of one week. The results revealed substantial 
intrasubject variation, especially with the hexobarbital sodium containing do­
sage forms. An example is given in Fig. 11. With the free acid differences in 
plasma concentrations between the two occasions were considerable during 
the absorption phase. Changes in bioavailability were not very great (10 -
15%). It is concluded that considerable intrasubject variation exists with 
respect to hexobarbital or hexobarbital sodium absorption. Obviously with this 
information available, the even greater intersubject variation may be under­
stood. It is interesting to note that the elimination half-life of hexobarbital in 
TABLE VII. Comparison of hexobarbital half-lives in the same volunteer deter­
mined at different times1) 
M.S. 
t,/,2) Δί3) 
4.7 0 
5.4 12 
4.1 31 
4.5 32 
4.3 37 
S.S. 
t,/, ΔΙ 
3.0 0 
3.2 14 
3.0 29 
3.3 30 
Subject 
F.P. 
t./, 
3.2 
3.3 
3.8 
3.4 
At 
0 
20 
21 
26 
E.W. 
t./. At 
3.6 0 
4.3 20 
4.1 21 
J.K. 
tv, At 
4.7 0 
4.1 22 
4.1 23 
!) The half-lives were determined after oral or i.v. administration of hexobarbital 
or its sodium salt. 
2) Plasma half-life in h. 
3) Interim in weeks of the separate half-life determinations, reckoned from ΔΙ = 0. 
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the different experiments was found to be quite constant for the same volunteer 
(Fig. 11). In a recent article Wagner (1973) pointed out that there may be 
appreciable intrasubject variation in elimination half-life for drugs which are 
completely metabolized by man. When hexobarbital was given with an interim 
of one week to the same volunteer the difference in half-life did not exceed 
10% in general. This variation must be considered as falling within the ex-
perimental error and the half-life should be regarded therefore as unchanged. 
In Table VII the hexobarbital half-lives have been compared for the volunteers 
who received the drug more than two times with interims of one week or more. 
It appears that if the interim between the consecutive experiments is longer 
than one week, then real differences in half-life may become apparent. 
CONCLUSIONS 
From the pharmacokinetic point of view, hexobarbital should be regarded 
as a suitable compound for hypnotic drug therapy. Due to its short half-life, the 
risk of residual effects the following morning is minimal. When hexobarbital is 
taken each night, no accumulation occurs. 
For patients who have difficulty getting to sleep, a satisfactory therapy may 
be achieved by hexobarbital sodium (capsule VI). The rapid absorption of a 
300 - 600 mg dose is expected to induce sleep within 30 min, assuming a mi-
nimal effective plasma level of 2 - 4 mg/1. If the difficulty involves the mainte-
nance of sleep, then hexobarbital free acid in the form of capsule I or the 
EVIPAN tablets could be used. The minimal effective level may be reached 
1 - 2 h after drug intake and the concentration should remain above this level 
for a few hours. Thus, a dose of 600 mg may be adequate. Obviously, hexo-
barbital free acid should not be used for the treatment of difficulties getting 
to sleep. Finally, the suppositories containing hexobarbital or hexobarbital 
sodium could be used in sedative drug therapy. During 4 - 7 hours the plasma 
level remains quite constant, which possible causes a constant degree of se-
dation. This must be regarded as beneficial in sedative therapy. 
It should be emphasized that the use of hexobarbital in hypnotic and sedative 
drug therapy is not primarily advocated; rather, the compound has been used 
as a tool to illustrate how the principles of biopharmacy may be applied for 
the design of rational drug products. It becomes evident from the present 
investigation that the same active drug substance, incorporated in different 
pharmaceutical formulations, may serve different therapeutical goals. Further-
more it should be emphasized that the pharmacokinetic properties of a drug 
such as hexobarbital, in principle, may be favourable with respect to rational 
hypnotic drug therapy. 
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SUMMARY 
Intravenous administration 
The pharmacokinetics of hexobarbital were studied in fourteen healthy volunteers. 
Plasma levels were determined during and after a 30 or 60 min zero-order i.v. in-
fusion of hexobarbital sodium (7.23 - 8.82 mg/kg). Hexobarbital kinetics were suitably 
described by assuming that the body exhibited two distinct compartments. The 
plasma concentrations were fitted according to the post-infusion equation and the 
parameters intrinsic to the two-compartment open model were estimated. The elimi-
nation half-lives varied considerably for the fourteen individuals (160 - 441 min, with 
a mean value of 261 min). This variation was explained mainly by the different 
metabolic clearance constants of the compound (123 - 360 ml/min). The apparent 
volume of distribution was relatively constant (1.10 ± 0.12 1/kg). Adipose tissue did 
not play a major role in hexobarbital elimination. The excretion of unchanged drug 
and of 3-keto-hexobarbital in urine was measured for five volunteers; less than 0.5% 
of the administered dose was excreted as unchanged hexobarbital and 29 - 63 % as 
3-keto-hcxobarbital. 
Oral and rectal administration 
The absorption rate of hexobarbital and hexobarbital sodium from different dosage 
forms was studied after oral and rectal administration. Seven dosage forms were 
used in this investigation; their composition is outlined in Table III. Each preparation 
was administered to at least six healthy volunteers, who had fasted overnight. The 
administered dose was 600 mg hexobarbital or 600 mg hexobarbital sodium. Hexo-
barbital plasma concentrations were measured at frequent intervals, usually until 4 h 
after drug administration. Absorption with the dosage forms containing the sodium 
salt occurred more rapidly than with the preparations containing the free acid. For 
example the mean peak concentration with capsule VI (sodium salt), was reached 
after 50 min, as compared with more than two hours for the oral free acid prepara-
tions. Statistically significant differences were found for Cm l x and tma4 between 
capsule VI and the oral free acid preparations. Differences among the latter and 
also among the capsules V and VI were not significant. Relative bioavailabilities of 
the oral preparations were estimated by comparing the average areas under the plasma 
concentration curves and taking capsule VI as the reference dosage form (100%). 
The bioavailability of capsule III was found to be substantially lower (63%) than 
that of the other preparations (86 - 89%). After rectal administration of hexobarbital 
or hexobarbital sodium, the plasma concentrations during the first 4 h remained 
much lower than after oral administration. Absorption was not complete after 4 h 
and when the concentrations were followed for longer time periods, it was found 
that the levels remained constant (around 2 mg/1) for several hours. Bioavailability, 
relative to capsule VI, was 4 0 - 6 0 % . When a dose of 100 mg, instead of 600 mg, 
hexobarbital sodium was administered rectally, bioavailability increased per unit of 
dose, which indicated that the extent of absorption was related to the dosage. 
A substantial variation in the absorption profile of the volunteers was apparent 
for each dosage form. Some additional experiments revealed that the absorption of 
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the same preparation in the same volunteer also was subject to considerable variation. 
However, for the same volunteer the hexobarbital half-lives, determined at different 
occasions, were relatively constant. Also, when hexobarbital was administered each 
night, for a period of 9 days, the half-life of the drug prior to and after the ex-
periment remained constant. 
As a result of these pharmacokinetic studies hexobarbital should be regarded as a 
suitable compound in hypnotic drug therapy. Due to its short half-life the risk of 
residual effects is minimal. Hexobarbital sodium may be used for a rapid induction 
of sleep, hexobarbital free acid for sleep maintenance and the suppositories for 
sedative drug therapy. 
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CHAPTER 2 
( + )- AND (—)-HEXOBARBITAL 
A. PHARMACOKINETICS IN MAN 
B. PHARMACOKINETICS IN RATS AND IN THE ISOLATED PERFUSED 
RAT LIVER 
A. PHARMACOKINETICS IN MAN 
INTRODUCTION 
Early investigations (Hsueh and Marvel, 1928; Kleiderer and Shonle, 1934) 
did not reveal any real differences in anaesthetic potency between the optical 
antipodes of barbituric acid derivatives. In recent years, however, such differen-
ces have become evident in animal studies, e.g. secobarbital (Gibson et al., 
1959; Haley and Gidley, 1970a), methylphenobarbital (Buch et al., 1968) and 
pentobarbital (Buch et al., 1969). Christensen and Lee (1973) have studied the 
anaesthetic activity and acute toxicity of the enantiomers of pentobarbital, seco-
barbital, thiopental and thiamylal. The S(—)-isomer was found in every case 
to be significantly more toxic and potent than the R( + )-isomer. Furthermore 
Downes et al. (1970) found that the ( + )-isomer of 5-(l,3-dimethylbutyl)-5-ethyl 
barbituric acid caused tonic extensor seizures preceded by brief tonic flexion. 
In contrast, the (—)-isomer induced preanaesthetic excitation without tonic 
seizures and antagonized the seizure activity of the ( + )-isomer. Similar findings 
on these compounds were reported by Sitsen and Fresen (1974). 
The observations above-mentioned suggest that considerable differences in 
pharmacological respect may exist between the enantiomers of barbiturates. 
Knabe and Kräuter (1965) have described a procedure for the separation of 
the optical antipodes of hexobarbital. Wahlström (1966) and Wahlström et al. 
(1970) showed that with (—)-hexobarbital a higher total dose was required to 
produce anaesthesia in rats than with ( + )-hexobarbital. Rummel et al. (1967) 
and Furner, McCarthy et al. (1969) noted that a longer sleeping time was in-
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duced after ( + )-hexobarbital administration to rats, whereas the same authors 
found that the ( + )-isomer was metabolized more rapidly. In the second part 
of this Chapter the pharmacokinetics of the hexobarbital antipodes in rats will 
be described in detail and the differences in anaesthetic potency will be discus-
sed. 
Since no data were available on the differences in potency or rate of metabo-
lism of the enantiomers of any barbiturate in man, it was considered of interest 
to study these aspects of the hexobarbital antipodes in man. For this purpose 
the enantiomers as well as racemic hexobarbital were administered to the same 
healthy volunteers. The central depressant symptoms were recorded and from 
the plasma concentration curves the elimination half-lives were determined 
(Breimer and van Rossum, 1973). In addition, the urinary excretion of un-
changed hexobarbital and 3-keto-hexobarbital were measured. 
MATERIALS AND METHODS 
Samples of the hexobarbital optical antipodes were supplied by Prof. Dr. 
J. Knabe, Saarbrücken, GFR and by BAYER AG (Prof. Dr. G. Kroneberg), 
which are greatfully acknowledged. The preparation of further amounts of the 
antipodes was carried out by Mr. van Gemert according to the method of Knabe 
and Kräuter (1965). The specifications of the compounds were: ( +^hexobar-
bital [a]D20 = + 1 1 . 4 ° (ethanol), m.p. 153-154°; (—)-hexobarbital [a]n20 
= —11.2° (ethanol), m.p. 152-153.5°. Racemic hexobarbital (m.p. 142-
144°) was obtained from Onderlinge Pharmaceutischc Groothandel, Utrecht, 
The Netherlands. 
Five healthy male volunteers, ranging in age from 20 - 25 years and in body-
weight from 68 to 79 kg, participated in the study. They had received no regular 
medication during the 4 weeks preceding initiation of the experiments. The trials 
began in the morning (9 a.m.), after the subjects had fasted overnight and 400 
mg of one of the compounds in powder form was administered orally together 
with 200 ml water. Initially they were asked to remain in an upright position 
for at least 15 min and then to lie down for at least 3.5 h. No food, fluid or 
tobacco was allowed for 3.5 h after drug administration. Blood samples were 
taken from a forearm vein at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 7.0, 9.0 and 11 
or 12 h after intake of drug. Plasma concentrations were determined by gas 
chromatography with nitrogen selective detection (Chapter 2, Section II). Each 
volunteer received all three compounds with an interval of at least two weeks 
between two consecutive trials. The sequence of administration of the drugs 
was randomly chosen. 
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Two of the volunteers collected their urine for 24 h each time after admini­
stration of one of the compounds. Hexobarbital and 3-keto-hexobarbital con­
centration in urine was determined by gas chromatography as described in 
Chapter 2 and 3 of Section II. 
RESULTS AND DISCUSSION 
Half-lives and metabolic clearance of ( + )- and (—)-hexobarbital 
The mean hexobarbital plasma levels following oral administration of 400 
mg ( + )-, (—)- and (±)-hexobarbital to five healthy volunteers are presented 
in Table I. In Fig. 1 the three plasma concentration curves of one volunteer 
are shown. It is evident that the plasma disappearance rate of (—)-hexobarbital 
was much greater than that for ( + )-hexobarbital. Elimination occurred accor­
ding to a first-order process and from the descending part of the curves the 
elimination half-lives have been deduced. These are given in Table II for the 
five volunteers. In man the half-life of (—)-hexobarbital is more than three 
times shorter than of ( + )-hexobarbital. In rats the reverse has been observed, 
the half-life of the (—)-isomer being about 2.5 times longer than that of the 
(-l-)-isomer (Breimer and van Rossum, 1974; part В of this Chapter). The 
reason for this species difference is not clear. In in vitro experiments with rat 
liver microsomes Degkwitz et al. (1970) and Furner, McCarthy et al. (1969) 
TABLE I. Mean plasma concentrations (mg/1) of hexobarbital after oral admini­
stration of ( + )-, (—)- and (i^)-hexobarbital to five volunteers. 
Time 
0.5 
1 
1.5 
2 
3 
4 
5 
7 
9 
12 
(h) 
* Concentrât 
0.83 
1.47 
1.73 
2.71 
1.63 
0.85 
0.59 
0.28 
0.10 
— 
ion rai 
(—) 
(0.32-2.12)* 
(0.48-2.60) 
(0.56-3.38) 
(1.42-3.92) 
(0.88-2.28) 
(0.54-1.22) 
(0.28-0.96) 
(0.11-0.42) 
(0.04-0.18) 
nge in parentheses. 
( + ) 
1.20 (0.41-1.69) 
3.49 (2.22-4.04) 
4.15 (3.70-4.77) 
3.96 (3.30-4.79) 
3.39 (3.09-4.10) 
2.71 (2.39-2.87) 
2.32 (1.94-2.45) 
1.93 (1.38-2.33) 
1.24 (0.96-1.49) 
0.84 (0.58-1.29) 
(±) 
0.55 (0.16-0.95) 
1.78 (0.86-2.69) 
2.63 (1.35-4.08) 
2.51 (1.71-3.24) 
2.38 (1.88-3.06) 
1.85 (1.63-2.08) 
1.59 (1.44-1.88) 
1.18 (0.90-1.55) 
0.87 (0.66-1.32) 
0.50 (0.25-0.71) 
158 
mgbrxobarb\ta\/¡ plasma (log·ecale) 
subject J cíe В 
10.0 -
50 
1.0 -
05 
0.1 
0.05 
0 0 2 , , , , , , , , , , , , 
2 f б β 10 И 
time ( h ) 
FIG. 1. Hexobarbital plasma concentration curves (semi-logarithmic scale) after oral 
administration of ( + )-, (—)- and (-t)-hcxobarbital (400 mg) to the same volunteer. 
showed a comparable affinity of the two isomers for the mixed function oxy­
genase system (cytochrome P-450), but a higher rate of conversion by this 
system for the ( + )-isomer. Similar experiments with human liver homogenates 
are in progress in order to explain this reversed situation in man. It is in­
teresting to note that a species difference for the elimination of the pento­
barbital optical antipodes also has been found. Buch et al. (1969) found that 
(—)-pentobarbital was more rapidly inactivated in rats than ( + )-pentobarbital, 
whereas Mark et al. (1971) observed the reverse in dogs. 
Since the hexobarbital enantiomers have identical physico-chemical proper­
ties, except optical rotation, there is no reason to assume that a significant 
difference in apparent volume of distribution for the isomers in the same subject 
will exist. Moreover it was shown that, at least at higher concentrations, there 
exist no significant differences in protein binding between ( + )- and (—^hexo­
barbital (part В of this Chapter). Therefore, the differences in half-life must be 
explained on basis of a difference in the rate of metabolism. The metabolic 
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hexobarbital ¡comers 
400 immoral 
TABLE II. Plasma half-lives (h) of ( + )-, (—)- and (±)-hexobarbital after oral ad­
ministration to five volunteers. 
Subject 
W.K. 
B R . 
J. de В. 
F.I. 
W.D. 
mean 
(±) 
3.8 
4.3 
2.6 
4.0 
5.0 
4.0 
Compounds 
' " " ( + ) 
4.0 
6.3 
3.5 
4.3 
4.7 
4.6 
(—) 
1.3 
1.6 
1.4 
1.3 
1.6 
1.4 
Ratio ( + ) / ( — ) 
3.1 
3.9 
2.5 
3.3 
2.9 
3.2 
clearance constant for (—)-hexobarbital in man must be approximately three 
times greater than for ( + )-hexobarbital. The exact values for this parameter 
cannot be estimated from the present experiments, since the bioavailability after 
oral administration remains an uncertain factor. However, after intravenous in­
fusion of racemic hexobarbital sodium into man the metabolic clearance con­
stant for the racemate was found to be approximately 260 ml/min (Chapter 1, 
Section III). This means that the value of this parameter for (—)-hexobarbital 
may be in the range of 650 - 750 ml/min, because the half-life is almost a 
factor three shorter than that of the racemate. Rowland (1972a) has shown 
that if hepatic clearance of a drug is large, the amount of drug that reaches the 
general circulation intact may be substantially lower than the dose administered 
orally. After absorption a relatively large fraction of the amount of drug that 
reaches the portal blood may be metabolized during the first passage through 
the liver. It may be expected that this so-called "first-pass effect" applies in the 
case of (—)-hexobarbital, since its clearance is relatively high in relation to 
blood flow through the liver (1500 - 2000 ml/min). For any linear pharma­
cokinetic model the following applies: 
Q = к,,. \ Cpdt = k e l . AUC 
where Q is the amount of drug that reaches the general circulation intact, k
cl 
is the clearance constant, C p is the plasma concentration and AUC is the area 
under the plasma concentration curve from t = 0 to t = °c. The average area 
for (—)-hexobarbital was determined and found to be 7.8 mg.h/1. If it is as-
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sumed that the average kj., for the five volunteers was 700 ml/min (42 1/h), then 
Q = 328 mg. If absorption was complete, it follows that about 18% of the 
(—)-isomer was metabolized during the first passage through the liver. This is 
less than expected on basis of the equation derived by Rowland (1972a) for the 
unmetabolized fraction 0: 
hepatic clearance 
Θ = 1 Î-- — 
liver blood flow 
When the liver blood flow is assumed to be about 1500 - 2000 ml/min theore-
tically 30-50% should have been metabolized during the first passage through 
the liver. The discrepancy between this value and the experimental one indicates 
that the situation for (—)-hexobarbital is probably more complicated than 
expressed by Rowland's formula. Further information will be obtained by 
administering the substance i.v. so that a more accurate clearance value can 
be determined. 
The average AUC for ( + )-hexobarbital was also determined (30.7 mg.h/1). 
Assuming an average clearance constant of 218 ml/min (the value for the 
(—)-isomer divided by the half-life ratio) Q is found to be 402 mg. This may 
indicate that the absorption of ( + )-hexobarbital was complete and, in addition, 
that there is no notable "first-pass effect" with this isomer. 
The elimination phase of racemic hexobarbital 
Theoretically, a straight line for the elimination phase of racemic hexobarbital 
should not be obtained, since the two different time constants for the antipodes 
are underlying this process. While the (—)-isomer contributes to the elimination 
in the first few hours, this is also the time during which absorption takes place, 
the pure elimination phase having not yet been reached. The calculated half-
lives are based on the points 3 - 4 h after administration and it can be deduced 
from the concentrations in Table I that in the period between 4 and 12 h the 
plasma concentration of the (—)-isomer, when compared with the (-(-)-isomer 
is so low that it makes little contribution to the curve of the racemate. In Fig. 2 
the theoretical line for the racemic mixture has been calculated, which is based 
upon the experiments of Fig. 1. The experimental lines of (+) - and (—)-hexo-
barbital were plotted and the curve for the racemate was calculated, taking at 
each time the sum of half the concentration of each isomer. It may be ob-
served that the theoretical elimination line obtained hardly deviates from linea-
rity. In practice the scatter in the experimental data will not distinguish between 
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FIG. 2. Theoretical plasma concentration curve for racemic hexobarbital, based upon 
the experimental curves for ( + )- and (—)-hexobarbital (subject J. de В., Fig. 1). The 
theoretical line was obtained by taking at each time the sum of half the concentration 
of ( + )-hexobarbital and half the concentration of (—)-hexobarbital. Note that this 
line hardly deviates from linearity, due to the small contribution of the (—)-isomer. 
The experimental plasma concentrations of racemic hexobarbital are slightly higher 
than expected, which may be caused by a slightly varying bioavailability. 
the two distinct phases in the elimination process of the racemate. The con­
centrations fit a straight line and in most instances a slightly shorter half-life is 
estimated for the racemate, than that estimated for the ( + )-isomer (Table II). 
Also, after a 30 min or 60 min zero-order i.v. infusion differentiation between 
the two elimination time constants was impossible, as was discussed in Chapter 1 
of this Section. The question arose as to whether, after rapid i.v. administration, 
such a differentiation could be made. In preliminary experiments 300 mg of 
racemic hexobarbital sodium was administered by rapid i.v. infusion to two 
healthy human volunteers. The results of one experiment are given in Fig. 3. 
After perusal of the curve three distinct phases could be distinguished: a rapid 
distribution phase corresponding to a half-life of 14 min, a slower phase with 
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a half-life of 1.2 h and finally a phase with a half-life of 5.7 h. It seems likely 
that the two latter phases are due to the different rates of elimination of the 
antipodes, since these half-lives are in the same order of magnitude as found 
after oral administration of the individual isomers. Surprisingly, in the second 
volunteer such a distinction could not be made, only a distribution phase and 
a single first-order elimination phase became apparent. Further experiments of 
rapid i.v. administration are being done in order to determine the critical factors 
that play a role in such complex elimination patterns. 
concentration hcxobarbital (mg/l plaema-, \ogscale) 
10.0 
300mg-(!)HEXOBARBITAL »оА'шп 
linear i.v. infueion llmin 
11 12 
t i m e ( h ) 
FIG. 3. Hexobarbital plasma concentration curve after rapid zero-order i.v. infusion 
of raccmic hexobarbital sodium into a healthy volunteer. By „peeling-off" the post-
infusion curve three phases can be distinguished. It is likely that the half-lives of 
1.2 h and 5.7 h correspond to the elimination of (—)-hexobarbital and (-f)-hexo-
barbital respectively. 
Urinary excretion of unchanged hexobarbital and 3-keto-hexobarbital 
Since the rate of metabolism of the hexobarbital antipodes in man exhibits 
considerable differences, it was considered of interest to obtain additional in­
formation on the metabolic fate of these compounds. Therefore the renal ex­
cretion of unchanged hexobarbital and 3-keto-hexobarbital was determined for 
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two volunteers who received the racemic mixture and the two isomers, sub­
sequently. No quantitative data are available in the literature on the excretion 
of hexobarbital or metabolites. Previously, Tsukamoto et al. (1957) and Frey 
et al. (1959) identified 3-kcto-hexobarbital in human urine after administration 
of racemic hexobarbital. In Fig. 4 an example is given of the renal excretion 
curves obtained. The cumulative urinary excretion (0 - 24 h) of unchanged 
drug and 3-keto-hexobarbital is summarized in Table III. Hexobarbital is hardly 
TABLE III. Cumulative renal excretion of hexobarbital and 3-keto-hcxobarbital after 
oral administration of ( + )-, (—)- and (±)-hexobarbital (400 mg). 
Hexobarbital 3-keto-hexobarbital 
administered 
( + ) 
(—) 
( ± ) 
( + ) 
(—) 
( —) 
mg 
2.02 
0.23 
0.28 
2.28 
0.07 
0.56 
% of dose 
0.51 
0.06 
0.07 
0.57 
0.02 
0.14 
mg 
65 
274 
164 
60 
161 
105 
% of dose 
16 
65 
39 
15 
38 
26 
excreted unchanged into the urine. (—)-Hexobarbital appears to be metabolized 
substantially more to 3-keto-hexobarbital than ( + )-hexobarbital. Whether the 
quantitative differences in metabolism between the isomers is caused by stereo­
selective metabolism of hexobarbital itself, or that the intermediate 3-hydroxy-
hexobarbital (Bush and Weiler, 1972) is involved, is uncertain and requires 
further investigation. In all instances 3-keto-hexobarbital was rapidly eliminated, 
its urinary half-life varied from 3 - 5 h. This may be regarded as a true elimina­
tion half-life, since also after (—)-hexobarbital administration the half-life was 
in the above-mentioned range. 3-Keto-hexobarbital does not possess hypnotic 
properties (Bush et al., 1953; Yoshimura, 1958). 
Hypnotic potency of the enantiomers in man 
With respect to hypnotic potency in man, the subjects experienced severe 
drowsiness which lasted several hours after 400 mg ( + )-hexobarbital, whereas 
Subject 
J. de В. 
W.K. 
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FIG. 4. Urine flow, urine pH, cumulative renal excretion of 3-keto-hexobarbital, 
renal excretion rate of 3-keto-hexobarbital and hexobarbital, and plasma concen­
tration (mg/1) of hexobarbital after oral administration of 400 mg racemic hexo­
barbital. Only a very small fraction (0.14%) of the administered dose was excreted 
unchanged into the urine. 
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after (—)-hexobarbital no noticeable effect was experienced. After admini-
stration of the racemic mixture moderate feelings of lethargy became apparent, 
which were of relatively short duration. Although it seems likely that in man the 
( + )-isomer has a greater activity than the (—)-isomer, as is the case in rat, one 
must be aware of the fact that the above observations might also be explained 
on the basis of the differences in disappearance rate of the two isomers in man. 
B. PHARMACOKINETICS IN RATS AND IN THE ISOLATED PERFUSED 
RAT LIVER 
INTRODUCTION 
Hexobarbital possesses a chiral centre at C5 due to the presence of a methyl-
group on one of the nitrogen atoms in the barbituric acid ring. Since Knabe and 
Kräuter (1965) described a procedure for the separation of the optical antipodes, 
some reports on the activity and on the fate of the isomers in animals have 
appeared. Wahlström (1966) and Wahlström et al. (1970) showed that with 
(—)-hexobarbital a higher total dose was required to produce anaesthesia in 
rats than with (-)-)-hexobarbital. Rummel et al. (1967) and Furner, McCarthy 
et al. (1969) noted a longer sleeping time in rats after i.p. injection of ( + )-hexo-
barbital than after (—)-hexobarbital and the latency time appeared also to be 
shorter with the ( + )-isomer. In addition, Furner, Me Carthy et al. (1969) found 
that ( + )-hexobarbital was metabolized more rapidly in vitro by rat liver micro-
somes and had a shorter half-life in vivo. Degkwitz et al. (1969) studied the 
binding of the two antipodes to cytochrome P-450 and reported differences in 
the magnitude of the spectral change. A detailed investigation on the kinetic 
differences in the microsomal metabolism of the isomers and of the racemate 
in rats, rabbits and mice was carried out by McCarthy and Stitzel (1971). 
In all three species (—)-hexobarbitaI is metabolized at a slower rate than 
( + )-hexobarbital. In contrast to these results it was found by us, studying the 
pharmacokinetics of the two antipodes in healthy human subjects, that the half-
life of the (—)-isomer is approximately three times shorter than the half-life 
of the ( + )-isomer, suggesting that in man the latter isomer is slower metabolized 
(Breimer and van Rossum, 1973). 
Because of the reported differences in rate of metabolism and possibly also 
in distribution behaviour (Rummel et al. 1967) of the enantiomers in rats, it was 
considered to be of interest to study the pharmacokinetics of the compounds in 
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more detail. We decided to compare the pharmacokinetics of the two com-
pounds in the same individual rat, since in preliminary experiments with racemic 
hexobarbital it was found that the half-life did not differ more than 20 per cent 
when determined in the same rat at interims of 1 week. Apparently the in-
traindividual variability is not so great, whereas Alvarez (1971b), studying the 
pharmacokinetics of barbiturates in individual rats, noted a substantial inter-
individual variability. 
A comparison is made of some important pharmacokinetic parameters such 
as the total body clearance constant (kcl) and the apparent volume of distribution 
(Vt), which are the main factors governing the overall disappearance rate of a 
drug from the body (van Rossum, 1971). These and other parameters, deter-
mined in the same animal, will give more information about stereoselective 
metabolism and distribution of hexobarbital. The binding to serum albumin was 
also determined to see whether or not stereospecific interaction exists, which 
could contribute to stereoselective distribution. Furthermore the data in vivo 
are compared to those obtained in vitro in the isolated perfused rat liver. 
Finally the pharmacokinetic results are discussed with respect to possible dif-
ferences in anaesthetic potency between the enantiomers. 
MATERIALS AND METHODS 
Drugs 
The enantiomers of hexobarbital were prepared according to the method of 
Knabe and Kräuter (1965); 
( + )-hexobarbital: [a]D20 = + 11.4° (ethanol), m.p. 153° - 154°; 
(—)-hexobarbital: [a]D20 = — 11.2° (ethanol), m.p.l520 - 153.5°. 
Shortly before use each compound was dissolved in an equimolar quantity of 
sodium hydroxide and diluted with 0.9% sodium chloride solution to a con-
centration of 30 mg barbiturate per ml. 
In vivo experiments 
Male Wistar rats, weighing approximately 200 g, were used for the in vivo 
experiments. They were maintained at standard laboratory diet and fasted 
overnight before the experiments. Water could be taken ad libitum. The animals 
were injected i.v. in the dorsal vein of the penis at 9 o'clock a.m. No anaesthe-
sia was applied and during the injection procedure the animals were kept in such 
a cage, that moving was impossible. The mean injection time was about 10 sec. 
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The injection volume dit not exceed 0.5 ml. Sleeping times were determined as 
the time elapsed from the loss till the regaining of the righting reflex. Blood 
samples (0.2 - 0.5 ml) were taken at several times after injection through orbital 
puncture, using heparinized micro-hematocrit tubes. The blood was collected in 
tubes containing a minute amount of heparin. Both isomers were administered 
to the same animal in random order with interims of one week. The dose of 
the compounds was always the same per animal and they are given in Table IV. 
The isolated perfused rat liver 
Male Wistar rats (the same strain as used in the in vivo experiments), weighing 
approximately 200 g, were used for these in vitro experiments. The perfusion 
technique was modified after the method described by Miller et al. (1951). 
The surgical procedure and perfusion apparatus have been outlined by Northrop 
and Parks (1964). The perfusion fluid was equilibrated with oxygen, containing 
5% C 0 2 and was supplied to the isolated liver by a portal vein cannula. Bile 
was collected with a bile duct catheter. The temperature in the perfusion 
chamber was kept at 38° ± 0.2° С An artificial perfusion liquid was used 
according to Schimassek (1962), consisting of electrolytes, human erythrocytes, 
bovine albumin and glucose. The preparation of this fluid was carried out under 
aseptic conditions. The volume of the perfusate was 100 ml. The routine criteria 
for the performance of the liver were: bile production, perfusate flow through 
the liver (15 - 20 ml/min) and macroscopic appearance of the liver. After an 
equilibration time of 30 min, 5 or 10 mg of one of the hexobarbital antipodes 
was introduced into the perfusion fluid, while 0.5 ml samples were taken at 
intervals of 5 min. After 45 minutes the other isomer was added to the perfusate 
and again samples were taken every 5 minutes. 
Determination of hexobarbital blood concentrations 
Hexobarbital blood concentrations were determined by means of gas chroma­
tography, according to a modified method described by Jain and Kirk (1967). 
To the blood sample (0.2 - 0.5 ml) 10 μ% of pentobarbital dissolved in 0.1 ml 
ethanol was added as internal standard. 
Extraction was carried out twice with 2 ml ether/acetone ( 1 : 1 ) (both analyti­
cal-reagent grade) on the whirlmixer. The combined extracts were evaporated 
to dryness and the residue was redissolved in a small volume (50 μ\- 100 /Л) of 
chloroform or methanol. Of this solution 2 - 5 «1 was injected into a Hewlett & 
Packard, Model 402, gaschromatograph with flame ionization detection. Glass 
columns (1.8 m χ 3 mm i.d.) were packed with 5% SE-30 on Diatoport S. 
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60 - 80 mesh. The injection block was kept at 230° C, the column at 200° С 
and the detector at 250° C. Gas flow rates were: carrier (nitrogen) 30 ml/min, 
air 400 ml/min and hydrogen 40 ml/min. Hexobarbital concentrations were 
calculated by measuring the ratio of the area of the hexobarbital peak to the 
area of the internal standard peak and multiplying by a factor derived from a 
calibration curve. 
Protein binding studies 
The binding of the two isomers and of racemic hexobarbital to bovine serum 
albumin was investigated by equilibrium dialysis. This was carried out in cylin­
drical metal cells (i.d. 2.5 cm), separated by a semipermeable membrane (cel­
lulose acetate, AKU, Amhem). Both cells contained equal volumes (2.0 ml) of 
phosphate buffer (0.1 M), pH 7.4; in addition one of the cells contained 3% 
demineralized bovine serum albumin (Povite, Amsterdam) and one of the com­
pounds, at start concentrations of 0.25, 0.125 or 0.063 mM. The cells were 
placed in a water bath at 37° С and rotated at 1 r.p.m. for 24 hours (this 
equilibrium period was selected in preliminary experiments). The hexobarbital 
concentrations were measured in both dialysis chambers by extracting 0.5 ml 
aliquots with 5 ml ether and further using the gas chromatographic procedure 
as described for the determination of hexobarbital in blood. Occasionally the 
albumin content after dialysis was checked by measuring UV-absorption at 
279 nm. In the albumin-containing compartment the total hexobarbital con­
centration (Ct) measured, equals the albumin bound concentration plus the 
unbound or free concentration (C
r
). In the equilibrium state the concentration 
measured in the protein free compartment equals C t. The percentage of binding 
C t - C , 
is calculated from χ 100. 
Q 
RESULTS 
In VÌVO 
I.v. administration of either antipode generally resulted in the loss of the 
righting reflex within 10 sec (the average injection time). This means that there 
is no measurable difference in onset of anaesthetic action between the two com-
pounds after i.v. injection. However, the times elapsed until the regaining of the 
righting reflex (sleeping time) were found to be quite different. All animals 
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TABLE IV. Sleeping times and blood concentrations at the moment of awakening 
of ( + )- and (—)- hexobarbital in the same rat. 
Dose 
( + ) 
15 
15 
15 
10 
15 
12.5 
12.5 
12.5 
(mg) 
(—) 
15 
15 
15 
10 
15 
12.5 
12.5 
12.5 
Sleeping 
( + ) 
38 
29 
37 
21 
22 
23 
12 
19 
time 
(-
: (mi 
- ) 
3 
15 
3 
5 
0 
2 
4 
0 
¡n) Cone. 
( + ) 
14 
18 
17 
18 
18 
12 
12 
13 
15±2.8* 
(/(g/ml) 
(—) 
64 
62 
72 
48 
— 
37 
45 
— 
55 ± 13.4* 
* Significantly different at Ρ < 0.005 (Student's t-test). 
slept much longer after receiving ( + )-, than after receiving (—)-hexobarbital 
(Table Г ). There is a 1.5- to 12-fold difference in sleeping time in the various 
animals. After receiving (—)-hexobarbital only a very short loss of the righting 
reflex was observed, while even in two animals no such an effect occurred at 
all. A difference in behaviour was noted after regaining the righting reflex; 
after ( + )-hexobarbital the animals were quite normal in their motor activity 
compared to uninjected rats, whereas after (—)-hexobarbital their spontaneous 
movements were much diminished for about 30 to 60 minutes. Similar obser­
vations have been reported by Furner, Me Carthy et al. (1969). The hexobar­
bital blood concentrations at the moment of awakening are also given in 
Table IV. They have been deduced from the total blood concentration-time 
curves. The concentration at the moment of awakening in the same rat after 
injection of ( + )-hexobarbital is three to four times lower than after (—^hexo­
barbital. It is also evident that these concentrations for the ( + )-antipode fall 
within a narrow range, with a mean value of 15 μg/ml blood. This value for 
the (—)-isomer was 55 μg/ml, however with a substantial standard deviation. 
These mean values can approximately be considered as the average minimum 
effective levels exerting an anaesthetic effect in rats. Furner, Gram and Stitzel 
(1969) determined this level for racemic hexobarbital in different rat strains 
and they found for Wistar rats 36 μg/ml blood, which is halfway between the 
two values for ( + )- and (—)-hexobarbital. 
170 
The blood concentrations were determined at several time intervals after 
taking small blood samples by orbital punction. It was attempted to get at least 
three samples during the first 5 min after injection, as in that period there is a 
rapid fall in blood concentration mainly due to distribution of the drug from 
the blood into the tissues. In the next 50 min at least five more samples were 
taken. Fig. 5 shows a typical example of blood concentration-time curves of 
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FIG. 5. Hexobarbital blood concentration curves after i.v. administration of ( + )- and 
(—)-hexobarbital to the same rat. 
the two antipodes in the same rat on semi-logarithmic scale. Apparently the 
time course of these curves can be described by the sum of two exponential 
equations, which is characteristic for the so-called two-compartment open model 
(Riegelman et al., 1968). The second phase represents the overall elimination 
process of the drug in the body. The blood concentration can be described by 
the following equation (van Rossum, 1971): 
C„ = A, . e •Φι + A, .e -t/r 
in which Cp is the blood concentration at time t and A1 and A2 are the zero-
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time concentration intercepts. Aj and A2 are associated to the small (τ,) and to 
the large (τ2) time constant respectively. These four parameters can easily be 
deduced from the experimental curve and then various kinetic parameters ac­
cording to the two-compartment open model after rapid i.v. infusion can be 
calculated as outlined in the Appendix. The time constants т1 and т2 depend 
on the volume of the first compartment and that of the second compartment, 
as well as on the distribution clearance constants (k1 2 and k21) and the total 
body elimination clearance constant (k
cl). The time constant of the slowest 
phase is simply related to the biological half-life (t,/,): 
t./, = 0.69 . τ,. 
which is a general measure for the overall elimination rate of a drug from the 
body. In Table V the half-lives of ( -f )- and (—)-hexobarbital are given, as well 
TABLE V. Half-lives of ( + )- and (—)-hexobarbital in the same rat. 
Rat no. 
1 
2 
3 
4 
5 
6 
7 
δ 
mean ± S.D. 
t./, ( + ) (min) 
14 
16 
2β 
21 
23 
14 
16 
17 
18.4 ± 4.4* 
м-
—) min 
30 
46 
32 
57 
73 
34 
36 
46 
44.3 ± 14.7 
'ν, (—) 
Ratio ,
 ч 
*./,( + > 
2.2 
2.9 
1.2 
2.7 
3.2 
2.4 
2.3 
2.7 
2.5 ± 0.6 
Significantly different at Ρ < 0.001 (Student's t-test). 
as the ratio t/, (—)lt4, ( + ). The half-life of (—)-hexobarbital is two to three 
times longer than of ( + )-hexobarbital, with a mean ratio of 2.5. The diffe­
rences are clear in the individual animals as well as expressed in the mean 
values. These mean values of 44.3 and 18.4 min are in close agreement with 
those measured by Furner, Me Carthy et al. (1969), who found 48.2 and 17.4 
min respectively in male rats. It is evident that the ( + )-isomer disappears 
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faster from the blood than the (—)-isomer. Calculation of the total body 
clearance constant revealed that for this parameter there is also a 2- to 3-fold 
difference between the two compounds (Table VII). The apparent volumes of 
distribution did not differ more than a factor 1.5 (Table VII), neither did the 
volume of the first compartment (Vj) nor did the distribution rate constants. 
So the only rate determining parameter which is essentially different for the 
antipodes is the total body elimination clearance constant. As elimination of 
hexobarbital in rats takes place by metabolism only (less than 1 per cent of 
unchanged drug was found in bile and urine), this means that the rate of 
metabolism of ( + )-hexobarbital is 2 to 3 times higher than of (—)-hexobarbital 
in vivo. So the difference in half-life is directly related to a difference in meta­
bolic clearance and not to a difference in volume of distribution. 
The isolated perfused rat liver 
The isolated perfused rat liver preparation is a useful in vitro tool for the 
study of drug metabolism (e.g. Von Bahr et al., 1970). Alvarez (1971a) con­
ducted a comparative study of barbiturate metabolism in the perfused liver and 
in vivo in rats. Good correspondence was found between clearance values in 
vitro and in vivo for the compounds eliminated by metabolism mainly. 
To allow comparison, the kinetics of ( + )- and (—)-hexobarbital further were 
investigated in the isolated perfused rat liver. Since metabolism of the two com­
pounds is relatively fast, it was possible to study the fate of both compounds 
in the same liver. A 45 min interval was chosen between the introduction of 
one compound or the other into the perfusion fluid. When (—)-hexobarbital 
was added firstly, it was found by extrapolation that still 10-20% of this 
compound was present after 45 min. In that case the ( + )-hexobarbital concen­
trations were corrected for the presence of (—)-hexobarbital, assuming that the 
rates of metabolism were not influenced by the presence of each other. Prelimi­
nary experiments revealed that the uptake of the two compounds by the liver 
in the perfusion system could be neglected. The distribution in the system is 
quite homogeneous and therefore it can be considered as one compartment. 
This is consistent with the results shown in Fig. 6, in which the blood concen­
tration-time curve for the two antipodes in the same isolated rat liver system 
is shown on semi-log scale. Elimination occurs apparently according to a first-
order process and the concentration of the drugs can be described by a mono-
exponential equation (van Rossum, 1971): 
Cp = С . e - т.і 
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200 
100 
r a t liver 3 (-) hexobarbital 5 m g / 1 0 0 m l perfusate 
45min later (+) hexobarbital 10mg/100ml perfusate 
FIG 6 Hexobarbital liver perfusate concentration curves after adding 5 mg 
(—)-hexobarbital at zero time and 10 mg ( + )-hexobarbital at 45 mm to the per­
fusate of the same isolated liver The concentrations of (+)-hexobarbital were 
corrected for the presence of (—)-hexobarbital, assuming that the rate of metabolism 
was not influenced by the presence of each other 
where Cp is the blood concentration (perfusion fluid concentration) at time t, 
C0 is the zero-time concentration and τοΙ is the elimination time constant. 
Elimination is considered as a clearance from a single compartment with a 
volume Vf, where 
V, 
*el = or t./, = — 
0 69 . V, 
к,-
The half-life can easily be deduced from the experimental curve, whereas Vf 
equals Dose/C0. The metabolic clearance constant can now be calculated. In 
Table VI the half-lives of the antipodes m the same perfused rat liver systems 
are given, as well as the ratio fc/, (—)/t,/l ( + ). The disappearance of ( +^hexo­
barbital is extremely rapid and there exists a 2- or 3-fold difference in half-life 
between the ( + )- and the (—)-isomer. This is approximately the same ratio as 
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TABLE VI. Half-lives of ( + )- and (—)-hexobarbital in the same isolated perfused 
rat liver. 
Liver no. 
1 
2 
3 
4 
5 
6 
mean rfc S.D. 
M + Hmn) 
11 
7 
10 
11 
9 
6 
9.0 ± 2.2* 
t./, (—) (min) 
28 
10 
17 
23 
22 
21 
20.2 ± 6.1* 
Ratio M-) 
t./.( + ) 
2.5 
1.4 
1.7 
2.1 
2.4 
3.5 
2.3 ± 0.8 
* Significantly different at Ρ < 0.005 (Student's t-test). 
found in vivo, although the absolute values for the half-lives differ quite sub­
stantially. 
As already mentioned, the rate of elimination of a drug is mainly dependent 
on the total body clearance and on the apparent volume of distribution. In 
Table VIII the apparent volumes of distribution of the isolated perfused liver 
systems are given. They are about the same for the two antipodes, but smaller 
than those in vivo. The clearance constants on the other hand (Table VIII) are 
almost equal to those in vivo. So the differences in half-life between the in vivo 
and the in vitro situation is due to a difference in volume of distribution. When 
comparing the kinetics of a drug in the isolated perfused liver system to the 
kinetics in vivo, the clearance is the meaningful parameter to look at. Alvarez 
(1971b) already did so for some barbiturates and Rowland (1972) paid atten­
tion to this point in reevaluating data by Von Bahr et al. (1970). Clearance is 
dependent on blood flow through the liver and the capacity of the liver to 
eliminate the drug (Rowland et al. 1973). Blood flow is the same for the two 
compounds and excretion into the bile of the unchanged compounds was less 
than 1 per cent. It can be concluded that in rats metabolism is a stereospecific 
process, since the clearance constants for the two antipodes show a 2- to 3-fold 
difference. Degkwitz et al. (1970) showed that the microsomal mixed function 
oxygenase system is involved in the metabolism of both antipodes in the rat and 
that the specific activity of this system was 1.6 times higher for ( + )-hexobar-
bital than for (—)-hexobarbital. Approximately the same ratio was found by 
Fumer, Mc Carthy et al. (1969) in hepatic microsomes of male rats. No sub-
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TABLE VII. Pharmacokinetic parameters of ( + )- and (—)-hexobarbital in rats. 
Rat no. 
Dose (mg/kg) 
Weight (g) 
Aj (¿tg/ml) 
A2 (/ig/ml) 
Tj (min) 
τ2 (min) 
Vj (ml) 
Vi/kg 
V, (ml) 
V(/kg 
k
el (ml/min) 
k12 (ml/min) 
r12 (1/min) 
г (1/min) 
1 
( + ) 
75 
200 
101 
86 
1.7 
20.3 
80 
400 
150 
750 
7.8 
19.4 
0.24 
0.30 
(—) 
75 
200 
85 
57 
1.5 
43.2 
110 
550 
238 
1190 
5.8 
37.2 
0.35 
0.28 
2 
( + ) 
75 
200 
89 
60 
2.9 
23.4 
100 
500 
182 
900 
9.0 
13.4 
0.13 
0.16 
(—) 
75 
200 
75 
77 
3.5 
67.0 
99 
495 
177 
885 
2.8 
11.9 
0.12 
0.15 
3 
( + ) 
75 
200 
136 
38 
3.4 
37.4 
86 
430 
231 
1155 
7.9 
12.3 
0.14 
0.08 
(—) 
75 
200 
168 
45 
3.3 
46.0 
70 
350 
211 
1055 
5.7 
11.4 
0.16 
0.08 
4 
( + ) 
47.6 
210 
17 
39 
4.1 
30.2 
177 
844 
229 
1092 
8.0 
9.4 
0.05 
0.18 
(—) 
54.0 
185 
39 
45 
2.4 
82.1 
119 
641 
211 
1142 
2.6 
21.1 
0.17 
0.23 
( + ) 
75 
200 
94 
37 
3.1 
33.3 
114 
570 
270 
1350 
9.8 
17.6 
0.15 
0.11 
5 
(-) 
75 
200 
109 
37 
2.6 
105.1 
102 
510 
352 
1760 
3.6 
26.1 
0.25 
0.10 
TABLE VII continued. 
Rat no. 
Dose 
Weight 
\ 
\ 
τ
ι 
T 2 
\ 
V^kg 
v f 
ν,/kg 
k.i 
K2 
Γ 12 
Г21 
6 
(+) (-) 
62.5 
200 
100 
38 
0.8 
20.2 
90 
450 
270 
1350 
14.7 
68.3 
0.76 
0.38 
65.8 
190 
84 
34 
1.2 
48.9 
105 
555 
327 
1719 
7.1 
56.2 
0.53 
0.25 
( + ) 
62.5 
200 
77 
27 
1.0 
23.0 
120 
600 
387 
1835 
17.9 
72.4 
0.6Ó 
0.29 
7 
(—) 
56.8 
220 
93 
32 
0.7 
51.8 
100 
562 
361 
1643 
7.2 
99.5 
0.99 
0.38 
( + ) 
65.8 
190 
83 
35 
1.6 
24.5 
106 
557 
270 
1420 
12.6 
35.2 
0.33 
0.21 
8 
(—) 
62.5 
200 
70 
38 
2.3 
66.2 
115 
575 
291 
1455 
4.7 
28.5 
0.25 
0.16 
Mean values 
( + ) 
2.3 
26.5 
112 
544 
249 
1232 
11.0 
31.0 
0.30 
0.22 
— 
— 
— 
± 1.2 
± 6 . 4 * 
± 32 
± 141 
± 7 1 
± 3 3 7 
± 3 . 7 * 
± 2 6 
±0 .25 
± 0 . 1 0 
± S . D . 
1 
2.2 
63.8 
103 
530 
271 
1356 
4.9 
36.5 
0.36 
0.21 
(—) 
— 
— 
— 
± 1.0 
± 2 1 . 3 * 
± 15 
± 8 5 
± 7 1 
± 3 3 2 
± 1.8* 
± 2 9 
± 0 . 2 9 
± 0 . 1 0 
* Significantly different at Ρ < 0.001 (Student's t-test); all other values Ρ > 0.05. 
Liver no. ( + ) (—) ( + ) (—) ( + ) (—) ( + ) (—) 
Dose (mg) 
C 0 (//g/ml) 
т
е 1 (min) 
V
r
 (ml) 
k
c l (ml/mm) 
10 
75 
15.8 
133 
8.6 
10 
72 
40.3 
139 
3.4 
10 
90 
10.1 
111 
11.0 
5 
41 
14.4 
122 
8.6 
10 
69 
14.4 
146 
10.1 
5 
40 
24.5 
123 
5.0 
10 
78 
15.8 
128 
8.1 
10 
96 
33.1 
104 
3.1 
TABLE VIII continued. 
Liver no. ( + ) (—) ( + ) (—) 
Mean values ± S.D. 
( + ) (—) 
Dose 
V. 
10 
82 
12.9 
122 
9.4 
5 
39 
31.7 
128 
4.0 
10 
80 
8.6 
125 
14.5 
5 
43 
30.2 
116 
3.8 
— 
— 
13.0 ± 3.2* 
127 + 12 
10.2 ± 2.4* 
— 
— 
29.0 ± 8.8 
122 ± 12 
4.6 it 2.0 
stantial differences in K
m
 or K
s
 values were found by these groups. It seems 
likely that the clearance differences are due to differences in rate of metabolic 
conversion of the antipodes by the mixed function oxygenase system. 
Proteinbinding 
The binding of ( + )-, (—)- and (±)-hexobarbital to 3% serum albumin was 
investigated by equilibrium dialysis at pH 7.4 and 37° C. The binding was deter­
mined at three barbiturate concentrations which were in the range of those 
encountered in vivo (14.75, 29.5 and 59 /<g/ml). The results obtained (Table IX) 
TABLE IX. Proteinbinding of ( + )-, (—)- and (±)-hexobarbital*. 
Cone. 0.063 mMol 0.125 mMol 0.250 mMol 
Comp. 
( + ) 25.4 ± 1.1 (7) 26.0 ± 1.0 (6) 21.4 ± 1.3 (5) 
(—) 27.2 ± l.e (4) 26.5 ± 1 . 1 (4) 22.5 ± 0.3 (4) 
(±) 28.5 ± 2.9 (5) 24.5 ± 1.2 (6) 20.6 ± 0.8 (4) 
* Mean values ± S.E.; 3% BSA; phosphate buffer pH 7.4; 37° С Number 
of experiments in parentheses. The differences in protein binding of the com­
pounds at the same concentration were not statistically significant (Student's t-test, 
Ρ > 0.05). 
show that, although there is substantial binding at all three concentrations, at 
no concentration a statistically significant difference in binding between the 
antipodes exists (P > 0.05). It can be concluded that there is no stereospecific 
interaction between albumin and the hexobarbital antipodes. 
DISCUSSION 
In the present experiments it was shown that the same rat slept much longer 
after receiving ( + )-hexobarbital than after receiving the same dose of (—^hexo­
barbital. There are at least four possible explanations for this observation: 
1. ( + )-hexobarbital is eliminated from the brain at a slower rate; 
2. ( + )-hexobarbital is metabolized into an active metabolite to a 
greater extent; 
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3. there exists a stereoselective distribution process, such that more 
( + )-hexobarbital can pass into the brain or throughout the brain 
to the active sites; 
4. ( + )-hexobarbital is more potent at the active site. 
Our detailed pharmacokinetic study probably does provide information which 
allows a distinction between these four possibilities. 
1. The rate of metabolism is the determining factor in the elimination of 
hexobarbital from blood and because equilibrium between plasma and brain is 
achieved very rapidly after i.v. injection (Richards and Taylor, 1956), this will 
also be true for the rate of elimination from the brain as shown in mice by 
Noordhoek (1969). It was found that ( + )-hexobarbital disappears two to three 
times faster from the blood than (—)-hexobarbital, while the contrary could 
have explained the longer sleeping time. 
2. Norhexobarbital (N-demcthylated hexobarbital) is the only known meta-
bolite of (±)-hexobarbital that has anaesthetic properties (Bush et al., 1953). 
Although our gaschromatographic assay was sufficiently sensitive and selective 
for the determination of norhexobarbital in blood, (the pure compound was 
synthesized for reference purposes), only traces could be detected after admini-
stration of the two antipodes. These results are in contrast with those of Rummel 
et al. (1967), who found substantial amounts of norhexobarbital in serum after 
administration of (-(-)-and (—)-hexobarbital to female rats. These investigators 
measured norhexobarbital by UV-spectrophotometry after TLC-separation. We 
checked this procedure, after i.p. administration of 100 mg/kg (±)-hexobarbital 
to female Wistar rats (150 g) and found that the spot on TLC of a serum sample 
extract with the same Rf value as authentic norhexobarbital, certainly was not 
the demethylated product. This was verified with the aid of combined gas 
chromatography-mass spectrometry. So it seems very unlikely that the nor-
hexobarbital does contribute to the duration of anaesthetic activity of one of the 
hexobarbital antipodes. 
3. Distribution of most body foreign substances from the blood into the 
brain occurs by passive diffusion and is determined by lipophility, pKa-value 
and plasma protein binding (Goldstein et al., 1969). As optical antipodes have 
the same physico-chemical properties except optical rotation, their intrinsic 
ability to pass the blood-brain barrier by passive diffusion must be considered 
to be equal. Only the free fraction in the plasma contributes to penetration 
into brain and other tissues, so a higher free concentration would result in a 
higher brain level. For the antipodes of N-methyl - 5-cyclohexenyl - 5-ethyl-
barbital and of N-methyl - 5-phenyl - 5-ethylbarbitaI, both structurally closely 
related to hexobarbital, differences in in vitro albumin binding at low protein 
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concentration have been shown by Buch et al. (1970). At 4% albumin concen-
tration however the differences became less pronounced. We studied the binding 
of the hexobarbital antipodes to 3% serum albumin in order to ascertain 
whether differences in binding did exist. The results show that binding in vitro 
is equal for the two compounds at each concentration investigated. Thus it is 
very unlikely that a difference in protein binding is a contributing factor to 
stereoselective brain penetration of the hexobarbital enantiomers. Great diffe-
rences in distribution behaviour between the antipodes would also have been 
reflected in different volumes of distribution (V1 and V,) or in the distribution 
rate constants (r12 and r21). Although there is quite some variation in these 
parameters (Table VIII), significant differences between the two compounds do 
not exist in this respect. 
So the pharmacokinetic results provide no reasons to assume that the hexo-
barbital antipodes distribute in a stereoselective way in rats. However, Rummel 
et al. (1967) found that ( + )-hexobarbital achieved a higher brain/blood con-
centration ratio than (—)-hexobarbital between 1 and 7 min after i.v. admini-
stration. At 7 min the difference is only small and as one might assume that 
equilibrium between plasma and tissues has been reached by this time, it does 
not explain the great difference in sleeping time between the antipodes. Ob-
viously, a stereoselective distribution throughout the brain cannot be excluded. 
4. Wahlström et al. (1970) already showed that the hexobarbital antipodes 
had unequal anaesthetic potency, despite equal brain concentration. As equili-
brium between plasma and brain concentration of hexobarbital is very rapid 
(Richards and Taylor, 1956), the plasma or blood concentration is a good reflec-
tion of brain concentration. Therefore, the blood concentration at the moment 
of awakening, which can be considered as the minimum effective level to cause 
anaesthesia, is a measure for central depressant potency. This level is approxi-
mately three to four times lower for ( + )-hexobarbital than for (—^hexobar-
bital. Even if one assumes a somewhat higher brain/blood ratio for (-i-)-hexo-
barbital, it still can be concluded that at least a 2- to 3-fold higher blood con-
centration of (—)-hexobarbital is required to produce anaesthesia in rats. 
The fact that the latency time was less than 10 sec after i.v. administration 
of the two compounds can be explained by the high lipophility of hexobarbital, 
which does allow rapid brain penetration, and by the high blood flow to the 
brain. There is an immediate building up of high concentration in the brain 
after i.v. injection, which in most cases far exceeds the minimum effective level. 
This in contrast to i.p. administration, when first diffusion of the compounds 
to the bloodstream must take place and now it takes some time before the 
minimum effective level has been reached. As this is higher for (—^hexo-
barbital it seems rational that more time for this isomer is required. It explains 
181 
the difference in latency after i.p. administration reported by Rummel et al. 
(1967) and Furner, Mc Carthy et al. (1969). Our finding that there is quite 
some variation in minimum effective level for (—)-hexobarbital can be explained 
by the fact that awakening occurs mostly already during the distribution phase, 
when a rapid change of concentration occurs. The equilibrium state concen­
tration is below the minimum effective level, so that a more accurate value 
cannot be obtained from these experiments. 
In conclusion it can be stated that the results strongly suggest that a stereo-
specific mechanism at the active sites in the CNS is involved in hexobarbital 
anaesthesia. It certainly could explain the differences noted in sleeping time 
after administration of the antipodes to rats. 
APPENDIX 
The equations for the two-compartment open model are valid if i.v. injection is in­
stantaneous. In fact injection lasted 10 sec = 0.17 min and therefore the experimental 
coefficients A * and A2* have to be corrected. Injection is looked upon as a linear 
i.v. infusion and it can be derived that: 
A / . 0.17 
І=
~т70~с-0-"ВД" 
A2* . 0.17 
The other pharmacokinetic parameters have been calculated according to the 
equations given in Chapter 1, Section I. 
SUMMARY 
Pharmacokinetics in man 
The pharmacokinetics of ( + )-, (—)- and (±)-hexobarbital were studied in five 
healthy volunteers after oral administration. Each volunteer received the three com­
pounds (400 mg) with an interval of about 2 weeks. Hexobarbital plasma concen­
trations were determined at regular times after drug administration. 
The elimination half-life of (—)-hexobarbital was approximately 3.2 times shorter 
than that of ( + )-hexobarbital (1.4 and 4.6 h respectively). From the areas under the 
plasma concentration curves it was estimated that about 18% of the administered 
dose of the (—)-isomer was metabolized during first passage through the liver 
("first-pass effect"). This is due to its high metabolic clearance. The elimination phase 
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of the racemic mixture (average half-life 4.0 h) should not give, in principle, a 
straight line. However, it was discussed that after oral administration the contribution 
of the (—)-isomer to the pure elimination phase of the racemate was almost negligible. 
An additional experiment revealed that after rapid i.v. infusion of the racemic mixture 
it may be possible to distinguish between the different elimination rates of the two 
enantiomers. Hexobarbital was hardly excreted unchanged into the urine after 
administration of the three compounds, whereas (—)-hexobarbital was metabolized 
to 3-keto-hexobarbital to a greater extent than ( + )-hcxobarbital. 
The volunteers experienced severe drowsiness after ( + )-hexobarbital admini­
stration. It seems likely that this isomer has a greater central depressant activity than 
the (—)-isomer, although the differences in disappearance rate also may explain the 
differences in observed activity. 
Pharmacokinetics in rats and in the isolated perfused rat liver 
The pharmacokinetics of ( + )- and (—)-hexobarbital were studied in the same 
intact rat after i.v. administration, as well as in the same isolated perfused rat liver. 
The blood half-life of ( + Hiexobarbital was 2 - 3 times shorter than that of 
(—)-hcxobarbital, both in vivo and in vitro. No differences in apparent volume of 
distribution were observed, but the metabolic clearance constant of ( + Hiexobarbital 
was 2 - 3 times greater. Clearance values in vivo were found to be equal to those in 
vitro for the same compound. No differences in binding to 3% albumin were ob­
served at 3 physiological concentrations, determined by equilibrium dialysis. The 
animals slept much longer after injection of (+Hiexobarbital and the blood con­
centration at the moment of awakening was approximately 4 times lower than after 
injection of (—Hiexobarbital. It is suggested that a difference in anaesthetic potency 
between the hexobarbital enantiomers at the CNS level is likely to exist. 
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CHAPTER 3 
METHOHEXITAL SODIUM 
INTRAVENOUS AND ORAL ADMINISTRATION 
INTRODUCTION 
Methohexital sodium (BRIETAL) was introduced in 1959 as an intravenous 
anaesthetic agent. The drag has been investigated, for this purpose, in several 
clinical trials which have been reviewed recently by Whitwam (1972). Metho-
hexital was found to be one of the most potent intravenous induction agents 
and it is approximately three times as potent as thiopental (Thomas, 1967; 
Clarke et al., 1968). Complete recovery after methohexital sodium administra-
tion from anaesthesia has been observed and this is significantly more rapid 
than for thiopental sodium (Egbert et al., 1959; Elliott et al., 1962; Barry et al., 
1967). This is beneficial to the patient and also the hospitalisation during the 
day cases can be safely shortened when using methohexital (Barlow and Gottlich, 
1962; Whitwam, 1972). 
Methohexital sodium has been included in the present investigations, because 
of the rapid and complete recovery that has been reported after i.v. administra-
tion. Also, after oral administration (Bush et al., 1966) recovery was found to 
be complete within a few hours. This may indicate that the drug is rapidly in-
activated in the body, which is an advantage when the drug is used in the 
treatment of insomnia. Many patients have difficulty in getting to sleep, but 
experience little difficulty in remaining in that state once achieved. In such cases 
satisfactory therapy may be achieved by the use of a short-acting barbiturate 
(Way and Trevor, 1971). 
The metabolism and excretion of the drug have been studied in both rat and 
dog by Welles et al. (1963) and in man by Brand et al. (1963). In the latter 
study, however exceptionally high doses of at least 1.2 g were given. Further-
more, Sunshine et al. (1966) measured blood levels after clinical doses (1.5 - 2 
mg/kg) of methohexital, by gas chromatography. The sensitivity of their assay 
was such, that it was not possible to measure concentrations for more than 
10 min after drug administration. Bush et al. (1966) included methohexital 
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sodium in a study concerning ultra short-acting barbiturates as oral hypnotic 
agents in man. Blood levels up to 3 or 4 h after drug administration (7 mg/kg) 
were determined and it appeared that both absorption and distribution or elimi-
nation were relatively rapid. Due to the limited amount of data, however, the 
accurate determination of a half-life from these experiments was not possible. 
Improvements in the sensitivity of the assay for methohexital (Chapter 4, Section 
II) now make it feasible to determine the pharmacokinetics after administration 
of therapeutic doses to man. Firstly, the drug was administered intravenously in 
order to establish an appropriate pharmacokinetic model and also to accurately 
calculate parameters. Administration occurred by slow zero-order i.v. infusion 
in order not to discomfort the volunteers and to avoid systemic reactions. 
Secondly, methohexital sodium was administered orally and the rate of absorp-
tion and elimination was estimated. 
METHODS 
Intravenous administration 
Methohexital sodium (BRIETAL sodium) for i.v. injection was obtained from 
LILLY, USA. Solutions for i.v. infusion were prepared, immediately before use, 
by dissolving the sterile contents of a sealed container in sterile physiological salt 
solution (10 mg/ml). 
Four healthy male volunteers, ranging in age from 23 - 27 years and in body-
weight from 5 5 - 8 1 kg, participated in the study of i.v. administration. They 
had received no regular medication during the 4 weeks preceding initiation of 
the experiments. After an overnight fast, the volunteers received methohexital 
intravenously by a 60 min zero-order infusion. The doses applied were 3 mg/kg 
of the sodium salt. The volunteers were resting supine during infusion and 
for 3 h after infusion. Blood samples were taken from a forearm vein at the 
following times during infusion: 10, 20, 30, 40, 50 and 60 min. After infusion 
blood samples were withdrawn usually after 5, 10, 15, 25, 35, 45, 55, 75, 
95 min and after 2, 3, 4, 5 and 6 or 7 h. 
Oral administration 
Methohexital sodium for i.v. injection (BRIETAL sodium) was also used for 
the oral experiments. Hard gelatine capsules were filled with the appropriate 
amount of drug. Four healthy male volunteers (two of them had received 
methohexital by i.v. infusion), ranging in age from 21-27 years and in body-
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weight from 74-81 kg participated in the study of oral administration. After 
an overnight fast, the volunteers received methohexital sodium (3 mg/kg) 
together with 150 ml water. They were requested to lie down for at least 2 h 
after drug administration. Blood samples were taken at the following times: 
10, 20, 30, 45, 60 min and 1.5, 2, 2.5, 3, 4, 5 and 6 h after drug administration. 
Methohexital plasma concentrations were determined by gas chromatography 
as described in Chapter 4, Section II. 
RESULTS AND DISCUSSION 
Intravenous infusion 
During i.v. infusion of methohexital sodium a rapid rise in the methohexital 
plasma concentration occurred until the zero-order infusion was terminated. 
After this event the plasma concentration-time curve exhibited at least two 
phases; an early phase with relatively steep slope and a latter phase with a 
more gradual slope (Fig. 1). This suggests that the kinetics of methohexital 
after i.v. administration fit the two-compartment open model. The entire curve 
may be represented mathematically as a sum of two exponentials, as has been 
outlined in detail for hexobarbital (Chapter 1, Section III). The methohexital 
plasma concentrations were fitted according to the equations which are valid 
during and after infusion, by using the FARMFIT computer program. The 
initial graphical estimates of τ1 and τ, were used as a start guess. A relative 
error of 5% in the concentrations was taken into account, since this was the 
standard deviation estimated in the assay procedure (Chapter 4, Section II). 
An example of a fitted and plotted curve is given in Fig. 1 and it illustrates 
the agreement between the plasma levels and the two-compartment model. The 
consistency also follows from the relatively small standard errors calculated 
for the fitted parameters (Table I). In contrast with hexobarbital, the concen­
trations for methohexital during the infusion period were included in the fitting 
procedure. It appeared that by doing this, the fit was improved as judged by 
the smaller standard errors in the fitted parameters. Since in most cases the 
concentrations 5 or 6 h after infusion were higher than expected on the basis 
of the two-compartment kinetics, the possibility of the existence of a third 
compartment was considered. The fitting procedure was now accomplished by 
the assumption of a three-exponential equation underlying the concentration 
course during and after infusion (Eq. 5 and 6, Chapter 1, Section HI). In Fig. 2 
an example of such a fitted curve is given for the same experimental data of 
Fig. 1. Although a good fit of the data to the curve is apparent, the standard 
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FIG. 1. Methohexital plasma concentration curve (semi-logarithmic scale) during 
and after a 60 min zero-order i.v. infusion of methohexital sodium to a healthy 
volunteer. The concentrations were fitted according to Eq. 5 and 6, Chapter 1, 
Section III, assuming that a two-compartment model is valid for methohexital i.v. 
kinetics. See Table I for the fitted parameters, including standard errors. The repro­
duction was obtained from a direct computer plot. 
errors in the fitted parameters are much higher than in the case of a two-
compartment model. This is due to the fact that six parameters had to be fitted 
with the same amount of experimental data. Unfortunately the sensitivity of 
the assay did not allow measurements of the plasma concentrations for longer 
periods of time. For comparative purposes the fitted parameters of the three-
compartment model are given in Table II. A reasonable three-compartment fit 
was obtained only for two of the volunteers (H.K. and R.C.). A three-com­
partment fit of the data was not possible for the other two volunteers. The 
present experiments do not indicate that the use of the three-compartment model 
is valid for methohexital kinetics. Further experiments, with higher doses, or 
repeated administration are needed in order to follow plasma concentrations 
for longer periods of time. It seems likely that methohexital will be similar to 
thiopental and hexobarbital in its pattern of distribution immediately after i.v. 
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FIG. 2. Mcthohexital plasma concentration curve (semi-logarithmic scale) based 
upon the same experimental data as in Fig. 1. In this instance, the concentrations 
were fitted according to Eq. 5 and 6, Chapter 1, Section III, assuming that a three-
compartment model is valid for methohexital i.V. kinetics. See Table II for the fitted 
parameters, including standard errors. The reproduction was obtained from a direct 
computer plot. 
injection. Rapid recovery of consciousness, after a single i.v. dose of each of 
these drugs, is caused largely by a redistribution of the drugs from the highly 
perfused viscera, including the central nervous system, into lean body mass 
(Price et al., 1960). However, methohexital as well as hexobarbital, are less 
extensively localized in fat tissue than thiopental (Brand et al., 1963). If fat 
uptake plays a minor role in methohexital elimination, then there is no im­
portant physiological reason to suppose that a three-compartment model is 
required to explain methohexital kinetics. It has been shown for thiopental 
that it takes a few hours before equilibrium is reached between the concen­
tration in blood and in adipose tissue (Price et al., 1960). Probably the meta­
bolism of methohexital is so rapid that the poorly perfused fat tissue does not 
experience substantial drug uptake. Only for very high doses would it become 
a factor to be considered. The plasma levels obtained by Brand et al. (1963), 
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jTj TABLE I. Fitted and calculated pharmacokinetic parameters of methohexital, according to a two-compartment open model, 
о after i.v. infusion of methohexital sodium to four healthy volunteers (standard errors in parentheses). 
Name 
Age (yr) 
Body-weight (kg) 
Dose (mg free acid) 
Dose/kg (mg) 
Inf. time (min) 
Tj (min) 
т2 (min) 
U,, (min) 
Aj (mg/l) 
A 2 (mg/l) 
Vi (1) 
Vj/kg (1) 
Vf (1) 
V(/kg (1) 
k
e l (mi/min) 
k
el/kg (mi/min) 
k 1 2 (mi/min) 
r 1 2 (I/min) 
r 2 1 (1/min) 
AUC (mg.min/1) 
AUC/kg (mg.min/1) 
H.K. 
23 
74 
204 
2.76 
60 
9.7 
138 
95 
10.7 
1.38 
16.8 
0.23 
64.1 
0.87 
692 
9.35 
858 
0.051 
0.018 
295 
3.99 
(14.7%) 
( 6.4%) 
(12.8%) 
( 8.4%) 
R.C. 
25 
55 
152 
2.76 
60 
9.8 
181 
125 
9.87 
0.74 
14.3 
0.26 
71.7 
1.30 
657 
11.95 
702 
0.049 
0.012 
232 
4.22 
(17.2%) 
(12.8%) 
(16.8%) 
(13.3%) 
R.H. 
27 
81 
224 
2.76 
60 
10.1 
141 
97 
6.67 
1.11 
28.7 
0.35 
101.4 
1.25 
999 
12.33 
1465 
0.051 
0.020 
224 
2.77 
(25.4%) 
( 6.5%) 
(34.9%) 
( 8.5%) 
P.A.* 
24 
64 
177 
2.76 
60 
7.2 
101 
70 
7.50 
1.30 
20.1 
0.31 
70.4 
1.10 
955 
14.93 
1455 
0.072 
0.029 
185 
2.89 
Mean 
24.8 
68.5 
189.3 
2.76 
60 
9.2 
140 
97 
8.69 
1.13 
20.0 
0.29 
76.9 
1.13 
829 
12.14 
1120 
0.056 
0.020 
234 
3.47 
* Experimental parameters graphically determined by hand. 
TABLE II. Fitted and calculated pharmacokinetic parameters of methohexital, ac­
cording to a three-compartment open model, after i.v. infusion (standard errors in 
parentheses). 
Name 
Tj (min) 
τ 2 (min) 
т., (min) 
\ (mg/1) 
A 2 (mg/1) 
A3 (mg/1) 
k
e l (ml/min) 
Vf (1) 
H.K. 
3.8 (34.7%) 
63.4 (32.1%) 
415 (128%) 
22.7 (38.6%) 
2.02 (11.0%) 
0.31 (111%) 
595 
108 
R.C. 
3.4 
48.0 
557 
19.6 
1.68 
0.25 
530 
150 
(29.2%) 
(16.9%) 
(49.9%) 
(24.9%) 
(12.8%) 
(29.8%) 
after i.v. infusion of 1.2 to 1.8 g methohexital to four volunteers, indicate that 
there may be a slower phase with these high doses, corresponding to a half-life 
of 4 - 5 h. However, in these experiments plasma levels were not followed long 
enough to draw definite conclusions. Further, it should be considered that 
methohexital is used in practice as a raccmic mixture (Chapter 4, Section II). 
Similar to hexobarbital, the possibility exists that the kinetics of methohexital 
are more complex due to differences in elimination rate of the two enantiomers. 
In Table I the pharmacokinetic parameters of methohexital are given, accor­
ding to the two-compartment open model. The apparent volume of distribution 
is in the same order of magnitude as found for hexobarbital. The elimination 
half-life of the drug is very short, which is mainly due to the high metabolic 
clearance. Obviously, the clearance is smaller when calculated according to a 
three-compartment model, whereas the apparent volume of distribution is much 
larger (Table II). Sunshine et al. (1963) found only small amounts of metho­
hexital in urine and bile of man; less than 1% of the administered dose was 
excreted as unchanged methohexital. Welles et al. (1963) studied the meta­
bolism and excretion of methohexital in the rat and the dog. They found no 
unchanged drug in the urine, but by using paper chromatography they found 
evidence for the existence of several metabolites in urine. The most abundant 
of these metabolites was identified as l-methyl-5-allyl-5-(l-methyl-4-hydroxy-
2-pentynyl)-barbituric acid which is formed by hydroxylation of the penul­
timate carbon of the pentynyl side chain. Demethylation of the N-methyl group 
did not occur to a great extent. An interesting observation has been that 
faecal excretion of metabolites in rats amounted to 82% of the administered 
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dose, whereas in the dog this value was 30%. In man no data on metabolic 
pathways or excretion routes in quantitative terms are available. 
It is highly probable that the rapid and complete recovery after methohexital 
administration, after regaining consciousness, is due to the rapid inactivation of 
the drug by metabolism. The present findings substantiate earlier speculations 
in this direction and in conclusion it may be stated that this is of great benefit 
for the use of methohexital in i.v. anaesthesia for operations of short duration. 
It should be mentioned that in the present experiments the volunteers ex-
perienced drowsiness and were inclined to sleep generally fifteen minutes after 
the commencement of infusion. Throughout the infusion period they could 
however, easily be awakened and after termination of infusion recovery was 
complete apparently within one hour, as judged subjectively. 
Oral administration 
Methohexital sodium, after oral administration in a hard gelatine capsule, 
gave results indicative of rapid absorption. The peak level times and the 
maximum concentrations reached, are given in Table III. A rapid absorption 
was expected, since salts of barbiturates are, in general, rapidly absorbed, due 
to their high dissolution rate in the gastrointestinal tract (compare hexobarbital 
sodium, Chapter 1, Section III and heptabarbital sodium, Chapter 5, Section 
III). In all cases the volunteers reported initial feelings of euphoria, followed 
by symptoms of sleepiness for about half an hour, including the times of the 
TABLE III. Pharmacokinetic parameters of methohexital after oral administration 
of methohexital sodium to four healthy volunteers. 
Name 
Age (yr) 
Body-weight (kg) 
Dose (mg free acid) 
Dose/kg (mg) 
Wv ( m i n ) 
Cmax (mg/» 
t,/, (min) 
AUG (mg.min/1) 
AUC/kg (mg.min/1) 
S.R. 
24 
78 
217 
2.76 
30 
0.77 
43 
51 
0.65 
H.R. 
25 
76 
210 
2.76 
60 
0.42 
46 
35 
0.46 
R.H. 
27 
81 
224 
2.76 
30 
0.98 
62 
98 
1.21 
H.K. 
23 
74 
204 
2.76 
20 
1.20 
55 
100 
1.35 
Mean 
24.8 
77.3 
214 
2.76 
35.0 
0.84 
51.5 
71 
0.92 
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peak plasma concentration. Also, subject H.R. with the lowest peak concen-
tration, experienced drowsiness for a short time. Recovery in all cases was 
apparently complete within one hour after the peak level time. A dose of 
3 mg/kg should be sufficient to induce sleep at night quite rapidly. 
The elimination phase after oral methohexital administration could in all 
cases be described by a single first-order process (Fig. 3), however, the half-life 
concentration methohexital {mg/I plasma,log scaie) 
20 -, 
10 
05 -
02 
01 
005 
0.02 
Methohexital eodium 
(3!Tig7k3)oral 
subject H K. 74kg 
1 
M 
FIG. 3. Methohexital plasma concentration curve (semi-logarithmic scale) following 
oral administration of methohexital sodium (3 mg/kg) in a hard gelatine capsule to 
a healthy volunteer. 
was shorter than after i.v. infusion. The reason for this finding is not clear, 
although a possibility exists that a combination of pure elimination and distri-
bution of the drug into peripheral tissues, is actually measured. The curve 
could not be followed long enough to see whether a distinct second phase with 
a longer half-life existed. The high metabolic clearance after i.v. administration 
suggests that a "first-pass effect" may influence the bioavailability of metho-
hexital after oral administration to a considerable extent (Rowland, 1972). 
The average ratio of the areas under the plasma concentration curves is a 
measure of the bioavailability. In Table I these values are given for i.v. ad-
ministration, obtained by dividing dose by the clearance constant (AUC = 
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D/k,,]). The AUC's of the oral experiments were determined by weighing the 
areas up to 5 or 6 h and correcting for the remaining area by adding the 
product of the last concentration measured and the elimination time constant, 
to the experimental area (Dost, 1968). Results are given in Table II and it 
appears that the average AUC/kg of body-weight is only 26% of the i.v. value 
(0.92 versus 3.47 mg.min/1). For the volunteers who participated in both ex-
periments (H.K. and R.H.) this value was 34% and 44% respectively. When 
assuming that pharmaceutical factors are not involved in lowering bioavailability 
after oral administration, these results would indicate that there is a considerable 
"first-pass effect" of methohexital after oral administration. It is possible that 
the effect is overestimated due to the short half-life after oral administration, 
since this may indicate that the clearance was higher than after i.v. infusion. 
In that case the oral AUC-values are not comparable with the i.v. values, since 
it is the product of AUC and clearance which have to be compared. Thus bio-
availability may be slightly higher than the determined average value of 26%. 
Nevertheless the present findings are in agreement with the theory that a sub-
stantial amount of a drug, with a high clearance when administered orally, is 
metabolized during first passage through the liver. 
CONCLUSIONS 
Methohexital is rapidly metabolized in man, which is highly favourable when 
anaesthesia is required for operations of short duration. The rapid and complete 
recovery, which is reported in the literature, after i.v. methohexital anaesthesia 
is in agreement with the rapid inactivation of the drug. 
After oral administration, methohexital sodium is rapidly absorbed, and its 
half-life appears to be even shorter than after i.v. administration. Bioavailability 
is low, due to a considerable "first-pass effect". Methohexital sodium may be 
used orally for the rapid induction of sleep, although further experiments would 
be required in order to ascertain the optimal dose and the pharmaceutical for-
mulation in which the drug should be incorporated. 
SUMMARY 
Methohexital kinetics were studied in man after i.v. and oral administration of 
methohexital sodium. For the i.v. experiments the drug was administered by a 60 min 
zero-order infusion (3 mg/kg) to four healthy volunteers. During and after infusion 
the plasma concentrations were determined at regular intervals. The concentrations 
were fitted according to the equation that is valid for both a two-compartment open 
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model (Fig. 1) and a three-compartment open model (Fig. 2). In the latter case a 
satisfactory fit could be obtained for only two of the volunteers. It was discussed 
that two-compartment kinetics may be more valid for methohexital during and after 
i.v. infusion. Elimination of methohexital in .the volunteers was extremely rapid; 
plasma half-lives of 70 - 125 min were estimated. This is due to the high metabolic 
clearance of the compound, which varied from 657 to 999 ml/min. The average 
volume of distribution was 1.13 1/kg. It was concluded that the rapid inactivation 
of the drug in the body leads to a rapid and complete recovery when the drug is 
used as an intravenous anaesthetic agent for operations of short duration. 
After oral administration of methohexital sodium to four volunteers (3 mg/kg), 
in a hard gelatine capsule, rapid absorption was noted. The elimination half-lives 
were shorter than after i.v. administration (43 - 62 min). Due to the high metabolic 
clearance a substantial "first-pass effect" was evident. An average bioavailability of 
26% was estimated for methohexital after oral administration. It was concluded that 
methohexital sodium may be used orally for the rapid induction of sleep. 
REFERENCES 
Barlow, M. B. and J. Gottlich (1962), Med. Proc. 8, 462. 
Barry, С. T., R. Lawson and D. G. D. Davidson (1967), Anaesthesia 22, 228. 
Brand, L., L. С Mark, M. M. Snell, Ρ Vrindten and P. G. Dayton (1963), Anesthe­
siology 24, 331. 
Bush, M. T., G. Berry and A. Hume (1966), Clin. Pharmacol. Ther. 7, 373. 
Clarke, R. S. J., J. W. Dundee, D. W. Barron and L. McArdle (1968), Brit. J. Anaesth. 
40, 593. 
Dost, F. H. (1968), Grundlagen der Pharmakokinetik, p. 156, Georg Thieme Verlag, 
Stuttgart. 
Egbert, L. D., S. R. Oech and J. E. Eckenhoff (1959), Surg. Gynec. Obstet. 109, 427. 
Elliot, С J. R., R. Green, T. H. Howells and H. A. Long (1962), Lancet 2, 68. 
Price, H. L., P. J. Kovnat, J. N. Safer, E. H. Cormier and M. L. Price (1960), Clin. 
Pharmacol. Ther. 1, 16. 
Rowland, M. (1972), J. Pharm. Sci. 61, 70. 
Sunshine, I., J. G. Whitwam, W. W. Fike, B. Finkle and J. LeBeau (1966), Brit. J. 
Anaesth. 38, 23. 
Thomas, E. T. (1967), Anaesthesia 22, 16. 
Way, W. L. and A. J. Trevor (1971), Anesthesiology 34, 170. 
Welles, J. S., R. E. McMahon and W. J. Doran (1963), J. Pharmacol. Exp. Ther. 139, 
166. 
Whitwam, J. G. (1972), Anaesthesiologie und Wiederbelebung, Band 57, p. 1, 
Springer Verlag, Heidelberg. 
195 
CHAPTER 4 
VINYLBITAL 
ORAL AND RECTAL ADMINISTRATION 
INTRODUCTION 
Vinylbital is one of the newer barbiturates which was introduced into therapy 
in 1963. It is used in the treatment of insomnia and also as a sedative agent. In 
the Netherlands the drug is available in tablet form under the trade name 
BYKONOX, while in France suppositories also are in use (SUPPOPTANOX). 
The tablets contain 150 mg vinylbital and the suppositories 200 mg. Several 
reports have appeared on the effectiveness of the drug in the treatment of in-
somnia in patients with various diseases and also in healthy people (Zara, 1963; 
Dumrauf, 1964; Perkhof, 1964; Baptist, 1965; Beck, 1968; Dziuba, 1968; 
Meyer, 1968). Jovanovic (1967a) extensively studied the effect of vinylbital on 
the sleeping process in patients with slight to marked disturbances of sleep. 
He concluded that the drug was able to restore sleep, more or less to normal, 
and also that side effects, both encéphalographie and clinical, were fewer than 
with other barbiturates. Also, REM sleep was not greatly influenced after a 
normal dose of 150 or 200 mg. The same author (Jovanovic, 1967b) reported 
on the neurophysiological aspects of vinylbital action. 
Although Hofmann (1971) measured some vinylbital blood levels in man 
after relatively high doses, no detailed pharmacokinetic information is available. 
Therefore, it was decided to study the rate of elimination, the rate of absorption 
and the relative bioavailability, both after oral (BYKONOX) and after rectal 
(SUPPOPTANOX) administration of vinylbital. Furthermore, plasma levels 
during chronic vinylbital administration were determined, in order to see if 
accumulation of the drug in the body would occur and also to ascertain whether 
the half-life would remain unchanged. 
METHODS 
The BYKONOX tablets and SUPPOPTANOX suppositories were obtained 
from BYK-Nederland, Zwanenburg, The Netherlands. 
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The vinylbital content of the tablets was determined at the Dutch Pharma-
cist's Laboratory, The Hague, by Potentiometrie titration with alkali (0.1 N) in 
nitrogen atmosphere. An average content of 147.5 mg (98.3%) was found, with 
a variation coefficient of 1%. The suppository base consisted of a mixture of 
polyethylene glycols. The vinylbital content of the suppositories was determined 
by gas chromatography, after extraction of the active ingredient by diethyl ether. 
An average content of 198 mg (99%) was found, with a variation coefficient 
of 2%. 
Six healthy male volunteers, ranging in age from 19 -25 years and in body 
weight from 55 - 84 kg, participated in the study. 
They had received no regular medication during the 4 weeks preceding 
initiation of the experiments. After an overnight fast, the subjects were given 
150 mg vinylbital as a BYKONOX tablet with 150 ml water, or 200 mg vinyl-
bital as a SUPPOPTANOX suppository. No food, fluid or tobacco was allowed 
for 3.5 h after drug administration. At first, the subjects were asked to remain 
in an upright position for 15 min and then to lie for at least 3.5 h. This 
procedure was undertaken in order to simulate as closely as possible the situation 
of taking a hypnotic drag and going to bed. Blood samples (5 ml) were taken 
from a forearm vein, usually at the following times: 20 min, 40 min, 1, 1.5, 
2, 3 (4), 5, 7 (8), 9, 12, 24, 30, 34 and 48 h after administration. 
Every subject received both preparations with an interval of at least 2 weeks. 
The sample schedule was the same in the two trials. The plasma samples were 
stored frozen until the time of analysis. Three subjects collected their urine 
during 3 - 4 days after the administration of a BYKONOX tablet. Vinylbital 
concentration in plasma and in urine was determined by gas chromatography, 
as described in Chapter 5 of Section II. 
Two subjects participated in a study of repetitive vinylbital administration. 
On the first day of the experiment the half-life of the drug was determined and 
from the second night on they took one BYKONOX tablet with 150 ml water. 
The next morning, nine hours after drug intake, a blood sample was taken and 
the vinylbital concentration was determined. On the eighth day vinylbital was 
given again in the morning, in order to determine the half-life of the drug after 
repetitive administration. In Fig. 6 the time schedule of drug intake and blood 
sampling is indicated. 
RESULTS 
The individual plasma concentration curves during the first 12 h are shown 
in Fig. 1 (BYKONOX) and in Fig. 2 (SUPPOPTANOX). Absorption, after 
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concentration vinylbital (me"/I ptaemaj 
5- , 
vinylbital 150m¿",oral 
tablet Bykonov 
time ( h ; 
FIG. 1. Plasma concentration curves of vinylbital after oral administration of a 
BYKONOX tablet to six healthy volunteers. 
oral administration, occurs more rapidly than after rectal administration, since 
the peak levels are reached earlier. This occurs in the first case between 1 and 
2 h and in the latter case between 2 and 6 h. Maximum concentrations vary 
from 2.2 to 3.9 mg/1 and from 1.8 to 3.8 mg/1 respectively. It is apparent that 
plasma levels are higher when the body-weight is lower. 
CNS depression was experienced by all subjects and they were inclined to 
sleep after ^h-lYzh when receiving the tablet and somewhat later with the 
suppositories. It could be deduced, from the plasma concentration curves, that 
sleepiness consistently occurred when the plasma concentration had reached a 
value between 2.0 and 2.5 mg/1. 
In Fig. 3 the plasma concentration curves of the two preparations, in the same 
individual, are shown on semi-logarithmic scale. Apparently, in both cases, 
absorption and elimination are first-order kinetic processes. This is inferred 
because the descending part of the curves yields a straight line (elimination 
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concentration vinylbital (mg/l p l a s m a ) 
5 ι 
vmylbital 2 0 0 mg",rectal 
aupp Suppoptanox 
time ( h ) 
FIG. 2. Plasma concentration curves of vinylbital after rectal administration of a 
SUPPOPTANOX suppository to the same healthy volunteers as in Fig. 1. (Key the 
same as in Fig. 1). 
phase) and also the absorption phase, obtained with the subtraction method, 
yields straight lines. The plasma concentration (Cp) can be described by the 
following equation: 
CD = A . (e -tftei— e "V*.) 
where т
а
 and r
el are the time constants of absorption and elimination respecti­
vely and A is the "zero-time concentration". The time constants may be deduced 
easily from the experimental curve, while т
а
 = 1.44 χ ti/ta and теІ = 1.44 χ ti/iel. 
A is obtained by extrapolating the elimination line and the subtracted absorption 
line back to zero time. Theoretically these should cross at the same concen­
tration at that time. However, in practice crossing often occurs some time after 
zero (see Fig. 3). When assuming first order absorption, this means that it lasts 
some time before absorption starts, which could be due, for example, to a slow 
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time(h) 
FIG. 3. Plasma concentration curves on semi-logarithmic scale of vinylbital in the 
same subject after oral and rectal vinylbital administration. Upper: time scale up to 
49 h; the descending part of the curves represents the elimination phase, which is 
apparently a first-order process with a half-life (t1/seI) of approximately 18 h in both 
cases. These values were hand calculated while the fitted half-lives were found to be 
19.4 h after oral and 17.6 h after rectal administration (Table I). Lower: time scale up 
to 12 h; the dotted lines represent the absorption phase which have been obtained 
by the subtraction method. Apparently absorption is a first-order process, with 
half-lives (t,/ia) of 20 min and 58 min. At is the extrapolated concentration at t0 (lag 
time) of the tablet and A
e
 is the extrapolated concentration at t0 of the suppository. 
In Table I the fitted values for t,/ia, t0 and A are given. 
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FIG. 4. Example of a fitted and directly computer plotted vinylbital plasma con­
centration curve. See Table I for the parameter values. 
disintegration of the dosage form. This "lag time" (t„) has to be taken into 
account in the above equation, where t = t„p-t0. For the extrapolated con­
centration at t0 the symbol "A" is used: "zero-time concentration". 
All of the individual plasma concentration curves have been fitted according 
to the above equation (including correction for the lag time) by means of the 
FARMFIT computer program (fitted parameters: т
а
, т
с
і, A and t0). An 
example of such a fitted and plotted curve is given in Fig. 4. In Table I all of 
the fitted parameters are given. In most subjects the lag time is shorter with 
the suppository, indicating that absorption starts earlier from the rectum than 
from the upper part of the gastrointestinal tract. However, absorption occurred 
2 to 4 times faster after oral administration than after rectal administration. 
Average half-lives of 14.4 min and 38.4 min were obtained, respectively, for 
the absorption phase. The half-life of elimination of vinylbital varies from 17.6 
to 33.5 h, but is reasonably constant within the same subject. Apparently 
there is no essential difference in elimination rate after oral and after rectal 
administration, the mean values being 23.5 and 23.8 h. 
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TABLE I. Fitted pharmacokinetic parameters of vinylbital after oral and rectal 
administration. 
t-/.. 
(h) 
0.15 
0.38 
0.24 
0.55 
0.25 
0.95 
0.15 
0.83 
0.15 
0.44 
0.47 
0.70 
0.24 
0.64 
T
e I 
(h) 
31.6 32.8 
29.1 
34.7 
27.9 
25.3 
ЪТ.в 
34.5 
41.5 
49.8 
35.1 
29.7 
33.8 
34.5 
1
 іс1 
(h) 
21.9 
22.8 
20.2 
24.2 
19.4 
17.6 
26.0 
23.9 
28.8 
33.5 
24.4 
20.6 
23.5 
23.8 
A 
(mg/l) 
3.74 
3.47 
3.52 
3.86 
3.00 
3.66 
2.30 
3.58 
2.24 
3.82 
2.36 
2.22 
2.86 
3.44 
* These values have not been corrected for the assayed vinylbital content of the 
dosage forms, since the deviations did not exceed ±5%. 
It can be derived that: 
D.F t
e l 
A = . — 
V
r *
e l - Ta 
where D is the dose administered, F is the fraction of the drug that reaches 
the general circulation intact (bioavailability; 0 < F < 1) and Vf is the apparent 
volume of distribution. With oral or rectal data only, F cannot be estimated, 
this is only possible by comparison with i.v. administration (F = 1). Therefore 
the quotient Vt/F is calculated, as well as the clearance constant (kcl) divided 
by F (k^/F = Vt/F. l/rei; Table II). In principle, the relative bioavailability 
(F
r c l) of the two preparations in one subject can be easily calculated, by as­
suming that Vf or kel is constant and taking the tablet as the reference dosage 
form: 
S u b
" wpmht D o s a S e D o s e * Dose/kg t0 та 
ject £1™ form (mg) (mg) (h) (h) 
N.H. 59 tabi. 150 2.54 0.13 0.22 
supp. 200 3.39 0.26 0.56 
J.K. 55 tabi. 150 2.73 0.20 0.35 
supp. 200 3.64 0.10 0.80 
J.H. 75 tabi. 150 2.00 0.20 0.36 
supp. 200 2.67 0.18 1.37 
W.B. 75 tabi. 150 2.00 0.54 0.21 
supp. 200 2.67 0.23 1.20 
G.V. 70 tabi. 150 2.14 0.32 0.22 
supp. 200 2.71 0.01 0.64 
P.K. 84 tabi. 150 1.79 0.23 0.67 
supp. 200 2.39 0.13 1.01 
mean values tabi. 150 2.20 0.27 0.34 
supp. 200 2.90 0.13 0.93 
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TABLE IL Calculated pharmacokinetic parameters of vinylbital after oral and rectal 
administration. 
(supp) 
Sub­
ject 
N.H. 
J.K. 
J.H. 
W.B. 
G.V. 
P.K. 
mean 
mean 
Body-
weight 
(kg) 
59 
55 
75 
75 
70 
84 
values 
Dosage 
form 
tabi. 
supp. 
tabi. 
supp. 
tabi. 
supp. 
tabi. 
supp. 
tabi. 
supp. 
tabi. 
supp. 
tabi. 
supp. 
of lowest values 
F 
(1) 
40.0 
58.5 
43.2 
53.0 
50.6 
57.8 
65.3 
57.9 
67.3 
53.0 
64.9 
93.2 
55.3 
62.2 
51.7 
( F ) / k g 
(1) 
0.68 
0.79 
0.67 
0.77 
0.76 
0.77 
0.74 
(ml/min) (ml/min) 
21.0 
29.7 
24.7 
25.3 
30.2 
38.2 
29.2 
28.1 
27.3 
17.7 
30.8 
52.3 
27.2 
31.9 
25.1 
0.36 
0.41 
0.40 
0.37 
0.25 
0.37 
0.36 
r c l
 (tabi) 
(V t/F) t t l l I 
(%) 
69 
82 
88 
113 
127 
70 
92 
(kei/F)
s
„p, 
(%) 
71 
98 
79 
104 
154 
59 
94 
') The relative bioavailability (F
r e l) of the suppository has been calculated in two 
ways, which yield different results. For explanation see text. 
F
r e l = —
8 U P L
 =
 _Y' : Z i u ^ -
 =
 -
 ( V f / F ) t a b L (X 100%) 
Ftabl V f · Ftabl (Vf/F)
eupp 
or F
r c I = (x 100%) 
(ке]/г)
в 1 1рр 
The relative bioavailability has been calculated in both ways and it follows 
from the results in Table II, in most subjects, there are substantial differences 
between the values obtained. This can be explained by the fact that the time 
constant of elimination т
е1 in the same individual is not identical during the 
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FIG. 5. Renal vmylbital excretion rate, urine pH, urine production and cumulative 
renal excretion of unchanged drug after oral administration of 150 mg vinylbital. 
Parallelism can be observed between the plasma concentration curve and the average 
renal excretion rate curve. 
two trials. When single compartment kinetics are valid this must be due either 
to a change in apparent volume of distribution, to a change in total body 
clearance or to a simultaneous change in both. Since it is impossible to differen-
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FIG. 6. Half-lives and plasma concentrations of vinylbital before, during and after 
repetitive vinylbital administration to two healthy volunteers. During the first and 
second day of the experiment the half-life of the drug was determined. From the 
second night on a BYKONOX tablet was taken and the next morning (9 h later) the 
plasma concentration was measured. During day 8 and day 9 the half-life of the drug 
was again determined. 
tiate between these possibilities, one cannot predict which of the two methods 
of relative bioavailability calculation is preferable. Therefore, the values in 
Table II should be looked upon as the limits of a range in which the real F
r e l 
might be found. In any case, bioavailability of vinylbital from the suppository in 
four subjects is lower than from the tablet, while the reverse seems true in the 
two subjects. However, when comparing plasma concentrations, after tablet 
administration of the latter to the other ones, this observation seems to be due 
to a low bioavailability of the oral preparation rather than to a high bioavaila-
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bility of the suppository. So it seems justified to conclude that the suppository 
is less capable of delivering vinylbital to the body than the tablet. The difference 
in dosage (150 mg oral compared to 200 mg rectal), can be considered as a 
correction for the loss of drug when rectally administered. On the average, 
the plasma levels do not differ substantially when BYKONOX or SUPPOP-
TANOX is given, apart from the concentrations during the absorption phase. 
Vinylbital appears to be excreted unchanged in the urine to a very small 
extent. For the three subjects, who collected their urine after the administration 
of a BYKONOX tablet during 3 - 4 days, cumulative excretion amounted to 
1.0, 1.5 and 2.3% of the dose administered. Most probably the remainder is 
metabolized to more polar metabolites, but no attempt has been made to identify 
these. The renal excretion rate of vinylbital fluctuates and appears to be depen-
dent on the plasma concentration and also on the urine flow (Fig. 5). A certain 
parallelism can be observed between the plasma concentration and the average 
renal excretion rate. 
Results of repetitive vinylbital administration are given in Fig. 6. The half-
lives in the two subjects, before and after intake of 150 mg vinylbital during 
a period of six nights, did not differ significantly. Self-induction of the meta-
bolizing enzyme system had not occurred during this (short) period of time. 
Also, the plasma concentrations at 9 h after drug administration were quite 
constant. An important accumulation of the drug in the body did not take 
place, which is in agreement with the fact that the dosage interval (24 h) is 
greater than one half-life of the drug in these subjects. Nevertheless, a relatively 
high plasma level after 9 h remains, since by that time only about 2 0 - 3 0 % of 
the dose administered has been eliminated. 
DISCUSSION 
Absorption rate and relative bioavailability 
The complete cross-over design in this investigation on vinylbital in man, 
permits comparison of the pharmacokinetic parameters and also of relative 
bioavailability in the same subject. This is of advantage when assuming that 
intrasubject variation is less than intersubject variation with respect to physio-
logical factors. Now differences in absorption rate, lag time or bioavailability 
of a drug administered in different dosage forms, can mainly be attributed to 
differences in pharmaceutical formulation or to a different route of admini-
stration. 
Absorption of vinylbital from the rectum starts as soon as the suppository 
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has dissolved in the rectum contents, which occurs apparently faster than tablet 
disintegration in the gastrointestinal tract. This follows from the shorter lag time 
for the suppository. Also, in the case of oral administration the rate of gastric 
emptying might be a determining factor, as has been shown for paracetamol 
(Heading et al., 1973). The dissolution of the active substance in the surroun-
ding fluids is the next step in drug absorption and the rate at which this happens, 
probably determines the rate of appearance of the drug in blood. This is faster 
with the tablet and an important reason might be the enormous absorption 
surface area of the small intestine, together with the greater amount of fluid 
in the upper part of the gastrointestinal tract, which enhances dissolution of 
the drug (Benet, 1973). The rectum on the other hand contains a limited 
amount of fluid, its surface area is relatively small and there occurs almost no 
convection. Many other factors could influence rectal absorption and these 
have recently been reviewed by Bevernage and Polderman (1973). Absorption 
from the hydrophilic polyethylene glycol suppository base definitely occurs at 
a faster rate than was observed for hexobarbital from a lipophilic base (Chapter 
1, Section III). It also follows from the relative bioavailability calculations that 
the polyethylene glycol base is able to deliver vinylbital to the blood to a satis-
factory extent, since a 200 mg dose rectally yields blood levels in the same range 
as 150 mg orally. Preliminary in vitro experiments revealed that the dissolution 
rate of vinylbital from the present dosage forms was very rapid: within half an 
hour 70% had dissolved when the tablet was studied, whereas 85% had dissol-
ved with the suppository (Levy beaker method; 37° C; 500 ml 0.1 N HCl). 
It is doubtful however whether this in vitro method has any predictive value for 
the in vivo process of rectal absorption, as the amount of fluid in vitro far 
exceeds the actual situation. 
Elimination 
The half-life of vinylbital in man is quite long with respect to its intended 
duration of action in hypnotic drug therapy. Hofmann (1971), who measured 
vinylbital blood levels after oral administration of 300 - 450 mg vinylbital to 
three healthy volunteers, observed that the duration of hypnotic - CNS depres-
sant action lasted from 18-33 h. Each subject felt fit again when the blood 
concentration had decreased to about 2 mg/1. As already mentioned, in the 
present study the subjects felt a strong tendency to sleep at the time when the 
plasma concentration exceeded 2 mg/1. They slept mostly for a few hours 
- while they could easily be wakened - then took some food and went back to 
their daily work. All of them, except subject P.K., reported feelings of drow-
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siness during the rest of the day, both after having received the tablet as well 
as after the suppository. It is striking that in subject P.K. the plasma con-
centrations were the lowest of all, and apparently below the minimal effective 
level. The subjects who participated in the study of repetitive vinylbital admini-
stration at night, complained of drowsiness the next morning, a few days after 
the beginning of the study. Plasma concentrations close to 3 mg/1 were measured 
during these periods. It may be concluded that a level of 2 mg/1 is a critical 
one, with respect to the appearance of feelings of CNS depression. Especially in 
the case of subjects with a low body-weight the plasma concentration remains 
a long time above this level after a 9 h night's rest (Fig. 1 and 2). It is possible 
that a lower concentration is required for the induction of sleep at night. This 
is substantiated by the fact that after administration of one BYKONOX tablet 
Jovanovic (1967a) noticed an insleep time of 17-27 min in his patients. By 
this time plasma concentrations have reached values of around 1 mg/1. For 
this reason, it might be recommendable to give a lower dose than 150 mg, 
when vinylbital is chosen for the treatment of insomnia. 
Although vinylbital contains a chiral centre, the elimination phase in all 
volunteers could be described by a single first-order process. There were no 
indications for a biphasic decay of the plasma concentration, with a possible 
exception of subject G.V. after rectal administration. However, the latter curve 
could also be fitted by first order kinetics and this was preferred for reasons 
of uniformity. At present it is assumed that the enantiomers of vinylbital in man 
are eliminated with approximately the same rate, or at least that a possible 
difference is in the order of magnitude that there cannot be differentiated 
between in our experiments. 
Elimination of vinylbital occurs to the greatest extent by metabolism, since 
only a small amount of the drug was excreted in the urine unchanged. 
Geldmacher - von Mallinckrodt et al. (1968; ib. 1971) identified two metabolites 
in human urine: 5-(l-methyl-3-hydroxybutyl)-barbituric acid (complete vinyl-
group removed, which is the result of a rarely occurring C-dealkylation) and 
5-vinyl-5-(l-methyl-3-hydroxybutyl)-barbituric acid. Of the dose administered 
8 - 45 % was excreted in the form of these two metabolites. These and other 
possible metabolites of vinylbital have been synthesized by Preuss and Müller 
(1968), but no definite identification of other metabolites in urine has been 
published so far. 
With respect to the true values of the total body clearance constant (kcl) and 
the apparent volume of distribution (Vf) of vinylbital in man, it is important 
to realize that a smaller bioavailability (F) results in higher values for Vf/F and 
kpi/F. The smaller values of the two, in the same individual, are the closer to 
the true Vr and kol. These have been calculated per kg body-weight (Table II) 
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and it appears that Vf/F per kg is quite constant among the subjects. If a linear 
relationship between body-weight and Vf is assumed, it is likely that the average 
value of 0.74 1/kg is a realistic one and that bioavailability now approaches 
100%. This is true also for kcl, which is then approximately 0.36 ml/min/kg. 
The apparent volume of distribution of vinylbital in man is smaller than of 
hexobarbital, which is in agreement with its lower lipophility. Also, the clearan-
ce constant is much smaller compared to hexobarbital, indicating a less efficient 
drug - metabolizing enzyme interaction. In this respect the lower lipophility 
might also be a factor to be considered (Hansch, 1972). The results in man are 
consistent with the findings in rats, because van Kroonenburgh (1971) found 
a much lower clearance for vinylbital than Alvarez (1971) did for racemic 
hexobarbital. 
Repetitive administration 
Hypnotic drugs are taken frequently for longer periods of time and it is 
important therefore to obtain information of plasma levels during repetitive ad-
ministration. Barbiturates in general, are considered to be potent enzyme in-
ducers, also with respect to the induction of their own metabolism (Remmer, 
1972). In this study on vinylbital, however, no such induction could be demon-
strated despite its own extensive metabolism and persistence in the body (Fig. 
6). To what extent vinylbital is incapable of increasing the rate of metabolism 
of other drugs, especially when it is given for longer periods of time, cannot be 
predicted and awaits further investigation. 
In Fig. 7 the plasma concentration profile during repetitive vinylbital admini-
stration has been simulated (subject J.H.), assuming a constant half-life of 18 h. 
Also the theoretical curve is given, based upon the first single administration 
of the drug. It can be observed that the actual plasma concentrations are lower 
than the theoretical ones. This might be due to a lower bioavailability of vinyl-
bital when it is taken at night, caused by the fact that the subjects are not fasting 
in that situation. After 3 - 4 days the equilibrium (steady state) situation has 
been reached. Following this, the lower and upper concentrations per dosage 
interval are about the same: the concentration fluctuates between discrete 
values. This observation is in agreement with the theory that an equilibrium 
state is reached during chronic administration, after approximately four times 
the half-life of the drug (van Rossum, 1971). It is evident that the plasma con-
centration during day-time varies from 3.5 to 2.2 mg/1, which is undesirably 
high when no day-time sedation is required. If, however, sedative therapy is the 
main objective of vinylbital administration, then a lower dose (e.g. 50 mg) twice 
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FIG. 7. Simulation of the plasma level profile during repetitive vinylbital admini­
stration, using the data of Fig 6 (solid line) It was assumed that peak levels were 
reached after 1 5 h and that the elimination half-life of 18 h remained constant 
throughout the trial. The dotted line represents the theoretical plasma level profile, 
based upon the first single administration of the drug. To the concentration at the 
end of each dosage interval a value equal to A0 (3 7 mg/1) was added to obtain the 
curve for the next interval. The actual plasma concentrations remain below the 
theoretical ones and this might be due to a lower bioavailability of the drug when 
it is taken at night. 
daily, would be more appropriate In this case a lower steady state level with 
less fluctuations would result, which is desirable in sedative drug therapy. 
CONCLUSIONS 
From the pharmacokinetic point of view, vinylbital cannot be considered as a 
suitable drug for the treatment of insomnia in non-bedridden persons. The long 
half-life of 17 - 32 h, especially in relation to a dose of 150 or 200 mg and a 
minimal effective plasma level of 2 mg/1, causes a high risk of drowsiness the 
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next morning. This is a factor that should be given serious consideration. When 
day-time sedation is required, as is often the case in hospitalized patients, 
vinylbital could be used beneficially, as the drug seems to have satisfactory 
pharmacodynamic properties (Jovanovic, 1967a; ib. 1967b). 
The tablets are generally more suitable for sleep induction than the sup-
positories, as the absorption rate from the upper part of the gastrointestinal 
tract is higher. There are situations, however, where oral administration meets 
with difficulties; in that case the suppository could be used. Also in sedative 
drug therapy the suppository is a suitable dosage form, however then the dose 
should be diminished. 
SUMMARY 
The pharmacokinetics and relative bioavailability of vinylbital after oral and rectal 
administration were studied in man. Tablets (BYKONOX), containing 150 mg vinyl-
bital, were used for the oral experiments and suppositories (SUPPOPTANOX, 
polyethylene glycol base), containing 200 mg vinylbital, were used for rectal ad-
ministration. Six volunteers participated on two occasions in this study and received 
both preparations. Vinylbital plasma concentrations were determined at regular in-
tervals after drug administration. 
Absorption and elimination of vinylbital appeared to occur according to a single 
first-order process and the plasma concentrations were fitted by computer according 
to the equation intrinsic to the one-compartment open model after oral or rectal 
administration. The lag time was shorter for the suppository than for the tablet, 
whereas the absorption rate was faster for the tablet (mean absorption half-life 0.24 h 
compared with 0.64 h for the suppository). The elimination half-life of vinylbital 
varied from 17.6 to 33.5 h, with a mean value of 23.5 h for oral administration and 
23.8 h for rectal administration. The half-lives were not considerably different on 
the two occasions for the individual volunteers. The average bioavailability of vinyl-
bital for the suppository, relative to the tablet, was approximately 93 %. Drowsiness 
was experienced by all volunteers, after receiving both dosage forms, and persisted 
for the remainder of the day. 
Three volunteers collected their urine during 3-4 days after administration of a 
tablet. Unchanged vinylbital was determined and approximately 1.6% of the ad-
ministered dose was excreted as unchanged drug. 
Two volunteers participated in a study of repetitive vinylbital administration, 
during which a tablet was administered each night. Plasma concentrations were 
determined during and after repetitive dosing. Substantial accumulation of the drug 
in the body was not observed, although a relatively high plasma concentration was 
monitored during the day. The half-life of vinylbital was the same prior to and 
after the experiments of repetitive administration. 
It has been concluded that the half-life of vinylbital is rather long with respect 
to its intended duration of action in the treatment of insomnia. Only when sedation 
is required during the day can vinylbital be used beneficially. 
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CHAPTER 5 
HEPTABARBITAL AND HEPTABARBITAL SODIUM 
ORAL ADMINISTRATION 
INTRODUCTION 
Heptabarbital was introduced into hypnotic drug therapy in 1942 and it is 
available under the trade name MEDOMIN (tablets containing 200 mg of 
active substance). This preparation has been evaluated in several trials and it 
was shown to be effective in the treatment of insomnia (e.g., Steininger, 1953; 
Kotsovsky, 1954; Lienert, 1954; Brusca, 1955; Weithaler and Biedermann, 
1960; Lienert, 1956; Bauer and Reckendorf, 1956; Ainley, 1957; Gillhespy, 
1960; General Practioner Research Group, 1968). Heptabarbital is regarded as 
an intermediate-acting barbiturate with mild sleep maintaining properties (Mar-
tindale, 1972; Lienert, 1956). An important observation from many of the 
above studies has been that hardly any residual effects became apparent the 
following morning, after administration of the usual oral dose of 200 - 400 mg 
heptabarbital the previous night. This may indicate that the drug is rapidly 
inactivated in the body. However, this supposition has not been substantiated 
yet, since the half-life in man is not known. 
In view of the general lack of information concerning the pharmacokinetics 
of heptabarbital in man, it was decided to investigate its rate of absorption and 
elimination after oral administration of MEDOMIN tablets. Preliminary expe-
riments revealed that the rate of heptabarbital absorption from the tablets was 
relatively slow and for this reason heptabarbital sodium was included in the 
study. The sodium salt is very soluble in water and it was expected that this 
would cause an increased absorption rate, as was shown in the case of hexo-
barbital sodium (Chapter 1, Section III). The tablets as well as the sodium 
salt (in hard gelatine capsules) were administered to the same human volun-
teers, and this allowed the estimation of individual relative bioavailability. 
Furthermore, plasma levels during repetitive heptabarbital administration 
were determined in order to ascertain whether accumulation of the drug in the 
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body occurred and also to determine whether the half-life of the drug would 
remain unchanged. 
METHODS 
The MEDOMIN tablets were obtained from CIBA-GEIGY, Arnhem, The 
Netherlands. The heptabarbital content was determined at the Dutch Pharma-
cist's Laboratory, The Hague, by Potentiometrie titration with alkali (0.1N) in 
a nitrogen atmosphere. An average content of 203.5 mg (101.8%) was found, 
with a variation coefficient of 3.3%. Heptabarbital sodium which is not com-
mercially available, was prepared by treating the free acid with an equimolar 
quantity of sodium hydroxide solution and precipitating the sodium salt with 
diethyl ether. The heptabarbital sodium content of the white crystalline product 
obtained was 98.5%, determined by Potentiometrie titration with hydrochloric 
acid (0. IN). 
Seven healthy male volunteers, ranging in age from 19 - 25 years and in 
body-weight from 55 - 85 kg, participated in the study. They had received no 
regular medication during the 4 weeks preceding initiation of the experiments. 
After an overnight fast, at 9 a.m., the subjects were given 200 mg heptabarbital 
as a MEDOMIN tablet or 218 mg heptabarbital sodium (this amount is equi-
valent to 200 mg free acid), in a hard gelatine capsule without additives, 
together with 150 ml water. They were requested to remain in an upright 
position for 15 min and then to lie down for at least 3.5 h. This procedure 
was undertaken in order to simulate as closely as possible the situation of taking 
a hypnotic drug and going to bed. No food, fluid or tobacco was allowed for 
at least 3.5 h after drug administration. Blood samples (5 ml) were taken from 
a forearm vein, usually at the following times: 20 and 40 min, 1, 1.5, 2, 2.5, 3, 
4, 6, 8, 12 and 24 h after drug administration. Every subject received both 
preparations with an interval of at least 4 weeks in a random sequence. The 
time schedule was the same for both trials. 
Four of the volunteers collected their urine during 2 days after administra-
tion of a MEDOMIN tablet. Heptabarbital concentration in plasma and in 
urine was determined by gas chromatography, as described in Chapter 6, 
Section II. 
Four volunteers participated in a study of repetitive heptabarbital adminis-
tration. On the first day of the experiment the half-life of the drug was determin-
ed, by administering a MEDOMIN tablet in the morning at 9 a.m. and collecting 
blood samples at regular intervals. Beginning on the second night, the volun-
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concentration heptabarbital (mg/\ різагла) 
FIG. 1. Plasma concentration curves after oral administration of 200 mg hepta-
barbital as a MEDOMIN tablet (dotted line) and 218 mg heptabarbital sodium in a 
hard gelatine capsule (solid line) to seven healthy male volunteers. Also, the average 
curves are given. Note the more rapid absorption with the sodium salt in almost 
every volunteer. Also note that the area under the plasma concentration curve is 
generally smaller with the sodium salt, indicating a lower bioavailability of hepta­
barbital when administered as the sodium salt (Table II). 
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teers took a MEDOMIN tablet with 150 ml water. Usually the next morning, 
nine hours after drug intake, a blood sample was taken and the heptabarbital 
plasma concentration was determined. After eight (two volunteers) or ten days 
(two volunteers), heptabarbital was again given in the morning, in order to 
determine the half-life of the drug after repetitive administration. In Fig. 5 the 
time schedule of drug intake and blood sampling is indicated. 
RESULTS 
Rate of absorption and elimination 
In Fig. 1 all of the individual plasma concentration curves are shown, which 
were obtained after oral administration of 200 mg heptabarbital as free acid 
(MEDOMIN) and 200 mg heptabarbital as sodium salt to each volunteer. It 
is evident that the absorption of heptabarbital was quite slow, e.g. it took 1.5-
4 h before the maximum plasma concentrations were attained, which were in 
the range of 1.3 - 2.4 mg/1. When heptabarbital was administered as the sodium 
salt a more rapid rise of the plasma concentration occurred; peak concentrations 
were reached after У
я
 - 2 h, except for volunteer T.R. The maximum plasma 
concentrations varied from 1.3-2.8 mg/1 (Table I). CNS depression was 
experienced by all subjects, 1.5 - 2.5 h after receiving the MEDOMIN tablet 
and approximately 1 h after receiving the sodium salt. Usually heptabarbital 
plasma concentrations had exceeded 1 mg/1 when drowsiness was experienced 
and in some cases these were substantially higher. For instance, when early 
peak concentrations with the sodium salt had been reached, it was noticed that 
CNS depression became apparent some time after the peak level time. This 
indicates that a latency time exists for heptabarbital with respect to penetration 
into the brain. The physicochemical properties of a drug determine its rate of 
penetration through the blood-brain barrier (Goldstein et al., 1969) and it has 
been shown that for the less lipophilic barbiturates, to which heptabarbital 
belongs, there is a latency with respect to the onset of anaesthetic action after 
i.v. administration (Butler, 1942). Despite the high amount of drug that is 
carried by the bloodstream to the brain immediately after i.v. injection, it takes 
some time before an effective brain concentration has been reached. Obviously, 
after oral administration a similar phenomenon may only become apparent if 
absorption is very rapid in comparison to distribution of the drug into the 
brain. In such a case a relatively rapid decrease in plasma concentration directly 
after termination of absorption may be observed, which is due to the distribu­
tion of heptabarbital from plasma into tissues (subjects G.V. and H.E.). 
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TABLE I. Absorption characteristics of heptabarbital and heptabarbital sodium after 
oral administration to the same healthy volunteers. 
Subject 
B.F. 
T.R. 
B.W. 
H.J. 
G.V. 
H.F. 
H.E. 
Body-weight 
(kg) 
70 
68 
85 
75 
71 
80 
55 
Mean values 72 
Chemical formi) 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
Dose«) 
(mg) 
200 
218 
200 
218 
200 
218 
200 
218 
200 
218 
200 
218 
200 
218 
200 
218 
Dose/kg 
(free acid; 
mg) 
2.86 
2.86 
2.94 
2.94 
2.35 
2.35 
2.67 
2.67 
2.82 
2.82 
2.50 
2.50 
3.64 
3.64 
2.83 
2.83 
t 3) 
ma.v ' 
(min.) 
180 
120 
180 
240 
240 
120 
180 
60 
90 
40 
120 
60 
150 
20 
163 
96 
С з) 
(mg/l) 
1.84 
1.48 
1.96 
1.61 
1.31 
1.28 
1.46 
1.59 
2.29 
2.26 
2.38 
1.42 
2.32 
2.84 
1.94 
1.78 
!) Heptabarbital as free acid was administered in the form of a MEDOMIN tablet. 
Heptabarbital sodium was administered in hard gelatine capsules, without addi­
tives. 
2) 218 mg of the sodium salt is equivalent to 200 mg of heptabarbital as free acid. 
3) tniax refers to the time after which the maximum plasma concentration (C
m a x
) 
is reached. 
In many of the present experiments the absorption phase of heptabarbital 
could not be described accurately by first-order kinetics. Absorption was some­
times irregular or occurred in other cases so rapidly, that sufficient data were 
not available during the absorption phase to permit first-order fitting. As a 
measure for the rate of absorption, therefore, the time after which the maximum 
plasma concentration was reached, is given (Table I). This is a common pro­
cedure used in biopharmaceutical studies (Ritschel, 1972). In contrast with 
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FIG. 2. Plasma concentration curves on semi-logarithmic scale representing the elimi-
nation phase of heptabarbital after oral administration of a MEDOMIN tablet (dotted 
line) and heptabarbital sodium (solid line) to the same volunteers. These data are 
from the same experiments as in Fig. 1. Note that the half-lives in a particular 
volunteer are approximately the same on different occasions (interval of more than 
4 weeks). 
absorption, elimination of heptabarbital may be described by a first-order pro-
cess, since on all occasions straight lines were obtained for the decrease in 
concentration after plotting these data on a semi-logarithmic scale (Fig. 2). The 
plasma half-lives varied from 6.1 -11.2 h, which is a relatively short period for 
the barbiturates (Table II). Also, it was observed that the half-lives of the 
barbiturate were about the same for each individual at both occasions (Fig. 2; 
Table II). The small differences measured may not be meaningful since they 
are in the same order as the experimental error. 
Relative bioavailability estimation 
With respect to the bioavailability of heptabarbital the following equation 
applies, assuming linear kinetics: 
F χ D = k
e l . Í Cn dt = kPl. AUC 
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where F = bioavailability (0 < F < 1), D = dose administered (mg), Cp = 
plasma concentration (mg/1), k
el = total body clearance constant (ml/min), 
AUC = area under the plasma concentration curve from t = 0 to t = oc 
(mg.h/1). The clearance constant can only be estimated accurately after i.v. 
administration and therefore absolute bioavailability cannot be determined if 
only data of oral administration are available. However, the cross-over design 
of the present investigation permits an estimation of the relative bioavailability 
of heptabarbital to be made for each individual, assuming that kd had the 
same value on both occasions of drug administration. Evidence for this sup­
position lies in the fact that the half-life had almost the same value on both 
occasions for the same individual. The following equation now applies, taking 
the tablet (free acid) as the reference dosage form: 
AUl^frce acid 
Frei = 
AUC9aIt 
If the AUC is not determined to t = oo, then a correction should be made to 
include the undetermined AUC. This is possible by assuming that at the last data 
point, at time t', absorption is complete. Using Dost's law of corresponding 
areas (Dost, 1968), the infinite area is given by: 
Τ Cp dt = \ Cp dt + ~ Cp dt = AUC /+ CV'. τβ1 
о о t' о 
where т
еІ
 is the elimination time constant (TCI = 1.44 χ U,,) and Ср'' is the last 
plasma concentration measured at time t'. The AUC's from t = 0 to t = t' 
(AUC/), in the present experiments, were determined by weighing the cor-
0 
responding areas under the plasma concentration curves, usually up to 12 h 
after administration. The remaining area was calculated by multiplying the 
concentrations at 12 h by the average tei. In Table II the results are given for 
the seven volunteers. In all but one case (subject B.W.) the sodium salt showed 
a lower bioavailability than the free acid. 
If an average bioavailability of 100% is assumed for the tablets, then the 
average clearance constant and apparent volume of distribution in man can be 
estimated. When the average plasma concentration curve for the tablet was 
plotted on semi-logarithmic scale, it became apparent that the absorption phase 
could be described by first-order kinetics (Fig. 3). The parameters deduced 
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TABLE II. Elimination half-lives and relative bioavailability of heptabarbital after 
oral administration of heptabarbital as free acid and as the sodium salt to the same 
healthy volunteers. 
Subject 
B.F. 
T.R. 
B.W. 
H.J. 
G.V. 
H.F. 
H.E. 
Mean 
values 
Chemical 
form 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
acid 
salt 
(h) 
6.6 
6.1 
6.4 
6.5 
6.2 
6.4 
8.4 
7.9 
8.2 
6.2 
6.2 
6.2 
11.0 
11.2 
ΪΊ.ι" 
7.8 
8.0 
7.9 
7.3 
7.1 
Т.г 
7.7 
7.5 
77б 
Average т
е1 
(h) 
9.2 
9.2 
11.8 
8.6 
15.8 
11.4 
10.4 
10.9 
AUC 
0 - 1 2 h 
(mg.h/1) 
12.7 
11.5 
15.2 
11.0 
11.1 
7.0(8h) 
10.1 
11.2 
19.4 
13.7 
15.4 
11.2 
18.2 
16.5 
14.6 
12.5 
Conc. 
12h 
(mg/1) 
0.73 
0.51 
0.74 
0.55 
0.76 
0.63(8h) 
0.42 
0.60 
1.17 
0.82 
0.74 
0.58 
0.92 
0.72 
0.78 
0.63 
AUC 
0 - o c 
(mg.VI) 
19.4 
16.2 
22.1 
16.1 
20.1 
14.4 
13.7 
16.4 
37.9 
26.7 
23.8 
17.8 
27.9 
23.9 
23.6 
18.8 
Fro, 
% 
100 
81 
100 
73 
100 
72 
100 
119 
100 
70 
100 
75 
100 
86 
100 
83 
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FIG. 3. Mean plasma concentration curve of heptabarbital on semi-logarithmic 
scale, obtained after oral administration of a MEDOMIN tablet to seven healthy 
volunteers. For the individual curves and for the mean curve on linear scale, see 
Fig. 1. The average absorption phase and elimination phase can be described by 
first-order kinetics. The half-life of absorption has been estimated by means of the 
subtraction method (dotted line). From the experimental parameters the average 
volume of distribution and clearance constant of heptabarbital in man can be 
estimated (see text). 
from this curve were: t0 (12 min), A (2.35 mg/1), ti/!a (43 min), t1/2el (7.7 h). 
Furthermore kei and Vj were calculated (Section I, Chapter 2) and found to 
be 138 ml/min and 94 1 respectively. 
Renal excretion 
Heptabarbital was excreted unchanged in the urine to a very small extent. 
For the four volunteers, who collected their urine after the administration of 
200 mg heptabarbital (MEDOMIN tablet) during a period of about two days, 
cumulative urinary excretion amounted to 0.16 - 0.30% of the dose adminis­
tered. The excretion plateau was reached after 26 - 40 h had elapsed, which is 
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FIG. 4. Urine pH, urine flow, cumulative renal excretion of unchanged drug and 
renal heptabarbital excretion rate after oral administration of 200 mg heptabarbital. 
The excretion rate increases with increasing urine pH and increasing urine flow. 
Only a very small fraction of the administered dose is excreted into the urine as 
unchanged drug. 
consistent with the short plasma half-life of heptabarbital. The drug could be 
measured unchanged up to this time (Fig. 4) which is in contrast to the results 
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of Gilbert et al. (1973) who detected unchanged drug only in the first 8 h 
urine batch after oral administration of 400 mg heptabarbital to a human 
volunteer. The same authors identified by combined gas chromatography -
mass spectrometry, two heptabarbital metabolites in urine, the З'-hydroxy -
and the З'-keto-derivative. The formation of the latter compound had pre­
viously been demonstrated by Pulver (1943) and Bernhard and Bickel (1957). 
The metabolites mentioned, however, account for only part of the total amount 
of heptabarbital administered. Nothing is known about the further biodégrada-
tion of this drug. It can be observed from Fig. 4 that the renal excretion rate of 
heptabarbital fluctuates considerably and appears to be dependent on urine pH 
and urine flow. As a consequence of the relatively low pKa value of the drug 
(7.45) (Doornbos and de Zeeuw, 1969), the excretion rate is found to increase 
when the urine pH exceeds 7. This is important in the management of hepta-
barbital overdosage, where alkalinization of the urine may be beneficial. 
Repetitive heptabarbital administration 
After repetitive heptabarbital administration the half-lives in three of the 
four subjects did not change significantly (Table III). The possibility of the 
development of enzyme induction must, however, be taken into consideration, 
since in one subject (F.H.) the half-life had clearly decreased. Due to the short 
half-life, no accumulation occurred during repetitive heptabarbital administra-
tion (Fig. 5). The concentrations, measured each morning 9 h after drug intake, 
were similar whereas with volunteer F.H. with the shortening half-life, these 
values were inclined to decrease after a few days. In Fig. 6 the theoretical 
plasma concentration profile has been simulated (volunteer B.F.). This is 
based upon the curve which was obtained after the first single dose, assuming 
TABLE III. Elimination half-lives of heptabarbital before and after repetitive 
administration of 200 mg each night. 
Subject 
M.W. 
B.F. 
G.V. 
F.H. 
Before 
8.2 
5.8 
10.5 
7.1 
Jy, (h) 
After 
7.8 
6.0 
10.8 
4.6 
Number of doses 
10 
10 
8 
8 
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FIG. 5. Plasma concentrations of heptabarbital during and after repetitive hepta-
barbital administration to two volunteers. During the first and the last day of the 
experiment the half-life of the drug was determined. From the second night on a 
MEDOMIN tablet was taken each night and usually the next morning (9 h later) the 
plasma concentration was measured. Note that these concentrations were always 
about the same. Also note the shortened half-life of the drug in one of the volunteers 
at the end of the trial, indicating the development of enzyme induction. 
a constant half-life of 6.4 h. It may be observed that the experimental data 
closely fit this curve. With the half-life of 6.4 h and a dosage interval of 24 h, 
only 5 - 1 0 % of the previously administered dose remains in the body before 
the next dose is taken. This is such a small amount, that in practice each dose 
can be considered as a repetition of the first single dose. 
DISCUSSION 
Prior to the passage of a drug through a biological membrane, dissolution 
in the fluids surrounding that membrane must occur (Garrett, 1971; Benet, 
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i t t i î t 
FIG. 6. Theoretical plasma level profile during repetitive heptabarbital administra-
tion, based upon the curve obtained after the first single dose. The arrows indicate 
drug intake (200 mg every 24 h). The plasma concentrations determined 9 h after 
drug administration and the experimental data after the last dose, closely fit the 
calculated curve. 
1973). It has been demonstrated that the rate of absorption of several drugs, 
which are slightly water-soluble, is limited by their solubility, e.g. griseofulvin 
(Atkinson et al., 1962) and prednisone (Levy et al., 1964). The slow absorption 
of heptabarbital, when administered as the free acid, is probably due to its 
poor water-solubility, which is less than 0.5 g/liter (Martindale, 1972). Pre-
liminary in vitro experiments (Levy beaker method; 37° C; 80 r.p.m.; 500 ml 
0.1N HCl) have demonstrated that the dissolution of heptabarbital from the 
tablets is greater than dissolution of heptabarbital as a bulk substance (the 
same material as used for tablet compounding); 25% of the tablet form and 
5% of the bulk substance had dissolved after 3 h. Usually, tablets contain a 
wetting agent (e.g. gelatine) which favours dissolution and thereby increases 
the rate of drug absorption. This was shown for secobarbital by Sjögren (1971). 
The present findings indicate that the absorption of heptabarbital is dissolution 
rate-limited when the drug is administered as the free acid. 
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Sodium salts of barbiturates are readily soluble in water, which is the 
explanation for the higher heptabarbital absorption rate of the sodium salt-
containing capsules. In general, salts will show higher dissolution rates than the 
corresponding non-ionic drug at any pH, even though the final equilibrium 
solubility of the drug and its salt are the same (Higuchi et al., 1958). This is 
explained by the fact that if precipitation occurs, generally a suspension of 
fine particles results, which has the proper characteristics for rapid redis-
solution. This phenomenon apparently applies in the case of barbiturates, since 
their sodium salts will be precipitated in the acid medium of the stomach, 
but nevertheless a much higher absorption rate is observed than with the 
corresponding free acids (compare hexobarbital and hexobarbital sodium, 
Chapter 1, Section III). Sjogren et al. (1965) reported similar findings for 
pentobarbital and secobarbital absorption. The preliminary in vitro experiments 
on the heptabarbital sodium capsules showed a rapid dissolution of hepta-
barbital in 0.1N HCl; within 30 min 40% had dissolved, which almost corres-
ponded to the saturation concentration. 
The results on the bioavailability of heptabarbital revealed that the drug 
reaches the general circulation to a greater extent after administration as the 
free acid than as the sodium salt. This is an unexpected finding, since it is 
a common belief that a high dissolution rate favours high bioavailability (Nel-
son, 1961; Wagner, 1970; Garrett, 1971). Bioavailability problems most often 
arise with preparations which show relatively poor dissolution characteristics 
(Blake, 1971; Benet, 1973). Heptabarbital sodium, however, is rapidly absorbed 
(Fig. 1), which indicates that the dissolution rate of the drug in the gastroin-
testinal fluid is also high. As already discussed, the precipitation of the free 
acid in the stomach after heptabarbital sodium administration will for the 
greater part result in a suspension of fine particles, which readily redissolve. 
However, the possibility that also relatively gross crystalline particles are being 
formed, which do not redissolve completely, cannot be excluded. This would 
result in incomplete bioavailability. Other contributing factors may be that the 
gelatine of the capsule is interfering or that part of the precipitate is formed 
in a different crystalline form, with poor dissolution characteristics. Several 
examples are known of polymorphism influencing drug absorption (Haleblian 
and McCrone, 1969). Further experiments, in vitro and in vivo, are required 
to clarify the present findings. 
The average half-life (7.6 h) of heptabarbital in man is relatively short, which 
is quite advantageous with respect to its intended duration of action in the treat-
ment of insomnia. After a night's rest of 9 hours approximately 6 0 - 7 5 % of 
the drug is inactivated. Thus, it is very likely that the plasma concentration 
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has decreased below the minimal effective level, if a 200 mg dose has been 
given. This level may vary from 1-2 mg/1, since the subjects who participated 
in the present study displayed evidence of lethargy at these plasma concentra-
tions or higher ones. After a period of 4 - 6 h following drug administration, 
the volunteers expressed a general return to fitness. Lienert (1954) and Wei-
thaler and Biedermann (1955) have shown that after oral intake of 200-400 
mg heptabarbital at night, no residual effects were present the following morn-
ing. In our experiments with chronic heptabarbital administration, the vo-
lunteers did not complain of drowsiness after arising. Lienert (1956) noticed 
that the onset of hypnotic action with MEDOMIN tablets was relatively slow. 
Weithaler and Biedermann (1955) have concluded that MEDOMIN requires a 
certain „induction time" (1 - 2 h) before causing CNS depression. Furthermore, 
Fernandez-Guardiola et al. (1972), who performed a polygraphic study on 
hypnotic drugs in healthy volunteers, found that approximately 1 h after oral 
administration of a MEDOMIN tablet psychological changes became apparent. 
These findings are consistent with the slow absorption of heptabarbital from 
the tablets, as demonstrated in the present investigation. It must be concluded 
that heptabarbital as free acid is not capable of causing a rapid onset of hyp-
notic action. The sodium salt, however, although never studied clinically in 
this respect, may be expected to induce sleep more readily. 
From the experiments of repetitive heptabarbital administration it is evident 
that there is a risk of enzyme induction with heptabarbital, since in one of the 
four subjects a shortened half-life was found. It was shown previously that 
repetitive administration of 400 mg heptabarbital resulted in a shorter half-life 
of coumarin anticoagulants in man when the drugs were taken concomitantly 
(Dayton et al., 1961; Aggeler and O'Reilly, 1969). The development of enzyme 
induction due to the influence of heptabarbital is somewhat surprising, since 
with the doses applied there is no persistence of a great amount of the drug 
in the body. Enzyme induction is often associated with compounds that accu-
mulate in the body because of their long half-lives, e.g. butobarbital (Chapter 6, 
Section III), phénobarbital (Remmer, 1972). This author has remarked how-
ever, that, in principle, all lipid soluble organic substances are potential inducers. 
Also, it has been shown previously that enzyme induction in man is very 
inconsistent. Many people respond differently even when treated with the same 
compound at the same dose regimen (Cucinell et al., 1965). A similar finding 
was made in the present study, when only one of the four subjects developed 
enzyme induction. The risk of accelerated drug metabolism must be considered, 
when heptabarbital is used simultaneously with other drugs. 
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CONCLUSIONS 
These pharmacokinetic studies reveal that heptabarbital may be regarded as 
a suitable drug for the treatment of insomnia. The relatively short half-life of 
6 - 1 1 h in relation to a 200 mg dose, minimizes the risk of residual effects the 
following morning. During repetitive heptabarbital administration no accumu-
lation of the drug occurs in the body. It should be considered, when other 
drugs are prescribed, that acceleration of drug metabolism may develop. 
Since the absorption of heptabarbital from the MEDOMIN tablets is rela-
tively slow, this preparation may be applied in instances where the maintenance 
of sleep is the primary prerequisite of hypnotic drug treatment. Heptabarbital 
is more rapidly absorbed when administered as the sodium salt, and this formu-
lation is preferred for rapid sleep induction. 
SUMMARY 
The pharmacokinetics and relative bioavailability of heptabarbital and hepta-
barbital sodium were studied after oral administration. MEDOMIN tablets, con-
taining 200 mg heptabarbital, and hard gelatine capsules, containing an equivalent 
amount of the sodium salt, were used. Seven healthy volunteers participated on two 
occasions in the investigation and received both preparations. Heptabarbital plasma 
concentrations were determined at regular intervals. 
The absorption of heptabarbital from the tablets was quite slow, peak level times 
varied from 1.5 to 4 h. A more rapid absorption occurred when the sodium salt was 
administered, with peak level times between 1/3 and 2 h. In all cases the elimina-
tion of heptabarbital could be described by a single first-order process with an 
average half-life of 7.6 h (range 6.1 -11.2 h). The half-life of the drug, for each 
individual, was about the same at the two trials. The relative bioavailability was 
estimated for each volunteer by comparing the areas under the plasma concentration 
curves. For the sodium salt an average bioavailability of 83% relative to the free 
acid was estimated. In some volunteers urinary excretion of unchanged heptabarbital 
was measured; cumulative excretion amounted to 0.16-0.30% of the administered 
dose. Four volunteers received a MEDOMIN tablet each night for eight or ten days; 
accumulation of heptabarbital during repetitive administration did not occur. In 
three volunteers the half-life of the drug, prior to and after these experiments, had not 
changed whereas in one volunteer the half-life had decreased from 7.1 to 4.6 h. The 
development of enzyme induction should be considered when heptabarbital is 
prescribed. 
It was concluded that heptabarbital may be regarded as a suitable drug for the 
treatment of insomnia, since its half-life is rather short. Heptabarbital sodium may 
be used for sleep induction, whereas MEDOMIN tablets may be prescribed in cases 
where the maintenance of sleep is the primary prequisite of hypnotic drug treatment. 
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CHAPTER 6 
BUTOBARBITAL 
ORAL ADMINISTRATION 
INTRODUCTION 
Butobarbital, which was introduced in 1931, is one of the oldest barbiturates 
used in drug therapy. It is still widely applied in the treatment of insomnia, 
although its former popularity has decreased since the introduction of non-
barbiturate hypnotics. The compound has been classified as an intermediate-
acting barbiturate (Martindale, 1972), but this classification is controversial 
(Mark, 1969; Chapter 3, Section I). In several clinical trials butobarbital was 
found to be an effective hypnotic drug for sleep induction and sleep mainte-
nance (e.g., Stewart, 1956; Hare, 1959; Lodge-Patch et al., 1960; Parsons, 
1963; Zelvelder, 1971; Bond and Lader, 1972). This drug is also available 
under the trade name SONERYL (tablets containing 100 mg butobarbital). 
The usual oral dose is 100 - 200 mg at night. 
In view of the paucity of knowledge regarding the pharmacokinetics of buto-
barbital in man, it was considered pertinent to investigate both the rate of 
absorption and the rate of elimination of this drug after oral administration. 
Furthermore, plasma levels during repetitive butobarbital administration were 
determined in order to see if accumulation of the drug in the body would occur 
and also to ascertain whether the half-life of the drug would remain unchanged. 
METHODS 
Butobarbital was obtained in bulk from Onderlinge Pharmaceutische Groot-
handel, Utrecht, through the Pharmacy of the St. Radboudhospital, Nijmegen. 
Hard gelatine capsules were loosely filled with 200 mg of this drug. 
Five healthy male volunteers, ranging in age from 21 -25 years and in body-
weight from 66 - 81 kg, participated in the study. They had received no regular 
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medication during the 4 weeks preceding the initiation of the experiment. After 
an overnight fast, at 9 a.m., the subjects were given 200 mg butobarbital orally 
with 150 ml water. Initially, the volunteers were asked to remain in an upright 
position for 15 min and then to lie down for at least 3.5 h. This procedure 
was undertaken in order to simulate as closely as possible the situation of 
taking a hypnotic drug and going to bed. No food, fluid or tobacco was 
allowed for 3.5 h after drug administration. Blood samples (5 ml) were 
taken from a forearm vein, usually at the following times: 20 and 40 min 
an 1, 1.5, 2, 5, 8, 24, 48, 72 and 96 h after drug administration. Buto-
barbital concentration in plasma was determined by gas chromatography, as 
described in Chapter 7, Section II. 
Approximately two weeks after the single dose experiment, four of the same 
volunteers participated in a study of repetitive oral butobarbital administration. 
Two of them received 200 mg butobarbital for three consecutive nights and 
the other two received 100 mg or 50 mg for nine consecutive nights. The 
subjects were instructed neither to take alcoholic beverages during the entire 
course of the experiment nor to drive a motor vehicle. Blood samples were 
taken usually 9 h after drug intake and the butobarbital plasma concentration 
was determined. After administration of the last dose blood samples were taken 
at regular times in order to determine the butobarbital plasma half-life after 
repetitive administration. In Table III the time schedule of drug intake and 
blood sampling is indicated. 
RESULTS 
The individual plasma concentration curves for the first 8 h after a single 
oral dose of butobarbital are shown in Fig. 1. Absorption was quite rapid, 
since a relatively high plasma concentration was attained 20 min after drug 
administration. Peak levels were reached between 40 min and 2 h; absorption 
apparently continued in subject R.C. for up to 8 h. CNS depression became 
evident in all volunteers after % - 1 % h, when the plasma concentration had 
exceeded 2 - 3 mg/1. 
In Fig. 2, the plasma concentrations of the same volunteers are given on 
semi-logarithmic scale from 2 to 96 h. Butobarbital elimination can be de-
scribed by a first-order kinetic process, because in all cases straight lines were 
obtained for the decrease in concentration. The half-lives deduced from these 
curves varied from 34 to 42 h. If it is assumed that absorption also is a first-
order process, then the plasma concentration (Cp) can be described by the 
following equation (single-compartment model with absorption phase): 
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cone, butobtrb'ilal (mg/l рімггы) 
FIG. 1. Plasma concentration curves after oral administration of 200 mg butobarbital 
in a hard gelatine capsule to five healthy male volunteers (linear scale). 
CD = A . (e - * е ] _ e "ι/τ») 
where г
я
 and Tei are the time constants of absorption and elimination respect­
ively and A is the „zero-time concentration". The individual curves have been 
fitted according to the above equation (including correction for the lag time to) 
by means of the FARMFIT computer program; fitted parameters: т.,, toi, A 
and to (Table I). An example of a fitted and plotted curve is shown in Fig. 3. 
Good fits were obtained, although the relative errors in the absorption time 
constant and in the lag time were generally substantial. This is due most likely 
to the limited number of data points during the absorption phase. With refer­
ence to the volunteers R.C. and K.S., the relatively long lag time when 
compared with the very small та does not seem to be realistic after perusal of 
the individual curves. In addition it was observed that for volunteers W.M. and 
H.E. the maximum plasma concentrations were higher than expected on basis 
of mono-exponential absorption and elimination (Fig. 3). This may indicate 
that in these cases absorption of the drug was more rapid than distribution into 
tissues. Thus, two-compartment kinetics may be more appropriate. 
The apparent volume of distribution (V
r
) and the clearance constant (k,,i) 
of butobarbital in man, cannot be estimated accurately from the present 
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FIG. 2. Plasma concentration curves on semi-logarithmic scale of the same experi­
ments as in Fig. 1. Note the long half-life of butobarbital in man (34 - 42 h). 
2.9 
2.6 
2.4 
ω 
-• 2.0 
¿ »•· 
- J 
еитвепаітп. гоо ис 
OWL XOHlNlSIBflTION 
ОС СІМРЙЯТИЕНТ MODEL 
1.2 J · ' ' ' ' ' 1 · · 1 1 1 1 • * 1 1 1 1 1 1 1 1 1 
o.oo 4.00 e. oo іг.оо le.oo 20.00 24.00 20.00 зг.оо эе.оо чо.оо ч-і.оо чв.оо 
TIME (HOURS) 
FIG. 3. Example of a fitted and directly computer plotted butobarbital plasma 
concentration curve. See Table 1 for parameter values. 
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TABLE I. Fitted pharmacokinetic parameters of butobarbital after oral admini­
stration. 
Subject 
R.C. 
K.S. 
F.H. 
W.M. 
H.E. 
uoay-
weight 
(kg) 
81 
66 
81 
70 
76 
Mean values 
Dose 
(mg) 
200 
200 
200 
200 
200 
200 
Dose/kg 
(mg) 
2.47 
3.03 
2.47 
2.86 
2.63 
2.69 
tn 
(h) 
0.23 
0.27 
0.05 
0.00 
0.00 
0.11 
т
а 
(h) 
0.10 
0.04 
0.85 
0.30 
0.24 
0.31 
t./,a 
(h) 
0.07 
0.03 
0.60 
0.21 
0.17 
0.22 
Tel 
(h) 
57.7 
49.8 
54.7 
48.0 
59.3 
53.9 
1,/іс1 
(h) 
40.3 
34.8 
37.2 
33.6 
41.5 
37.5 
A 
( т
е
Л ) 
4.05 
4.01 
3.56 
3.25 
2.86 
3.55 
TABLE II. Calculated pharmacokinetic parameters of butobarbital after oral admini­
stration. 
Subject 
R.C. 
K.S. 
F.H. 
W.M. 
H.E. 
Mean values 
Body-
weight 
(kg) 
81 
66 
81 
70 
76 
Vf 
F 
(1) 
49.5 
50.0 
57.1 
62.0 
70.2 
57.8 
( F 1 ) / k g 
0) 
0.61 
0.76 
0.70 
0.89 
0.92 
0.78 
Κι 
F 
(ml/min) 
14.3 
16.7 
18.0 
21.5 
19.7 
18.0 
(-eì)/kg 
(ml/min) 
0.18 
0.25 
0.22 
0.31 
0.26 
0.24 
experiments. After oral administration the bioavailability F remains unknown. 
On the other hand, there is no reason to assume that absorption has not been 
complete, since the drug was administered in a loosely filled capsule on an 
empty stomach. Assuming complete absorption (F = 1), the values for
 { and 
kel on the average in man may be close to 58 1 and 18 ml/min respectively 
(Table II). The volume of distribution is in the same order of magnitude as 
was found for vinylbital (Chapter 4, Section III) and this is consistent with the 
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FIG. 4. Simulation of the plasma level profile during repetitive butobarbital admini­
stration (solid line). Butobarbital was taken each night and usually 9 h later the 
plasma concentration was measured. After the last dose the concentration was 
measured for three more days, in order to determine the half-life of the drug after 
repetitive dosing. Note the decrease in half-life from 40 h - 32 h, which is probably 
due to the induction of drug metabolizing enzymes. With the simulation it has been 
assumed that a gradual decrease in half-life from 40 h to 32 h occurred The dotted 
line represents the theoretical plasma level profile, based upon the single dose 
experiment in this subject, with constant half-life. To the concentration at the end 
of each dosage interval a value equal tot %A was added in order to obtain the 
curve for the next interval. Note that accumulation in reality occurred to a lesser 
extent than theoretically expected. The mam reason for this observation is the shor­
tening of the butobarbital half-life during chronic administration. 
fact that both drugs have almost equal lipophilic properties (Chapter 1, Section 
II). The clearance constant is lower than in the case of vinylbital, which thus 
explains the longer half-life of butobarbital. Elimination occurs largely by 
means of biodégradation and an important metabolite is 5-ethyl-5-(3-hydroxy-
n-butyl)-barbituric acid (Maynert, 1952). This pen-ultimate oxidation is a 
common pathway in barbiturates with a straight alkyl-chain (Maynert, 1965). 
The results after repetitive butobarbital administration are summarized in 
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TABLE III. Plasma concentrations of butobarbital during and after repetitive oral butobarbital administration* 
day 
dose 
cone. 
dose 
cone. 
dose 
cone. 
dose 
cone. 
(mg) 
(mg/1) 
(mg) 
(mg/1) 
(mg) 
(mg/1) 
(mg) 
(mg/1) 
1 
100 
1.08 
100 
1.47 
200 
n.d. 
200 
n.d. 
2 
100 
2.02 
100 
1.89 
200 
n.d. 
200 
n.d. 
3 
100 
2.85 
100 
2.71 
200 
6.50 
200 
6.43 
4 
100 
2.85 
50 
2.12 
-
3.58 
-
3.10 
* Butobarbital was taken usually at midnight and the plasma s¡ 
n.d. = not determined. 
5 
100 
n.d. 
50 
n.d. 
1.90 
2.00 
6 
100 
n.d. 
50 
n.d. 
n.d. 
n.d. 
7 
100 
2.35 
50 
1.31 
0.55 
0.55 
8 
100 
2.25 
50 
1.43 
n.d. 
n.d. 
9 
100 
2.32 
50 
1.40 
n.d. 
n.d. 
10 
_ 
1.42 
-
0.69 
0.11 
0.09 
:s were obtained 9 h later. 
Table III. Accumulation of the drug was evident in the two volunteers who 
received 200 mg dosages for three nights. The plasma concentration 9 h after 
the third dose was 6.4 and 6.5 mg/1, which was considerably higher than the 
average concentration found 9 h after a single dose of 200 mg (3.1 mgA). The 
butobarbital half-life had changed in this three-day period from 37 to 30 h 
(F.H.) and from 40 to 31 h (R.C.). The induction of drug metabolizing enzymes 
is the most likely explanation for this finding. Similar observations were found 
for the two volunteers who received 100 or 50 mg of the drug for nine conse-
cutive nights. Accumulation became apparent, although to a lesser extent than 
expected on basis of the initial half-life of 40 h (Fig. 4; H.E.). The half-life, in 
this instance, had decreased to 32 h. Volunteer K.S. complained of severe 
drowsiness during the day and therefore the dose was changed from 100 mg to 
50 mg after three nights. The half-life of butobarbital decreased from 35 h 
before, to 27 h after the chronic experiment. 
DISCUSSION 
The half-life of butobarbital must be regarded as very long with relation to 
its intended duration of action in hypnotic drug therapy. During a night's rest 
of 9 hours no more than 1 5 - 2 0 % of the administered dose is eliminated. The 
remaining drug possesses the potentiality of exerting a persistent CNS depressant 
action during the day. This is obviously undesirable, when no day-time sedation 
is wanted. In a study on the residual effects of hypnotic drugs, Bond and Lader 
(1972) tested volunteers with a large number of psychological tests, 12 h after 
they had received butobarbital (sodium salt, 100 or 200 mg), nitrazepam (5 or 
10 mg) or placebo. The psychological tests were interpreted as showing dose-
related impairment with both drugs, whereas after butobarbital administration 
more subjective hang-over was experienced. The observations are consistent 
with the long persistence of butobarbital in the body and also with the relatively 
long half-life of nitrazepam, which is 21 - 28 h in man öfter oral administration 
(Rieder, 1973). The volunteers who participated in the present single dose 
experiments slept for a few hours after drug intake and complained of sleepi-
ness during the rest of the day. In the case of chronic butobarbital use the 
situation becomes worse, since the drug accumulates in the body (Fig. 4). The 
volunteers generally experienced drowsiness the next morning, especially those 
who had taken 200 mg the previous night. Accumulation on the other hand is 
counteracted by the induction of metabolic enzyme activity, which becomes 
evident. The development of this so-called „drug disposition tolerance" (Sharp-
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less, 1970) results in a shorter half-life of the drug and is a common phenome-
non of barbiturates (Remmer, 1972). The decrease in half-life was about 
2 0 - 2 5 % in the present experiments. A half-life of 14 h was measured in a 
patient, chronically treated with several psychofarmaca in a neurose-clinic, who 
received in addition 100 mg butobarbital daily. A similar short half-life of 12 h 
was reported by Prescott et al. (1973) in a barbiturate addict, following over-
dosage of the drug. From these observations it follows that the induction of 
drug metabolizing enzymes may result eventually in a relatively short buto-
barbital half-life. Also it should be taken into consideration that the enzyme-
induction may lead to increased elimination rates of other drugs which are con-
comitantly administered, e.g. anticoagulants (van Dam, 1968). Whether pharma-
codynamic tolerance develops, which involves adaptation of the central nervous 
system to the presence of the drug, cannot be explained at present. However, 
it was noticed after interrogating the volunteers, that the increase in plasma 
concentration during chronic butobarbital administration was not accompanied 
by a parallel increase in CNS depression. This may indicate that pharmaco-
dynamic tolerance evolves quite readily. 
Another consequence of the persistence of butobarbital in the body is the 
interaction with alcohol, which may lead to dangerous situations. Doenicke 
(1962) studied the influence of a single dose of 200 mg butabarbital (isomer of 
butobarbital with an iso-butylgroup instead of the n-butylgroup) combined 
with alcohol on traffic safety. He concluded that abstention from alcohol is 
essential for up to 24 h after barbiturate administration, since even small 
quantities of alcohol in the presence of butabarbital caused severe impairment 
of physical and mental performance. 
CONCLUSIONS 
From the pharmacokinetic point of view, butobarbital cannot be regarded 
as a suitable drug for the treatment of insomnia. Impairment of mental and 
physical performance during the day is likely to occur, since the half-life of the 
drug is in the range of 34 - 42 h after a single oral dose. Accumulation takes 
place when the compound is administered each night, whereas the induction of 
metabolizing enzymes develops within a few days. This results in a shortening 
of the half-life of butobarbital itself and possibly also of concomitantly adminis-
tered drugs. In fact, repetitive butobarbital administration should be avoided 
and incidental use should be restricted to hospitalized patients, when day-time 
sedation is wanted, e.g. for preoperative sedation. 
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SUMMARY 
The pharmacokinetics of butobarbital after oral administration were studied. The 
drug (200 mg) was administered in hard gelatine capsules to five healthy volunteers. 
Butobarbital plasma concentrations were determined at regular intervals. 
Absorption and elimination of butobarbital could be described by single first-
order processes. The plasma concentrations were fitted to the equation valid for the 
one-compartment model after oral administration. The average lag time was 0.11 h 
and the absorption half-life 0.22 h. The elimination half-life varied from 33.6 to 
41.5 h, with an average value of 37.5 h. By assuming that absorption had been 
complete, an average volume of distribution of 0.78 1/kg and an average clearance 
constant of 0.24 (ml/min)/kg was estimated. Due to the long half-life of the drug, 
substantial accumulation of butobarbital occurred during a period of repetitive drug 
administration. The elimination half-life after these experiments had decreased with 
about 2 0 - 2 5 % of its initial value, probably due to the development of enzyme-
induction. 
It was concluded that butobarbital cannot be regarded as a suitable drug for the 
treatment of insomnia; repetitive butobarbital administration should be avoided and 
incidental use should be restricted to patients who require day-time sedation. 
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CHAPTER 7 
CYCLOBARBITAL CALCIUM 
ORAL ADMINISTRATION 
INTRODUCTION 
Cyclobarbital, which was introduced in 1928, is one of the oldest barbiturates 
used in drug therapy. It has been evaluated in several trials and it was shown 
to be effective in the treatment of insomnia (e.g., Rushbrooke et al., 1956; 
Fastier, 1957; Parsons and Thomson, 1961; Itil, 1962; Janke and Schmatzer, 
1962; Hinton, 1963). The compound has been classified as an intermediate-
acting barbiturate (Martindale, 1972). Since Ahlander (1956) found that cyclo-
barbital free acid gradually decomposes on storage, the more stable cyclo-
barbital calcium is now usually preferred. This salt is also available under the 
trade name PHANODORM (tablets containing 200 mg cyclobarbital calcium). 
The usual oral dose is 200 - 400 mg at night. 
With respect to the pharmacokinetics of cyclobarbital in man, only half-lives 
after intake of toxic doses have been reported (Brilmayer and Loennecken, 
1962). An average elimination half-life of 18 h was found under these con-
ditions. In the present investigation the rate of absorption and elimination in 
man after oral administration of 300 mg cyclobarbital calcium was estimated. 
Three preparations, including two types of tablets and an aqueous solution 
were studied in a cross-over design. This allowed a comparison to be made of 
the absorption rate and relative bioavailability of the three preparations in the 
same individual. 
METHODS 
The following preparations were used: 
1. F.N.A.-tablets, containing 200 mg cyclobarbital calcium, 60 mg potato 
starch, 27 mg lactose, 7 mg talc, 3 mg magnesium stéarate and gelatine as a 
granulating agent (Formularium Nederlandse Apothekers, 1968). The tablets 
were prepared at the Dutch Pharmacist's Laboratory, The Hague; the cyclo-
barbital calcium content was determined in the same laboratory by Potentio-
metrie titration with acid (0.1N) in a nitrogen atmosphere. An average content 
of 104% was found. 
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2. PHANODORM tablets, containing 200 mg cyclobarbital calcium, obtained 
from MERCK/BAYER. A cyclobarbital calcium content of 101% was deter­
mined. 
3. An aqueous solution of cyclobarbital calcium, which was freshly prepared 
before use (300 mg/150 ml water). The drug was obtained as a bulk substance 
from Onderlinge Pharmaceutische Groothandel, Utrecht, through the Pharmacy 
of the St. Radboudhospital, Nijmegen. 
Six healthy male volunteers, ranging in age from 21-26 years and in body-
weight from 63 - 83 kg, participated in the study. They had received no regular 
medication during the 4 weeks preceding initiation of the experiments. After 
an overnight fast, at 9 a.m., the volunteers were given 300 mg cyclobarbital 
calcium incorporated in one of the above mentioned preparations, together 
with 150 ml water. They were requested to remain in an upright position for 
15 min and then to lie down for at least 3.5 h. This procedure was undertaken 
in order to simulate as closely as possible the situation of taking a hypnotic 
drug and going to bed. No food, fluid or tobacco was allowed for at least 
3.5 h after drug administration. Blood samples (5 ml) were taken from a 
forearm vein, usually at he following times: 20 and 40 min., 1, 1.5, 2, 2.5, 3, 
5, 8, 12, 24 and 32 h after drug administration. Every volunteer received the 
three preparations, in a random sequence, with an interval of at least 1 week. 
Cyclobarbital concentrations in plasma were determined by gas chromatogra­
phy, as described in Chapter 8, Section II. 
RESULTS 
In Fig. 1 all of the individual plasma concentration curves are shown, which 
were obtained after oral administration of the three preparations to each 
volunteer. In most instances the cyclobarbital plasma concentration rose rapidly, 
suggesting a rapid absorption of cyclobarbital when administered as the calcium 
salt. In Table I the peak level times (1
та][) are given. Slight differences between 
the preparations became apparent for almost every volunteer. The most rapid 
absorption occurred when the drug was administered in aqueous solution; 
generally the peak concentrations were attained within one hour after admini­
stration. PHANODORM and the F.N.A.-tablets may be regarded as equivalent 
with respect to their absorption rate. The maximum concentrations reached 
showed little variation among the three preparations. Drowsiness was exper­
ienced by the volunteers, usually 15 - 30 min after intake of each preparation. 
Cyclobarbital plasma concentrations were approximately 3 mg/1 or higher 
when feelings of CNS depression became apparent. The volunteers were in­
clined to sleep for three or four hours before they were able to go for lunch. 
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TABLE I. Absorption characteristics of three cyclobarbital calcium preparations 
after oral administration to the same healthy volunteers. 
Body-
Subject weight 
(kg) 
H.P. 70 
R.D. 72 
J.W. 63 
B.W. 73 
W.B. 83 
G.W. 72 
Mean values 72 
Dose 
(mg) 
300 
300 
300 
300 
300 
300 
300 
Dose/kg 
(mg) 
4.29 
4.17 
4.76 
4.19 
3.61 
4.17 
4.17 
Preparation 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
tmax 
(min) 
120 
90 
40 
60 
60 
60 
40 
60 
15 
20 
40 
20 
20 
40 
30 
180 
150 
90 
73 
73 
42 
*--max 
(mg/l) 
8.5 
8.5 
5.8 
7.7 
8.3 
8.8 
10.8 
10.3 
11.7 
9.8 
9.8 
9.7 
8.1 
7.6 
7.2 
7.3 
7.4 
6.6 
8.3 
8.7 
8.3 
Occasionally, they reported that drowsiness was absent by this time, while at 
other times they reported persistent lethargy for the remainder of the after-
noon. 
Although absorption generally occurred quite regularly, it was not possible 
to deduce the correct absorption parameters according to single first-order 
kinetics from each concentration curve. This was mostly due to the lack of 
sufficient data points during the absorption phase. With early peak concentra-
tions an initial rapid decline of the plasma concentration was often observed. 
243 
TABLE II. Elimination half-lives and relative bioavailability of cyclobarbital after 
oral administration of three cyclobarbital calcium preparations to the same healthy 
volunteers. 
Subject Preparation 
H.P. 
R.D. 
J.W. 
B.W. 
W.B. 
G.W. 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
F.N.A. 
PHANODORM 
Solution 
Mean values 
F.N.A. 
PHANODORM 
Solution 
tv, 
(h) 
17 
15.5 
15 
15^8 
10 
11 
10 
ТоГз 
11 
10 
9 
"1Ö_ 
9.5 
9.5 
8 
~~9 ' 
17 
17 
15 
16.3 
8 
9 
9 
"8.7 
12.1 
12.0 
10.7 
11.6 
average
 Tc l 
(h) 
22.8 
14.9 
14.4 
13.0 
23.5 
12.5 
16.7 
AUC 
0-12 h 
(mg.h/l) 
60.9 
67.5 
49.9 
55.0 
70.0 
59.6 
85.2 
84.3 
56.9 
62.7 
58.6 
57.0 
66.1 
65.2 
49.1 
67.2 
60.8 
51.9 
66.2 
67.7 
54.1 
conc. 
12 h 
(mg/1) 
4.2 
3.7 
3.2 
3.0 
4.4 
2.7 
4.9 
4.2 
3.0 
3.3 
3.3 
2.8 
4.7 
4.8 
3.4 
3.9 
3.4 
2.8 
4.0 
4.0 
3.0 
AUC 
0 - o c 
(mg.h/1) 
156.7 
151.9 
122.9 
99.6 
135.5 
99.8 
155.8 
144.8 
100.1 
105.5 
101.4 
93.3 
176.6 
180.5 
129.1 
115.9 
103.2 
86.8 
135.0 
136.2 
105.3 
(%) 
100 
97 
78 
100 
136 
100 
100 
93 
64 
100 
96 
88 
100 
102 
73 
100 
89 
75 
100 
101 
78 
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This suggests that, in such a situation, distribution of the drug from plasma into 
tissues is slower than drug absorption. Similar observations were encountered 
for hexobarbital sodium and heptabarbital sodium (Chapter 1 and 5, Section 
III). The subsequent slower decrease of plasma concentration represents the 
elimination phase, which proceeds according to a single first-order process. 
On all occasions straight lines were obtained for the decrease in plasma con­
centration after plotting on semi-logarithmic scale (Fig. 2). The plasma half-
lives of cyclobarbital varied from 8-17 h (Table II). In addition, it was 
observed that the half-lives of the barbiturate were about the same for each 
individual on the three occasions (Fig. 2; Table II). The small differences 
measured may not be meaningful, since they are in the same order as the 
experimental error. 
With respect to relative bioavailability estimation of cyclobarbital, the same 
procedure was applied as described in detail for heptabarbital (Chapter 5, 
Section III). It was assumed that the total body clearance was constant for a 
certain individual. The areas under the plasma concentration curves were esti­
mated, including a correction for the undetermined area. The bioavailability was 
calculated relative to the F.N.A.-tablets (Table II). Surprisingly, the aqueous 
conctfntrishon cyclobarbital (mg/l plaema ,iog5cate) 
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FIG. 2. Plasma concentration curves of cyclobarbital plotted on semi-logarithmic 
scale, representing the elimination phase of cyclobarbital after oral administration 
of the three preparations to subject G.W.; F.N.A.-tablets (solid circles), PHANO­
DORM (open circles) and aqueous solution (triangles). The elimination half-life of 
cyclobarbital in this subject varied from 8 to 9 h. 
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solution showed the lowest bioavailability. Absorption of cyclobarbital from 
the F.N.A.-tablets and from PHANODORM generally occurred to a compa-
rable extent. 
If the absolute bioavailability of cyclobarbital for the F.N.A.-tablets is 
assumed to be 100%, then the average clearance constant and apparent volume 
of distribution may be estimated. The zero-time concentration (A) of the 
average plasma concentration curve for the F.N.A.-tablets was found to be 
8 mg/1. Since absorption is much more rapid than elimination, an estimation 
for Vf may be obtained by the quotient Dose/A, whereas kcl = Vf/1.44. t4t. 
This yields 37 1 for Vf and 35 ml/min for kei of cyclobarbital. These values may 
be regarded as relatively low when compared with the other barbiturates 
studied. The small apparent volume of distribution is in accordance with its 
relatively low lipophility (Chapter 1, Section II). 
Cyclobarbital, for the major part, is eliminated by metabolism. In 1932 
Fretwurst et al. reported that only 2.5-6.3% of the administered dose was 
excreted as unchanged drug in the urine. More recently some oxidized meta-
bolites were detected in human urine after cyclobarbital administration (Seifert, 
1956; Frey et al., 1959; Eberhardt et al., 1962). These were identified by 
Arnold and Grützmacher (1969) as З'-keto- and З'-hydroxy-cyclobarbital, with 
the aid of mass spectrometry. 
DISCUSSION 
The complete cross-over design in this investigation on the kinetics of cyclo­
barbital calcium in man, permits a comparison to be made of the absorption 
and elimination parameters in the same volunteer. Each individual serves as 
his own control, which minimizes the variability attributable to physiological 
factors. Differences in the absorption rate or bioavailability of a drug from 
certain dosage forms, encountered in the same volunteer, may now be attributed 
to pharmaceutical factors rather than to physiological factors. Although there 
is a substantial variation between individuals, it is evident that the rank order in 
absorption rate and bioavailability of the three cyclobarbital calcium containing 
preparations is generally the same for each volunteer. For instance, the ab­
sorption of cyclobarbital was relatively slow for subject G.W., but still the 
solution was absorbed more rapidly and also to a lesser extent. 
The calcium salt of cyclobarbital is appreciably soluble in water (1 g/100 ml; 
Martindale, 1972) which explains the rapid absorption of the preparations 
used in this study. The importance of salt formation and aqueous solubility for 
barbiturate absorption was discussed in detail for heptabarbital (Chapter 5, 
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Section III). As expected, the cyclobarbital calcium solution showed the highest 
absorption rate, since the primary dissolution of the active ingredient, which 
often is a rate determining step in drug absorption (Benet, 1973), does not 
apply in the case of an aqueous solution. However, the finding that the solution 
showed the lowest bioavailability in these experiments, is unexpected. Often it 
is recommended in comparative bioavailability studies to use an aqueous solution 
of a water-soluble drug as the reference dosage form (Guidelines, 1972). This 
is rational, since it eliminates all of the factors involved in the dissolution 
process. Such factors are often involved when bioavailability is found to be 
reduced (Wagner, 1971). With barbiturate salts a complicating factor may be 
the fact that the poor solubility of the free acid causes precipitation when the 
drug reaches the acidic gastric fluids. The precipitate which is formed after cyclo-
barbital calcium solution administration, may have unfavourable redissolution 
properties when compared with the precipitate formed after tablet administra-
tion. However, this only counts for part of the precipitate, since the rapid 
absorption of the solution also suggests that rapid dissolution occurs. Additional 
experiments, in vitro and in vivo, are required in order to determine the cause 
of the lower bioavailability of cyclobarbital from the solution. 
The half-life of cyclobarbital, for four of the volunteers who participated in 
the present experiments, were between 8 and 11 h. This is relatively short and 
advantageous with respect to the intended duration of action in the treatment 
of insomnia. After a night's rest of 9 h approximately 40-55% of the drug 
has been inactivated and it is likely that the plasma concentration has decreased 
below the minimal effective level, if a normal dose of 200 or 300 mg has been 
given. This level varied from 3-7 mg/l with respect to the onset of action. 
The duration of action, as judged by subjective feelings of CNS depression, 
varied considerably among the volunteers. Janke and Schmatzer (1962) ob-
served impairment of mental performance in volunteers 12 h after they had 
received 400 mg cyclobarbital calcium. Obviously, the risk of residual effects 
after a lower dose is less, whereas it may still be effective in the induction and 
maintenance of sleep. On the other hand, also the longer half-life of cyclo-
barbital in the two volunteers should be considered. This was 15 - 17 h, which 
must be regarded as too long for rational hypnotic drug treatment. Residual 
effects may be expected the following morning. Only when day-time sedation 
is required, should such a long half-life be advantageous. The reason for the 
considerable difference in half-life of cyclobarbital between the subjects is not 
clear. Many factors may be involved, which were discussed recently by Gillette 
(1971). At present it is difficult to judge whether cyclobarbital could be safely 
used in a certain individual for the treatment of insomnia, since a relatively 
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long half-life should be reckoned with. Furthermore, experiments of repetitive 
cyclobarbital calcium administration are required, in order to ascertain if 
important accumulation of the drug in the body becomes apparent and also 
to determine if the half-life of the drug remains unchanged. A preliminary 
experiment has revealed that substantial accumulation did not occur and that 
the half-life had not changed after repetitive cyclobarbital calcium administra-
tion (200 mg every night). 
CONCLUSIONS 
These pharmacokinetic studies reveal that the half-life of cyclobarbital in 
some subjects is sufficiently short to be regarded as suitable for the treatment 
of insomnia. Due to the fact that a much longer half-life became apparent in 
some other subjects, cyclobarbital cannot, however, uniformly be recommended 
for use in general practice. For subjects with a half-life of 15 - 17 h residual 
effects are likely to occur the following morning. 
In principle, the calcium salt containing preparations are suitable for the 
rapid induction of sleep, since the rate of absorption of cyclobarbital from these 
preparations is rapid. 
SUMMARY 
The pharmacokinetics and relative bioavailabililty of cyclobarbital calcium were 
studied after oral administration. Tablets, according to the Formularium Neder-
landse Apothekers (1968), PHANODORM, and an aqueous solution were used. Six 
healthy volunteers participated on three occassions in this investigation and received 
the three preparations. The administered dose was 300 mg cyclobarbital calcium. 
Cyclobarbital plasma concentrations were determined at regular intervals. 
The absorption of cyclobarbital from the three preparations was rapid and highest 
for the solution. Peak concentrations were usually attained within 1 h. The elimi-
nation of cyclobarbital could be described by a single first-order process with an 
average half-life of 11.6 h (range 8-17 h). Little intrasubject variation was noted 
with respect to the half-life. Relative bioavailability was estimated for each volunteer 
by comparing the areas under the plasma concentration curves. The F.N.A.-tablets 
and PHANODORM showed comparable bioavailability, whereas for the solution 
an average bioavailability of 78% relative to the F.N.A.-tablets was estimated; the 
reason for this unexpected finding is unknown. 
It has been concluded that cyclobarbital cannot uniformly be regarded as a 
suitable drug for the treatment of insomnia. The long half-life that became apparent 
in some of the volunteers (15 -17 h) causes a substantial risk of residual effects to 
occur the following morning. In principle, the calcium salt of cyclobarbital may 
be used for rapid sleep induction, because of its rapid absorption. 
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CHAPTER 8 
CHLORAL HYDRATE 
Λ. GENERAL INTRODUCTION 
B. PHARMACOKINETICS AND METABOLISM 
С BIOPHARMACEUTICS 
1. RECTAL ADMINISTRATION 
2. ORAL ADMINISTRATION 
A. GENERAL INTRODUCTION 
Chloral hydrate (СС1зСН(ОН)2) was first synthesized by Liebig in 1832. 
Liebreich (1869) described its hypnotic action and he suggested that the drug 
was effective because it was metabolized in the body to chloroform. However, 
subsequent work failed to substantiate this hypothesis (Tomaszewicz, 1874). 
Von Mering (1882) found that the product isolated from the urine of patients 
receiving chloral hydrate was a conjugation product of trichloroethanol and 
glucuronic acid. Kiilz (1882, 1884) showed that trichloroethanol has hypnotic 
activity and he proposed that the pharmacological effect of chloral hydrate 
may be attributed to trichloroethanol, which is formed in the body by reduction 
of the parent drug. This theory has been supported by the work of Butler (1948) 
and of Marshall and Owens (1954), who found that the reduction of chloral 
hydrate to trichloroethanol occurs so rapidly in man and in dogs, that it is 
difficult to detect any unchanged chloral hydrate in the blood or plasma after 
oral administration. In comparative evaluations of the clinical efficacy of the 
two compounds, trichloroethanol was found to be at least as effective as chloral 
hydrate (Owens et al., 1955; Imboden and Lasagna, 1956). On the other hand 
Mackay and Cooper (1962) as well as Buchel (1964) have shown that chloral 
hydrate itself has hypnotic activity. In a recent study, Grüner et al. (1973) 
compared the effects of chloral hydrate and of trichloroethanol on the EEG of 
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the isolated perfused rat brain and they found that both compounds exhibited 
CNS depressant activity. 
In conclusion, it seems most likely that chloral hydrate has in itself hypnotic 
properties, its action being limited, however, by a rapid reduction to trichloro-
ethanol and the latter compound continuing the hypnotic activity. Only after 
rapid i.v. administration, chloral hydrate must be expected to contribute sub-
stantially to the induction of sleep. After oral or rectal administration the 
sedative or hypnotic action must be attributed entirely to trichloroethanol, since 
no measurable amount of parent drug reaches the general circulation intact 
(Marshall and Owens, 1954; Breimer, Ketelaars and van Rossum, unpublished 
results). Thus, chloral hydrate may be regarded as a transport form for the 
active metabolite trichloroethanol (Breimer, 1973). 
Marshall and Owens (1954) showed that, with respect to absorption and 
excretion rates, it probably did not make a great difference whether chloral 
hydrate or trichloroethanol was given. One advantage of using chloral hydrate, 
in general practice, is the fact that it is a solid, whereas trichloroethanol is a 
liquid which is more difficult to handle. Both compounds are appreciably 
soluble in water, while trichloroethanol also has substantial lipophilic properties 
(Garrett and Lambert, 1966). It is not known whether the side-effects of chloral 
hydrate such as irritation to mucous membranes and occasional nausea and 
vomiting, are different with trichloroethanol. Usually it is recommended that 
chloral hydrate should be administered as a dilute aqueous solution in order to 
prevent these side-effects. In a recent article Fairbrother (1973) has reviewed 
extensively the physical and chemical properties of chloral hydrate. 
Chloral hydrate was introduced into medicine when only alcohol, opium 
and Cannabis were available for hypnosis and sedation. Although its popularity, 
in the treatment of insomnia, diminished after the introduction of the barbitu-
rates, it is still a widely used hypnotic drug, especially in children and in elderly 
patients (Ferguson Anderson, 1973). Also in the treatment of infantile convul-
sions the drug seems to be of value (Renner, 1962; Martindale, 1972). The 
central depressant actions of chloral hydrate, or better still of trichloroethanol, 
resemble those of alcohol, the barbiturates and the gaseous anaesthetics. Like 
many hypnotic drugs, chronic use of chloral hydrate can lead eventually to 
habituation, tolerance and addiction (Maynert, 1965). Small doses produce 
sedation (0.5 g), larger doses facilitate sleep ( 1 - 2 g), whereas overdosage leads 
to anaesthesia or coma (4 - 20 g). Clinical trials have proved the effectiveness 
of chloral hydrate (the usual hypnotic doses of 1 or 2 g) in inducing and main-
taining sleep in adults (Owens et al., 1955; Imboden and Lasagna, 1956; Shapiro 
et al., 1969). Rickeis and Bass (1963) however, showed that the dose of 1 g 
was only slightly better than a placebo and it seems likely that many individuals 
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may require 1.5 or 2 g. Up to 200 mg may be given to infants under 1 year 
of age, 250 - 500 mg to children from 1 to 5 years and 500 - 1000 mg from 6 
to 12 years (Martindale, 1972). For preoperative sedation 40 - 60 mg/kg can 
be used (Anderson, 1962; Illingworth, 1968). 
Chloral hydrate may be advantageous when compared with the barbiturates, 
since Kales et al. (1969) reported that chloral hydrate, as well as certain ben-
zodiazepines, did not suppress REM-sleep. However chloral hydrate was ad-
ministered, in these experiments, in doses of 0.5 and 1.0 g, which can hardly 
be considered to be effective hypnotic doses (Sharpless, 1970). Whether larger 
doses would suppress REM-sleep remains unknown. 
From the pharmacokinetic and biopharmaceutical point of view, no satis-
factory literature data are available to judge the usefulness of chloral hydrate 
in rational hypnotic drug therapy. It was for this reason that the present in-
vestigations were initiated, as will be further outlined in the following. Besides, 
the assay method which was developed (Chapter 9, Section II; Breimer et al., 
1974) not only permitted the blood and urine analysis of the active compound 
trichloroethanol, but also of some other metabolites of chloral hydrate. There-
fore, the kinetics of these compounds were studied simultaneously. 
B. PHARMACOKINETICS AND METABOLISM 
INTRODUCTION 
As already mentioned chloral hydrate is very rapidly reduced to trichloro-
ethanol; this reaction occurs in the liver and in other tissues, including erythro-
cytes (Butler, 1949; Sellers, Lang et al., 1972). Friedman and Cooper (1960) 
found that the reduction is catalyzed by the enzyme alcohol dehydrogenase. 
Due to this observation, quite some attention has been paid to the interaction 
between chloral hydrate and alcohol. Concurrent administration enhances the 
depressant action of chloral hydrate (Kaplan et al., 1969; Gessner and Cabana, 
1970; Sellers et al., 1972a). Kaplan et al. (1967) and Sellers et al. (1972) 
showed that the interaction in man results in higher trichloroethanol and also 
in higher alcohol blood concentrations. 
A small amount of trichloroethanol is excreted unchanged into the urine, the 
rest is further metabolized by conjugation with glucuronic acid (urochloralic 
acid) before excretion (Marshall and Owens, 1954). 
Apart from reduction, chloral hydrate can be oxidized to trichloroacetic acid 
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(Butler, 1948; Marshall and Owens, 1954). This conversion is catalyzed by 
NAD-dependent aldehyde dehydrogenase in the liver, for which, surprisingly, 
no naturally occurring substrate could be found (Cooper and Friedman, 1958). 
Purified human acetaldehyde dehydrogenase docs not metabolize chloral 
hydrate (Kracmer and Deitrich, 1968; Blair and Bodley, 1969). The enzyme 
which catalyzes the oxidation is not yet known. Also, after trichloroethanol 
administration trichloroacetic acid has been detected (Marshall and Owens, 
1954). Is seems likely that in this case chloral hydrate is an intermediate, but 
in in vitro studies this compound could not be identified (Friedman and Cooper, 
1960). Trichloroacetic acid is predominantly excreted unchanged into the urine 
(Paykoç and Powell, 1954). 
In Fig. 1 the fate of chloral hydrate in the body is summarized, as far as 
known up to now. Few quantitative studies on the pharmacokinetics of chloral 
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FIG. 1. Schematic representation of the fate of chloral hydrate in man. 
hydrate and its metabolites in man have been carried out. The investigations 
by Marshall and Owens (1954) and Owens and Marshall (1955) give detailed 
information, however, their data hardly permit the calculation of half-lives or 
other important pharmacokinetic parameters. Sellers et al. (1972) determined an 
average half-life of 8.2 h for trichloroethanol, when studying the interaction 
of chloral hydrate and alcohol. It should be mentioned further that Garrett and 
Lambert (1973) extensively investigated the kinetics of trichloroethanol and 
metabolites in dog. 
It was the aim of the present investigation to study the pharmacokinetics of 
chloral hydrate and its known metabolites in man. This became possible since 
the assay method permits the simultaneous determination of chloral hydrate, 
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trichloroethanol, trichloroethanol-glucuronidc and trichloroacetic acid in blood 
and in urine. Chloral hydrate was administered orally and rectally in this study, 
since both routes of administration are important in general practice. Phar-
macokinetic data after rectal chloral hydrate administration seem to be com-
pletely lacking in the literature. 
METHODS 
Oral administration 
Six healthy male volunteers, aged 20 - 26 years, who did not take any regular 
medication, participated in the study. They were not allowed to consume al-
coholic beverages from 12 h before the experiment until 24 h after the experi-
ment. The trials began in the morning after the subjects had fasted overnight 
and 15 mg/kg of chloral hydrate (obtained from OPG, Utrecht), dissolved in 
150 ml water, was administered orally. One volunteer (J.G.) received trichloro-
ethanol 15 mg/kg (obtained from Koch & Light, Colnbrook, Great Britain) 
dissolved in 150 ml water. After intake of the drug the subjects were asked to 
stay in an upright position for 15 min and then to lie down for at least two 
hours. Usually blood samples were taken by vein puncture at 10, 20, 30, 40 
and 60 min and further at 1.5, 2, 3, 5, 7, 9 and 11 or 12 h after drug intake. 
The same subjects collected their urine at frequent intervals for about 50 hours. 
Subject A.H. collected his urine over a period of 9 days. 
Total blood concentrations and urine concentrations of trichloroethanol, 
trichloroethanol-glucuronide and trichloroacetic acid were determined by gas 
chromatography with electron capture detection, utilizing head-space analysis, 
as described in Chapter 9 of Section II. In subject J.G. there was no differen-
tiation made between free and conjugated trichloroethanol. 
Subject J.H. received chloral hydrate also for three consecutive nights after 
the start of the trial and for several days the trichloroacetic acid blood con-
centration was determined. 
Rectal administration 
For three volunteers, who participated in the study of the biopharmaceutical 
aspects of rectal chloral hydrate administration, also the concentration of 
trichloroethanol-glucuronide and of trichloroacetic acid in blood was followed. 
Two subjects received the drug (1000 mg), dissolved in polyethylene glycol 300 
(PEG 300) and another received it dissolved in sesame oil. A rectiole was used 
for the introduction of the solutions into the rectum. Details concerning the 
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preparation and the composition of these dosage forms are given in this chapter 
under "biopharmaceutics of rectal chloral hydrate administration". For the rest 
the procedure as described under "oral administration" was followed. 
RESULTS 
After oral and rectal administration of chloral hydrate no unchanged parent 
drug could be detected in the blood. There was a rapid rise of trichloroethanol 
concentration after oral intake of the aqueous solution. Peak levels were attained 
after 20 - 60 min with a mean height of 7.6 mg/1 (range 5.2 -11.2 mg/1). In 
most subjects the trichloroethanol-glucuronide concentration reached its 
maximum value at the same time as the free trichloroethanol. In Table I these 
results have been summarized. After the absorption had finished a rapid decline 
in trichloroethanol concentration occurred, followed by a slower monoexponen-
tial decay. A similar profile was found for trichloroethanol-glucuronide. In Fig. 
2 a typical example of the blood concentration - time curves is shown as 
measured for subject A.H. In Table II the blood half-lives of trichloroethanol 
and of trichloroethanol-glucuronide are given, together with the trichloroacetic 
acid concentrations at 12 h. The average half-life of the slower phase was 8.0 h 
for trichloroethanol (range 6.5 - 9.5 h) and 6.7 h for trichloroethanol-glucuroni-
de (range 6.0 - 8.0 h). Also trichloroacetic acid was rapidly formed after a 
single oral dose of chloral hydrate. A relatively high concentration of this 
TABLE I. Peak blood concentrations of trichloroethanol and trichloroethanol-
glucuronide after oral administration of chloral hydrate in aqueous solution to five 
human volunteers. 
Trichloro- Trichloroethanol-
Subject 
H.H. 
W.E. 
T.L. 
P.W. 
A.H. 
mean 
Body-
weight (kg) 
70 
76 
54 
65 
85 
70 
Dose (mg) 
1050 
1140 
810 
975 
1275 
1050 
Dose/kg 
(mg) 
15.0 
15.0 
15.0 
15.0 
15.0 
15.0 
ethanol 
max ma\ 
(mg/1) (min) 
11.2 
7.6 
6.5 
7.4 
5.2 
7.6 
20 
60 
40 
60 
20 
40 
glucuronide 
max max 
(mg/1) (min) 
10.8 20 
2.7 60 
5.7 40 
6.6 30 
7.9 20 
6.7 34 
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FIG. 2. Blood concentration curves on semi-logarithmic scale of trichloroethanol 
(TCE), trichloroethanol-glucuronide (TCE-Glu) and trichloroacetic acid (TCA) after 
oral administration of chloral hydrate (15 mg/kg) in aqueous solution. 
metabolite in the blood was reached within one hour. Even to 12 h an increase 
in this concentration was noticed (Fig. 2). The half-life of trichloroacetic acid 
appeared to be about 4 days (100 h) in subject A.H. (Fig. 6). 
After rectal administration of chloral hydrate the half-lives of the compounds 
measured were in the same range as when chloral hydrate was given orally 
(Table III). Also, trichloroacetic acid accumulated for at least 12 h. In Fig. 3 
the blood concentration - time curves are shown for subject K.S. Absorption 
apparently occurred much slower than after oral intake of an aqueous solution. 
Details of the rectal absorption characteristics and the influence of vehicle com­
position will be given in this chapter under "biopharmaceutics of rectal chloral 
hydrate administration". 
The results of the one subject receiving trichloroethanol are given in Fig. 4. 
No differentiation was made between free trichloroethanol and trichloroethanol-
glucuronide, since the aim of this single experiment was just to find out whether 
(also after trichloroethanol administration) a substantial amount of trichloro­
acetic acid would be formed. This does indeed occur, although its initial rate 
of formation is slower than after chloral hydrate administration. 
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TABLE II. Blood half-lives of trichloroethanol and trichloroethanol-glucuronide after 
oral administration of chloral hydrate. Blood concentrations of trichloroacetic acid 
at 12 h. 
Subject 
H.H. 
W.E. 
T.L. 
P.W. 
A.H. 
mean 
Trichloroethanol 
4 (h) 
8.5 
6.5 
9.5 
7.0 
8.5 
8.0 
Trichloroethanol-
glucuronide 
t./. (h) 
6.5 
6.0 
6.0 
7.0 
8.0 
6.7 
Trichloroacetic 
acid blood concentration 
at 12 h (mg/1) 
16.7 
17.4 
10.7 
11.1 
11.0 (11 h) 
13.4 
bloodconcentretion ( mg/i i loj'ecal·) 
5 0 -, 
2 0 -
10 
5 0 
2 0 
10 
0 3 
0 2 
0 1 
TCA 
TCE-Glu 
CHORALHYDRATE recial lOOOmg-
( rectiole, eeeame сч( ) 
subject K.S. 
- I 1 1 1 1 I 
2 * 6 Ю 12 
time ( h j 
FIG. 3. Blood concentration curves on semi-logarithmic scale of trichloroethanol 
(TCE), trichloroethanol-glucuronide (TCE-Glu) and trichloroacetic acid (TCA) after 
rectal administration of chloral hydrate (1000 mg) dissolved in 3 ml sesame oil. 
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TABLE III. Blood half-lives of trichloroethanol and trichloroethanol-glucuronide 
after rectal administration of chloral hydrate. Blood concentrations of trichloroacetic 
acid at 12 h. 
Subject 
K.S. 
P.A. 
R. T. 
Body-
weight 
(kg) 
67 
65 
66 
Dose 
(mg) 
1000 
1000 
1000 
Dose/kg 
(mg) 
14.9 
15.2 
15.1 
Trichloro­
ethanol 
t./, (h) 
7.5 
8.5 
7.0 
Trichloro­
ethanol-
glucuronide 
4 (h) 
7.0 
8.0 
determination 
not possible 
Trichloro­
acetic acid 
blood 
concentration 
at 12 h 
(mg/1) 
29.8 
27.3 
12.9 
For the five subjects receiving chloral hydrate orally, also the urinary ex­
cretion of trichloroethanol, trichloroethanol-glucuronide and trichloroacetic 
acid was determined for about 50 h (Table IV). As expected, no unchanged 
chloral hydrate could be detected and only a small amount was excreted as 
free trichloroethanol (2.6 - 7.7 mg). Varying amounts of the glucuronide were 
found: 108 - 307 mg (calculated as chloral hydrate), which is equivalent to 
10 - 24% of the dose administered. The amount of trichloroacetic acid excreted 
bloodconcentivitan (mg/t , l o j ecale 
2 0 0 η 
Ьггчг ( Ь ) 
FIG. 4. Blood concentration curves on semi-logarithmic scale of free + conjugated 
trichloroethanol (TCE + TCE-Glu) and of trichloroacetic acid (TCA) after oral ad­
ministration of trichloroethanol (15 mg/kg) in aqueous solution. 
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in the first 50 h is not the total quantity to be excreted, because of the very long 
half-life of this compound. This can be seen in Fig. 6, where a plateau for 
cumulative trichloroacetic acid excretion has not been reached even after 9 days. 
Urine collection during 15 - 20 days will be required to measure all of the 
trichloroacetic acid formed after a single dose of chloral hydrate. 
In general, the rate of renal elimination of a drug is directly proportional to 
the plasma - water concentration (Cp): 
dQ
r 
dt 
ν С 
where da 
dt 
is the renal excretion rate (mg/h) and k
r
 is the renal clearance 
constant (ml/min or 1/h). The curve, obtained by plotting the renal excretion 
rate versus time, should have the same shape as the plasma-water concentration 
curve. This might also be true for the total blood concentration curve, if protein 
binding is relatively low or dissociation of the drug-protein complex is very 
rapid and exchange, alternatively, between plasma and erythrocytes is a rapid 
process or does not occur at all. Protein binding of trichloroethanol and its 
glucuronide is about 37% (determined at concentrations of 5 mg/1 and 9 mg/1 
respectively), while the former does and the latter does not partition into red 
blood cells (Garrett and Lambert, 1973). For trichloroacetic acid the situation 
may be more complicated as its binding to plasma proteins is much higher: 
TABLE IV. Cumulative urinary excretion of trichloroethanol, trichloroethanol-
glucuronide and trichloroacetic acid after oral administration of chloral hydrate 
(calculated as chloral hydrate). 
Subject 
H.H. 
W.E. 
T.L. 
P.W. 
A.H. 
Dose 
(mg) 
1050 
1140 
810 
975 
1275 
Trichloroethanol 
(mg) 
2.6 
7.7 
5.3 
4.9 
3.5 
Trichloroethanol-
glucuronide (mg) 
239 (23 Го)1) 
108 (11%) 
147 (19%) 
149 (15%) 
307 (24%) 
Trichloroacetic 
acid (mg) 
8.7 ( 48 h?) 
55.6 ( 42 h) 
46.2 ( 32 h) 
36.9 ( 52 h) 
90.1 (216 h) 
') Percentage of the dose excreted in 48 h. 
2) Time interval in hours, after intake of chloral hydrate, during which trichloro­
acetic acid was measured in urine. 
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renal excretion rate 
(mgYh ,\og3cale) 
100 
cumulative renal excretion 
TCtGlucuronide (m^ free TCE) 
320 
240 
60 
- 0 
FIG. 5. Average renal excretion rate curves (semi-logarithmic scale) and cumulative 
renal excretion of trichloroethanol (free TCE) and trichloroethanol-glucuronide (TCE-
glucuronide) after oral administration of chloral hydrate (1275 mg). See Fig. 2 for 
the blood concentration curves of this subject. 
84 and 94% determined at plasma concentrations of 100 mg/1 and 30 mg/1 
respectively (Sellers and Koch-Weser, 1971). In cases where the above equation 
is valid, the biological half-life can be deduced from the renal excretion rate 
curve. Experimentally the excretion rate is not determined over infinitely small 
time intervals, but over discrete periods of time (Fig. 5 and 6). Therefore, it is 
sometimes more convenient to use the renal excretion deficit for the calculation 
of half-life. If single-compartment kinetics are valid and absorption is fast com-
pared to elimination, the following applies (van Rossum, 1971): 
iog(Q,. - Q r , t ) = log Q r , t - 0.301 t/tv, 
where Qrj t = ^ is the total amount excreted (mg), Q,. t is the amount excreted 
until time t (mg) and (Qr t _ ^ - Qr t) is the excretion deficit. The log of the 
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FIG. 6. Average renal excretion rate curve, blood concentration curve (semi-logarith­
mic scale) and cumulative renal excretion of trichloroacetic acid (TCA) after oral 
administration of chloral hydrate (1275 mg). These data are from the same experiment 
as Fig. 2 and Fig. 5. The blood half-life of TCA is about 100 h. 
renal excretion deficit is a linear function of time. With trichloroethanol and 
trichloroethanol-glucuronide indeed straight lines have been obtained, as shown 
in Fig. 7. In Table V the urine half-lives of the two compounds are given and 
they appear to be somewhat longer than the blood half-lives. 
DISCUSSION 
Chloral hydrate 
The reduction of chloral hydrate seems to occur more rapidly than chloral 
hydrate absorption, since no unchanged parent drug can be detected, even in 
the first blood sample. On the other hand already a substantial concentration of 
trichloroethanol is measured at this time. As soon as chloral hydrate reaches 
the blood in the intestinal wall capillaries the reduction by the erythrocytes 
begins and during the first passage through the liver the remainder is reduced 
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TABLE V. Half-lives of trichloroethanol and trichloroethanol-gluciironide obtained 
from urinary excretion deficit curves. 
Subject 
H.H. 
W.E. 
T.L. 
P. W. 
A.H. 
Trichloroethanol 
tv, (h) 
—') 
10.0 
10.0 
11.5 
9.0 
mean 10.1 
Trichloroethanol-glucuronide 
t./, (h) 
7.5 
8.0 
8.0 
10.5 
7.5 
8.3 
') Irregular excretion. 
Excretion deficit (mg · \og ecale) 
300 
200 
10 
5 
2 -
1 -
as­
ci 
ТСЕ 
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time ( h ) 
FIG. 7. Renal excretion deficit curves on semi-logarithmic scale of trichloroethanol 
(TCE) and trichloroethanol-glucuronide (TCE-Glu). Data have been obtained from 
the cumulative renal excretion in Fig. 5. 
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by liver alcohol dehydrogenase or oxidized to trichloroacetic acid. It is not 
known if any biotransformation of chloral hydrate takes place in the gastrointes-
tinal tract. The rate at which trichloroethanol appears in the general circulation 
is assumed to be a measure for the rate of chloral hydrate absorption. 
Marshall and Owens (1954) showed that, only after relatively high oral 
doses to dogs ( > 50 mg/kg), unchanged chloral hydrate could be detected in 
the plasma for a short period of time. The same was found in horses by 
Alexander et al. (1967) who gave a total oral dose of 25 g (166 mg/kg). 
Apparently in these cases saturation of the metabolizing enzyme systems during 
first passage through the liver had occurred. That the enzymes must have a high 
capacity in metabolizing chloral hydrate, follows from i.v. experiments in dogs, 
where a half-life of 3 min was found (Butler, 1948; Garrett and Lambert, 1973). 
The same result was obtained in our own dog experiment, when testing the 
applicability of the gas chromatographic assay for chloral hydrate and meta-
bolites (Breimer et al., 1974). In children (4 - 8 yr), Rezza (1956) determined 
a half-life of about 10 min after i.v. administration of chloral hydrate. The 
results of Bemstine et al. (1957), who reported chloral hydrate blood concen-
trations as high as 30 mg/1 12 h after rectal administration of 1.2 g to human 
subjects, are contradictory with the results of other investigators and are not 
substantiated by our own studies on chloral hydrate kinetics and metabolism in 
man. 
Trichloroethanol 
The initial relatively rapid decline of trichloroethanol blood concentration 
(Fig. 2) is probably due to a distribution process into fluids and tissues outside 
of the blood. Its low molecular weight and its relatively good lipophility 
suggests that extensive distribution could be expected. A further indication for 
a rapid distribution process lies in the fact that in the two subjects who reached 
their maximum concentration only after 60 min, no clear biphasic decay was 
observed. This indicates that now distribution of trichloroethanol occurred more 
rapidly than chloral hydrate absorption. 
The final exponential decay of trichloroethanol blood concentration is due 
most likely to the metabolic conversion into its glucuronide and also to the 
oxidation to trichloroacetic acid. The concentration of the latter compound 
increases up to 12 h. The mean trichloroethanol blood half-life of 8.0 h is 
consistent with the plasma data of Sellers et al. (1972), who reported 8.2 h. 
However, in the latter study plasma concentrations were followed only until 
6 hours after administration, while in our study this was done until 11 or 12 h. 
Both periods of time are relatively short with respect to a half-life of 8 h and a 
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question of the reliability of this half-life after 12 h occurs. In some subjects 
the trichloroethanol concentrations at 24 h were measured and these appeared 
to be slightly higher than expected on basis of an 8 h blood half-life. In dogs 
Garrett and Lambert (1973) also found a slower third phase, which they 
attributed to the existence of a third or "deep" compartment, from which the 
rate of return of trichloroethanol to the general circulation is slow. If on the 
other hand this phase in humans would be very much slower than that corres-
ponding to a half-life of 8 h, then the urinary excretion rate curves or excretion 
deficit curves of trichloroethanol and possibly also of trichlorocthanol-glucuro-
nide should show a distinct second slower phase. This has not been observed 
in our experiments, although the urine half-lives are slightly longer than the 
blood half-lives. It can be concluded that if a slower phase in the elimination 
of trichloroethanol exists, it is probably not much slower than that corresponding 
to an average half-life of 10 h (* see note p. 284). 
Trichloroethanol-glucuronide 
The rapid rise of trichloroethanol-glucuronide blood concentration after oral 
intake of chloral hydrate indicates, that conjugation already occurs to a great 
extent during first passage of trichloroethanol through the liver. Otherwise, the 
peak level time of the glucuronide could not coincide with unconjugated 
trichloroethanol. A further indication for such a "first-pass effect" lies in the 
fact that the half-life of the glucuronide was found to be shorter than that of 
free trichloroethanol. According to theory a metabolite cannot be eliminated 
faster than it is produced from its precursor, unless such a great amount is 
formed during the first liver passage that it is initially kinctically independent 
of the precursor. Later, a slower phase would be expected when the rate of 
formation becomes ultimately the rate-determining step for elimination. There 
is no direct indication for such a behaviour in our experiments, although the 
urine half-lives are longer than the blood half-lives. The average urine half-life 
of the glucuronide is in close agreement with the average blood half-life of 
unconjugated trichloroethanol, but the agreement for each individual is not so 
evident. 
The kinetic behaviour of trichloroethanol-glucuronide in these experiments is 
difficult to understand, unless one assumes that during the first passage through 
the liver by far the greater part of this product is being formed. The initial rapid 
decline in blood concentration must be due to distribution into a deeper com-
partment and it is in agreement with similar findings in the dog (Garrett and 
Lambert, 1973). The reason why such a phase also appears after rectal ad-
ministration, remains unclear (Fig. 3). In one subject, receiving chloral hydrate 
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rectally, the glucuronide concentrations were so irregular that no half-life could 
be determined. 
Trichloroacetic acid 
Another effect of chloral hydrate administration is the rapid formation of 
trichloroacetic acid. After oral or rectal intake it seems likely that during first 
passage of chloral hydrate through the liver a certain part is oxidized by alde-
hyde dehydrogenase and possibly also by the mixed function oxygenase system. 
The slower increase in trichloroacetic acid blood concentration, up to 12 h, 
must be due to the oxidation of trichloroethanol. When the latter compound is 
administered, there is also a substantial formation of trichloroacetic acid, 
although its formation rate is slower than after choral hydrate intake (Fig. 4). 
The half-life of trichloroacetic acid is very long, a period of 100 h in subject 
A.H. was measured. Paykoç and Powell (1945) found 80 - 100 h after i.v. in-
fusion of the sodium salt to six human volunteers. This large value may be due 
to the high binding of the compound to human plasma proteins: 94 - 84% in 
the concentration range 30 - 100 mg/1 plasma respectively (Sellers and Koch-
Weser, 1971). 
During repetitive administration of chloral hydrate, trichloroacetic acid ac-
cumulated substantially as can be seen from Fig. 8. Concentrations up to 100 
mg/1 blood were measured after four daily dosages of 1275 mg. In a hospitalized 
bloodconcentration TCA (mg/1) 
eubjfct J.H. 
1 1 1 1 1 1 ι 1 1 1 1 
2 4 б β 10 12 
t t t t *>· 
1Z75 mg chloralhydrate, oral 
FIG. 8. Blood concentrations of trichloroacetic acid following four oral doses of 
chloral hydrate (1275 mg), administered with an interval of approximately 24 h. 
Note the accumulation of trichloroacetic acid in the blood and the strongly fluctua­
ting concentration. 
265 
80-
60-
40-
20-
patient, who received chloral hydrate repetitively for more than a fortnight, the 
trichloroacetic acid blood levels were determined each day at the same time; 
these varied from 48.0 to 83.3 mg/1. In spite of presumed steady state con-
ditions there was still a great fluctuation in trichloroacetic acid concentration. 
These findings are in agreement with those of Owens and Marshall (1955), 
but no satisfactory explanation for this phenomenon is available yet. 
Trichloroacetic acid has no hypnotic properties of its own (Marshall and 
Owens, 1954). The toxicity of this compound is not known. However, it is 
one of the strongest organic acids known and its use in vitro as a protein 
precipitant suggests that it may be harmful at certain concentrations. This 
becomes the more important when such a compound accumulates in relatively 
high concentrations in the body during chronic administration of the parent 
drug. It is possible that protein binding protects the organism against toxic 
effects. The substantial binding to plasma proteins on the other hand may 
cause displacement of other drugs from their binding sites at human albumin 
as has been shown for warfarin (Sellers and Koch-Weser, 1970; ib., 1971). 
Cucinell et al. (1966) attributed the decreased half-life of coumarins in subjects 
receiving chloral hydrate to an induction of drug metabolism. In this instance, 
however, displacement from albumin may also be involved. The net effect of 
such interaction cannot always be predicted, as a greater amount of free drug 
initially causes potentiation of activity, which is on the other hand counteracted 
by an increased rate of elimination. 
Although no literature data are available about unwanted effects of trichloro-
acetic acid, apart from interaction with other drugs at the protein binding sites, 
it must be emphasized that the formation of such a metabolite is highly undesi-
rable. 
The overall fate of chloral hydrate in the body 
In pharmacokinetic and metabolic studies of chloral hydrate previous at-
tention has been given to three metabolites; trichloroethanol, trichloroethanol-
glucuronide and trichloroacetic acid. After perusal of the total urinary ex-
cretion of these metabolites, it is apparent that only part of the administered 
dose can be accounted for (Table IV). Although only part of trichloroacetic 
acid excretion was measured, it seems unlikely that the rest was responsible 
for the remaining amount of the dose to be recovered. Owens and Marshall 
(1955) found that in some subjects excretion of trichloroethanol-glucuronide 
and of trichloroacetic acid could account for nearly the entire dose of chloral 
hydrate, while in other subjects this was only a small fraction. They also found 
that after continued daily administration of chloral hydrate the percentage 
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excreted as trichloroacetic acid in 24 h varied substantially, not only in dif-
ferent individuals but also in the same individual. This latter fact seems con-
sistent with the fluctuating blood levels of trichloroacetic acid which was men-
tioned earlier. From the data of Paykoç and Powell (1954) it can be concluded 
that at least 90% of the administered dose of trichloroacetate anion was ex-
creted unchanged in the urine. Garrett and Lambert (1973) showed that in 
the dog only trace amounts of the metabolites were excreted via faeces. Initially, 
about 5% of the glucuronide was secreted in the bile, but hydrolysis occurred 
and trichloroethanol was reabsorbed. No data on faecal excretion in humans 
are available. It seems likely that unknown pathways are involved in the elimi-
nation of chloral hydrate and of trichloroethanol. This could occur by other 
metabolic routes and also by excretion via the lungs or in the sweat. Further 
investigations are required in order to elucidate the overall fate of chloral 
hydrate in the body. 
CONCLUSIONS 
After oral and rectal administration of chloral hydrate the hypnotic activity 
must entirely be attributed to the active metabolite trichloroethanol. From the 
pharmacokinetic point of view chloral hydrate seems to be a suitable drug for 
hypnotic drug therapy, as the half-life of trichloroethanol is no longer than 10 h. 
It is difficult to state whether an oral dose of 15 mg/kg is sufficient to induce 
and maintain sleep. In these studies no definite effects of CNS-depression 
became apparent. Combining our data with clinical studies it might be con-
cluded that the minimum effective trichloroethanol blood concentration for 
adults is in the range of 4 - 7 mg/1. 
The formation of trichloroacetic acid, after chloral hydrate administration, 
is a matter of concern. More information is required about the possible harmful 
actions of this metabolite, especially during chronic use of chloral hydrate. 
Trichloroacetic acid is highly bound to plasma proteins and therefore, chloral 
hydrate should not be combined with drugs that also show substantial protein 
binding. 
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С. BIOPHARMACEUTICS 
Chloral hydrate is usually administered orally, but it causes irritation to 
mucous membranes. Therefore, it is generally recommended that the drug 
is greatly diluted wtih water or milk in order to avoid gastric irritation 
(Martindale, 1972). Chemical dérivâtes have been prepared which are claimed 
not to cause the unpleasant side-effects and which can be dispensed in tablet 
form. They release chloral hydrate or trichloroethanol in the stomach or small 
intestine, e.g. chloral betaine, dichloralphenazone and triclophos (Sharpless, 
1970; Sellers et al., 1973). 
Quite often, chloral hydrate is administered rectally in enemas or supposito-
ries. This is of special advantage with respect to children, as it avoids the 
irritation and bad taste of oral preparations. 
Few biopharmaceutical studies haven been performed concerning the ability 
of the different dosage forms in delivering the drug to the bloodstream. Such 
data are important for assessing the effectiveness of a certain preparation in 
the treatment of insomnia and convulsions. The rate of absorption and the 
bioavailability, both related to trichloroethanol blood concentrations, are im-
portant in this respect. In fact detailed information is available only for an 
aqueous solution after oral intake, from which the drug is rapidly absorbed 
(Marshall and Owens, 1954; Sellers et al., 1972). In our study on the phar-
macokinetics of chloral hydrate it was found that peak concentrations of 
trichloroethanol were reached 20 - 60 min after administration of the parent 
drug in aqueous solution (Table I, p. 255). 
In view of the fact that no in vivo data were available on the rectal absorption 
of chloral hydrate, it was decided, firstly to study some rectal dosage forms. 
In addition, it was considered pertinent to study two oral capsule preparations, 
which are supplied in the Netherlands under the trade names of CHLORAL-
DURAT-Red and CHLORALDURAT-Blue. 
1. RECTAL ADMINISTRATION 
INTRODUCTION 
Despite the widespread use of rectal application of chloral hydrate, no data 
on the effectiveness of rectal absorption have appeared until now. The purpose 
of this investigation was to study the absorption of chloral hydrate by the rectal 
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route and to establish the influence of vehicle composition. It has been discus­
sed already (refer to "pharmacokinetics and metabolism" of this chapter) that 
the initial rise of trichloroethanol concentration in blood is related to the ab­
sorption rate of chloral hydrate. Also, bioavailability calculations will be based 
on trichloroethanol blood concentrations. 
A review of the various dosage forms for rectal administration has been 
published by Cox (1971). For the present study four different pharmaceutical 
formulations, two types of suppositories and two types of enemas, were chosen: 
1. suppository with 1000 mg chloral hydrate dissolved in 2.20 g Estarine 
D; 
2. suppository with 1000 mg chloral hydrate dissolved in a mixture of 
2.08 g polyethylene glycol 1540 and 0.52 g polyethylene glycol 6000; 
3. rectiole with 1100 mg chloral hydrate dissolved in 2.16 g sesame oil; 
4. rectiole with 1100 mg chloral hydrate dissolved in 2.67 g polyethylene 
glycol 300. 
Details on the preparation of these dosage forms, as well as an outline of the 
reasons why these preparations were chosen, have been described elsewhere 
(Breimer, Cox and van Rossum, 1973).It should be mentioned here that the 
rectioles contained 100 mg of excess chloral hydrate, because it was estimated 
that this amount was left behind after administration. 
METHODS 
The dosage forms were prepared at the Dutch Pharmacist's Laboratory, The 
Hague, and they were used for the in vivo studies 2-6 weeks after preparation. 
The chloral hydrate content was determined according to a modified method 
described by Schoorl (1929). The sesame oil rectioles and the PEG-rectioles 
contained 100% and 101% respectively; the Estarine D suppositories and the 
PEG-suppositories contained 96% and 102% respectively. 
The subjects who participated in the study were healthy male volunteers, 
ranging in age from 20 - 25 years and in weight from 67 - 83 kg. They had not 
received regular medication during the 4 weeks preceding initiation of the 
experiments. The subjects had fasted overnight prior to the trial and for З 2 
hours after administration of the drug preparation. At 9 a.m. the chloral 
hydrate dosage form was introduced into the rectum and blood samples were 
taken from a forearm vein, usually at J4, у
г
, 1, l1/^ 2, 3, 5, 7, 9 and 12 hours 
after administration. Sometimes a sample had to be omitted due to organization 
problems. The blood was drawn into tubes containing a small drop of heparin 
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FIG. 9. Individual trichloroethanol blood concentration curves following rectal 
administration of 1000 mg chloral hydrate in two types of suppositories. 
solution as anticoagulant. Immediately after taking the blood 1.0 ml was in-
troduced into a 25.0 ml glass vial, containing 1 ml of lead acetate solution and 
the free trichloroethanol blood concentration was determined as described in 
Chapter 9, Section II. 
Early removal of the rectum contents by defaecation was never experienced. 
For those subjects who participated twice in the investigation, there was at 
least an interim of 7 days between the two consecutive experiments. 
RESULTS 
The individual curves obtained are shown in Fig. 9 (suppositories) and Fig. 10 
(rectioles). Unfortunately, two subjects in the study with the rectioles and one 
with the suppositories were not able to participate more than once in the study. 
In Fig. 11 the curves per individual, who received two different dosage forms, 
are given. There is a significant variation in absorption rates and blood levels 
between the individuals per dosage form. Between lipophilic bases and PEG 
bases there are great differences in concentration values. A rapid initial rise in 
trichloroethanol occurred in all subjects receiving a suppository. Absorption was 
fast and peak concentrations were reached between 1/2 a n d 2 hours after ad-
270 
time (h ) 
FIG. 10. Individual trichloroethanol blood concentration curves following rectal 
administration of 1000 mg chloral hydrate in two types of rectioles. 
ministration. If absorption is regular and takes place according to a first-order 
process, as is often the case, the half-life of absorption (ti/fa) is characteristic 
for the absorption rate or rate of availability. The dose, the ti/ia and ti/iel deter­
mine the 1
ш а х
 and CII iax, which can be calculated. 
However, a careful analysis of the concentrations in the first few hours 
reveals that in most cases the absorption process cannot be described accurately 
by a first-order kinetic process, and therefore it seems ill-advised to calculate 
these parameters. Consequently one can obtain only an overall impression of 
the time necessary to reach the maximum concentration. It seems that both 
suppository bases are able to deliver the drug with approximately the same rate 
to the blood stream. With the PEG-rectioles absorption also appears to be rapid 
in two subjects, while in the other cases absorption is slower and takes place 
over a longer period of time. The slow absorption from the sesame oil rectiole 
is striking. 
Bioavailability refers to the fraction of the dose of a drug administered that 
reaches the general circulation intact. In the case of chloral hydrate the amount 
becoming available is related to trichloroethanol, as this is the compound 
measured in vivo. The following may be derived: 
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FIG. 11. Comparison of individual trichloroethanol blood concentration curves 
following rectal administration of 1000 mg chloral hydrate in different vehicles to 
the same subjects. 
F x D = k
c l J c p d t = kcl.AUC 
0 
in which: 
F = bioavailability (0 < F < 1), 
D = dose administered, 
C p = blood or plasma concentration, 
k
cl = total body clearance constant, 
AUC = area under the plasma concentration-time curve 
from t = о to t = oo. 
The k
el of trichloroethanol can be determined only after intravenous ad­
ministration and therefore the absolute bioavailability cannot be determined if 
only rectal data are available. Moreover, the dose in this case is related to 
chloral hydrate and not to trichloroethanol, so that the fraction of the dose 
that is converted to trichloroethanol also remains uncertain. 
However, it is a reasonable assumption that in the same individual this 
fraction is constant and also that к., for trichloroethanol remains constant. 
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TABLE VI. Relative bioavailability of chloral hydrate from rectioles and supposito­
ries in the same individual after rectal administration. 
Subject 
P.W. 
G.E. 
H.H. 
K.S. 
W.B. 
»& "SS· 
(kg) 
75 
82 
75 
67 
83 
supp. PEG 
supp. Est D 
supp. PEG 
supp. Est. D 
supp. PEG 
supp. Est. D 
rect. PEG 
rect. SO 
rect. PEG 
rect. SO 
Dose* 
(mg) 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
Dose/kg 
(mg) 
13.3 
13.3 
12.2 
12.2 
13.3 
13.3 
14.9 
14.9 
12.0 
12.0 
; AUG 0-12 h 
(mg.h/I) 
36.5 
22.2 
51.8 
20.1 
41.0 
32.5 
45.4 
27.2 
33.4 
19.6 
cone. Total AUG 
12h O-oo 
(mg/1) (mg.h/1) 
2.3 
1.3 
2.9 
1.2 
2.6 
2.3 
3.4 
1.4 
2.4 (9 h) 
1.6 (9 h) 
69.8 
40.9 
93.6 
37.1 
78.4 
65.7 
94.4 
47.8 
68.0 
42.8 
F
r
e. 
(%) 
100 
59 
100 
40 
100 
84 
100 
51 
100 
63 
*) These values have not been corrected for the assayed chloral hydrate content of 
the dosage forms, since the deviations did not exceed ± 5 % . 
Then the relative bioavailability of chloral hydrate from a certain dosage form 
(I) can be determined by comparison to a reference dosage form (II) in the 
same subject. The following now applies: 
AUC, 
frei = — 
AUC I r 
If the AUC is not determined to t = σο, then it must be corrected to include 
the undetermined AUC. This is quite possible assuming that at the last data 
point, at time t = t', absorption has been completed, using Dost's law of 
corresponding areas (Dost, 1968). The infinite area is given by: 
oo t' oo t' 
J Cp dt = J Cp dt + \ Cp dt = AUC/+ СУ'. т., 
o o i ' о 
in which т
е
і is the overall elimination time constant and С
р
' ', the last blood con­
centration measured for the determination of AUC from t = 0 to t = t '. 
The AUC's in the experiments of this investigation were determined by 
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FIG. 12. Average trichloroethanol blood concentration curves after rectal admini­
stration of the four dosage forms, each containing 1000 mg of chloral hydrate. 
weighing the corresponding areas under the blood concentration-time curves 
up to 12 hours after administration. The remaining area was calculated by 
multiplying the concentrations at 12 hours by the overall elimination time con­
stant r
el. Because of irregularities in absorption it was not possible to determine 
an exact т
е
і (т
с1 = 1.44 χ іЧг) in each subject and it was decided to take one 
value for all individuals: ti/t = 10 hours-*- те1 = 14.4 hours. Results per in­
dividual will hardly be influenced by this assumption. 
In Table VI the results are given for the five subjects to whom two dosage 
forms were administered. In all cases the PEG vehicles resulted in a higher 
bioavailability and they were considered as the reference dosage form. These 
data show clearly a lower bioavailability per individual of the suppositories 
with Estarinc D and the rectioles with sesame oil. 
In Fig. 12 the mean plasma concentration curves for all four dosage forms 
are given and their bioavailability is calculated relative to the PEG suppository 
(Table VII). Although the number of subjects is limited, it can be seen that 
the suppositories and rectioles with PEG are both quite efficient, whereas the 
Estarine D and sesame oil arc both unsatisfactory. These data confirm the 
results in the individual subjects. So the oily vehicle for the rectal administration 
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TABLE VII. Relative bioavailability of chloral hydrate from rectioles and supposi-
tories after rectal administration (mean values). 
No. 
4 
3 
4 
2 
subjects Dosage form 
supp. PEG 
supp. Est. D 
rect. PEG 
rect. SO 
Dose 
(mg) 
1000 
1000 
1000 
1000 
Dose/kg 
(mg) 
13.7 
12.9 
14.3 
13.5 
A U C 0 - 1 2 h 
(mg.h/1) 
44.4 
27.1 
38.6 
23.7 
cone. Total AUC 
12 h O-oo 
(mg/1) (mg.h/1) 
2.6 
1.6 
2.3 
1.8 (9 h) 
82.1 
50.1 
69.3 
49.3 
Fre. 
(%) 
100 
61 
84 
60 
of chloral hydrate seems to be an inferior delivery system compared to the 
hydrophilic PEG system. 
DISCUSSION 
The design and purpose of the study were, for practical reasons, very simple: 
comparison of the same dosage form, but with two different vehicles, in the 
same subject after rectal administration. This allows relative bioavailability 
measurement per individual under the assumptions mentioned. Unfortunately 
some of the volunteers were not able to participate in the study for a second 
time, so that only part of the design of the experiments could be realized. 
Nevertheless the results are sufficiently important to be reported, although the 
conclusions drawn must be considered against the background of a limited 
number of observations. 
Some individual curves are given in Fig. 11. Representation of the results 
in this way immediately gives an impression of the differences between dosage 
forms. It is also important to show all the individual curves as this gives insight 
into the variability between different individuals. The differences are quite great 
as can be seen from Fig. 9 and Fig. 10. Often in the literature only mean data 
are reported and these are then treated mathematically. The results of such a 
manipulation are given in Fig. 12 and it may be noted that smoother curves 
are obtained in this way. Irregularities in absorption are not reflected in these 
mean curves, whereas they are obvious from the individual ones. Information 
is lost therefore by giving only mean values. 
The results indicate a poor bioavailability of chloral hydrate from the lipo-
philic vehicles sesame oil and Estarine D, compared to the hydrophilic PEG. 
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The reason for these differences is not clear. In the rectioles, and probably 
also in the suppositories, chloral hydrate is dissolved in the vehicle. Con-
sequently, the differences cannot be due to particle size. Chemical incom-
patibilities with chloral hydrate are reported for many substances including 
sesame oil, Carbowax (a PEG brand) (Fairbrother, 1973) and the suppository 
bases Witepsol and Imhausen (Petricic and Jalsenjak, 1971) which are chemi-
cally related to Estarine D. It seems likely that "chemical incompatibility" in-
fluences the extent of chloral hydrate release from the different bases to varying 
degrees, probably depending on the nature of interaction between chloral hydrate 
and the base. The in vitro disintegration results (Breimer, Cox and van Rossum, 
1973) of the suppositories do not give any further explanation. On the contrary, 
as far as disintegration is concerned the in vitro results do suggest a better ab-
sorption from the lipophilic base. 
Another important factor is the rate at which the active compound becomes 
available in the general circulation. This seems to be relatively high for PEG 
suppositories and much slower for sesame oil rectioles. The absorption rate of 
chloral hydrate from PEG suppositories is lower than after oral administration 
of an aqueous solution, but higher than from CHLORALDURAT-Red capsules 
(Fig. 13, p. 279). 
Central nervous system (CNS) depressant effects after administration of 
chloral hydrate in these dosage forms are difficult to assess objectively as the 
subjects received the drug in the morning, just after waking up. Generally no 
definite feelings of CNS depression became apparent. However, two subjects 
(W.B., Fig. 10 and G.E., Fig. 9) did report feelings of drowsiness at the time 
of trichloroethanol peak concentration (8.5 and 7.5 mg/1 respectively). 
There were no complaints about irritation of the rectum after administration 
of these dosage forms and as already mentioned in no instance was the de-
faecation reflex initiated. For one subject, who was suffering from haemorr-
hoids, the Estarine D suppository was irritating while the PEG suppository was 
not. 
Of the dosage forms used in this study, the rectioles and the PEG supposito-
ries are the easiest to prepare. A disadvantage of the rectioles is that the quan-
tity administered is probably less exact. From the stability point of view, sesame 
oil rectioles and PEG suppositories are preferable (Cox, 1973). 
CONCLUSIONS 
The PEG suppository must be regarded as the best rectal chloral hydrate 
delivery system of the dosage forms investigated. Its high bioavailability and 
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rapid absorption make it suitable for the treatment of insomnia and possibly 
also in the treatment of convulsions. When using this dosage form in children, 
the dose has to be reduced according to the age of the child. 
2. ORAL ADMINISTRATION 
INTRODUCTION 
Oral administration of chloral hydrate in an aqueous solution or in an elixir 
must be considered as an effective method of treating insomnia. Peak concen-
trations of trichloroethanol are generally reached within one hour, which makes 
it highly probable that at an earlier time the minimum effective concentration 
is exceeded, provided that an appropriate dose has been given. 
As already mentioned, in the Netherlands chloral hydrate is also supplied in 
gelatine capsules of 250 mg under the trade name CHLORALDURAT. There 
are two types available: CHLORALDURAT-Red, which is claimed to be 
suitable for the induction of sleep (dose recommended 2 - 4 capsules) and 
CHLORALDURAT-Blue which is claimed to be suitable in the treatment of 
early morning awakening (dose recommended 2 - 3 capsules). From the latter 
capsules the release of chloral hydrate is supposed to take place about 4 hours 
after intake (Pohl-Boskamp, information sheet on Chloraldurat). However, 
no blood levels have been measured to substantiate these claims and even in 
vitro data are lacking in the literature. Because of the general lack of infor-
mation about these dosage forms, it was decided to perform a biopharmaceutical 
study on these preparations, in vivo and in vitro. The in vitro dissolution studies 
have been carried out in the Dutch Pharmacist's Laboratory, The Hague and 
details will be reported elsewhere. 
METHODS 
The CHLORALDURAT dosage forms were commercially obtained. The 
chloral hydrate content was determined at the laboratory of the hospital phar-
macy, St. Radboudziekenhuis, Nijmegen, according to a modified method by 
Schoort (1929). CHLORALDURAT-Red contained 250 mg (100%) of chloral 
hydrate and CHLORALDURAT-Blue 240 mg (96%). Healthy male volunteers, 
ranging in age from 20 - 25 years and in weight from 55 - 80 kg, participated 
in the study. They had not received regular medication during the 4 weeks 
preceding initiation of the study. The subjects had fasted overnight and those 
277 
receiving the CHLORALDURAT-Red capsules were not allowed to take food 
or fluid for 3.5 h after administration. A 5.5 h period was applied similarly for 
CHLORALDURAT-Bluc. At 9 a.m. 4 capsules of chloral hydrate, 250 mg 
each, were administered orally together with 150 ml water. The subjects were 
asked to remain in an upright position for about 15 min and then to lie down 
for 3.5 h (Red-capsules) or 5.5 h (Blue-capsules) periods. This procedure was 
undertaken in order to simulate as closely as possible the situation of taking 
a hypnotic drug and going to bed. Blood samples were taken from a forearm 
vein, usually at the following times when CHLORALDURAT-Red was given: 
%, y2, 1, 11/2, 2, 2У2, 3, 4, 5, 7, 9 and sometimes at 12 h; when CHLORAL-
DURAT-Blue was given at times of 1, 2, 3, 4, 41/2, 5, 6, 7, 9 and 12 h 
approximately. The blood was drawn in tubes containing a small drop of heparin 
solution as anticoagulant. Immediately after collection of the blood 1.0 ml was 
introduced into a 25.0 ml glass vial, containing 1 ml of lead acetate solution, 
and the free trichloroethanol blood concentration was determined as described 
in Chapter 9, Section II. 
RESULTS 
The individual blood level curves obtained are shown in Fig. 13 (CHORAL-
DURAT-Red) and in Fig. 14 (CHORALDURAT-Blue). A careful analysis of 
the concentrations in the first few hours reveals that in most cases the absorption 
behaviour cannot be described accurately by a first-order kinetic process. An 
overall impression about the absorption rate can be obtained by looking at the 
time required to reach the maximum blood concentration (Table VIII and IX). 
In three individuals relatively high blood concentrations were achieved after 
intake of the Red-capsules, but the peak concentrations were reached only after 
2-4 h. In two subjects receiving this dosage form absorption, apparently, 
occurred slower or to a lesser extent. With the Blue-capsules the trichloroethanol 
blood concentration slowly increased up to 3-5 hours. After that, in three 
subjects the blood concentration quite suddenly increased. The peak concen­
trations ultimately reached were lower than with the Red-capsules and the peak 
times varied widely. In two subjects no such a change in the blood concentration 
profile was observed and the trichloroethanol concentrations remained very low 
at all times up to 12 h. 
In Fig. 15 the mean curves for the two preparations are given and these 
permit a general view on their blood level profile. However, it should be 
realized that they are composed of strongly varying individual curves, which 
should be considered as more valid for the practical situation. 
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concentration ТСС ( m g / I blood ) 
C H L O R A L D U R A T Red 
oral U capa І 2 5 0 mg-
i 1 1 Γ 
10 12 
FIG. 13. Individual trichloroethanol blood concentration curves following oral ad­
ministration of four CHLORALDURAT-Red capsules (1000 mg chloral hydrate). 
concerbahon T C E ( m g / l blood 
CHLORALDURAT Blue 
oral, Ucape à 250mg· 
FIG. 14. Individual trichloroethanol blood concentration curves following oral ad-
ministration of four CHLORALDURAT-Blue capsules (1000 mg chloral hydrate). 
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TABLE VIII. CHLORALDURAT-Red absorption characteristics after oral admini­
stration. 
Subject 
P.A. 
H.S. 
M.B. 
E.H. 
F.T. 
Body-
weight 
(kg) 
64 
58 
59 
55 
80 
Dose 
(mg) 
1000 
1000 
1000 
1000 
1000 
Dose/kg 
(mg) 
15.6 
17.2 
17.1 
18.2 
12.5 
tmax4 
(h) 
2.0 
4.0 
7.0 
3.0 
2.5 
Γ
 2) 
(mg/l) 
8.4 
9.9 
4.1 
8.0 
3.5 
AUC 0 - 9 h 
(mg.h/1) 
40.1 
63.2 
30.1 
51.2 
23.4 
cone. 
9 h 
(mg/l) 
2.2 
3.8 
3.2 
3.6 
1.8 
mean 63 1000 16.1 3.7 6.8 41.6 2.9 
mean A U C 0 - oo : 41.6 + (2.9 χ 14.4) = 83.4 mg.h/1 
^ Time after which the maximum trichloroethanol blood concentration was reached. 
2) The maximum trichloroethanol blood concentration. 
TABLE IX. CHLORALDURAT-Blue absorption characteristics after oral admini­
stration. 
Subject 
G.V. 
A.T. 
F.T. 
A.A. 
H.S. 
Body-
weight 
(kg) 
71 
65 
78 
80 
58 
Dose 
(mg) 
1000 
1000 
1000 
1000 
1000 
Dose/kg 
(mg) 
14.1 
15.4 
12.8 
12.5 
17.2 
max ^ m a x 
(h) (mg/l) 
no real max. 
3.75 5.0 
no real max. 
8.75 6.3 
5.25 β.Ο 
AUC 0 - 1 2 h 
(mg.h/1) 
16.8 
33.4 
19.2 
34.3 
40.5 
cone. 
12 h 
(mg/l) 
1.6 
2.2 
1.4 
2.9 
1.8 
mean 70 1000 14.4 5.55 5.5 
mean AUC 0 - oo : 28.9 + (2.0 χ 14.4) = 57.7 mg.h/1 
28.9 
relative bioavailability Blue/Red: 
57.7 
83.4 
χ 100% = 69% 
2.0 
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FIG. 15. Average trichloroethanol blood concentration curves after oral admini-
stration of CHLORALDURAT-Red and CHLORALDURAT-Blue to five subjects. 
The AUC's from t = 0 to t = °o in these experiments were determined in 
the same way as described for rectal administration. If it is assumed that in the 
two groups of volunteers the average amount of chloral hydrate converted to 
trichloroethanol has been the same and also that the mean clearance for 
trichloroethanol was the same, then the mean AUC's will give reliable in-
formation about the relative bioavailability of chloral hydrate from the two 
preparations. It was calculated that this is 69% for CHLORALDURAT-Blue, 
relative to CHLORALDURAT-Red (Table IX). In the two individuals who 
received both dosage forms, these values were 56% (H.S.) and 82% (F.T.). 
DISCUSSION 
The purpose of this study was to obtain information about the rate of ab-
sorption of chloral hydrate from the two CHLORALDURAT dosage forms. 
This parameter is important in relation to the use of these preparations; sleep 
induction (Red) and sleep continuation (Blue). No special attempt therefore 
was made to study both preparations in the same individuals. It was hoped 
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that sufficient information would be obtained from different subjects. The mean 
AUC values would provide an indication of relative bioavailability. 
It is evident that rapid absorption of a hypnotic drug from its dosage form is 
required if it is intended to be used in patients who drop off too late. It could 
be claimed, in this respect, that the time necessary to reach a minimal effective 
blood concentration, should not exceed 30 min. After studying the initial rise 
in trichloroethanol blood concentration, when CHLORALDURAT-Red is 
given, it can be observed that an effective concentration is not reached in any 
of the subjects, even within a period of one hour. Despite the relatively high 
concentrations which are reached ultimately in the three subjects receiving this 
dosage form, it is concluded that CHLORALDURAT-Red is not a suitable 
preparation for the rapid induction of sleep. Consequently, if chloral hydrate 
is required for this purpose, an aqueous solution of this drug should be used. 
The reason why, in two of the subjects, the blood levels were much lower than 
in the other three, remains unclear. It is possible that release of the drug from 
the capsules was not complete in these subjects. It is possible also, that fasting 
regulations were not obeyd, so that food is another interfering factor. 
With respect to CHLORALDURAT-Blue it is clear that some chloral hydrate 
is released at an early time. The release sharply increases after 3 - 5 h in some 
subjects, since the concentration of trichloroethanol in blood rapidly rises 
during this time. The concentrations ultimately reached are lower than with 
CHLORALDURAT-Red and it remains uncertain whether these are sufficient 
to maintain sleep. This is even more doubtful when the recommended doses of 
250 - 750 mg are given. There is also a possibility, with these capsules, that 
the peak concentration time is attained long after a period of 4 h. In subject 
A.A. this occurred 9 h after administration, which is a period when the subject 
had to begin daily work. Drowsiness and hang-over effects are to be expected. 
In two other subjects no sharp increase in trichloroethanol blood concentration 
occurred. The reason for this could again be an incomplete disintegration or 
release from the capsules or the influence of food. It is striking that in subject 
F.T., who received both dosage forms, absorption was incomplete on both 
occasions (Fig. 16). After enquiries, when the results were available, this 
subject denied having consumed food before the experiments. It might be that 
some physiological cause is underlying this observation. In conclusion, 
CHLORALDURAT-Blue is not a very reliable dosage form with respect to the 
treatment of early morning awakening. However, CHLORALDURAT-Red, 
although not meant for this purpose, could be used instead. Results show that 
blood concentrations between 4 and 6 h after administration of Red-capsules 
are at least as high as the Blue peak concentrations. Besides, there is less risk 
of residual effects with Red-capsules the following morning. 
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FIG. 16. Comparison of individual trichloroethanol blood concentration curves 
following oral administration of CHLORALDURAT-Red and CHLORALDURAT-
Blue to the same subjects. 
The lower bioavailability of CHLORALDURAT-Blue indicates that a 
smaller fraction of chloral hydrate is released from these capsules in the 
gastrointestinal tract. The in vitro results revealed that the Blue-capsules did not 
disintegrate completely in artificial gastric or intestinal juice. This in contrast 
to CHLORALDURAT-Red which disintegrated quite rapidly at pH 7.5. 
A further interesting observation has been that the mean AUC of the chloral 
hydrate aqueous solution is lower than of the Red-capsules: 63.2 mg.h/1 (cor-
rected for an average dose of 1000 mg). This implies a relative bioavailability 
of 76% when compared with the Red-capsules. Further experiments are needed 
to clarify this observation. 
Finally it should be mentioned that none of the subjects complained about 
gastric irritation after intake of the capsules. Central nervous system depression 
was only experienced by subject H.S., who also showed the highest trichloro-
ethanol blood concentrations. 
CONCLUSIONS 
CHLORALDURAT-Red is not a suitable preparation for the rapid induction 
of sleep, as absorption is too slow. It might however be used in the treatment 
of early morning awakening, since trichloroethanol blood concentrations are 
relatively high 4 h after drug intake. 
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CHLORALDURAT-Blue cannot be regarded as a reliable preparation for 
the maintenance of sleep, as the blood concentration profile is liable to con-
siderable variation. 
For a rapid induction of sleep with chloral hydrate the most reliable prepara-
tion is an aqueous solution when orally administered. The second choice is the 
chloral hydrate PEG-suppository for rectal administration. 
SUMMARY 
Pharmacokinetics and metabolism 
The pharmacokinetics of chloral hydrate and its metabolites were studied in man 
after oral and rectal administration. Healthy volunteers received oral doses of 
chloral hydrate (15 mg/kg), dissolved in 150 ml water, or 1000 mg rectally in a 
rectiole. The subjects, participating in the oral experiments collected their urine for 
a period of about 50 h. Blood and urine concentrations of trichloroethanol, trichloro-
ethanol-glucuronide and trichloroacetic acid were determined at regular intervals. 
Unchanged chloral hydrate did not reach the blood circulation in measurable 
amounts. The CNS depressant effects, after oral or rectal chloral hydrate admini-
stration, are entirely attributed to trichloroethanol. Peak levels of trichloroethanol 
as well as trichloroethanol-glucuronide were reached 20 - 60 min after oral drug 
administration. The average blood half-lives of trichloroethanol and the glucuronide 
were 8.0 h and 6.7 h respectively. The half-lives of these compounds when deduced 
from the renal excretion deficit curves were slightly longer. After rectal admini-
stration absorption was slower, but the half-lives of the two metabolites were in the 
same range as after oral administration. A third important metabolite of chloral 
hydrate is trichloroacetic acid. An additional experiment revealed that trichloro-
ethanol administration resulted also in a substantial formation of trichloroacetic 
acid. The half-life of this metabolite was about 4 days in man and during repetitive 
chloral hydrate administration considerable accumulation (up to 100 mg/1 blood) 
was observed. Due to its high protein binding, interaction with other drugs should 
be considered. 
Unchanged chloral hydrate could not be detected in the urine and only small 
amounts of free trichloroethanol were excreted (2.6 - 7.7 mg). The glucuronide 
excretion amounted to 11 - 24% of the administered dose of chloral hydrate, whereas 
NOTE: 
*) Recently a paper by Ertle et al. (1972) on the metabolism of trichloroethylene in 
man, came to our attention. Trichloroethanol is an important metabolite of this 
industrial solvent and for comparative reasons these authors included an oral 
experiment with chloral hydrate (15 mg/kg) administered to two human volun-
teers. They measured trichloroethanol blood concentrations until 51 h after intake 
and found a half-life for the slowest phase of about 12 h. 
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9 - 57 mg trichloroacetic acid were excreted within two days. There may be additional 
pathways for the elimination of chloral hydrate and trichloroethanol. 
It has been concluded that chloral hydrate may be a suitable drug for the treatment 
of insomnia, although the formation of trichloroacetic acid remains a matter of 
concern. The properties of this metabolite should be subject of further research. 
Biopharmaceuiics 
1. Rectal administration 
The relative bioavailability of chloral hydrate was investigated in man after rectal 
administration of different dosage forms. The following preparations were used: 
a rectiole with 1100 mg chloral hydrate dissolved in sesame oil, a rectiole with 1100 
mg chloral hydrate dissolved in PEG 300, a suppository with 1000 mg chloral 
hydrate in a base of PEG 1540/6000 (4: 1). These dosage forms were administered 
to healthy volunteers and blood concentrations of trichloroethanol were determined 
at regular intervals. Relative bioavailability was calculated by measuring the area 
under the blood concentration-time curve from t = 0 to t = oo (AUC) and com-
paring it to the AUC obtained with the PEG suppository (100%). The mean value 
found for the suppository with Estarine D was 61%, for the PEG rectiole 84% 
and for the sesame oil rectiole 60%. Consequently, the lipophilic bases were found 
to be less effective chloral hydrate delivery systems when compared with the PEG 
bases. Absorption from the suppository bases was quite rapid and peak levels were 
attained after Vi - 2 hours. 
It is concluded that in general practice the PEG suppository is the preferable 
dosage form for rectal administration of chloral hydrate. 
2. Oral administration 
The preparations of CHLORALDURAT-Red and -Blue were investigated. Four 
capsules (1000 mg chloral hydrate) were administered to healthy volunteers and 
blood concentrations of trichloroethanol were determined at regular intervals. Peak 
concentrations after administration of the Red-capsules were reached after 2 - 4 h 
and it has been concluded that the absorption from these capsules was too slow, 
in order to be effective in the treatment of difficulties getting to sleep. CHLORAL-
DURAT-Blue, which is supposed to deliver its active ingredient about 4 h after 
administration, showed a varying blood level profile with peak concentrations occur-
ring between 3 and 9 h. Bioavailability of the Blue-capsules was estimated to be 
69% relative to the Red-capsules. It has been concluded that CHLORALDURAT-
Blue is not a reliable preparation to be used in hypnotic drug therapy. CHLORAL-
DURAT-Red may be used for sleep maintenance. 
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P H A R M A C O K I N E T I C S A N D L I V E R D I S E A S E * 
In co-operation with Dr. W. Zilly and Dr. E. Richter, Medizinische Universitäts-
klinik, Würzburg, GFR. 
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CHAPTER 1 
PHARMACOKINETICS OF HEXOBARBITAL IN PATIENTS 
WITH LIVER DISEASE 
INTRODUCTION 
In the biotranstormation of drugs the liver plays the major role. Until recently 
it was considered that drug metabolism was impaired in patients with liver 
disease, which resulted in an increased sensitivity of these patients towards 
drags which are primarily inactivated by metabolism (Sherlock, 1963; Bush, 
1963). However, the evidence for this supposition is rather conflicting (Brodie 
et al., 1959; Sherlock, 1968). Patients with chronic liver disease have failed 
to exhibit delayed biodégradation of such drugs as dicumarol, salicylates and 
antipyrine (Brodie et al., 1959). Only some of the patients with impaired liver 
function displayed a slower disappearance for phénobarbital and Phenytoine 
(Kutt et al., 1964), phenylbutazone (Levi et al., 1968) and pentobarbital (Held 
et al., 1970). A longer half-life was found in most patients with chronic liver 
disease for meprobamate (Held and von Oldershausen, 1969), chloramphenicol 
(Azzollini et al., 1972), rifampicin and isoniazid (Acocella et al., 1972), amo-
barbital (Mawer et al., 1972) and lidocaine (Thomson et al., 1973). Alter-
natively, Held et al. (1973) found that tolbutamide was eliminated more quickly 
in patients with acute hepatitis than in healthy persons. Furthermore, liver 
disease may also affect the plasma levels of compounds which are not primarily 
eliminated by metabolism in the liver, e.g. digoxin (Zilly et al., 1973c). 
It seems evident from the literature data above cited that it is impossible to pre-
dict at present whether the elimination of a certain compound will be changed in a 
patient with liver disease. No correlations have been found between the com-
mon liver function tests (BSP retention, galactose elimination capacity, etc.) 
and drug metabolizing capacity of the liver. The liver content of cytochrome 
P-450, which is one of the most important drug metabolizing enzymes, may be 
determined after biopsy (Schoene et al., 1972). However, this is meaningful 
only as a measure of biotransformation capacity if the total liver volume is 
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known. At present it seems impossible to perform the determination of cyto-
chrome P-450 and liver volume with acceptable accuracy. A complicating 
factor is that the enzyme may not be homogeneously distributed throughout the 
liver (Richter, 1974). Therefore, the estimation of the biological half-life of 
drugs which are completely metabolized in the human liver, has been applied in 
order to obtain information concerning an enhanced or decreased drug meta-
bolism (Gillette, 1971). Hexobarbital has been used for such purposes in 
animal experiments, since the change in sleeping time may be related to the 
change of oxidative enzyme activity (Remmer, 1966). For a similar reason 
Richter et al. (1972) studied hexobarbital in patients with acute hepatitis and 
in healthy controls by measuring hexobarbital tolerance during i.v. infusion. 
Significantly less hexobarbital was required for the loss of counting ability in 
the patients when compared with the healthy subjects. On the basis of this 
finding, which at first instance would indicate an impaired hexobarbital meta-
bolism in patients with impaired liver function, the present investigations on the 
pharmacokinetics of hexobarbital were initiated. In this Chapter pharmaco-
kinetic data are presented for 38 patients with liver disease. These data should 
be compared to those obtained from healthy volunteers (Chapter 1, Section 
III). An attempt to correlate the results of hexobarbital pharmacokinetics with 
clinical and biochemical findings and common liver function tests will form 
the subject of further research. Ultimately, the utility and the predictive value 
of a hexobarbital test, for quantitative drug metabolism, may be evaluated. 
METHODS 
Hexobarbital sodium (EVIPAN) for i.v. injection was obtained from 
BAYER AG, Leverkusen, GFR. Solutions were prepared immediately before 
use by dissolving the sterile contents of an ampoule in sterile water. 
All patients with liver disease, who participated in the present investigation, 
were hospitalized in the Medizinische Universitätsklinik at Wiirzburg, GFR 
(physicians in charge: Dr. W. Zilly and Dr. E. Richter). The patients gave their 
written consent to the experiments. Provisionally, they have been divided into 
two main subgroups: hepatitis and cirrhosis. Patients with hepatitis were diag-
nosed by histological examination after biopsy; cirrhotic patients by peritoneo-
scopy. Laboratory data, which were determined just prior to the experiments, 
and pathological findings are given in Table I and II. Prior to the experiments 
the patients had fasted overnight and they were resting in a supine position 
during the experiments. Hexobarbital sodium was intravenously administered 
by zero-order infusion. The infusion time and the administered dose are given 
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for each individual in Table I and II. Normally, infusion lasted 60 min, when 
8 mg/kg of the sodium salt (equivalent to 7.32 mg/kg of the free acid) was 
administered. In some instances the drug was infused at a constant rate of 0.5 
(mg/kg)/min until the loss of counting ability occurred. Blood samples (5 ml) 
were taken every 4 min during infusion, when the infusion time was shorter 
than 60 min. During a 60 min infusion, samples were taken at 10, 20, 30, 40, 
50 and 60 min. After the termination of infusion, samples were taken at 10, 
20, 30 min and 1, 2, 4, 6, 8, 10, 12, 18 and 24 h. The blood was centrifuged 
and the plasma was separated and frozen prior to assay. The hexobarbital 
plasma concentrations were determined by gas chromatography with nitrogen 
selective detection. Few times a purification step was necessary, which involved 
column chromatography, when the samples contained a high bilirubin content 
(Breimer and van Rossum, 1974; Chapter 2, Section II). A 48-hour urine 
specimen was collected from some patients. Unchanged hexobarbital and 
3-keto-hexobarbital were assayed as described in Chapter 2 and 3, respectively, 
Section II. 
RESULTS 
The hexobarbital plasma concentration curves after termination of the in­
fusion were bi-exponential, with an initial rapid decline followed by a slower 
decay (Fig. 1 and 2). This kinetic behaviour is consistent with the two-compart­
ment open model, which was also valid for hexobarbital kinetics in healthy 
subjects (Chapter 1, Section III). It suggests that hexobarbital distributes almost 
spontaneously into an initial dilution space (central compartment) consisting of 
blood and some well-perfused tissues, from which further distribution and 
elimination occur. The initial rapid decline of the plasma concentration is 
mainly due to distribution of the drug into less well-perfused tissues (peripheral 
compartment), whereas the subsequent more gradual slope is a reflection of 
the elimination of the drug by metabolism. The post-infusion plasma concen­
trations (C„; mg/1) were fitted by the FARMFIT nonlinear regression analysis 
program (Chapter 1, Section I) according to the following equation (Chapter 1, 
Section III; Loo and Riegelman, 1970): 
Cp = ^ . - 4 1 — e-
T/ r i)e CT-t)/^
 + ^ ^{\—^ІЧ)й (T-t)/r2 ( E q ^ 
where Aj and A2 are the coefficients (mg/1), Τ the infusion time (min) and τ1 
and Tg the time constants (min) of the rapid and the slower phase respectively. 
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FIG. 1. Hexobarbital plasma concentration curve on semi-logarithmic scale during 
and after a 60 min zero-order i.v. infusion into a hepatitis patient (patient P.W., 
no. 3). The post-infusion concentrations were fitted according to Eq. 1. The 
curve during infusion was calculated on basis of the parameters of the post-
infusion curve; the concentrations during infusion (triangles) have not been used in 
the fitting procedure. The reproduction was obtained from a direct computer plot. 
See Table I for the parameter values. 
The initial graphical estimates of τ1 and τ2 were used as start guess for the 
fitting procedure. A relative error of 5% in the plasma concentrations was 
taken into account, since this was the standard deviation that was determined 
in the assay procedure (Chapter 2, Section II). Examples of fitted and 
directly plotted curves are given in Fig. 1 and 2. The most relevant parameters, 
intrinsic to the two-compartment open model, were calculated and these are 
given in Table I. Results for each patient are reported, since it was considered 
important to show the degree of variability in the patient population together 
with their clinical and biochemical data. The pharmacokinetic parameters of 
hexobarbital may be compared to those obtained for the healthy volunteers 
(Chapter 1, Section III). It may be argued that a comparison with a control 
group consisting of students between 20 and 25 years of age may not be valid, 
since the patient group is much more heterogeneous. Therefore additional 
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FIG. 2. Hexobarbital plasma concentration curve on semi-logarithmic scale during 
and after a 33.25 min zeroorder i.v. infusion into a cirrhotic patient (patient K.A., no. 
28). The post-infusion concentrations were fitted according to Eq. 1. The curve 
during infusion was calculated on basis of the parameters of the post-infusion 
curve; the concentrations during infusion (triangles) have not been used in the 
fitting procedure. The reproduction was obtained from a direct computer plot. 
See Table II for the parameter values. 
TABLE III. Mean pharmacokinetic parameters of hexobarbital after i.v. infusion. 
Hepatitis 
Cirrhosis 
Healthy 
η
 ν , /
· 
(min) 
18 483 ± 202* 
20 834 ± 523* 
14 261 ± 69 
kei/kg 
(ml/min) 
2.12 ± 0.95* 
1.48 ± 0.66* 
3.57 ± 0.83 
ν,/kg 
(1) 
0.35 ± 0.18 
0.47 ± 0.39 
0.43 ± 0.16 
V f/kg 
(1) 
1.16 ± 0.38 
1.42 ± 0.71 
1.10 ± 0.12 
* Significantly different from healthy controls at Ρ < 0.001 (Student's t-test). 
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experiments are being performed in healthy people of various ages and living 
circumstances, in order to allow more proper comparison. 
In most hepatitis patients the hexobarbital plasma concentrations dechned 
rapidly during the first hour after termination of infusion (mean tj, 22.5 min). 
Subsequently a slower phase followed, representing the elimination phase of 
the drug (mean τ2, 690 min; mean half-life, 479 min). Compared to healthy 
controls the initial decay (т1) was similar in both groups, whereas the elimination 
half-life was more variable and prolonged for many hepatitis patients (Table I). 
A prolonged half-life was usually accompanied by a reduced metabolic clear­
ance constant. Significant differences exist between the mean half-lives and 
clearance constants of the two groups (Table III). The average volume of the 
central compartment (V
v
 0.34 1/kg) and the average apparent volume of distri­
bution (Vf, 1.16 1/kg) were almost the same for the two groups, but the indivi­
dual values varied considerably among the diseased group. Comparable values 
were found for the distribution rate constants (r12, 0.039 ± 0.025 and r21, 0.018 
± 0.017). 
The variation in the parameters of the patients with liver cirrhosis was even 
greater than in the hepatitis group (Table Π). τ1 varied from 4.4 tot 110 min 
and the elimination half-life from 261 tot 2285 min (mean t,,, 834 min), conco­
mitantly with a reduced clearance constant. Significant differences exist 
between the mean half-lives and the clearance constants of the cirrhotic group 
and the healthy controls (Table III). The average distribution rate constants 
were not significantly different from those of the healthy group (r12, 0.059 ± 
0.046 and r21, 0.019 ± 0.015). 
For some patients the amount of unchanged drug and 3-keto-hexobarbital 
was determined in 48 hour's urine (Table IV). Compared to healthy controls 
(Chapter 1, Section III) it became evident that 3-keto-hexobarbital was excreted 
to a lesser extent in patients with liver desease. Urinary excretion of unchanged 
hexobarbital was mostly less than 1% of the dose administered. 
Diagnosis and pathological findings: 
1. acute hepatitis, prednisolone medication; 2. acute hepatitis; 3. acute hepatitis; 4. acute 
viral hepatitis, slight cholangitis; 5. acute viral hepatitis; 6. acute hepatitis; 7. acute viral 
hepatitis; 8. acute hepatitis, alcohol induced; 9. acute hepatitis, cholestasis; 10. acute hepa­
titis, cholestasis; 11. viral hepatitis, cholestasis; 12. viral hepatitis, cholestasis; 13. acute viral 
hepatitis, cholestasis; 14. hepatitis, cholestasis; 15. subacute viral hepatitis; 16. acute hepa­
titis; 17. subacute hepatitis; 18. no biopsy. 
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TABLE I. Hepatitis patients. Biochemical data and pharmacokinetic parameters of hexobarbital. 
Age Body- Total 
(yr) weight Bilirubin 
(kg) (mg/100 ml) 
SGOT SGPT Albumin γ-Glob Dose/kg Inf. time r, r2 t1/t VJkg Vf/kg kel/kg 
(mU/ml) (mU/ml) (g/100 ml) (g/100 ml) (mg) (min) (min) (min) (min) (1) (1) ml/(min) 
1. R.L. 
2. H.H. 
3. P.W. 
4. B.E. 
5. T.C. 
6. D.H. 
7. V.B. 
8. B.H. 
9. M.C. 
10. K.W. 
11. S.L. 
12. K.T. 
13. S.V. 
14. G.P. 
15. K.H. 
16. L.A. 
17. F.E. 
18. S.O. 
Mean 
SD. 
46 
28 
60 
37 
23 
23 
21 
33 
19 
26 
52 
21 
62 
75 
17 
17 
24 
58 
35.7 
18.4 
98 
68 
76 
63 
65 
80 
73 
76 
57 
65 
69 
65 
73 
75 
69 
47 
78.5 
67 
70.3 
10.6 
10.1 
7.9 
2.7 
8.7 
4.8 
6.9 
8.3 
7.3 
6.4 
7.1 
20.1 
11.0 
9.3 
8.5 
1.9 
3.7 
6.6 
5.9 
7.6 
3.9 
312 
240 
300 
840 
640 
360 
900 
536 
280 
42 
112 
28 
468 
880 
42 
92 
60 
70 
345 
302 
420 
444 
640 
1080 
1200 
1600 
2100 
564 
690 
300 
96 
60 
216 
1920 
52 
320 
440 
228 
687 
634 
4.1 
5.1 
4.6 
4.4 
4.5 
3.6 
4.2 
2.9 
3.9 
4.2 
4.0 
4.5 
4.1 
4.2 
0.5 
1.9 
0.8 
0.9 
1.7 
1.6 
1.3 
1.3 
2.0 
2.1 
1.8 
1.7 
1.1 
1.1 
1.5 
0.4 
2.97 
4.12 
7.32 
7.32 
7.32 
7.32 
7.32 
2.97 
7.32 
7.32 
4.80 
7.32 
5.72 
7.32 
7.32 
7.32 
7.32 
7.32 
6.43 
1.59 
6.5 
9.0 
60.0 
60.0 
60.0 
60.0 
60.0 
6.5 
60.0 
60.0 
10.5 
60.0 
12.5 
60.0 
60.0 
60.0 
60.0 
60.0 
45.8 
23.5 
13.9 
19.4 
11.0 
8.3 
29.7 
32.3 
15.4 
9.7 
17.0 
70.4 
20.2 
14.2 
15.4 
32.6 
36.0 
24.4 
21.6 
14.1 
22.5 
14.5 
604 
542 
1004 
1288 
557 
673 
602 
370 
734 
486 
656 
486 
1124 
1315 
713 
417 
346 
503 
690 
298 
419 
376 
697 
894 
387 
467 
418 
257 
510 
338 
456 
338 
781 
913 
495 
290 
240 
349 
479 
207 
0.17 
0.29 
0.16 
0.12 
0.29 
0.25 
0.23 
0.21 
0.35 
0.55 
0.61 
0.34 
0.68 
0.43 
0.46 
0.20 
0.35 
0.26 
0.34 
0.16 
0.83 
0.54 
1.34 
1.00 
1.06 
0.82 
1.35 
1.13 
1.19 
1.02 
2.21 
1.02 
1.05 
1.50 
1.53 
0.82 
0.86 
1.54 
1.16 
0.38 
1.53 
1.04 
1.47 
0.82 
2.34 
1.40 
2.62 
3.52 
1.73 
2.57 
3.71 
2.25 
0.94 
1.23 
2.51 
2.75 
2.80 
3.67 
2.16 
0.93 
to 
oo 
TABLE II. Patients with liver cirrhosis. Biochemical data and pharmacokinetic parameters of hexobarbital. 
Age Body- Total 
(yr) weight Bilirubin 
(kg) (mg/100 ml) 
SGOT 
19. S.K. 
20. D.F. 
21. K.F. 
22. M.H. 
23. G.H. 
24. N.E. 
25. B.A. 
26. B.G. 
27. B.F. 
28. K.A. 
29. R.E. 
30. H.E. 
31. S.F. 
32. M.P. 
33. K.R. 
34. Z.A. 
35. E.A. 
36. K.W. 
37. K.H. 
38. G.R. 
Mean 
S.D. 
45 
39 
44 
48 
36 
47 
43 
52 
51 
35 
38 
44 
62 
73 
38 
35 
46 
55 
45 
45 
46.0 
9.6 
58 
82 
103 
72 
83 
63 
92.5 
67.5 
76.5 
68 
80 
73 
67.5 
75 
75 
54.5 
82 
84.5 
66 
84 
75 
12 
1.9 
0.2 
0.8 
0.9 
1.0 
0.9 
0.8 
1.8 
6.8 
2.8 
1.7 
2.8 
3.0 
6.6 
2.0 
12.6 
8.4 
1.3 
2.0 
1.2 
3.0 
3.2 
17 
10 
24 
29 
13 
28 
16 
30 
140 
40 
24 
22 
26 
34 
300 
60 
180 
30 
74 
36 
57 
72 
GPT 
U/ml 
17 
6 
24 
17 
7 
19 
10 
18 
88 
36 
20 
28 
14 
14 
130 
70 
132 
22 
60 
8 
37 
39 
Albumin 
) (g/100ml) d 
3.9 
5.0 
4.0 
4.8 
4.2 
3.9 
3.5 
2.3 
2.6 
3.6 
4.0 
3.3 
2.0 
2.4 
3.3 
3.4 
3.4 
4.7 
3.3 
2.5 
3.5 
0.8 
y-Gldb 
g/100ml) 
1.3 
1.0 
1.1 
1.1 
1.3 
1.5 
1.8 
2.8 
2.5 
1.7 
1.3 
3.1 
5.5 
3.3 
4.4 
1.2 
2.2 
2.0 
2.3 
2.6 
2.2 
1.2 
Dose/kg 
(mg) 
10.75 
6.75 
4.57 
5.72 
6.97 
9.60 
5.49 
7.32 
7.32 
15.20 
7.32 
7.32 
7.32 
7.32 
7.32 
7.32 
3.09 
7.32 
7.32 
5.49 
7.34 
2.45 
Inf. time r, 
(min) 
23.5 
14.75 
10.0 
12.5 
15.25 
21.0 
12.0 
60.0 
60.0 
33.25 
60.0 
60.0 
63.5 
60.0 
60.0 
60.0 
6.75 
60.0 
60.0 
12.0 
38.2 
23.3 
τ2 »ν, 
(min) (min) (min) 
4.4 
42.3 
11.9 
15.2 
7.2 
35.6 
11.9 
11.1 
49.0 
7.3 
28.8 
14.6 
110 
6.6 
9.9 
22.6 
11.8 
21.1 
87.3 
4.6 
25.7 
28.2 
376 
528 
672 
609 
845 
948 
1171 
692 
1296 
1175 
821 
1150 
2924 
3290 
1624 
1890 
1363 
708 
1085 
859 
1201 
752 
261 
367 
467 
423 
587 
658 
813 
481 
900 
816 
570 
799 
2031 
2285 
1128 
1313 
947 
492 
753 
597 
834 
523 
ν,/kg 
(1) 
0.26 
0.31 
0.20 
0.22 
0.17 
0.55 
0.23 
0.34 
0.83 
0.27 
0.20 
0.24 
1.37 
0.31 
0.24 
1.15 
0.22 
0.35 
1.35 
0.67 
0.47 
0.39 
Vf/kg 
(1) rr 
1.15 
0.95 
1.05 
0.87 
0.89 
1.22 
1.57 
0.99 
1.36 
1.49 
0.69 
1.15 
1.78 
1.92 
1.25 
4.12 
1.38 
1.45 
1.72 
1.32 
1.42 
0.71 
kcl/kg 
[l/(min) 
3.20 
2.38 
1.71 
1.56 
1.09 
1.36 
1.43 
1.47 
1.08 
1.31 
0.94 
1.06 
0.62 
0.59 
0.79 
2.25 
1.06 
2.30 
1.87 
1.55 
1.48 
0.66 
Diagnosis and pathological findings: 
19. cirrhosis, ascites, developing portal hypertension, prednisolone medication; 20. cirrhosis; 
21. cirrhosis; 22. cirrhosis; 23. alcoholic cirrhosis, developing portal hypertension; 24. cir­
rhosis, cholestasis; 25. cirrhosis, portal hypertension; 26. cirrhosis, ascites, moderate portal 
hypertension, diabetes mellitus; 27. cirrhosis, portal hypertension, oesophageal varices; 28. 
progressive cirrhosis, portal hypertension, prednisolone medication; 29. post-necrotic cir­
rhosis portal hypertension, cholestasis, ascites; 30. cirrhosis, portal hypertension, oeso­
phageal varices; 31. progressive cirrhosis, portal hypertension, ascites; 32. cirrhosis with 
jaundice, ascites; 33. cirrhosis, moderate portal hypertension, severe fatty degeneration; 34. 
alcoholic cirrhosis, jaundice, ascites; 35. cirrhosis, (patient died, necropsy revealed severe 
intrahepatic cholestasis); 36. alcoholic cirrhosis (patient died from oesophageal varices 
bleeding); 37. cirrhosis, pancreatitis, diabetes mellitus; 38. cirrhosis, portal hypertension, 
oesophageal varices, ascites (patient died after shunt operation). 
-<-
TABLE III. Cumulative urinary excretion of hexobarbital and 3-keto-hexobarbital 
Hexobarbital 3-Keto-hexobarbital 
(% of dose administered) (% of dose administered) 
Hepatitis 
P.W. 
т.е. 
G.P. 
L.A. 
S.O. 
Cirrhosis 
G.H. 
B.G. 
M.P. 
K.H. 
0.58 
0.12 
0.31 
0.15 
0.14 
0.18 
0.19 
1.10 
0.30 
7.1 
16.3 
2.8 
18.3 
13.8 
33.2 
21.2 
5.1 
4.7 
DISCUSSION 
The metabolic clearance of hexobarbital 
It is evident that the rate of elimination of hexobarbital is retarded in many 
patients with liver disease; particularly in cases with chronic liver disease 
(cirrhosis) the half-life may be extremely long. It was outlined in Chapter 1, 
Section I, that the half-life of a drug is mainly dependent on its renal or 
metabolic clearance and on the apparent volume of distribution. The actual 
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elimination process of a drug from the body is characterized by the clearance 
constant (koi; ml/min). It is a measure of the functional ability of a substance 
to be removed by the eliminating organ (Riegelman and Rowland, 1973). In 
the majority of previous studies, concerning drug metabolism associated with 
impaired liver function, only the half-life of the drug was measured. The 
possibility exists that essential differences in metabolic clearance are obscured 
by simultaneously occurring alterations in the apparent volume of distribution. 
Therefore, in the present investigation with hexobarbital, it is focussed on the 
metabolic clearance constant which is significantly decreased for the patients 
with liver disease. The clearance constant depends on the enzymatic constants 
governing biotransformation (Chapter 1, Section I): 
k
el = —9
m
— (Eq. 2) 
K
m
 + С 
where Q,,, is the capacity of the liver enzymes involved (mg/min), which is related 
to V
niajl when only one enzyme is involved. Km is the apparent Michaelis-
Menten constant (mg/1) and С the drug concentration in the clearance tissue 
(mg/1). At low plasma concentrations (C^Km) kd is often a simple function 
of the enzymatic constants (k(,i = Q„,/Kni). If it is assumed that Km has not 
changed in the diseased situation, it may be concluded that a reduced clearance 
is caused by a decreased enzymatic capacity of the liver. For hexobarbital this 
may be due, for instance, to a reduced cytochrome P-450 content of the liver, 
which was shown in cases of severe hepatitis and liver cirrhosis (Schoene et 
al., 1972; von Oldershausen et al., 1973; Zilly et al., 1973b). However, it 
cannot be excluded that the affinity of the enzyme system for a certain drug 
(K
ni) is not influenced by liver disease. Conformational changes in the enzyme 
system or alterations in the microenvironment of the enzymes may be induced 
by the presence of abnormal amounts of endogenous substances, e.g. bilirubin 
during acute hepatitis, or bile acids during cholestasis (Gillette et al., 1957; 
McLuen and Fouts, 1961). An increased K
m
-value will reduce the metabolic 
clearance of a drug. A more complicated situation arises if the drug concen­
tration in the liver becomes critical with respect to K
m
. The clearance becomes 
concentration dependent and apparent saturation of the enzyme system may 
be encountered. An example of such a situation is given in Fig. 3 (upper), 
where the elimination rate shortly after infusion is slower than that at lower 
concentrations after longer periods. This may be due either to a reduced Km-
value or to an increased concentration of drug at the biotransformation site. 
Such a phenomenon was observed only in few patients. 
As well as on the enzyme constants, metabolic clearance may also be dependent 
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FIG. 3. Upper: Hexobarbital plasma concentration curve on semi-logarithmic 
scale during and after a 12.5 min zero-order infusion into a hepatitis patient. The 
shape of the post-infusion curve suggests that elimination may be capacity-limited. 
Some parameters were estimated, assuming an average half-life of 14 h. Lower: 
The experiment was repeated after 2 months, when the patient had recovered, as 
judged by clinical symptoms and laboratory data. It may be noted that the shape 
of the curve had returned to normal; however, the metabolic clearance constant 
was still very much reduced and the half-life prolonged. 
on the blood flow through the liver (Nagashima and Levy, 1968; Rowland et 
al., 1973). This becomes an important factor if the clearance for a certain drug 
is in the same order of magnitude as the blood flow through the liver (normally 
about 1500 ml/min). It was shown previously that lidocaine clearance, which 
is 700 - 800 ml/min in healthy persons (Rowland et al., 1971), was significantly 
reduced in patients with reduced cardiac output (Thomson et al., 1973). For 
hexobarbital, blood flow probably is a less critical factor, since its clearance 
is relatively small compared to blood flow. It is possible however, that with 
liver disease, alterations in the regional perfusion pattern may substantially 
contribute to a less effective extraction of the drug by the liver. This leads 
to an apparent reduction of drug metabolizing capacity. 
Obviously, there are several theories which may explain the reduced hexo-
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barbital clearance in patients with liver disease. Which of these is valid, is 
difficult to state since they may vary from patient to patient. All the mentioned 
processes are possibly involved to some extent, although the decreased amount 
of cytochrome P-450 in the liver seems one of the most important explanations 
(von Oldershausen et al., 1973). The reason that some patients, in spite of 
severe clinical symptoms, showed a quite normal clearance value, may be attrib-
uted to drug history of these patients. Levi et al. (1968) found that the phenyl-
butazone half-life was prolonged in those patients with liver disease, who had 
not received any previous drug treatment. On the other hand, patients who 
had received a variety of drugs known to induce microsomal enzymes, showed 
a quite normal half-life in the diseased state. These authors suggest that pre-
vious investigators may have failed to demonstrate the impairment of drug 
metabolism in patients with hepatic dysfunction, because the importance of 
other drug treatment was not taken into account. It is possible that in the 
present investigations with hexobarbital, drug treatment prior to hospitalization 
is a factor that should be considered. It may explain the relatively short half-
life in some patients. The influence of previous drug treatment on the pharma-
cokinetics of hexobarbital will be the subject of a further study. 
The hexobarbital experiment was repeated, for some patients, when clinical 
symptoms and biochemical data suggested apparent recovery from the liver 
disease. In Fig. 3 an example is given for such a patient who received the 
hexobarbital infusion with an interval of 2 months. The metabolic clearance 
was still much reduced on the second occasion, although the kinetic behaviour 
of hexobarbital was no longer capacity-limited as it was at the first trial. It was 
also found for other patients that apparent clinical recovery is not accompanied 
by a normalization of the metabolic capacity of the liver, as measured by the 
hexobarbital clearance. 
Hexobarbital tolerance and the volume of the central compartment 
It was shown previously that patients with acute hepatitis exhibited a reduced 
tolerance to the CNS depressant effect of hexobarbital (Richter et al., 1972; 
Zilly et al., 1973b). This tolerance was defined as the amount of drug (mg/kg) 
required to cause loss of counting ability during a constant-rate infusion. In 
these patients the plasma levels during infusion increased faster than in healthy 
controls, so that at an earlier stage the effective concentration was reached 
(Zilly et al., 1973a). The cytochrome P-450 content of the liver in patients 
with acute hepatitis was significantly reduced (Zilly et al., 1973b). For this 
reason, initially a correlation was supposed to exist between hexobarbital 
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FIG. 4. Simulation of the influence of т2 on the plasma concentration curve during 
infusion. It may be noted that despite a great variation of Тз» the influence on the 
rise of the concentration during infusion is almost negligible. 
tolerance and the metabolic capacity of the liver. From the kinetic experiments 
with hexobarbital it became evident that the metabolic clearance is generally 
reduced in these patients, causing a longer elimination half-life. In Fig. 4 the 
influence of the elimination rate on the concentration time course during a 
60 min infusion was simulated. It is evident that the influence of the elimination 
half-life on the rise of plasma concentration during a relatively short infusion 
period, is almost negligible. The responsible factor appears to be the volume 
of the central compartment (V,). This is smaller in many patients with acute 
hepatitis (Table I, patients 1-8) and in Fig. 5 the coefficient Aj has been 
varied, which is greatly determined by \
v
 It can be observed that this parameter 
greatly influences the plasma concentration during infusion. The physiological 
meaning of a reduced volume of the central compartment is uncertain, although 
it is likely that the liver is involved. The liver may not belong to the central 
compartment, which means that the drug does not instantaneously distribute 
into the liver. On the other hand, for a lipophilic drug such as hexobarbital, 
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FIG. 5. Simulation of the influence of A1 (which is greatly determined by the 
volume of the central compartment Vj) on the plasma concentration curve during 
infusion. It may be noted that the rise of the plasma concentration varies sub­
stantially with Aj. 
the brain is part of the central compartment. If W1 is reduced, the brain con­
centration rises more rapidly and the central tolerance is found reduced. 
The apparent volume of distribution 
The distribution of a drug outside the plasma is characterized by the apparent 
volume of distribution (Vf). This parameter is sometimes referred to by 
„volume at steady state", which indicates that it is the volume of distribution 
when equilibrium between plasma and tissues has been reached, as derived 
from the plasma concentration. As outlined in Chapter 1, Section I, the half-life 
of a drug is also greatly dependent on the volume of distribution. For hexo-
barbital this volume is more than 1 1/kg body-weight, which indicates extensive 
tissue localization of the drug once it has been distributed. The apparent 
increase in distribution volume for some patients, particularly with liver cir-
INF.tlME 60M1N 
DOSE 600 MG 
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FIG. 6. Concentration of hexobarbital in plasma and in ascitic fluid (semi-
logarithmic scale) of a patient with liver cirrhosis (patient S.F., no. 31) after a 
63.5 min zero-order i.v. infusion. Two hours after the termination of the infusion 
the concentration in the plasma and in the ascitic fluid have become almost 
identical. The elimination half-life was approximately 34 h, k
c
i = 41.9 ml/min and 
V, = 120 1. 
rhosis, is comparable to similar findings for lidocaine in patients with chronic 
liver disease (Thomson et al., 1973). Alterations in plasma protein binding or 
tissue binding due to the diseased state may be contributing factors (Reiden-
berg and Affirme, 1973). However, in the present investigation no correlation 
was found between the plasma albumin content and the apparent volume of 
distribution. Protein binding of hexobarbital to 5% albumin at 100 mg/1 is 
approximately 56% (Richter, 1974). An extensive study with pentobarbital 
revealed that binding of pentobarbital to plasma protein (about 70% at 50 
mg/1) in several patients with liver disease was comparable to healthy controls 
(Fuchshofen, 1974). These findings suggest that plasma protein binding is a 
factor of limited importance with respect to the volume of distribution of 
hexobarbital. Some of the cirrhotic patients with an enlarged volume of 
distribution for hexobarbital also exhibited ascites (Table II). An additional 
experiment revealed that the hexobarbital concentration in the ascitic fluid 
was equal to the plasma concentration shortly after the termination of infusion 
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(Fig. 6; patient S.F., no. 31). Since the volume of this fluid probably did not 
exceed 10 1 for this patient, the preliminary conclusion may be drawn that 
accumulation of hexobarbital in ascitic fluid does not contribute substantially 
to the enlarged volume of distribution. It is likely that other factors are involved 
and these will require further investigation. 
Concluding remarks 
The preliminary results, on the pharmacokinetics of hexobarbital in patients 
with liver disease, indicate that several changes in the kinetic behaviour of 
hexobarbital may occur when compared to healthy persons. A reduced meta-
bolic clearance, resulting in a prolonged half-life, is the most evident finding. 
Furthermore, alterations in the volume of the central compartment or the 
apparent volume of distribution are apparent in some patients. It will be the 
subject of further research to subdivide the patients who participated in the 
present study, according to more detailed clinical and biochemical data and 
an attempt will be made to find correlations between certain pharmacokinetic 
parameters and biochemical data or common liver function tests. 
SUMMARY 
The pharmacokinetics of hexobarbital were studied in 18 patients with hepatitis 
and 20 patients with liver cirrhosis. Hexobarbital sodium was administered by zero-
order i.v. infusion and plasma levels were determined at regular intervals during and 
after infusion. 
The kinetic behaviour of hexobarbital after infusion was consistent with the two-
compartment open model. Plasma concentrations were fitted according to the 
post-infusion equation and the pharmacokinetic parameters were estimated. These 
have been compared with the results obtained for healthy volunteers (Chapter 1, 
Section III). The elimination half-life was considerably prolonged for most patients; 
hepatitis: 257-913 min, mean 479 min; cirrhosis: 261 -2285 min, mean 834 min. 
The metabolic clearance constants were found to be significantly reduced, due to a 
decreased metabolic capacity of the liver. It was discussed also that changes in the 
apparent Michaelis-Menten constant may be involved, which in some instances lead 
to an apparent saturation of the metabolizing enzymes. The average distribution rate 
constants were found to be comparable to healthy controls. The metabolite 3-keto-
hexobarbital was excreted to a lesser extent into the urine. 
It was demonstrated that the previously reported reduced central tolerance of 
patients with acute hepatitis to hexobarbital during i.v. infusion, was due to a 
decreased volume of the central compartment. Plasma concentrations during in-
fusion rise more rapidly in such patients. Simulation experiments revealed that the 
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rate of drug elimination does not influence drug concentrations during infusion to any 
significant extent. 
The average apparent volume of distribution of the patients with liver disease was 
comparable to that of healthy controls. For some cirrhotic patients, however, this 
volume was considerably enlarged. An additional experiment showed that the hexo-
barbital concentrations in ascitic fluid were equal to the plasma concentration, which 
suggests that this fluid does not contribute substantially to an enlarged distribution 
volume. 
It was concluded that several changes in the kinetic behaviour of hexobarbital in 
patients with liver disease may become apparent. The underlying causes of their 
changes will require further investigation. 
REFERENCES 
Acocella, G., L. Bonollo, M. Garimoldi, M. Mainardi, L. T. Tenconi and F. B. 
Nicolis (1972), Gut 13, 47. 
Azzollini, F., A. Gazzaniga, E. Lodola and R. Natangelo (1972), Int. J. Clin. 
Pharmacol. 6, 130. 
Breimer, D. D. and J. M. van Rossum (1974), Л Chromatogr. 88, 235. 
Bush, M. T. (1963), In: Physiologic Pharmacology, Vol. I, p. 199, W. S. Root 
and F. G. Hofmann, eds., Academic Press, New York. 
Brodie, В. В., J. J. Burns and M. Weiner (1959), Med. exp. 1, 290. 
Fuchshofen, M. (1974), Methodische Untersuchungen zur Plasmabindungskapazität 
für Pentobarbital bei lebergesunden Normalpersonen und bei Patienten mit 
Lebererkrankungen, Inaugural Dissertation, Universität Würzburg. 
Gillette, J. R. (1971), Ann. N.Y. Acad. Sei. 179, 43. 
Gillette, J. R., B. B. Brodic and B. N. LaDu (1957), J. Pharmacol. Exp. Ther. 119, 
532. 
Held, H. and H. F. von Oldershausen (1969), Klin. Wschr. 47, 78. 
Held, H., H. F. von Oldershausen and H. Remmer (1970), Klin. Wschr. 48, 565. 
Held, H., R. Eisert and H. F. von Oldershausen (1973), Arzneim. Forsch. 23, 
1801. 
Kutt, H. W., W. Winters, R. Shennan and F. McDowell (1964), Arch. Neurol. 
(Chic.) 11, 649. 
Levi, A. J., S. Sherlock and D. Walker (1968), Lancet I, 1275. 
Loo, J. С. К. and S. Riegelman (1970), У. Pharm. Sci. 59, 53. 
Mawer, G. E., N. E. Miller and L. A. Turnberg (1972), Brit. J. Pharmacol. 44, 549. 
Mc Luen, E. F. and J. R. Fouts (1961), J. Pharmacol. Exp. Ther. 131, 7. 
Nagashima, R. and G. Levy (1968), J. Pharm. Sci. 57, 1991. 
Oldershausen, H. F. von, В. Schoene, H. Held, H. P. Menz, R. A. Fleischmann 
and H. Remmer (1973), Gastroenterologie 11, 403. 
Reidenberg, M. M. and M. Affirme (1973), Ann. N.Y. Acad. Sci. 226, 115. 
Remmer, H. (1966), Dtsche Med. Wschr. 91, 289. 
Richter, E. (1974), Personal communication. 
Richter, E., W. Zilly and D. Brachtel (1972), Dtsche Med. Wschr. 97, 254. 
Riegelman, S. and M. Rowland (1973), J. Pharmacokin. Biopharm. 1, 419. 
307 
Rowland, M., P. D. Thomson and A. Guichard (1971), Ann. N.Y. Acad. Sci. 179, 
383. 
Rowland, M., L. Z. Benet and G. G. Graham (1973), J. Pharmacokin. Biopharm. 
1, 123. 
Schoene, В., R. A. Fleischmann, H. Remmer and H. F. von Oldershausen (1972), 
Eur. J. Clin. Pharmacol. 4, 65. 
Sherlock, S. (1963), Diseases of the liver and biliary system, 3rd ed., p. 134, 
Blackwell, Oxford; (1968), ib., 4th ed., p. 350. 
Thomson, P. D., K. L. Melmon, J. A. Richardson, K. Cohn, W. Steinbrunn, R. 
Cudihee and M. Rowland (1973), Ann. Int. Med. 78, 499. 
Zilly, W., D. Brachte! and E. Richter (1973a), Klin. Wschr. 51, 346. 
Zilly, W., D. Brachte!, R. Löffler and E. Richter (1973b), Gastroenterologie 11, 
381. 
Zilly, W., M. Dreykluft, E. Richter and N. Rietbrock (1973c), Verhandl. Dtsche 
Ges. inn. Med. 79, 938. 
308 


CURRICULUM VITAE 
Douwe Durk Breimer werd geboren op 24 november 1943 te Oudemirdum 
(Gaasterland). Hij bezocht van 1956-1960 de Chr. Mulo-school te Balk 
(diploma Mulo-B) en van 1960 - 1962 het Bogerman Lyceum te Sneek (diploma 
H.B.S.-B). Hij studeerde van 1962-1970 farmacie aan de Rijksuniversiteit te 
Groningen; het kandidaatsexamen werd in 1965 cum laude afgelegd. In het 
kader van het gekozen bijvak farmaceutische chemie verrichtte hij in 1967 
gedurende 3 maanden onderzoek aan de University of Strathclyde te Glasgow, 
Schotland, onder leiding van Prof. J. B. Stenlake. Het doctoraalexamen werd in 
1969 cum laude afgelegd, terwijl hij in oktober van hetzelfde jaar de K.N.M.P.-
prijs ontving. Het apothekersexamen vond in juli 1970 plaats. 
In augustus 1970 trad hij in dienst van de Nederlandse Organisatie voor 
Zuiver Wetenschappelijk Onderzoek te 's-Gravenhage en vanaf die tijd is hij 
werkzaam op het Farmacologisch Laboratorium te Nijmegen. Hij heeft als lid 
van de werkgroep farmacokinetiek onder leiding van Prof. Dr. J. M. van Rossum 
onderzoek verricht naar farmacokinetische en biofarmaceutische aspekten van 
slaapmiddelen, voornamelijk bij de mens. Daarnaast werd tezamen met Dr. T. B. 
Vree, Drs. С A. M. van Ginneken en Prof. Dr. J. M. van Rossum gewerkt 
aan de analyse van cannabinoiden in hashish en marihuana, met behulp van 
gaschromatografie en gecombineerde gaschromatografie - massaspectrometrie. 
Sedert eind 1972 wordt samengewerkt met Dr. E. Richter en Dr. W. Zilly, 
Medizinische Universitätsklinik, Würzburg, West-Duitsland, in een projekt be-
treffende de farmacokinetiek van geneesmiddelen bij patiënten met leverziekte. 
Hij is lid van het Bestuur van de sectie Farmacochemie van de Koninklijke 
Nederlandse Chemische Vereniging en lid van de Centrale Commissie voor 
Studiezaken van de Koninklijke Nederlandse Maatschappij ter bevordering der 
Pharmacie. 
Hij is gehuwd en heeft drie dochters. 
Uit onderzoekingen waaraan is meegewerkt, zijn de volgende publikaties 
voortgekomen (chronologische volgorde): 
1. J. B. Stenlake, D. D. Brcimer, G. A. Small, Α. Stafford and W.C. Bowman: 
The preparation and properties of ( + )- and (—)-guanoxan. /. Pharm. Pharmacol. 
20, Suppl., 82S-93S (1968). 
311 
2. J. M. van Rossum, D. D. Breimer, C. A. M. van Ginneken, J. M. G. van 
Kordelaar and T. B. Vree: Gas-liquid chromatography in pharmacology and 
toxicology; pharmacokinetic analysis limited by the sensitivity of the analytical 
technique. Clin. Chini. Acta 34, 311 - 319 (1971). 
3. T. B. Vree, D. D. Breimer, C. A. M. van Ginneken, J. M. van Rossum, R. A. 
de Zeeuw and A. H. Witte: Identification of cannabivarins in hashish by a new 
method in combined gas chromatography - mass spectrometry. Clin. Chim. Acta 
34, 365-370(1971). 
4. T. B. Vree, D. D. Breimer, С A. M. van Ginneken and J. M. van Rossum: 
Identification of hashish constituents by a new method of combined gas chroma­
tography - mass spectrometry; identification of CBD, THC and CBN and their 
homologues with a propyl and methyl side chain. L.K.B. application note (1971). 
5. T. B. Vree, D. D. Breimer, С A. M. van Ginnekcn and J. M. van Rossum: 
Identification of the methyl and propyl homologues of CBD, THC and CBN 
in hashish by a new method of combined GC-MS. Acta Pharmaceut. Suec. 8, 
671-672(1972). 
6. T. B. Vree, D. D. Breimer, С A. M. van Ginneken and J. M. van Rossum: 
Identification of tetrahydrocannabinol, cannabinol and cannabidiol analogues 
with a methyl side chain. J. Pharm. Pharmacol. 24, 7 - 1 2 (1972). 
7. T. B. Vree, D. D. Breimer, C. A. M. van Ginneken, J. M. van Rossum, R. A. 
de Zeeuw, F. W. H. M. Merkus, A. H. Witte, A. M. A. Verwey, A. Baerheim-
Svendsen, C. A. L. Bcrcht, F. J. F. M. Küppers, R. J. J. Ch. Lousbcrg, C. A. 
Salemink and H. Samrah: Chemie en farmacokinetiek van hashish en marihuana 
bestanddelen. Chemisch Weekbl. 68, H 1 - H 16, 25 februari 1972. 
8. D. D. Breimer, T. B. Vree, С. A. M. van Ginneken and J. M. van Rossum: 
Some new Cannabis constituents. In: Biochemical and Pharmacological aspects 
of dependence and reports on marihuana research, p. 116-118. H. M. van 
Praag, Ed., Erven Bohn B.V., Haarlem (1972). 
9. D. D. Breimer, Т. В. гее, С. A. M. van Ginneken, P. Th. Henderson and J. M. 
van Rossum: Identification of Cannabis metabolites by a new method of com­
bined gas chromatography - mass spectrometry. Proceedings of the International 
Symposion on gas chromatography - mass spectrometry, p. 88 - 107, A. Frigerio, 
Ed., Tamburini Editore, Milano (1972). 
10. С. Α. Μ. van Ginneken, Т. В. Vree, D. D. Breimer, H. H. W. Thijssen and 
J. M. van Rossum: Cannabinodiol, a new hashish constituent identified by gas 
chromatography - mass spectrometry. Proceedings of the International Symposion 
on gas chromatography - mass spectrometry, p. 110-129, A. Frigerio, Ed., 
Tamburini Editore, Milano (1972). 
11. R. A. de Zeeuw, J. Wijsbeck, D. D. Breimer, T. В. гее, С. A. M. van Ginneken 
and J. M. van Rossum: Cannabinoids with a propyl side chain in Cannabis; 
occurrence and chromatographic behaviour. Science (New York) 175, 778 - 780 
(1972). 
12. T. B. Vree, D. D. Breimer, C. A. M. van Ginneken and J. M. van Rossum: 
Identification of cannabicyclol with a pentyl and propyl side chain by means 
of combined gas chromatography - mass spectrometry. J. Chromatogr. 74, 
124- 127 (1972). 
13. T. B. Vree, D. D. Breimer, C. A. M. van Ginneken and J. M. van Rossum: 
Gas chromatography of Cannabis constituents and their synthetic derivatives. 
J. Chromatogr. 74, 209 - 224 (1972). 
14. R. A. de Zeeuw, Т. В. Vree, D. D. Breimer and C. A. M. van Ginneken: 
Cannabivarichromene, a new cannabinoid with a propyl side chain in Cannabis. 
Experienta 39, 260 - 262 (1973). 
15. T. B. Vree, D. D. Breimer, C. A. M. van Ginneken, J. M. van Rossum and 
N. M. M. Nibbering: Gas chromatography of Cannabinoids. Gas chromato­
graphic behaviour of CIS-, TRANS- and ISO-THC. J. Chromatogr. 79, 8 1 - 9 0 
(1973). 
16. D. D. Breimer: Over de biologische beschikbaarheid van het geneesmiddel. 
I. Algemene en farmacokinetische beschouwingen. Pharm. Weekblad 108, 
309-323 (1973). 
17. D. D. Breimer: Over de biologische beschikbaarheid van het geneesmiddel. 
II. Chemische aspckten. Pharm. Weekblad 108, 661 -677 (1973). 
18. D. D. Breimer and J. M. van Rossum: Pharmacokinetics of ( + )-, (—)- and 
(±)-hexobarbital in man after oral administration. J. Pharm. Pharmacol. 25, 
762-764 (1973). 
19. D. D. Breimer, H. L. M. Cox and J. M. van Rossum: Relative bioavailability of 
chloral hydrate after rectal administration of different dosage forms. Pharm. 
Weekblad 108, 1101-1110 (1973). 
20. D. D. Breimer, H. C. J. Ketelaars and J. M. van Rossum: The determination of 
chloral hydrate, trichloroethanol and trichloroacetic acid in blood and urine, 
employing head-space analysis. Л Chromatogr. 88, 5 5 - 6 3 (1974). 
21. D. D. Breimer and J. M. van Rossum: Rapid and sensitive gas chromatographic 
determination of hexobarbital in plasma of man using a nitrogen detector. 
J. Chromatogr. 88, 235-243 (1974). 
22. D. D. Breimer and J. M. van Rossum: Pharmacokinetics of the enantiomers of 
hexobarbital studied in the same rat and in the same isolated perfused rat liver. 
Eur. J. Pharmacol. 26, 321 - 330 (1974). 
23. D. D. Breimer, С Honhoff, W. Zilly, E. Richter and J. M. van Rossum: 
Pharmacokinetics of hexobarbital in man after intravenous infusion. Submitted 
for publication. 
313 
24. W. Zilly, D. D. Brcimer and E. Richter: The influence of rifampicin on the 
pharmacokinetics of hexobarbital and tolbutamide in healthy volunteers. Sub-
mitted for publication. 
314 


STELLINGEN 
I 
Farmacokinetische en biofarmaceutische overwegingen behoren een belangrijke 
rol te spelen bij de keuze van een slaapmiddel. Daarbij verdienen in het 
algemeen stoffen met een vrij korte halfwaardetijd de voorkeur, terwijl de te 
verkiezen toedieningsvorm moet zijn afgestemd op de snelheid waarmee het 
effekt gewenst wordt. 
Dit proefschrift. 
II 
De gebruikelijke indeling van de barbituraten naar werkingsduur bij de mens 
is misleidend, mede omdat deze berust op onjuiste veronderstellingen betref-
fende de snelheid waarmee zij worden geïnaktiveerd. 
Martindale (1972), The Extra Pharmacopoeia, 26th ed., p. 891. 
Mark, L. С. (1969), Clin. Pharmacol. Ther. 10, 287. 
Dit proefschrift. 
I l l 
In onderzoekingen bij ratten, waarbij de verlenging of verkorting van de slaap-
tijd na toediening van hexobarbital geldt als maat voor verandering in de 
oxydatieve enzymaktiviteit, verdient het de voorkeur alleen de rechtsdraaiende 
isomeer van hexobarbital te gebruiken. 
McCarthy, J. S. en R. E. Stitzel (1971), J. Pharmacol. Exp. Ther. 176, 
772. 
Dit proefschrift. 
IV 
De toediening van 5 gram DDT ter behandeling van patiënten met barbituraat-
intoxicaties, met de bedoeling een snelle induktie van de metaboliserende 
enzymen te bewerkstelligen, is niet rationeel en moet als onverantwoord 
worden beschouwd. 
Rappolt, R. T. (1973), Clin. Toxicol. 6, 147. 
ν 
Voor de bepaling van AMetraliydrocannabinol in plasma verdient de methode 
van Agurell et al. (1973), welke gebruik maakt van massafragmentografie, de 
voorkeur boven de gaschromatografische methode van Garrett en Hunt (1973). 
Agurell, S. et al. (1973), J. Pharm. Pharmacol. 25, 554. 
Garrett, E. R. en С. A. Hunt (1973), J. Pharm. Sci. 26, 1211. 
Breimer, D. D. (1973), Pharm. Weekblad 108, 1017. 
VI 
De opvatting betreffende het bestaan van een funktionele relatie tussen de 
regionale verdeling van monoaminen binnen de hersenen en het slaap - waak 
mechanisme wordt niet gesteund door recent onderzoek. 
Jouvet, M. (1969), Science 163, 32. 
Jalowiec, J. E. et al. (1973), Exp. Neurol. 41, 670. 
VII 
De berekening van farmacokinetische parameters uit gemiddelde plasmacurves 
kan tot onjuiste konklusies leiden. Bij voorkeur dienen de parameters berekend 
te worden per individu, welke vervolgens eventueel statistisch kunnen worden 
bewerkt. 
VIII 
Het verdient aanbeveling voorschriften voor die bereidingen van geneesmiddel­
toedieningsvormen in de Nederlandse Farmacopee op te nemen, welke uit 
farmacotherapeutisch oogpunt zinvol zijn en biofarmaceutisch voldoende zijn 
onderzocht. De eis dat de apotheker „op de juiste wijze en nauwkeurig volgens 
het recept bereidt"1), behoort een waarborg in te houden voor het afleveren 
van betrouwbare toedieningsvormen. 
!) Besluit uitoefening artsenijbereidkunst art. 19, lid 1. 
IX 
Nu de drinkwaterfluoridering op de meeste plaatsen in Nederland is opgeschort, 
dienen ter noodzakelijke vervanging daarvan zodanige fluoride bevattende 
toedieningsvormen te worden ontwikkeld, dat zoveel mogelijk het lokale kontakt 
van fluoride met het gebit wordt bevorderd. 
χ 
De ruime aandacht die recent door de publiciteitsmedia is besteed aan de 
mogelijk nadelige aspekten van geneesmiddelen, heeft in sterke mate de nood­
zaak vergroot patiënten die noodzakelijk gedurende korte of langere tijd een 
geneesmiddel dienen te gebruiken te motiveren zich nauwkeurig aan het voor-
geschrevene te houden. 
XI 
Aangezien adoptie vóór alles in het belang van het kind moet zijn, verdient het 
aanbeveling art. 228 sub c, boek 1 van het burgerlijk wetboek, voor zover 
daarin vermeld dat ieder der adoptanten ten hoogste 50 jaar ouder dan het 
kind mag zijn, zodanig worden gewijzigd dat het maximum leeftijdsverschil 
wordt gesteld op 35 jaar. De richtlijnen inzake opname van buitenlandse 
adoptiefkinderen dienen overeenkomstig te worden aangepast. 
XII 
De suggestie van staatssecretaris Veerman om de eindexamens in het voort-
gezet onderwijs in tijd en niveau te spreiden, is voor scholen die werken met 
een systeem van jaarklassen om redenen van school- en onderwijsorganisatie 
niet funktioneel. 
XIII 
Vrouwenemancipatie betekent mannenparticipatie. 
XIV 
Een goed gefundeerde stelling staat op vier poten. 
D. D. BREIMER, Nijmegen, 14 juni 1974. 



